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Abstract 
Therapeutic proteins are often potent and have rapid onsets of action. Unfortunately protein-
based medicines can be immunogenic and have short half-lives. The circulation half-life of 
many proteins has been improved by the covalent conjugation of poly(ethylene)glycol (PEG) 
to the protein. For example, PEGylated interferon-2 (PEGASYS® and PEG-INTRON®) has 
become a first line treatment for hepatitis C. The aim of this thesis was to examine the 
possibility of using a homobifunctional PEG reagent to make protein dimers.  
 Our group has developed PEGylation reagents that undergo conjugation by bis-
alkylation to selectively conjugate either (i) two cysteine thiols from a native disulfide or (ii) 
two histidine residues in a polyhistidine tag. It was hypothesised that IFN dimers (IFN-PEG-
IFN) could be prepared with higher retained activity than monoPEGylated IFN. It was also 
hypothesised that a heterodimer of IFN and an antibody fragment (Fab) could be made while 
retaining the activity of both proteins within the heterodimer.  
His8IFN-PEG-His8IFN and IFN-PEG-IFN homodimers were prepared by site-selective 
conjugation to the N-terminal 8-polyhistidine tag and to one of the disulfides of IFN 
respectively. These homodimer conjugates were characterised in terms of purity and in vitro 
activity. The in vitro cell based assays were optimised to accurately elucidate the specific 
activities of the IFN conjugates. The His8IFN-PEG20-His8IFN homodimer was found to retain 
greater activity than IFN-PEG20-IFN. The increased activity was thought to be due to 
conjugation to the polyhistidine tag, which is distal from the IFN binding surface. It was also 
found that IFN-PEG10-IFN homodimer retained greater activity than PEG10-IFN, which could 
be due to the presence of the second IFN molecule in the IFN-PEG10-IFN homodimer.  
Two different Fabs were used to prepare the IFN-PEG-Fab heterodimers. Conjugation 
was conducted at one disulfide of IFN and the accessible interchain disulfide of the Fab. One 
Fab was derived from a polyclonal antibody to albumin (Fabalb) and the rationale for this 
heterodimer was that a longer lasting form of IFN could be made (IFN-PEG20-Fabalb). The 
other Fab was derived from bevacizumab (Fabbeva) to give an IFN-PEG20-Fabbeva heterodimer 
that could, in principle, display antiangiogenic properties. Both heterodimers were evaluated 
using antiviral and antiproliferative assays to determine the activity of IFN in the conjugate. 
The IFN-PEG20-Fabalb conjugate displayed a 10-fold reduction in activity compared to IFN-
PEG20-Fabbeva. It was thought that Fabalb underwent competitive binding with components of 
the media. Interestingly, the IFN-PEG20-Fabbeva heterodimer displayed greater activity than 
PEG20-IFN and IFN-PEG20-IFN in both the antiviral and antiproliferative assays. The binding 
5 
 
properties of Fabbeva were determined by SPR. It was observed that the dissociation rate of 
IFN-PEG20-Fabbeva was similar to Fabbeva and PEG20-Fabbeva. IFN-PEG20-Fabalb was found to 
have a similar dissociation rate to Fabalb. However, PEG20-Fabalb was found to have a slower 
dissociation to both IFN-PEG20-Fabalb and Fabalb, this result requires further investigation but 
was thought to be due to the sample impurity. The association rates of heterodimers were 
found to similar to the PEG-Fab conjugates but slower than their native Fabs. This data 
suggests that the novel IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb heterodimer conjugates 
have retained their binding affinities to their antigens. 
Overall, it was shown that a homobifunctional bis-alkylating conjugation reagent (e.g. 
PEG di(bis)sulfone 4) could be used successfully to prepare dimeric protein conjugates. This 
work highlighted the importance to ensure the homobifunctional conjugation reagent was 
pure, especially for the preparation of protein heterodimeric conjugates. To develop this work 
further, it would be important to investigate three broad areas: i) improving the purity of the 
starting homobifunctional reagents, ii) evaluate the in vivo efficacy of the resulting protein 
homo-/hetero-dimers and iii) determine the overall potential for efficient scaling of the 
process to make the desired protein homo-/hetero-dimers.  
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1.1  Therapeutic Proteins 
1.1.1 Therapeutic proteins  
Proteins are of critical importance as they play fundamental roles in all biological 
processes and their potential has now been realised as powerful therapeutic agents 
(Kobsa and Saltzman, 2008). Therapeutic proteins are naturally occurring 
macromolecules (>1000 Da), which can be used in the treatment, cure or prevention 
of disease. For example two prophylactic human papillomavirus (HPV) vaccines 
(Cervarix, GSK; Gardasil, Merck) have been recently licenced, aimed at preventing 
cervical cancer (Einstein et al., 2009). Currently therapeutic biologics are being used 
clinically to treat cancer, viral infections, diabetes, hepatitis and multiple sclerosis 
(Sekhon, 2010). The Food and Drugs Agency (FDA) defines biologics as any “virus, 
therapeutic serum, toxin, antitoxin or analogous product applicable to prevent, treat 
or cure of diseases or injuries to man” (Meibohm, 2006). Biologics are 
fundamentally different from conventional chemical drugs or small molecule drugs 
(e.g. aspirin, MW 180 Da), for two reasons. Firstly, therapeutic biologics are proteins 
(including antibodies) or nucleic acids (DNA, RNA or antisense oligonucleotides), 
which are much larger (e.g. interferon ~20,000 Da) than small molecules (Sekhon, 
2010). Secondly, biologics are derived from living material such as human, plant, 
animal or microorganisms (Meibohm, 2006). Under the umbrella heading of 
biologics, therapeutic proteins were once a subset of medical treatments. Now they 
play a significant role in almost all fields of medicine (Leader et al., 2008). As of 
2012, there are over 200-marketed therapeutic proteins such as recombinant blood 
factors, vaccines, hormones, growth factors, interferons, interleukins and antibody 
based products to name just a few (Mullard, 2012; Rader, 2012; Walsh, 2010).  
1.1.2 Factors affecting therapeutic efficacy of proteins 
From a biological and therapeutic perspective, proteins offer two unique advantages; 
i) having specific mechanisms of action and ii) being highly potent (Pisal et al., 
2010). Crucially for therapeutic proteins to be effective, they must reach their 
biological target. However many biological processes hamper the ability of the 
therapeutic protein to meet its biological target (Kobsa and Saltzman, 2008). The 
reasons for this could be poor solubility of the protein or the protein being denatured 
by pH or enzyme degradation (Kobsa and Saltzman, 2008; Pasut and Veronese, 
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2012). Further, the protein could be immunogenic or cause local toxicity, such as 
IFN β, where neutralising antibodies against IFN β have been shown to reduce the 
clinical efficacy during treatment of multiple sclerosis in 20% of patients (Malucchi 
et al. 2004). However a more common cause for poor efficacy is that many protein 
therapeutics have a poor PK-PD profile. With the exception of antibodies or 
Fc/albumin fused proteins, the majority of protein-based medicines are below 50 kDa 
and tend to have a short circulating half-life. Therefore, to maintain the 
therapeutically effective concentration over a prolonged period of time, frequent 
dosing is required. This reduces patient compliance (Kontermann, 2011). Further 
frequent dosing can pose an increased safety risk due to potential immunogenicity 
and an increased incidence of side effects from non-therapeutic concentration levels 
between doses.  
1.1.3 1st generation therapeutic proteins 
The development of genetic engineering and hybridoma technology in the 1970s 
revolutionised the production of biopharmaceuticals. First generation therapeutic 
proteins were un-engineered murine monoclonal antibodies or simple replacement 
proteins i.e. proteins displaying an identical amino acid sequence to that of a native 
human protein (Sekhon, 2010; Walsh, 2004). These replacement proteins were given 
in order to replace or enhance the levels of that protein e.g. human insulin (Walsh, 
2004). The first biologic to gain FDA approval was Humulin
®
 (recombinant human 
insulin) in 1982 (Johnson, 1983). 
  However to improve upon these first generation biopharmaceuticals, clinical 
performance (dosing regimen and routes of administration), product life-cycle 
management, immunogenicity, toxicity and side effects needed to be improved and 
reduced (Martin, 2006).  
 Even though recombinant forms of simple replacement proteins continue to 
come to the market, now modern biopharmaceuticals have been engineered in some 
way to tailor the therapeutic proteins properties. These ‘second generation’ 
biopharmaceuticals aimed to improve upon the progress made with first generation 
biopharmaceuticals. The biopharmaceutical strategies used to modify therapeutic 
proteins include polymer conjugation, encapsulation, hydrogels, fusion protein, 
hyper-glycosylation and acylation (Table 1–1) (Veronese and Pasut, 2005). These 
biopharmaceutical strategies were aimed at improving the efficacy, stability, 
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specificity, toxicity, immunogenicity and the pharmacokinetics (PK) of therapeutic 
proteins, in addition to improving properties such as solubility and maintaining the 
desired biological activity of the therapeutic protein (Marshall et al., 2003). However 
it must be considered that therapeutic proteins have evolved to play fundamental 
roles. By modifying therapeutic proteins, for example to improve stability, the 
activity of the protein may be affected, thus a balanced approach should be 
considered when developing ‘next generation biopharmaceuticals’ (Figure 1-1).  
 
Figure 1-1. Biopharmaceutical strategies used to modify therapeutic proteins (Marshall et 
al., 2003). Many strategies to modify therapeutic proteins target specific areas or residues, 
however these changes to the protein may affect other protein properties e.g. the conjugation 
of PEG to the therapeutic protein may reduce the protein activity.  
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Table 1–1. Comparisons of biopharmaceutical strategies used to modify therapeutic 
proteins, adapted from (Veronese and Pasut, 2005).  
Strategy Brief 
Description 
Advantages Disadvantages Marketed 
examples & 
references 
Hyper-
glycosylation 
New glycosylation 
sites are engineered 
into the protein 
sequence  
Glycosylation can 
occur away from 
active site, 
retaining protein 
activity 
Isomers prepared 
with varying 
activity and half-
lives  
Aranesp
®
 
(hyperglycosylated 
Erythropoietin), 
Sigma-Tau 
(Elliott et al., 2003) 
Protein-fusion Protein, albumin or 
Fc antibody 
fragments fused to 
N or C terminus of 
protein 
Protein obtained 
straight from 
expression system 
without the need 
for further 
modification 
Conjugation 
reduces protein 
activity, may form 
new antigenic 
epitopes and 
prevent the protein 
from folding 
correctly 
Etanercept®  
(TNF alpha 
receptor bound to 
the Fc portion of 
human IgG1), 
Amgen 
(Spencer-Green, 
2000) 
Polymer 
conjugation 
Conjugation of 
polymers (PEG, 
PSA, PGA) to 
therapeutic proteins 
Suitable for very 
immunogenic 
proteins, 
established 
approach with 
several products on 
the market 
Reduced activity 
due to steric 
hinderance 
PEGASYS
®
  
(PEG-IFN α-2a), 
Hoffman La Roche 
(Foser et al., 2003) 
 
Hydrogels Proteins are 
incorporated into a 
biodegrable gel, 
which are injected 
into the body 
Native protein 
released from gel 
Gel must be 
biodegradable 
which may 
denature the 
protein. Only non-
immunogenic 
proteins can be 
used. Gel can form 
fibrotic capsules, 
which slows 
protein release. 
Still in 
development 
(Tessmar and 
Göpferich, 2007) 
Acylation Protein or peptides 
modified with fatty 
acid to change pI 
and increase their 
affinity for albumin 
Prolonged half-life 
by albumin binding  
Mostly applicable 
for peptides and 
small proteins, may 
lead to large 
aggregates that 
may be 
immunogenic 
Levemir
®  
(Fatty acid bound 
to lysine residue of 
insulin) 
Novo Nordisk 
(Jones and Patel, 
2006) 
Encapsulation Proteins are 
encapsulated in 
micro/ 
nanoparticles or 
liposomes 
Protein released in 
native form 
Not suitable for 
proteins, protein 
may be denatured 
in preparation 
Doxil
®
 (a 
Doxorubicin 
encapsulated in a 
PEGylated 
liposome 
Johnson & Johnson 
1.2 Strategies to modify therapeutic proteins 
Outlined are some of the most common strategies used to modify therapeutic 
proteins, which can be categorised into two strategies: i) increasing the MW of the 
therapeutic protein or ii) utilising the FcRn recycling mechanism.  
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1.2.1 Strategies to increase size 
1.2.1.1 PEGylation 
PEGylation involves the covalent chemical conjugation of poly(ethylene glycol) 
(PEG) to a protein, and is the most established post-translational modification (PTM) 
technique in the clinic for delivering and modifying the PK properties of therapeutic 
proteins (Jevsevar et al., 2010; Marshall et al., 2003).  
 
Properties of PEG 
PEG is made up of repeating units of ethylene glycol, which are both inert and 
ampiphilic in nature. Methoxy PEG (mPEG) can be made in various molecular 
weights (MW), structures (linear and branched, Figure 1-2) and conjugating moieties 
(linkers). Many PEGylation reagents have been prepared. PEG has been shown to be 
non-toxic, non-immunogenic, non-antigenic and is FDA approved for administration 
to man (Fruijtier-Pölloth, 2005; Ryan et al., 2008). Currently, there are 12 PEGylated 
medicines on the market (Table 1–2).  
 
Figure 1-2. Structural formulae for linear Methoxy-PEG (mPEG), mPEG and branched 
mPEG (Pisal et al., 2010). mPEG can be made in various MW, structures (linear or 
branched) and can be conjugated to proteins with different linkers, showing the versatility of 
mPEG. 
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Table 1–2: Summary of current marketed PEGylated biologics, adapted from (Kontermann, 
2011; Marshall et al., 2003).  
Name Active agent Company Indication 
FDA approval 
date 
Adagen
®
 
(pegademase) 
Adenosine 
deaminase 
Sigma-Tau SCID 1990 
Oncaspar
®
 
(pegaspargase) 
Asparaginase 
Enzon/ Schering-
Plough 
Cancer 1994 
PEG-INTRON
®
 
(peginterferon α-2b) 
IFN
1
 α-2b Schering-Plough Hepatitis 2000 
Doxil
™
 
(Doxorubicin 
PEGylated 
liposome) 
Doxorubicin 
Ortho Biotech/ 
Schering-Plough 
Cancer 2001 
PEGASYS
®
 
(peginterferon α-2a) 
IFN α-2a Hoffman-La Roche Hepatitis 2001 
Somavert
®
 
(pegvisomant) 
Growth 
hormone 
Pfizer Acromegaly 2002 
Neulasta® 
(pegfilgrastim) 
G-CSF
2
 Amgen Leukopenia 2002 
Macugen
®
 
(pegaptanib) 
Anti-VEGF
3
 
aptamer 
Eyetech 
pharmaceuticals/Pfizer 
Age-related 
macular 
degeneration 
2004 
Micera
®
 
(mPEG-EPO β) 
EPO
4
 β Hoffman-La Roche Anaemia 2007 
Cimzia
® 
(Certolizumab 
pegol) 
Anti-TNF
5
 α 
Fab
6
 
UCB Inc/Nektar 
Crohn disease, 
Rheumatoid 
Arthritis 
2008 
Krystexxa
®
 
(pegloticase) 
Uricase Savient Chronic Gout 2010 
Omontys
® 
(Peginesatide) 
EPO 
Affymax/ Takeda 
Pharmaceuticals 
Chronic kidney 
disease 
2012 
Plegridy 
(Peginterferon β-1a) 
IFN β-1a Biogen-Idec 
Relapsing 
multiple 
sclerosis 
2014 
 
Methods of Protein PEGylation 
A variety of non-specific and specific conjugation strategies have evolved for protein 
PEGylation. Outlined are the most common approaches. 
                                                 
1
 Interferon 
2
 Granulocyte-colony stimulating factor 
3
 Vascular endothelial growth factor 
4
 Erythropoietin 
5
 Tumour necrosis factor 
6
 Fragment antigen binding 
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 Non-specific strategies of PEGylation 
Early research in PEGylation was directed at protein nucleophilic groups, typically 
the ε-amino group of lysine or the α-amino group of the N-terminal residue by using 
amine-reactive PEG reagents (Pasut and Veronese, 2012; Pisal et al., 2010). Amine-
reactive PEG reagents have been developed to undergo conjugation by acylation and 
alkylation. PEG reagents that are functionalised as N-hydroxysuccinimide (NHS) 
active esters have been widely used to undergo conjugation by acylation. An amide 
is prepared when an amine moiety on the protein undergoes acylation. The protein 
amine thus loses its ability to be protonated at physiological pH, often resulting in 
loss of positive charge on the protein. Whereas widely used aldehyde functionalised 
PEG reagents undergo conjugation by alkylation. A secondary amine is prepared 
when the PEG-aldehyde undergoes reductive amination with the multiple amino 
groups within the protein. The protein amino groups therefore maintain their positive 
charge (Roberts et al., 2002; Veronese and Pasut, 2005). 
 These methods allowed non-selective conjugation of PEG to protein and 
resulted in heterogenous mixtures of PEG isomers. This heterogeneity is problematic 
for the following reasons; i) there is no control over the site(s) of conjugation, ii) 
there is no control over the amount of PEG conjugation and iii) this results in batch-
to-batch variability, complicating purification and characterisation steps (Pasut and 
Veronese, 2012; Pisal et al., 2010). Further, for regulatory approval, full disclosure 
of the composition and evidence of process reproducibility are required, which is 
difficult for random conjugation strategies. Nevertheless, there are many examples of 
PEG-protein conjugates prepared by these non-specific acylation and alkylation 
routes that have achieved clinical approval, such as Adagen
®
 and Oncaspar
®
 (Table 
1–2).  
 Site-specific PEGylation  
To prepare more homogenous products, site-specific techniques were developed 
where theoretically the final product should be easier to characterise and purify. 
Furthermore the activity should be more uniform with a homogenous product. 
Kinstler and colleagues developed one such approach using PEG aldehyde 
conjugation, which takes advantage of different pKa values at the N-terminal α-
amino acid residues (7.6-8) or ε-amino group of lysine’s (9.3-9.5) (Kinstler et al., 
2002). This approach has been successful in producing monoPEGylated G-CSF 
conjugates in high yields (92%) (Kinstler et al., 2002). There are several challenges 
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with this approach, i) to find the optimum pH for conjugation and maintaining the pH 
throughout the process, ii) this approach may not be suitable for conjugation to all 
proteins due to the limited pH range required for conjugation. Nevertheless this 
approach has successfully prepared the FDA approved Neulasta
® 
(Table 1–2) 
(Piedmonte and Treuheit, 2008). 
 Another well-known alternative site-specific approach is the PEGylation of 
thiol groups. In native proteins, ‘free’ cysteine’s (i.e. cystine residues not involved in 
disulfide bonds) are rare (Doherty et al., 2005); therefore free cysteine’s often have 
to be genetically introduced for thiol-reactive maleimide or vinyl sulfone activated 
PEGylation. However, engineering in an uncoupled cysteine into a protein sequence 
is time consuming and technically challenging as disulfide coupling or scrambling 
during the refolding or purification process. Further the yield of the recombinant 
protein could be reduced due to protein dimerisation occurring from the introduction 
of unpaired cysteine residues. Advantageously, the site of the genetically introduced 
cysteine can be selected away from the receptor-binding site in order to retain high 
bioactivity (Doherty et al., 2005).  
 This approach has demonstrated with Fab fragments as cysteine residues 
within the hinge region are far away from the receptor-binding region (Figure 1-3). 
This cysteine conjugation approach has prepared FDA approved Cimzia
®
 (Table 1–
2). A chemical-recombinant approach was taken whereby an anti-TNF Fab' was 
engineered to lack its interchain disulfide bond. The interchain disulfide was reduced 
prior to PEGylation using mild reducing agents. The final 40 kDa branched PEG-
anti-TNF Fab' was devoid of a disulfide bond as the cysteine residues where 
conjugated to by PEG-maleimide. Humphreys and colleagues have shown Fab' 
devoid of a disulfide bond retained thermal stability and retained a normal PK profile 
(Humphreys et al., 2007). However, the main limitation with PEG-maleimide is 
instability whereby the reagents are labile to hydrolysis in vivo (Alley et al., 2008) 
and can undergo exchange reactions with thiol-reactive constituents in plasma (Shen 
et al., 2012). 
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Figure 1-3. PEG maleimide conjugation to the cysteine residues of Fab'. Anti-TNF Fab' was 
engineered to lack the interchain disulfide and was conjugated to by a 40 kDa branched 
PEG-maleimide away from the receptor binding region.  
How PEG modulates PK-PD 
 PEG is highly hydrophilic and is thought to bind to 2-3 water molecules per 
ethylene oxide unit. PEG is also a flexible random coiled molecule, so in water it is 
5-10 times larger in solution than would be expected for a protein of the same MW. 
This has been confirmed by size exclusion chromatography and gel electrophoresis 
(Roberts et al., 2002). Therefore, when PEG is conjugated to a protein, the MW and 
apparent Stokes radius are increased compared to the unconjugated protein, thus 
extending the half-life of the protein by reducing glomerular filtration. Jorgensen and 
Moller have shown a direct correlation between the MW of the conjugated PEG and 
the half-life of the PEG-protein conjugate (Jorgensen and Moller, 1979). This has 
also been observed with different PEG MWs and conformations (branched vs. linear 
structures) with Fab fragments (Chapman et al., 1999). Interestingly, Fee found no 
difference in the hydrodynamic volume or viscosity radii of linear or branched 
PEGylated-proteins (Fee, 2007). Suggesting the longer in vivo half-life achieved for 
branched PEGylated proteins is most likely due to the PEG masking the protein 
surface with greater effect when compared to linear PEGs (Fee, 2007).  
 By increasing the overall hydrodynamic volume, protein PEGylation can 
reduce side effects by sustaining serum concentrations. This is well documented in 
the example of Hepatitis C virus (HCV) treatment where 12 kDa linear PEG-IFN α-
2b (PEG-INTRON
®
) and 40 kDa (2× 20 kDa) branched PEG IFN α-2a 
(PEGASYS
®
) (Table 1–2) are now first line treatments when used in conjunction 
with ribavirin (Luxon et al., 2002a). IFN α-2b has a half-life of 7-9 h and is 
undetectable in the blood after 24 h (Figure 1-4) this fluctuation in effective IFN 
concentration may cause failure of viral suppression since HCV has a short plasma 
half-life and has a high turnover (Thomas et al., 1999). By conjugation to PEG, 
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thereby increasing the MW, PEG-INTRON
®
 showed sustained efficacious 
concentration for 48-72 h, whilst PEGASYS
®
 showed sustained concentration for up 
to 96 h (Table 1–3) (Glue et al., 2000; Luxon et al., 2002a). Both PEGylated IFNs 
were shown to be safe and well tolerated in patients, supporting once-weekly 
administration (Foster, 2010; Glue et al., 2000). Constant serum concentrations of the 
PEGylated IFNs reduced the side-effects caused by the peak and troughs caused by 
multiple dosing (Figure 1-4), furthermore, sustained PEG-IFN concentrations will 
prevent viral rebound and continued viral replication (Harris et al., 2001).  
 
Figure 1-4. IFN α-2b (1.5 μg/ kg, SC) and PEG12-IFN α-2b (3 mIU (1 IU=3.864 pg), SC) 
concentration-time profiles after 4 weeks of treatment. The second and third curves of IFN 
α-2b were superimposed on the first curve to represent sampling over 36 hours (Glue et al., 
2000; Luxon et al., 2002a). 
 As stated previously, PEG-positional isomers arise with random PEGylation 
strategies such as PEGylation directed at nucleophilic groups, typically the ε-amino 
group of lysine or the α-amino group of the N-terminal residue. This PEGylation 
strategy was used by PEG-INTRON
®
 and PEGASYS
®
. Both PEG-INTRON
®
 and 
PEGASYS
®
 are a mixture of PEG-positional isomers where the average antiviral 
activity is 28% and 7% respectively (Figure 1-4). Approximately 50% of the PEG 
molecules in PEG-INTRON
®
 are attached to histidine-34, with the remaining PEG 
molecules attached to other amino acids, namely lysine residues (Lys
121
, Lys
31
, 
Lys
83
, Lys
134
, Lys
131
) and the N-terminal cysteine residue (Cys
1
) (Foser et al., 2003) 
(Table 1–3). However, even though predominant activity of PEG-INTRON is due to 
the PEG-H
34
 bond, the PEG-H
34
 bond is unstable in solution. The PEG-H
34
 bond 
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undergoes hydrolysis in aqueous solution resulting in the de-conjugation of the PEG 
from the protein (Pedder, 2003; Wang et al., 2000). This inherent instability of PEG-
H
34
 bond contributes to the relatively short-half-life of PEG-INTRON
®
 (Pedder, 
2003). 
 Interestingly, the specific activity of PEGylated proteins is primarily affected 
by two factors; namely i) the MW of PEG and ii) the site of PEGylation. This is well 
demonstrated with PEG-INTRON
®
 and PEGASYS
®
, where PEG-INTRON
®
 is 
conjugated to a 12 kDa PEG and retains more activity than its counterpart, 
PEGASYS
®
 which has an average MW of 40 kDa and only retains 7% activity 
(Figure 1-4). However, PEGASYS
®
 has a longer systemic half-life, than PEG-
INTRON
®
 due to the larger PEG size. The site of PEGylation is important as 
conjugation near or at the binding site can drastically reduce activity, this is 
demonstrated with H
34
 which retained 34% activity compared to Lys
121
 which 
retained 9% activity of IFN (Table 1–3) (Foser et al., 2003; Grace et al., 2001). 
Whilst site-specific attachment of PEG to Fab fragments at the hinge region 
increased the in vivo half-life of the Fab fragments without loss of antigen binding 
affinity (Chapman et al., 1999). Suggesting site-specific PEGylation does not affect 
the activity of Fabs and is independent of PEG size, yet it can be observed with the 
PEG-Fab conjugates in vivo half-life is directly proportional to PEG size (Chapman 
et al., 1999). However it can be observed that the PEG sizes utilised in the study 
were of equivalent MWs or smaller than the Fab. It would be interesting to 
understand the effect of PEG on the protein activity with larger PEG MWs. For 
example, with PEGASYS
®
 a 40 kDa PEG has been conjugated to a 20 kDa protein, 
and the resulting activity was 7%, would this be the same with site-specific 
conjugation.  
Table 1–3. Biochemical and biological characterisation of PEG-INTRON® and PEGASYS®, 
adapted from (Bailon et al., 2001; Foser et al., 2003; Luxon et al., 2002a; Wang et al., 2002).  
Characteristic PEG-INTRON
® 
PEGASYS
® 
IFN isotype IFN α-2b IFN α-2a 
PEG molecule 12 kDa linear PEG 40 kDa (2× 20 kDa) 
branched PEG 
Positional isomers His
34
 (> 50%); Cys
1
 (~13%); 
Lys
121
 (~7%), Lys
31
 (~5%); 
Lys
49
 (~5%); remaining 20% 
consists of Lys
83
, Lys
112
, 
Lys
164
, Lys
131
, Lys
134
, His
7
, 
Tyr
129
, Ser
163
 
Lys
31
, Lys121, Lys131, 
Lys134, reaming 6%: Lys
164
, 
Lys
70
, Lys
83
, Lys
49
, Lys
112
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Antiviral activity 28% for mixture; 34% for 
His
34
 isomer 
7% for mixture;  
 PEG is a common method for reducing the renal clearance of proteins but 
PEG can also reduce the enzymatic degradation of proteins by increased steric bulk 
(Veronese and Pasut, 2005). The toxicology of PEG has also been extensively 
reviewed (Fruijtier-Pölloth, 2005), and PEG is generally regarded as having a little 
toxicity (Webster et al., 2007). PEG has been shown to be eliminated from the body 
by either the kidneys (PEG MW < 30 kDa) or more slowly in faeces (PEG MW > 20 
kDa) (Yamaoka et al., 1994). Some accumulation of PEG has been reported in the 
kidneys of animal models, this led to renal tubular vacuolation when PEG was given 
in high concentrations (Bendele et al., 1998). However the doses used in this study 
where far beyond that of typical therapeutic concentrations and the effects resolved 
after treatment finished. PEG is generally considered as weakly immunogenic. Since 
the 1990s, many patients have been administered with PEGylated proteins and little 
has been reported in literature regarding the clinical consequences of renal 
vacuolation. Further, the clinical doses administered to patients are much lower than 
those administered animal studies.  
 A new generation of degradable polymers are now being investigated as a 
possible alternatives to non-degradable polymers, such as PEG, to address possible 
toxicity, renal tubular vacuolation and anti-PEG antibodies (Bendele et al., 1998; 
Richter and Åkerblom, 1983, 1984). These new degradable biopolymers have been 
extensively reviewed and include HEPylation (heparosan polymer), HAPylation 
(homoaminoacid), PASylation (proline-alanine-serine repeats), polysialylation 
(polysialic acid) and HESylation (hydroxyethyl starch) (Chen et al., 2011). 
Alternative common polymeric delivery approaches include Polyglutamic acid 
(PGA), N-(2-hydroxypropyl)methacrylamide copolymer (HPMA), protein grafted 
copolymers PGC™ (Pasut and Veronese, 2007; Pisal et al., 2010). The majority of 
these new biodegradable biopolymers are within the preclinical phase. Degradable 
polymers are designed to be are stable when travelling to the site of action, but are 
degraded by intracellular degradation, by lysosomal thiol-dependent proteases or by 
pH dependent hydrolysis, for example PGA-paclitaxel (XYOTAX
™
) (Vicent and 
Duncan, 2006).  
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1.2.1.2 Glycosylation 
Introduction to Glycosylation 
Glycosylation represents the most widespread post-translational modification of 
proteins. The other main examples being; acetylation, amidation, γ-carboxylation and 
β-hydroxylation, disulfide bond formation, phosphorylation, proteolytic processing 
and sulfation (Walsh and Jefferis, 2006). Glycosylation is the addition of sugars, 
which can be attached by in situ chemical reactions or by site-directed mutagenesis. 
Protein glycosylation by site-directed mutagenesis is generally by N-linked or O-
linked oligosaccharides. O-linked glycosylation occurs at the later stage of protein 
processing, where N-acetylgalactosamine (GalNAc) is linked to a hydroxyl group, 
notably serine or threonine residues of a polypeptide (Figure 1-5) (Bause and Lehle, 
1979; Kontermann, 2011). Whereas N-linked glycosylation typically occurs in the 
lumen of endoplasmic reticulum and is the addition of N-acetylglucosamine 
(GlcNAc) to the reducing terminal of a polypeptide at the asparagine (Asn) residue 
(Figure 1-5) (Kontermann, 2011; Pless and Lennarz, 1977).  
 
Figure 1-5. The addition of sugars to glycoproteins occurs at N-glycosidic linkages 
specifically N-acetylglucosamine (GlcNAc) linked to asparagine with N-linked 
glycosylation and N-acetylgalactosamine (GalNAc) linked to serine or threonine for O-
linked glycosylation. This cellular process is dynamic and is directed by a set of 
glycosyltransferases, where their expression; topology and combined specificities control the 
glycan structures prepared. The examples outlined are usually prepared in mammalian cells.  
How does glycosylation improve therapeutic proteins? 
Approximately one third of biopharmaceuticals are glycosylated proteins and 
includes the following therapeutic protein classes; blood factors, anticoagulants, 
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thrombolytics, antibodies, hormones, EPO, GCSFs and IFN to name just a few 
(Walsh and Jefferis, 2006). These approved glycoproteins are a heterogenous 
mixture of glycoforms, which arise from several oligosaccharides at different N- or 
O-glycosylation sites. To prepare a consistent glycoform profile for therapeutic 
proteins still remains a challenge for the biopharmaceutical industry (Walsh and 
Jefferis, 2006). Additionally, producing glycoproteins within host-expression 
systems (e.g. CHO, NS0 or BHK) is technically challenging not only due to the 
intrinsically complex nature of glycan structures but also because of low 
glycoprotein expression yields (Solá and Griebenow, 2010). 
 As previously discussed with PEGylation, the attachment site of the 
carbohydrate is of the upmost importance. For example, if the glycosylation site is 
near or within the receptor binding site this could drastically reduce the activity or 
binding affinity of the therapeutic protein, however if the glycosylation is within an 
immunodominant epitope, this is advantageous as this could reduce the 
immunogenicity of the protein (Pisal et al., 2010). Similarly to PEGylation, 
glycosylation appears to modulate the in vivo efficacy of therapeutic proteins by 
altering their potency (PD) and exposure time (PK) (Solá and Griebenow, 2010). It 
has been reported that increased sialic acid and glycan contents within glycoproteins 
correlates within increased resistance times and that the naturally glycosylated 
proteins with sialic acid terminals have longer half-lives than partially or non-
glycosylated proteins (Byrne et al., 2007) . 
 The first marketed glycosylated product was Aranesp
®
 (darbepoetin α), a 
hyperglycosylated human erythropoietin (EPO) for the treatment of anaemia 
associated with chronic renal failure. Development studies of Aranesp
®
 showed a 
direct relationship between carbohydrate content of the molecule, its serum half-life 
and in vivo biological activity. However there was an inverse relationship with its 
receptor binding (Egrie and Browne, 2002). Aranesp
®
 was developed to have five 
hyperglycosylated sites, two more than human recombinant EPO (rHuEPO). 
Aranesp
®
 was found to have a three-fold longer half-life than rHuEPO. In spite of 
Aranesp
®
 having a four-fold lower binding affinity than rHuEPO it was found to be 
13-fold more potent than rHuEPO in vivo when injected once weekly compared to 
rHuEPO which was injected thrice-weekly (Egrie et al., 2003). The greater potency 
of Aranesp
®
 was found to be due to additional carbohydrate content increasing the 
MW of EPO, thus giving Aranesp
®
 a longer serum half-life (Egrie and Browne, 
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2002). Hyperglycosylation can also improve the stability of therapeutic proteins and 
has been found to be essential for IgG-Fc effector functions (Walsh and Jefferis, 
2006). Thus, glycosylation offers both challenges and opportunities in producing 
consistent reproducible glycosylated products with the optimum sites of 
glycosylation (Pisal et al., 2010; Walsh and Jefferis, 2006). Regardless, a 
glycoengineered mAb named obinutuzumab (Gazyva, Genentech) gained FDA 
approval in November 2013 for the treatment of chronic lymphocytic leukaemia. It 
selectively targets CD20 (Evans and Syed, 2014). Gazyva has an enhanced ADCC 
function whereby it can engage the CDC and induce caspase-independent 
programmed cell death. The combination of defucosylation (absence of fucosylated 
sugars) of this anti-CD20 mAb and the novel target has made Gazyva a successor to 
Rituximab (Ratner, 2014). 
1.2.2 FcRn recycling  
Conversely to increasing MW, there are two types of endogenous proteins that 
exhibit extended half-lives of weeks in humans. These are immunoglobulins (IgGs) 
and human serum albumin (HSA). HSA has a serum half-life of 19 days, whilst IgGs 
have a serum half-life of 3 to 4 weeks (Chen et al., 2011; Kontermann, 2011). The 
long serum half-lives of HSA and IgG are a consequence of a recycling process 
mediated by binding to the neonatal Fc receptor (Chaudhury et al., 2003; Rodewald, 
1976). The expression, mechanism and the interaction between FcRn, the Fc portion 
of IgG and albumin has been extensively reviewed (Roopenian and Akilesh, 2007).  
 Approaches have been developed to take advantage of these long serum half-
lives, these include fusion to Fc regions or albumin directly and fusion to albumin 
binding domains. Fusion proteins are designed to combine the properties of their 
component parts and are created by genetically fusing the genes encoding two or 
more different proteins or peptides (Carter, 2011). Often with fusion proteins, one 
protein overbears the function of the fusion protein partner.  
1.2.2.1 Albumin fusion 
HSA has been identified as an ideal ‘carrier’ protein for therapeutic proteins, not 
only because of its long serum half-life of 19 days but because HSA lacks both 
immunological and enzymatic functions (Chang et al., 2009a). Albumin is the most 
prevalent protein in the blood. Thus to exploit the albumin recycling mechanism, 
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high doses of the drug must be administered to compete for receptor sites. Albumin 
has been fused to peptides including, anti-HIV peptide (FB006M) (Xie et al., 2010), 
and proteins such as, antibody fragments (Smith et al., 2001), Factor IX (FIX), 
activated Factor VII, Factor VIII (Schulte, 2009, 2013). Albumin was fused to an 
anti-HIV peptide through Cys
34
; the resulting FB006M conjugate is being 
investigated as a long-lasting, safe and effective HIV-1 fusion inhibitor. 
Interestingly, the FB006 was modified by 3-maleimidopropionic acid, which allows 
an irreversible reaction between maleimide (Figure 1-3) and the free thiol (Cys
34
) to 
form a specific 1:1 peptide:albumin conjugate. Early pre-clinical studies have shown 
that the FB006M conjugate exhibited longer half-life and similar anti-HIV activity 
compared to the native anti-HIV peptide (Xie et al., 2010). However it is unclear 
how the anti-HIV peptide-albumin conjugate would be removed from circulation, as 
the peptide is irreversibly conjugated to albumin. Further, a therapeutic protein with 
such a long circulation half-life may cause an immune response.  
 Conversely, for the conjugation of albumin to Factor IX, Schulte describes 
the use of a cleavable peptide linker (Figure 1-6). The linker is cleaved at the same 
time as FIX being activated, thus the albumin-FIX fusion has a prolonged half-life. 
The albumin-FIX fusion was found to have ~50% potency compared to native FIX. 
The fusion was being developed and investigated as a possible treatment for 
haemophilia B (Schulte, 2009). However, it is unclear if the linker is stable for long-
term storage, which may be required if the fusion protein is to be given as a 
treatment. Further, the cleaved albumin with the linker would be a cause of 
immunogenicity due to the presence of the linker.  
 Phase I clinical trials demonstrated the albumin-FIX fusion to have a 5-times 
longer half-life than FIX alone. In patients with haemophilia B, injections of 50 
IU/kg were administered. The mean half-life of FIX-albumin fusion was 96 h. This 
was 5-times longer than the half-life of recombinant FIX. Due to these encouraging 
results a Phase II/III clinical trial is currently underway (Metzner et al., 2013).  
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Figure 1-6. Concept of recombinant factor IX (FIX) albumin fusion protein prepared with a 
cleavable linker (rIX-EP). Albumin is fused to the C-terminus of FIX and the cleavable 
linker is inserted between FIX and albumin, thus when activated the FIX the linker is 
cleaved (Schulte, 2009).  
 The most notable albumin fusion has been Albinterferon (a HSA-Interferon 
α-2b fusion) which was prepared as an improved treatment for Hepatitis C. 
Albinterferon was composed of recombinant human albumin fused at its C-terminus 
to the N-terminus of IFN α (Osborn et al., 2002). Albinterferon was prepared using a 
genetically modified yeast strain and purified using anion, cation and semi affinity 
chromatography (Osborn et al., 2002; Yeh et al., 1992). It was hoped that 
Albinterferon would reduce dosing, thus improve patient compliance, and improve 
patient response to treatment. Additionally, by maintaining a constant drug 
concentration for a sustained period of time it was anticipated that a reduced toxicity 
would be observed in patients treated with Albinterferon, which had been associated 
with peak plasma concentrations of Interferon α and PEGylated-Interferon α (Ahad 
et al., 2009; Osborn et al., 2002).  
 In phase II clinical trials, Albinterferon was given subcutaneously and 
achieved a half-life of 90 h, which was 3× greater than PEG-INTRON
®
 (30-34 h) 
and 18× greater than Interferon α-2b (5 h) (Osborn et al., 2002). In Phase III clinical 
trials, Albinterferon could be detected in blood plasma for >7 days after a single 
dose, supporting the administration of every 2-4 weeks (Chang et al., 2009a; Osborn 
et al., 2002). However, development of Albinterferon was stopped in October 2010, 
due to concern over dosing at 900 μg every 2 weeks. The reason for the high dose 
compared to PEGASYS
®
 180 μg per week, is that Albinterferon only possessed ~1% 
activity compared to native Interferon α-2b (Ahad et al., 2009; Bell et al., 2008; 
Osborn et al., 2002). The reduced activity of Interferon α-2b within Albinterferon 
could be due to either; i) the close proximity of the two proteins, as HSA (~65 kDa) 
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could be shielding the active site of Interferon α-2b (~20 kDa) (Figure 1-7), ii) the 
large size of Albinterferon (85.7 kDa) impedes the binding of Interferon α-2b to the 
IFNAR1/AR2 receptor (Osborn et al., 2002). Therefore, the main challenge of 
protein fusion is the maintenance of functional activity of the therapeutic proteins 
within the fusion. While linkers can be used and the orientation of the fused genes 
optimised to retain the biological activity, the presence of albumin can interfere with 
the interaction between the protein and its target(s) (Metzner et al., 2012). Secondly, 
minimising the risk of toxicity and immunogenicity could be an issue for new fusion 
partners (Subramanian et al., 2007). Thirdly, it has also been shown that predicting 
the in vivo half-lives of albumin fusion proteins may be difficult. As Andersen and 
colleagues have shown that there is cross-species differences in the binding of 
albumin fusions to the FcRn (Andersen et al., 2013). However, the application of 
albumin is limited to increasing the half-life and stability of proteins and does not 
have any secondary function, unlike Fc fusion, which does not only increase half-life 
but also has a cytotoxicity function (Metzner et al., 2012).  
 
Figure 1-7. Albumin fusion to (left) cytokines and (right) to peptides by fusion of the 
proteins cDNA at either the N- or C-terminal of human albumin (arrows indicating 
transcription initiation) (Subramanian et al., 2007). (left) Human albumin is fused with IFN 
α-2b, 19.2 kDa and (right) human albumin is fused to glucagon-like peptide 1 (GLP-1, 3.8 
kDa), demonstrating the varying sizes of biological molecules which haven been fused to 
albumin.  
1.2.2.2 Fusion to Albumin binding domains 
An alternative to albumin fusion is the preparation of therapeutic proteins or peptides 
that have albumin-binding domains (ABD). These ABDs bind to circulating serum 
albumin upon administration, thus extending the half-life of the therapeutic protein. 
Three high affinity ABDs are found naturally in certain streptococcus strains of 
protein G, of which albumin-binding domain 3 (ABD3) has been extensively studied 
(Akerström et al., 1987; Kraulis et al., 1996). Stork and colleagues genetically fused 
  
41 
ABD3 to bispecific single chain diabodies (scDb). Recombinant scDb’s are 
composed of the variable heavy and light chain domains of two antibodies joined by 
three linkers as VHA-VLB-VHB-VLA (Kontermann, 2005). The scDb was developed 
to re-target cytotoxic T cells to CEA-expressing tumour cells (Stork et al., 2007). 
This scDb-ABD3 fusion protein showed a 5 to 6 fold improvement in circulation 
half-life, however a 3-fold reduction in activity compared to scDb. The activity was 
further reduced (4-fold) when ABD-scDb was bound to albumin (Stork et al., 2007).  
 Interestingly, it has been reported that increased ABD affinity to albumin or 
increasing the number of ABDs attached to scDb does not influence half-life (Hopp 
et al., 2010). The affinity for FcRn has been found to dictate the recycling and thus 
the half-life of both IgG and albumin (Hopp et al., 2010). Streptococcal ABD 
domains have been reported to cause immunogenicity in mice, so would be expected 
to pose a risk of being immunogenic in humans (Libon et al., 1999). Furthermore, 
increased antibody responses have been reported in ABD-fusions (Sjölander et al., 
1997). Thus for ABD fusions to make successful therapeutics, the risk of 
immunogenicity would have to be greatly reduced. To determine accurate in vitro 
activity of ABD-fusions, accurate activity should be determined once the ABD is 
bound to albumin, as this will be the final product once administered. Reduced 
activity of the peptide or protein could be due to, i) site of ABD attachment being 
near or on the receptor binding site; ii) the large size of albumin and the ABD, 
impeding the ability of the peptide or protein to bind to its receptor.  
1.2.2.3 Protein fusion to IgG or the Fc domain 
The most clinically successful fusion protein therapeutics are Fc fusions with 
currently 10 Fc-fusions FDA approved (Table 1–4). The top selling Fc fusion is 
Enbrel
® 
(50 mg/week dose) (Table 1–4), a TNF-Fc fusion for the treatment of 
rheumatoid arthritis (Carter, 2011; Spencer-Green, 2000). Global sales of Enbrel
®
 in 
2012 were USD $7.3 billion, exceeding the most successful therapeutic, 
bevacizumab (USD $6.9 billion) (Beck and Reichert, 2011). With this success, Fc-
fusions represent 20% of all antibody-based medicines with FDA approval 
(Czajkowsky et al., 2012). Other Fc fusions include; Alprolix
®
 (50 IU/kg/week) 
(coagulation factor IX-Fc fusion) which was approved in March 2014 for treatment 
of Haemophilia B (Shapiro et al., 2012) and Nplate
®
 (thrombopoietin receptor 
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agonist-Fc fusion) (1 μg/kg/week), the first peptide-Fc fusion for the treatment of 
thrombocytopenia (Cines et al., 2008).  
 As previously discussed, the presence of the Fc-domain can increase the half-
life of fused therapeutic proteins by binding to the salvage FcRn receptor (Carter, 
2011; Roopenian and Akilesh, 2007) and reduces renal clearance for larger sized 
therapeutic proteins (Kontermann, 2011). Alprolix
®
 (Table 1–4) for example has a 
half-life of 56 h, this is ~3-fold longer than the reported half-life (~18 h) of 
recombinant factor IX and due to this reduces the number of injections required for 
effective hemeostasis and controls breakthrough bleeds in patients (Shapiro et al., 
2012).  
 An additional benefit is that the Fc domain folds independently, thus can 
improve the stability and solubility of a fusion protein both in vivo and in vitro 
(Czajkowsky et al., 2012). Whilst from a manufacturing perspective, the addition of 
an Fc domain allows for cost-effective purification by either protein A or G 
chromatography, thus leading to an easy scale-up process (Carter, 2011). Effector 
functions can be modified by engineering the Fc region, either to improve or reduce 
binding to Fc γ receptors (FcγRs) for antibody-dependent cellular cytotoxicity 
(ADCC) or complement receptors for cell mediated cytotoxicity (CDC) or FcRn for 
prolonged half-life (Kubota et al., 2009; Vincent and Zurini, 2012). Xencor uses the 
Fc region to improve the ADCC and CDC effector functions. The companies most 
advanced product is XmAb
®
5574 (MOR208), which targets CD19 for the treatment 
of B-cell lymphoblastic leukaemia and NHL (Evans and Syed, 2014). However, Fc-
fusions still face the issues of insufficient efficacy and high cost of the therapeutic 
agent (Kubota et al., 2009).  
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Table 1–4: Marketed Fc-fusion protein therapeutics, adapted from (Czajkowsky et al., 2012) 
Trade name 
(generic name) 
Active fused to FC 
of IgG1 
Indication Company 
Date of FDA 
approval 
Alprolix
™
 
(eftrenonacog 
alfa) 
Factor IX Haemophilia B Biogen Idec 2014 
Eloctate
™
 Factor VIII Hemophilia A Biogen Idec 2014 
Zaltrap
® 
(ziv-afilbercept) 
VEGFR1/VEGFR2
7
 Colorectal cancer 
Regeneron 
Pharmaceuticals 
2012 
Nulojix
®
 
(belatacept) 
CTLA-4
8
 Organ rejection 
Bristol-Myers 
Squibb 
2011 
Eylea
®
 
(aflibercept) 
VEGFR1/ 
VEGFR2 
Age related 
macular 
degeneration 
Regeneron 
Pharmaceuticals 
2011 
Arcalyst
®
 
(rilonacept) 
IL-1R
9
 
Cryopin-
associated 
periodic 
syndromes 
Regeneron 
Pharmaceuticals 
2008 
Nplate
®
 
(romiplostim) 
Thrombopoietin-
binding peptide 
Thrombocytopenia Amgen/ Pfizer 2008 
Orencia
®
 
(abatacept) 
Mutated CTLA-4 
Rheumatoid 
arthritis 
Bristol-Myers 
Squibb 
2005 
Amevive
®
 
(alefacept) 
LFA-3
10
 
Psoriasis and 
transplant 
rejection 
Astellas Pharma 2003 
Enbrel
®
 
(etancept) 
TNFR
11
 
Rheumatoid 
arthritis 
Amgen/ Pfizer 1998 
1.3 Multifunctional proteins as ‘next generation of protein therapeutics’ 
Next generation protein therapeutics aim to improve upon first and second generation 
biopharmaceuticals by having enhanced efficacy, greater safety and improved 
delivery (Carter, 2006; Kobsa and Saltzman, 2008). The majority of these ‘next 
generation protein therapeutics’ are multifunctional in design reflecting the complex 
diseases such as cancer or inflammatory disorders they are aimed at treating. 
Discussed in this section are the different strategies being investigated to develop 
multifunctional protein therapeutics. 
                                                 
7
 Vascular endothelial growth factor receptors-1/-2 
8
 Cytotoxic T-lymphocyte-associated protein 4 
9
 Interleukin-1 receptor 
10
 Lymphocyte function-associated antigen 3 
11
 Tumour necrosis factor receptor 
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1.3.1 Bispecific antibodies 
Monoclonal antibodies (mAbs) have high affinity for one target however, they are 
only able to target a single antigen, this is a limitation when treating complex 
inflammatory diseases they may have several proinflammatory cytokines. Multiple 
targets or sites can be targeted to improve therapeutic efficacy in two ways, i) 
combination therapy of mAbs or other therapeutic agents or ii) creating bispecific 
antibodies or therapeutic agents. Success in combinational therapy has been achieved 
with bevacizumab and interferon α for the treatment of renal cell carcinoma (Rini et 
al., 2008). Where propinquity has been exploited.  
 Thus dual targeting within one therapeutic agent is being investigated with 
numerous strategies which have been extensively reviewed (Kontermann, 2012). The 
most clinically advanced strategy has been bispecific antibodies (bsMAb), where 
Removab
®
 is FDA approved and there are many more in clinical trials (Chames and 
Baty, 2009). Currently there are two approaches in the production of bsMAbs; i) the 
fusion of two hybridoma cell lines creating a single ‘quadroma’ cell lines, this is a 
time consuming and difficult process and ii) the chemical coupling or genetic fusion 
of two Fab fragments. Chemical conjugation strategies are still in development, with 
no clinical examples yet. Bifunctional reagents such as 5,5’-dithiobis(2-nitrobenzoic 
acid) (Paulus, 1985) or o-phenylenedimelimide (Glennie et al., 1987) have been 
described to generate bsMAbs. Further, a PEG di(bis)sulfone 4 reagent has also been 
described in the conjugation of two different antigen binding fragments, to generate 
an anti-VEGF bispecific Fab’2 molecule (Fab-PEG-Fab’) (Khalili et al., 2013). The 
anti-VEGF Fab-PEG-Fab’ were found to display anti-angiogenic properties 
comparable to or better than bevacizumab, suggesting that chemical-linkers can be 
used to conjugate proteins together without impeding the biological activity of the 
protein (Khalili et al., 2013). 
 Along with a long serum half-life, bispecific antibodies can bind to two 
adjacent targets or they can cross-link two different antigens. BsMAbs hold great 
promise as therapeutic agents for cancer either; i) in the recruitment of cytotoxic T 
cells or, ii) to effectively target tumour-associated antigens and deliver a cytotoxic 
payload to tumour cells (Chapman et al., 1999). Removab
®
, a mouse CD3-human 
EpCAM bispecific, was approved in 2009 for the treatment of malignant ascites 
(MA) due to epithelial carcinoma. One side of the antigen binding site binds to T 
  
45 
cells via CD3, the other side binds tumour cells via EpCAM antigen (Figure 1-8). 
While, the Fc region adds a third functional binding site capable of binding and 
activate Fcγ receptor I-, IIa or III-positive accessory cells to enhance tumour killing 
(Figure 1-8) (Linke et al., 2010). Removab
®
 kills EpCAM positive tumour cells in 
the peritoneal cavity, which cause MAs, whilst leaving healthy cells alive, since the 
peritoneum lack EpCAM. Further, Removab
® 
enhances the activation of the patients 
own immune system against the tumour (Linke et al., 2010). Malignant ascites as 
associated with ovarian cancer, gastrointestinal malignancies the prognosis of 
patients with MA is approximately 1-6 months (Seimetz, 2011). In phase III clinical 
trials, Removab
®
 was found to improve the patients puncture free survival to 44 days 
compared to 15 days in the control group. Puncture-free survival was defined as the 
time to the next therapeutic puncture or time to death (Linke et al., 2010). 
 
Figure 1-8. Mechanism of action of Removab
®
, where the intact trifunctional antibody 
Removab
®
 accelerates the recognition and destruction of tumour cells by different immune 
cells. ADCC, antibody-dependent cellular toxicity; DC-CK1, dendritic cell cytokine 1; IL, 
interleukin; IFN γ, interferon gamma; TNF α, tumour necrosis factor alpha; LFA, 
lymphocyte function antigen; NK, natural killer; GM-CSF, granulocyte monocyte colony 
stimulating factor (Linke et al., 2010).  
 However, the major challenge with bsMAbs is to prepare them in sufficient 
quantity and purity to meet clinical needs (Presta, 2003). Bispecific antibodies in 
advanced clinical trials include Merrimack’s MM-111, targeting HER2 and HER3 
receptors on breast cancer cells and Trion’s Lymphomun/fBTA05, which targets 
CD20 on lymphoma cells and CD3 on T cells to treat B cell lymphoma (Chames and 
Baty, 2009; McDonagh et al., 2012). In July 2014, Amgen received FDA 
‘breakthrough Therapy Designation’ for its BiTE antibody blinatumomab which 
binds on T cells and CD19 which target lymphoma cells to treat acute lymphoblastic 
leukaemia (Davis, 2014).  
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1.3.2 Antibody Drug Conjugates (ADCs) 
Monoclonal antibodies (mAbs) are successful therapeutics with over 20 therapeutic 
mAbs on the market (Wang et al., 2008). Monoclonal antibodies are successful due 
to their site-selectivity, where they can bind or inhibit the functions of target antigens 
such as trastuzumab (Herceptin
®
) selectively binding HER2/neu and bevacizumab 
(Avastin
®
) selectively binding VEGF (Panowksi et al., 2014). To increase the 
functionality of mAbs against tumour cells, there is extensive research in ‘arming’ 
mAbs with cytokines (immunocytokines), drugs (ADCs) or radionucleotides (Wu 
and Senter, 2005). Alone cytotoxic drugs often display substantial toxicity, as they 
are not site-selective. Thus ADCs, a concept that dates back to the 1970s, hold great 
promise as ‘the magic bullets’ against cancer (Panowksi et al., 2014). As ADCs 
combine the site-selectivity of mAbs with the cell killing ability of cytotoxic agents 
creating an efficient therapeutic with reduced systemic toxicity (Alley et al., 2010; 
Casi and Neri, 2012; Sievers and Senter, 2013).  
 Even though the concept of ADCs has been around since the 1970s, only now 
are advances being made in producing them successfully. For example, gemtuzumab 
ozogamicin (Mylotarg
®
), an anti-CD33 humanised antibody conjugated to highly 
potent calicheamicin derivative was granted accelerated approved by the FDA in 
2000 for the treatment of acute myeloid leukaemia (Sievers and Linenberger, 2001). 
However, Mylotarg
®
 was later withdrawn from the market after safety concerns and 
clinical benefit. The mAb-drug linker was found to be unstable where 50% of the 
bound drug was released in 48 h (Ravandi, 2011).  
 Over the last decade the understanding of factors to prepare efficacious ADCs 
has improved. For example, site-specific conjugation chemistry has seen recent 
advancements, which have been implemented resulting in homogenous ADC 
production and improved PK properties of ADCs. To reduce immunogenicity, now 
humanised or recombinant human mAbs are used, rather than chimeric or murine 
versions. Further, the understanding of crucial factors such as antigen selection, 
antibody, linker and payload has improved, enabling efficacious ADCs to be 
prepared (Panowksi et al., 2014). There are three key components to an ADC, which 
need substantial optimisation these are the mAb (and related antigen target), linker 
and cytotoxic drug (Figure 1-9) (Alley et al., 2010).  
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Figure 1-9. Critical parameters that influence ADC therapeutics (Panowksi et al., 2014). 
ADCs are made up of a mAb conjugates to a cytotoxic drug by a linker. All the components 
can affect the ADC performance and thus must be optimised to ensure an efficacious ADC is 
prepared.  
Firstly, selection of the appropriate target and complementary mAb should be made. 
The appropriate target is the most important contributor to the antitumour activity 
and tolerability of an ADC (Sievers and Senter, 2013). To improve efficacy, without 
compromising safety, ADCs must deliver the cytotoxic payload to tumour cells 
specifically expressing the antigen receptor of interest without damaging healthy 
cells (Sievers and Senter, 2013).  
 Further, the linker must be considered and with this the conjugation method 
(Figure 1-9). The conjugation method is influenced by the mAb chosen, as 
developments in genetic engineering have influenced conjugation strategies away 
from reduced disulfide or lysine attachment where heterogenous mixtures of ADCs 
are prepared. Whereas, mAbs can now be engineered with cysteine residues or 
unnatural amino acids, resulting in homogenous ADC production and lower drug-
antibody ratios (DAR), which in turn improves ADC PK properties (Panowksi et al., 
2014). As it has been shown that the number of drugs per mAb and the position of 
  
48 
the drugs can influence ADC aggregation, antigen binding, stability, PK, potency and 
tolerability (Alley et al., 2010; Senter, 2009; Sievers and Senter, 2013). 
 Stability of the ADC is of the upmost importance. Bifunctional linkers have 
been designed and used to conjugate the cytotoxic payload to the mAb and allow 
release the cytotoxic payload at the tumour site (Casi and Neri, 2012). Linkers should 
deliver the cytotoxic drug in its active form to efficiently kill the tumour cells, and 
avoid non-specific killing and associated toxicities (Iyer and Kadambi, 2011). ADCs 
are internalised through receptor-mediated endocytosis. Thus most linker 
mechanisms of release take advantage of this where the drug is released in the 
lysosomal compartment, which is rich in proteolytic enzymes and is a high reducing 
environment (Casi and Neri, 2012; Iyer and Kadambi, 2011). The most common 
cytotoxic drugs (Figure 1-9) used within ADCs are maytansinoids and auristatin. 
These both exert their cytotoxic effects through binding to tubulin, causing cell cycle 
arrest at G2/M resulting in cell apoptosis (Alley et al., 2010; Casi and Neri, 2012). 
 Adcetris
®
 was FDA approved in 2011 to treat large cell and Hodgkins 
lymphoma and Kadcyla
®
 was approved in 2013 to treat metastatic HER2 positive 
breast cancer (Table 1–5). There are many more ADCs in late stage clinical trials, 
such as glembatumumab vedotin, which is currently undergoing accelerated clinical 
trials for non-metastatic melanoma (Evans and Syed, 2014). However, ADCs are 
costly to manufacture and often have complex PK profiles, thus ADCs can only be 
justified for severe diseases and must have higher therapeutic indexes than non-
targeted drugs (Casi and Neri, 2012). Nevertheless, ADCs prepared a value of $501 
million (Adcetris
®
 and Kadcyla
®
) in 2013 and are predicted to dominate half the 
market in 2021.  
Table 1–5: Current FDA approved antibody-drug conjugates  
Trade name 
(generic name) 
Active agent Indication Company 
Date of FDA 
approval 
Kadcyla
®
 
(ado-
trastuzumab-
emtansine)
 
Anti-HER2 mAb-
DM1 
Metastatic breast 
cancer (HER2 
positive) 
Genentech/ 
Roche 
2013 
Adcedris
®
 
(brentuximab 
vedotin) 
CD30 mAb-
MMAE 
Non-Hodgkins 
lymphoma 
Seattle Genetics 2011 
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1.3.3 Protein scaffolds 
Even though monoclonal antibodies are very successful with >20 mAbs having 
gained FDA approval, they have some limitations, which reduce their clinical 
effectiveness. In mouse xenograph models, mAbs directed at tumour-specific 
antigens were found to remain in the blood and only ~20% of the dose was found to 
interact with the tumour (Beckman et al., 2007). 
125
I-labelled-IgG, F(ab’)2, Fab’ and 
scFv tumour penetration and PKs have been compared in human colon carcinoma 
xenograph models (Yokota et al., 1992). Grain density was quantified as a function 
of tumour penetration. The study observed scFv demonstrated maximum tumour 
penetration after 6 h (1953 grains), whilst the IgG did not reach the same degree of 
penetration until 48-96 h (~900 grains) after injection (Yokota et al., 1992). It was 
also observed that the IgG (2705 grains), F(ab’)2 (1756 grains), Fab’ (3077 grains) 
and scFv (5921 grains) penetration correlated in a size-related manner (Yokota et al., 
1992). This highlights the main limitation with mAbs, which is there large size (~150 
kDa), limiting their ability to penetrate, accumulate and distribute evenly in tissues 
(Wurch et al., 2012). Further, Fc portion of the IgG molecule may not be required 
e.g. increasing the retention of the mAb in circulation or effector functions. For 
example, for cancer imaging and radiotherapy applications, the ideal targeting agent 
would have rapid tumour penetration and rapid blood clearance.  
 To overcome some of these shortcomings, about 50 different protein 
scaffolds have been documented over the past two decades (Carter, 2011; Wurch et 
al., 2012). ‘Protein scaffold’ is the term used to describe small protein domain-based 
frame works which can be used a therapeutic precursors. Protein scaffolds are 
generally understood to have distinguishing features which may include, high protein 
solubility and stability, single polypeptide chain format, high bacterial expression for 
cheap production, lack of disulfide bonds, small MW and possibly glycosylation sites 
(Carter, 2011; Nuttall and Walsh, 2008). Protein scaffolds can be categorised into 
two groups, IgG-based scaffolds and non-IgG based scaffolds (Mintz and Crea, 
2013). Further, protein scaffolds represent a novel way to overcome intellectual 
properties rights (Gill and Damle, 2006). 
 The most clinically advanced non-IgG derived protein scaffolds include 
Kunitz domains (Dennis and Lazarus, 1994), DARPins (Tamaskovic et al., 2012), 
Avimers (Silverman et al., 2005), Knottins (Moore and Cochran, 2012), Affibodies 
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(Feldwisch et al., 2010), Adnectins (Lipovsek, 2011), Pronectins (Mintz and Crea, 
2013), Fynomers (Schlatter et al., 2012), Nanofitins (Mouratou et al., 2007) and 
Affilins (Table 1–6) (Ebersbach et al., 2007; Mintz and Crea, 2013). These non-IgG 
derived protein scaffolds have naturally rigid structures, thus their existing binding 
sites can be genetically modified to recognise new or different target antigens 
(Gebauer and Skerra, 2009). Protein scaffolds are readily expressed in microbial 
hosts, reflecting their high stability, solubility, simple structure and small size. Plus 
their small size may allow for better tissue penetration vs. larger molecules such as 
IgG. Additionally, multivalent and/or multispecific protein biopharmaceuticals can 
be prepared out of the simple protein scaffold structures (Carter, 2011). Currently the 
only non-IgG protein scaffold to receive FDA approval is Kalbitor
®
 (Escallantide), a 
Kunitz domain that inhibits kallikrein (Farkas & Varga 2011). Kalbitor
®
 was 
approved in 2009 for the treatment of hereditary angioedema (Farkas and Varga, 
2011; Mintz and Crea, 2013).  
 
Table 1–6: Summary table of the most advanced types of IgG and non-IgG derived protein 
scaffolds (Mintz and Crea, 2013).  
Name of scaffold Characteristics 
Non IgG derived protein scaffolds 
Kunitz Domains Engineered Kunitz domains are human serine protease inhibitors can be 
genetically engineered for different target protease specificities 
DARPins
®
 Engineered single domain proteins are small and can be selected to bind to any 
protein target 
Avimers
®
 Prepared from multimerised low-density lipoprotein receptor class A 
Knottins Created from cysteine-rich knottin peptides 
Affibodies
®
 Based on Z-domain of staphylococcal protein A 
Adnectins
®
 
(monobodies) 
Based on 10
th
 domain of human extracellular matrix protein fibronectin type 3 
Pronectins Based on the 14
th
 domain of human fibronectin III 
Fynomers Derived from src-homology domain 3 of tyrosine kinase fyn 
Nanofitins 
(formerly Affitins) 
Derived from Sac7d, a dsDBA-binding protein from Sulfolobus acidocaldarius 
Affilins Derived from human γ-B crystalin or human ubiquitin 
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Name of scaffold Characteristics 
IgG derived protein scaffolds 
Single domains 
(dAbs
®
) 
Variable domain of heavy chain (VH) or light chain (VL) containing 3 CDRs
12
 
Nanobody
®
 Derived from camels and Illamas heavy chain only antibodies 
Single-chain 
variable fragment 
(scFv) 
Variable chain regions (VH and VL) fused together with a flexible peptide linker  
Antibody-binding 
fragment (Fab) 
Composed of variable regions (one heavy, one light) with a single antigen CDR 
Avibody
™
 VH and VL domains linked in a head-to-tail arrangement together to form 
multimeric antibody like proteins 
Minibody Comprised of linked VL-VH-CH3 domains  
Abdurins
™
 Variants of CH2 domains (CH2D) 
Fcab Derived from the Fc binding domain of an antibody 
Bispecific T-cell 
engager (BiTE) 
Bispecific scFv antibody fragments composed of α-CD3/mAb variable domains  
Diabody Two scFv (VH and VL) linked covalently or by a small peptide linker 
 
Small antibody derived protein scaffolds include single domain (dAbs
®
) (Holt et al., 
2003), nanobodies
®
, diabody, avibodies™, scFvs, Fabs, minibodies (Hu et al., 1996), 
Abdurins™ (Gehlsen et al., 2012), Fcabs and BiTEs (Baeuerle and Reinhardt, 2009). 
These IgG-based protein scaffolds are thermally stable, have retained binding and 
antigenic specificity (Carter, 2011; Mintz and Crea, 2013). IgG-derived protein 
scaffolds can be prepared either chemically or by non-mammalian expression 
systems, thus incurring lower manufacturing costs compared to mAbs (Mintz and 
Crea, 2013). Currently, the most clinically advanced product is blinatumomab, a 
BiTE scaffold that is in Phase III clinical trials. Blinatumomab is for the treatment of 
either non-Hodgkins lymphoma and/ or acute lymphoblastic leukaemia. 
 Protein scaffolds may potentially elicit an anti-drug response and may be 
potentially immunogenic in patients, however more clinical data is required to 
understand the factors that contribute to immunogenicity (Carter, 2011; Gebauer and 
Skerra, 2009). The main limiting factor of protein scaffolds is their short serum half-
life due to their small size. Further, if protein scaffolds were larger they could not 
compete with mAbs unless they were able to recycle via the FcRn. Current options 
                                                 
12
 Complementary determining regions 
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for extending the half-lives of protein scaffolds include PEGylation, adding a second 
scaffold that binds to albumin, Fc fusion or attaching half-life extending peptides 
(Carter, 2011; Mintz and Crea, 2013).  
 Single domain antibodies that recognise and bind to albumin, termed 
‘AlbudAbs’ have been developed as genetic fusions to prolong the half-life of 
therapeutic proteins (Holt et al., 2008). AlbudAbs have been shown in preclinical 
research to extend the half-life of interleukin-1 receptor antagonist and interferon α-
2b (Holt et al., 2008; Walker et al., 2010). The in vitro potency of AlbudAb-IFN α-
2b and HSA-IFN α-2b (Albuferon®) was tested using an antiviral assay (A549-
EMCV, §3.3.6.1). AlbudAb-IFN α-2b and HSA-IFN α-2b achieved activities of 
3.8×10
6
 IU/mg and 2.4×10
6
 IU/mg respectively. Compared to the IFN standard 
(6.6×10
7
 IU/mg), AlbudAb-IFN α-2b and HSA-IFN α-2b were calculated to have 
fold reduction in activity of 17.4 and 265 respectively. Specifically, AlbudAb-IFN α-
2b showed an 15.8-fold higher in vitro potency compared to the HSA-IFN α-2b 
(Albuferon
®
) and showed a half-life of 22.6 h, which was ~1.5 times longer than that 
observed for HSA-IFN α-2b (Walker et al., 2010). AlbudAb-IFN α-2b and HSA-IFN 
α-2b were also tested in vivo in a melanoma xenograph model, where human tumour 
(518A2) cells were transplanted into SCID mice. Subcutaneous injections of PBS, 
AlbudAb-IFN α-2b (8.75 mg/kg) and HSA-IFN α-2b (24 mg/kg) were administered 
1 and 8 days post-tumour implants (Walker et al., 2010). Even when, AlbudAb-IFN 
α-2b was administered at a 10-fold lower dose (on a mg/kg basis) than HSA-IFN α-
2b, the level of tumour growth was comparable. This is most likely due to the greater 
efficacy and in vivo half-life of the AlbudAb fused IFN α-2b compared to HSA 
(Walker et al., 2010). As discussed previously (§1.2.2.1), the reduced activity of 
Albuferon
®
 was most likely due to HSA shielding the active site of IFN or impeding 
the binding of IFN to the IFNAR1/AR2 receptor. Whereas, the use of AlbudAbs are 
much smaller at 11-13 kDa (Walker et al., 2010), thus do not impede the activity of 
IFN as drastically as HSA. However, the ‘AlbudAb’ must be genetically fused to the 
protein of interest, in this case at the N-terminus of the AlbudAb, which may be 
complex and time consuming to do (Walker et al., 2010).  
1.3.4 Protein fusion 
Protein fusions can be grouped into three categories: half-life extension, targeting (or 
binding) and toxicity (cell killing). Half-life extension can be achieved by albumin 
  
53 
binding domains or AlbudAbs, fusion to HSA or Fc-fusion (§ 1.2.2). Further 
transferrin fusion has also been proven to extend the half-life of therapeutic agents 
such as in the case with transferrin-insulin fusion for diabetes treatment (Xia et al., 
2000). 
 The cytokine family consist of interleukins, interferons, growth factors, 
colony stimulating factors, chemokine’s and due to their > ~20 kDa MW have short 
serum half-lives. Many cytokines are pleiotropic, redundant (i.e. IL-4 and IL-13) and 
are often secreted as a result of cell signalling. Currently, >10 engineered cytokines 
forms are FDA approved such as PEGASYS
®
 (PEG-IFN α) (Chang et al., 2009a; 
Vazquez-Lombardi et al., 2013). There has been significant clinical interest in the 
antitumour effects of IFNs, IL-2, IL-4, IL-12, IL-15, IL-24, GM-CSF and TNF α, 
where as therapeutics these cytokines can modulate tumour cells or the immune 
system or both (Chang et al., 2009a; Pasche and Neri, 2012). However, severe 
toxicities are associated with systemic infusions of cytokines (e.g. IL-12), thus dose 
related toxicities limit the administered dose of cytokines (Leonard et al., 1997). To 
utilise cytokines effectively for cancer treatment, reduced side effects would need to 
be achieved in conjunction with enhancing the local concentration of cytokines at the 
tumour site(s) (Pasche and Neri, 2012). To achieve this, different approaches have 
been investigated, such as fusing cytokines to HSA (Subramanian et al., 2007), Fc to 
improve half-life of cytokines (Bitonti et al., 2004; Jazayeri and Carroll, 2008) and 
transferrin fusion for specific tumours (Chang et al., 2009a). These fusions were 
designed to overcome the following, relative paucity of cytokine receptors on 
tumour, the lack of specificity of cytokines for the tumour site and their reduced half-
life. Alternatively, cytokines can be injected directly into the tumour site, this 
requires tumours to be accessible and visualised, yet this is not always possible with 
micrometastatic lesions (Forni et al., 1985).  
 Immunocytokines provide a novel bifunctional, tumour-targeting approach, 
similar to ADCs, combining the anti-tumour activity of cytokines with the binding 
specificity of antibodies. These fused molecules are designed to enhance the 
concentration of cytokines at the tumour site (List and Neri, 2013; Pasche and Neri, 
2012). Antibody formats being investigated to develop immunocytokines include, 
Fab, F(ab’)2, scFv, IgG, scFv-Fc and diabodies (Chang et al., 2009a; Pasche and 
Neri, 2012). Diabodies are well suited for immunocytokine development because 
they are bivalent. The combined diabody-cytokine MW is greater than renal filtration 
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cut-off, therefore a longer systemic half-life can be achieved (Pasche and Neri, 
2012). There are currently 7 immunocytokines in clinical development (List and 
Neri, 2013).  
 The most advanced immunocytokine in clinical development is Darleukin 
(L19-IL-2 fusion) in Phase IIb, for the treatment of metastatic melanoma in 
combination with dacarbazine (Eigentler et al., 2011). Darleukin is a diabody fusion 
consisting of human interleukin-1 (IL-2) fused to a scFv specific to the antigenic 
target site EDB fibronectin (Carnemolla, 2002). To test for targeted delivery of IL-2 
to the tumour site, syngeneic mice were grafted with F9 murine teratocarcinoma. 
Injections (12 μg in mouse of 20 g) with the fusion proteins, L19-IL-2, an irrelevant 
antibody (D1.3)-IL2 and saline alone occurred on days 3, 4, 5, 6, 7, 8 (Carnemolla, 
2002). Histologic analysis of the F9 tumours growth found mice treated with L19-
IL2 weighed 0.05 g ± 0.01. Mice treated with D1.3-IL2 and saline had tumours, 
which weighed 0.597 g ± 0.1 and 0.811 g ± 0.23 (Carnemolla, 2002). 
Immunohistochemistry analysis of the tumours treated with L19-IL-2 had a 70 times 
higher lymphocyte concentration compared to mice treated with D1.3-IL-2, and a 
100 times higher concentration compared to mice treated with saline. These 
concentration in lymphocytes, may help to explain the anticancer activity of L19-IL-
2 (Carnemolla, 2002). Phase I clinical trials, 83% of patients with advanced renal cell 
carcinoma achieved disease stabilisation after the second dose (22.5 Mio 
IU/patient/day three injections/week) (Johannsen et al., 2010). The study also found 
that the toxicities were manageable and reversible (Johannsen et al., 2010), showing 
the fusion of a delivery protein e.g. scFv against EDB to a cytokine e.g. IL-2 can 
reduce toxicity associated with cytokines to prepare a therapeutic effect. Therefore, 
multifunctional proteins can be used in either; i) directing therapeutic molecules to 
the site of need, i.e. tumour sites or ii) where proteins are in close proximity to one-
another, thus they are able to work simultaneously for a therapeutic outcome such as 
in the case of Darleukin.  
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Figure 1-10. A summary of molecular engineering approaches used and their effect to 
improve cytokines as therapeutic agents (Vazquez-Lombardi et al., 2013). A) PEGylation 
(with positional isomers), B) cytokine-toxin fusion, C) cytokine-Fc fusion, D) antibody-
cytokine immune complex, E-G) immunocytokines, E) cytokine-IgG, F) cytokine-scFv, 
cytokine-diabody, H) cytokine mutagenesis, I) cytokine-albumin fusion. 
 Another recombinant approach for producing novel multifunctional fusion 
proteins is the ‘Dock-and-Lock’ method. This method utilises two natural binding 
domains as a pair of linkers resulting in site-specific conjugation in a facile and 
quantitative manner (Chang et al., 2009a). The two binding domains are the 
dimerisation and docking domain (DDD), derived from cAMP-dependent protein 
kinase (PKA) and the anchor domain (AD) derived from A-kinase anchoring proteins 
(AKAP) (Figure 1-11). The AD and DDD peptide sequences can be fused to any 
protein (or other entity), once the DDD and AD are bound, they are covalently 
‘locked’ into place by the cysteine residues which form disulfide bridges (Rossi et 
al., 2012) (Figure 1-11). Any AD domain can be paired with any DDD module. 
Further modules have included PEG, dyes, drugs, and fluorescent molecules.  
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Figure 1-11. DNL method where the DDD molecule mediated protein (A) dimer e.g. 
Interferon, is tethered with the AD-molecule precursor (B), to prepare a DNL conjugate 
comprising of two copies of A and one copy of precursor B. Precursor B represents PEG, 
toxin or radiolabel which could be tethered to the protein dimer. Green rings indicate SH 
groups of the engineered cysteine residues of DDD (blue helix) and AD (yellow helix). The 
‘locking’ disulfide bonds are depicted as interlocking green rings. Adapted from (Rossi et 
al., 2012).  
 The most reported cytokine in the DNL literature is IFN α-2b, where IFN α-
2b has been included into monoPEGylated cytokine dimers (Figure 1-11) (Chang et 
al., 2009b), tetrameric immunocytokines (Rossi et al., 2009) and bispecific 
immunocytokines (Rossi et al., 2010). Chang and colleagues have prepared 
monoPEGylated IFN α-2b dimers with the following PEG structures and MWs, 
linear 20 kDa PEG, linear 30 kDa PEG and a 40 kDa branched PEG (Chang et al., 
2009b) (Figure 1-11). They found that all monoPEGylated dimers retained antiviral 
and antiproliferative activities higher than PEGASYS
®
 but similar or lower to PEG-
INTRON
®
. Interestingly, the 40 kDa monoPEGylated IFN α-2b dimer is being 
considered for clinical evaluation as it prepared a more favourable PK, but was not as 
effective as PEGASYS
®
 within the in vivo Daudi model, suggesting the 40 kDa 
monoPEGylated IFN dimer could be less toxic in vivo (Chang et al., 2009b).  
 Alternatively, IFN α-2b has been incorporated into immunocytokines using 
DNL, first a tetrameric immunocytokine comprised of an anti-CD20 mAb fused to 
four IFN α-2b as a possible B-cell lymphoma treatment (Rossi et al., 2009) and 
secondly, a bispecific immunocyotkine compromising of two IFN α-2b molecules, 
fused to anti-HLA-DR F(ab’)2 which is linked to veltuzumab mAb as a possible 
treatment for non-Hodgkin lymphoma (Rossi et al., 2010). The tetrameric IFN α-2b 
immunocytokine is reported to be 100 times more potent than veltuzumab or a non-
targeting mAb-IFN α-2b in an IFN sensitive Daudi model. Whilst in vitro, the 
tetramer inhibited lymphoma growth at a 25-fold lower concentration of veltuzumab 
plus IFN α-2b. These results could be due to either the increased local tumour 
concentrations of IFN α-2b or that CD20 binding may inhibit the 
internalisation/down-regulation of IFNAR1/IFNAR2 receptors, causing prolonged 
and more effective IFN α-induced signalling (Rossi et al., 2009). Consequently, the 
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tetrameric IFN α-2b immunocytokine is now under development for CD20 targeted 
immunotherapy of non-Hodgkins lymphoma (Rossi et al., 2010).  
 However, there are two reported disadvantages with the DNL method; i) the 
AD and DDD peptides must be fused to the proteins of interest, this requires the 
establishment of two host cell lines, therefore increased production costs may be 
incurred; ii) the AD and DDD peptides are ‘locked’ together by the cysteine residues 
forming a disulfide bridge, however during mild redox conditions during DNL 
conjugation some disulfides may reduce causing some proteins to aggregate or 
denature along with the AD and DDD peptides (Rossi et al., 2012). However, general 
disadvantages encountered with producing multifunctional fusion proteins, such as 
with DNL include; i) in some cases fusion partners may have incompatible 
manufacturing properties, resulting in protein aggregation or misfolding of one of the 
fusion proteins, whilst the other partner may be unharmed; ii) the functionality such 
as activity, affinity may be severely inhibited by fusion to another protein, such as in 
the case of Albinterferon where IFN only retained 1% activity (Subramanian et al., 
2007); iii) the dosing of each component may be complex as it difficult to control 
and tune the optimal amounts for efficacy and safety and iv) the high potential for 
immunogenicity, as novel epitopes may be prepared against the junction between 
fusion partners (Stefan R. Schmidt, 2013).  
1.3.5 Homodimers  
Within biological systems, proteins rarely act alone to prepare a biological response, 
rather proteins bind to other biomolecules, often self-associating to form dimers 
within a cascade or network to prepare a biological response (Marianayagam et al., 
2004). Homodimers are two of the same protein interacting or bound to one another. 
It is reported in literature that eukaryotic organisms contain significantly more self-
interacting proteins (homodimers) than expected which are a result of evolution 
(Ispolatov et al., 2005). The propensity of proteins to self-interact was found to be 
proportional to that of the total number of binding partners, where homodimers have 
twice as many binding partners than non-interacting proteins (Ispolatov et al., 2005). 
The ability of proteins to self-interact has several structural and functional 
advantages, including improved stability, specificity of active sites and greater 
structural complexity (Marianayagam et al., 2004). Additionally, by proteins self-
associating to create homodimers or heterodimers, the genome size remains small 
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whilst the advantages associated with protein complex formation are maintained 
(Ispolatov et al., 2005; Marianayagam et al., 2004). Many functionally important 
proteins including receptors (G-protein-coupled receptors, tyrosine kinase receptors), 
enzymes, chemokine’s and cytokines are homo- or heterodimers. The BRENDA 
enzyme database lists 452 human enzymes, of these only a third function as 
monomers, whilst ~70% (311) function as homo -dimeric/-multimers molecules. 
Important immunostimulatory and immunomodulatory cytokines such as human 
Interferon γ function as a dimer, formed in a head to tail conformation (Lunn et al., 
1992). Interleukin-10 (IL-10), an anti-inflammatory cytokine, also activates its 
receptor as a dimer (Nagabhushan, TL, Reichert P, 2002).  
 To improve biological molecules to prepare therapeutic agents to treat 
disease, homo- and hetero-dimeric molecules prepared by protein fusion or 
biological (DNL) conjugation are under investigation. For example, 
immunocytokines against the HER2/neu antigen made up of GM-CSF in 
combination with Interleukin-12 (IL-12) or IL-12 in combination with interleukin-2, 
fused to trastuzumab are being investigated for a treatment for breast cancer 
(Helguera et al., 2006). Whilst the DNL method was used to prepared homodimeric 
PEGylated Interferon α molecules (Figure 1-12), which showed enhanced and 
prolonged efficacy in vivo (Chang, 2010; Chang et al., 2009b). The preparation of 
Interferon α-2b dimers is well documented in literature, where under the influence of 
zinc, IFN α-2b forms dimers in crystal (Nagabhushan, TL, Reichert P, 2002; 
Radhakrishnan et al., 1996). The IFN α-2b dimers have been found to have similar 
crystal structures to IL-10 and IFN γ, which interact with their receptors in the dimer 
form (Nagabhushan, TL, Reichert P, 2002). Nagabhushan and colleagues, modelled 
the structure of the IFN α-2b dimer binding its IFNAR1/IFNAR2 receptor, their 
findings showed that the dimer could bind to two copies of IFNAR1/IFNAR2 
(Nagabhushan, TL, Reichert P, 2002). Although it is understood that IFN α-2b is 
active in the monomeric form, the IFN α-2b dimer has an unknown biological role. It 
has been suggested that the IFN α-2b dimer could serve to recruit various IFN α 
receptors to the signalling complex (Radhakrishnan et al., 1996).  
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Figure 1-12. Schematic of the monoPEGylated 'dock-and-lock' Interferon α-2b dimer 
(Chang et al., 2009b). Green and grey ribbons indicate the 40 kDa branched PEG, red helix 
represents the AD2 domain whilst the blue helix indicates the DDD2 domains and the ‘SH’ 
shows the free sulfhydryl groups of engineered cysteine residues.  
1.4 Recombinant-chemical approach 
Bioconjugation can be defined simply as the covalent linking of a polymer molecule 
to a macromolecular complex (Veronese and Morpurgo, 1999). Conjugation has 
been around since the 1920s, however it was the pioneering work of Ringsdorf, 
where bioconjugation became a central role in the pharmaceutical industry. 
Following this, the first bioconjugated drug to be successfully marketed was 
SMANCs in the early 1990s (Duncan, 2003). It is thought that bioconjugation can be 
utilised in an attempt to address the main fusion protein shortcomings of reduced 
activity due to fusion site, high immunogenicity, and antibody recognition. The 
advantages of bioconjugation include, stabilisation of labile drugs from chemical 
degradation, protection from proteolytic degradation, reduction of immunogenicity, 
decreased antibody recognition, increased body resistance time, modification of 
organ disposition, drug penetration by endocytosis and new opportunities for drug 
targeting (Veronese and Morpurgo, 1999). Further, there is greater flexibility as to 
the site of conjugation and length of the linker used. 
1.4.1 Site-specific conjugation 
Conjugation approaches have evolved since its conceptualism, from random to site-
specific conjugation approaches. For example, in the 1970s, PEGylation chemistry 
was limited to a single linking chemistry, succinimidyl succinate. In the 1980s 
succinimidyl carbonate, N-hydroxy succinimides linkages were developed (Bailon 
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and Won, 2009). However these linkages prepared heterogenous mixtures of 
conjugated product, which was problematic, resulting in batch-to-batch variability, as 
discussed previously (§1.2.1.1). Further linkages such as aldehyde and maleimide 
were then developed. However, as discussed previously (§1.2.1.1), PEG-maleimide 
is unstable in solution (Alley et al., 2008; Shen et al., 2012). Disulfide-bridging and 
histidine tag conjugation are discussed as alternative site-specific approaches for 
protein conjugation. 
1.4.1.1 Disulfide-bridging PEGylation 
As previously mentioned (§1.2.1.1), few proteins naturally contain free unpaired 
cysteine’s that can be utilised for site-specific conjugation (Doherty et al., 2005). 
However many therapeutic proteins have accessible disulfides. Our first conjugation 
approach utilises the selective chemistry of free thiols derived from disulfide bonds. 
It is reported that solvent accessible disulfide bonds are thought to contribute to 
protein stability whilst the biological activity of a protein is dependent on their buried 
disulfide bonds (Thornton, 1981). Therefore, by using mild reduction conditions, 
solvent accessible disulfide bonds can be reduced to allow for our disulfide-bridging 
PEGylation, whilst having little effect on the proteins structure or biological activity.  
 
Figure 1-13. Site-specific, disulfide bridging conjugation of an accessible protein disulfide 
achieved by mild-disulfide reduction followed by reaction with functionalised PEG 1 
(Brocchini et al., 2008). Disulfide-conjugation involves, i) first thiol addition to the PEG 
mono-sulfone 2, ii) sulfinic acid elimination to generate a second double bond and iii) a 
second thiol addition.  
 The first step of disulfide-bridging PEGylation is to liberate the two free 
thiols for conjugation using mild reductants such as dithiothreitol (DTT) or tris (2-
carboxyethyl) phosphine (TCEP-HCl). The first thiol addition to the PEG mono-
sulfone 2 (l, Figure 1-13) initiates the sequential addition-elimination reactions 
(Figure 1-13). The addition of the first thiolate allows the elimination of a sulfinic 
acid derivative and allows for the addition of a second thiolate resulting in the 
generation of a second double bond at the α, β’-position (Brocchini et al., 2008). The 
addition of the second thiolate forms the three-carbon bridge (bridged-disulfide, 
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Figure 1-13) situated between the two-cysteine molecules, which formed the original 
disulfide bond. Steric hindrance from the PEG inhibits the addition of a second 
protein with reduced thiols and similarly prevents the attachment of a second PEG 
molecule conjugating.  
 Advantages of this approach include; a) there is no need to recombinantly 
engineer the therapeutically relevant protein with free cysteine’s for conjugation, b) 
it is possible to chemically reduce the proteins to access the disulfide to its two free 
cysteine sulphur atoms and still maintain its tertiary structure and c) the high 
chemical reactivity of both sulphur atoms, which naturally occur in the disulfide and 
d) often disulfide bonds are in small numbers within proteins, leading to homogenous 
products. Conjugation is highly specific to thiols, as at neutral pH amines are 
protonated and thus far less reactive. Further disulfide-bridging conjugation is highly 
efficient as only a small stiochiometric excess of the PEG reagent is required for 
conjugation (typically 1 equivalent of PEG per disulfide). Further any unconjugated 
material can be recycled and reused. However, for proteins with more than one 
disulfide, the protein required careful re-folding to avoid disulfide scrambling or 
aggregation. The possible disadvantage with disulfide conjugation is that disulfide 
bonds are important for protein conformation, therefore any modification at this level 
could be harmful therefore the distance between the sulphur atoms must be 
preserved.  
1.4.1.2 Polyhistidine conjugation  
The second site-specific conjugation approach to be utilised is histidine conjugation. 
Histidine conjugation takes advantage of the histidine affinity tags (his-tags), which 
are used in purification of recombinant proteins during early studies of a protein, as it 
can increase expression yields and aid refolding. The benefits of conjugation on the 
his-tag are; PEGylation near or on the binding sites can be avoided, thus bioactivity 
of the protein is retained. Additionally, purification of the required conjugate is 
simpler as either ion affinity chromatography (IMAC) or ion exchange 
chromatography (CIEC) can be used effectively (Cong et al., 2012). Thirdly, there is 
control over the type of conjugate prepared whereas with random PEGylation 
multiple iterations are required to prepare the desired product. While there are his-
tagged proteins currently being used in the clinic (Endostar) and the use of a his-tag 
appears to be safe, care must be taken as to the location and size of the his-tag 
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inserted to retain protein activity. The use of his-tags for therapeutic use has been 
hindered due to, a) a lack of a definitive function after purification and b) an anxiety 
that there may be immunogenicity against the tag. PEGylation using the his-tag may 
overcome the first concern and may tackle the second (Cong et al., 2012). 
 
Figure 1-14. Proposed mechanism for site-specific polyhistidine conjugation with PEG 
mono-sulfone 2 (Cong et al., 2012). Histidine-conjugation involves, Michael addition-
elimination reaction with two nitrogen’s from two histidine imidazole rings, as previously 
observed for two thiols from a reduced disulfide.  
As previously described (§1.4.1.1), PEG bis-sulfone 1 can be used to undergo bis-
alkylation with two thiols derived from the two sulfurs within a disulfide bond in a 
protein (Brocchini et al., 2006). Similarly PEG bis-sulfone 1 can be used to site-
specifically conjugate a polyhistidine tag on a protein by the elimination of sulfinic 
acid to prepare PEG mono-sulfone 2. As with disulfide-bridging conjugation, a three-
carbon bridge is prepared after the sequential addition-elimination reactions (Figure 
1-14). The advantage of this conjugation approach is that few histidines are present 
in a row within a protein sequence; therefore a homogenous product can be prepared.  
1.4.1.3 Conjugation using bis-alkylating PEG reagents 
For both thiol and histidine specific conjugation, a bis-alkylating PEG reagents were 
used. These reagents consists of an electron-withdrawing carbonyl group, an α, β-
unsaturated double bond and a β’ sulfonyl group (Figure 1-15). The electron-
withdrawing group is required to promote conjugation to free thiols/imidazole and 
lower the pKa of the α-proton so that the elimination of the β’ sulfonyl leaving group 
takes place. This is necessary to generate the reactive mono-sulfone compound that is 
used for conjugation. Creation of the mono-sulfone compound can be conducted 
either in situ if the reaction is conducted in neutral or basic pH (this is dependent on 
protein stability and solubility) or by prior incubation (Brocchini et al., 2006). The 
rate of elimination of the β’ sulfonyl leaving group is dependent on pH, 
concentration and the temperature of the solution. 
Addition  Elimination  Addition  
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Figure 1-15. Sulfinic acid 3 elimination from PEG bis-sulfone 1 generating PEG mono-
sulfone 2 for conjugation (Brocchini et al., 2008). 
 For the conjugation of two proteins, PEG di(bis)sulfone 4 (Figure 1-16) was 
used. As with PEG bis-sulfone 1 reagent elimination of the β’ sulfonyl leaving group 
occurs; however in the case of the PEG di(bis)sulfone 4 this is required at each linker 
terminal.  
 
Figure 1-16. Structure of PEG di(bis)sulfone 4 used for homodimer or heterodimer 
preparation using either histidine or disulfide conjugation.  
1.4.1.4 Existing research on utilising PEG as a linker 
PEG di(bis)sulfone 4 has been used to link two Fabs using site-specific disulfide 
conjugation, to prepare Fab-PEG-Fab molecules. PEG di(bis)sulfone 4 of 6, 10 and 
20 kDa was used to make corresponding Fab-PEG-Fab molecules. Bevacizumab, 
trastuzumab and ranibizumab were enzymatically digested to prepare the Fabs, to 
prepare Fab-PEG-Fab molecules. The Fab-PEG-Fab molecules were shown to 
display similar affinities to parent IgG, but slower dissociation rates were observed 
for Fabbeva-PEG-Fabbeva compared to parent bevacizumab. The apparent KD (Kd/Ka) 
of the Fabbeva-PEG6-Fabbeva (1.54 nM), Fabbeva-PEG10-Fabbeva (1.27 nM), Fabbeva-
PEG20-Fabbeva (1.53 nM) products were found to be similar to that achieved for 
bevacizumab (1.33 nM). This showed that PEG size did not seem to affect the 
affinities of the Fabbeva-PEG-Fabbeva molecules to VEGF. Fabrani-PEG-Fabrani 
displayed in vitro anti-angiogenic properties comparable to or better than 
bevacizumab. Using a HUVEC-fibroblast angiogenesis assay, fewer angiogenesis 
tubules were observed in cells treated with Fabrani-PEG6-Fabrani at 0.08, 0.04 and 
0.013 μg/mL, 665, 294 and 73 tubule junctions were counted, respectively. While for 
bevacizumab at 0.12, 0.06 and 0.02 μg/mL 792, 354 and 179 tubule junctions were 
counted, respectively (Khalili et al., 2013). These studies suggested that the PEG 
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di(bis)sulfone 4 could be used to create Fab-PEG-Fab molecules with retained 
activity. Therefore it was thought that IFN dimers could be prepared using the 
homobifunctional reagent 4 and that these IFN-PEG-IFN dimers would retain 
activity.  
1.4.2 IFN as a therapeutic agent 
The interferons are a family of naturally secreted cytokines, which are released in 
response to stimulants such as viral, bacterial and tumour antigens (Ahad et al., 
2009). IFNs are classified into two distinct types, Type I IFNs (α/β) and Type II IFNs 
(γ) (Goodbourn, 2000). Type I IFNs are either prepared by human leucocytes (IFN α) 
or by fibroblasts (IFN β), whereas Type II IFNs are prepared by natural killer or 
activated T-cells (Borden et al., 2007; Goodbourn, 2000). The biological activities of 
Type I and II IFNs are initiated by there binding to their specific heterodimeric cell 
transmembrane receptors. Type II IFNs bind specifically to IFN γ receptors 1 
(IFNGR1) and 2 (IFNGR2), whilst Type I IFNs (α/β) bind specifically to IFN α 
receptor 1 (IFNAR1) and IFN α receptor 2 (IFNAR2) (Goodbourn, 2000).  
 Type I signalling occurs when IFN α/β binds to IFNAR1 and IFNAR2 
resulting in the cross-phosphorylation of receptors and associated Janus kinases 
(Tyk2 and Jak1). This provides docking sites on the receptor complex for STAT 
proteins. The STAT proteins are in turn phosphorylated and form homo- and 
heterodimeric complexes, which dissociate from the receptor and then translocate to 
the nucleus and bind an ISRE or GAS elements within the promoters of interferon-
regulated genes, leading to their transcription resulting in antiviral or antiproliferative 
activity (Figure 1-17) (Bekisz et al., 2010; de Weerd et al., 2007). IFN binding also 
leads to the induction of other non-canonical signalling pathways, including those 
pathways involving p38, MAPK, Akt and Crk. Upstream signalling from the IFNR 
complex leads to p38 phosphorylation, resulting in the growth inhibition of cells 
(Figure 1-17) (Bekisz et al., 2010). Whilst the downstream signalling of P13K, 
involving Akt and mTOR, or Protein Kinase C-δ confers antiviral activity regulation 
or regulation of apoptosis respectively (Figure 1-17) (Bekisz et al., 2010).  
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Figure 1-17. Signalling pathway for Type I IFNs (Bekisz et al., 2010). Type I IFNs bind to 
the transmembrane heterodimer receptor subunits of IFNAR1 and IFNAR2. This results in 
the activation of receptor kinases, Jak1 and Tyk2. The signal transducers and activator of 
transcription (Stat) proteins are recruited to the receptor docking sites, are phosphorylated 
and dimerise to form the active transcription factors, interferon stimulated gene factor 3 
(ISGF3), IRF9 (p48/ISGF3γ) and alpha activation factor/gamma activation factor 
(AAF/GAF). These transcription factors induce the transcription of hundreds of interferon-
stimulated genes (ISGs). Upstream signaling from IFNR complex leads to p38 
phosphorylation, modulating the activity of IFN leading to growth inhibition of cells. CrkL 
and CrkII are phosphorylated by tyrosine (Tyk2) after IFN treatment, CrkL also can form a 
transcription factor complex with Stat5, leading to antiviral and antiproliferative activity 
downstream. IFN signal pathways downstream of P13K involve Akt and mTOR, or PKCδ 
mediate other biological activities of IFN, such as apoptosis.  
Interferons as therapeutic medicines 
 Therefore, Type I IFNs are a group of heterogenous group of pleiotropic 
cytokines with antiviral, antiproliferative, antitumour and immunodulatory activities 
(Anguille et al., 2011; Goodbourn, 2000; Nanus et al., 1990). These unique 
biological properties have been exploited to treat a variety of clinical conditions 
(Table 1–7).  
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Table 1–7: Genetically engineered forms of IFNs approved by the FDA (Bekisz et al., 2010; 
Chang et al., 2009a).  
Product/ 
Company 
IFN type Indication 
FDA 
approval 
date 
Actimmune
®
 
InterMune 
IFN γ-1b 
Chronic granulomatous disease 
Malignant osteopetrosis 
1990 
2000 
Avonex
®
 
Biogen Idec 
IFN β-1a 
Relapsing-remitting forms of 
multiple sclerosis 
1996 
Betaseron
®
 
Berlex/Chiron 
IFN β-1b 
Relapsing-remitting forms of 
multiple sclerosis 
1993 
Infergen
®
 
InterMune 
IFN αcon-1 Hepatitis C 1997 
Intron A
® 
Schering-Plough
 IFN α-2b 
Hairy cell leukemia 
AIDS-related Kaposi’s sarcoma 
Hepatitis B 
Chronic malignant melanoma 
Chronic viral Hepatitis C 
Follicular lymphoma in 
chemotherapy patients 
Hepatitis B in pediatric patients 
1986 
1988 
1992 
1992 
1997 
1997 
 
1998 
PEG-INTRON
®
 
Enzon/Schering-
Plough 
PEGylated-IFN 
α-2b 
Chronic Hepatitis C 2001 
PEGASYS
®
 
Roche/Nektar 
PEGylated-IFN 
α-2a 
Chronic Hepatitis C 2002 
Plegridy 
Biogen-Idec 
1.4.3 PEGylated 
IFN β-1a 
1.4.4 Relapsing multiple 
sclerosis 
1.4.5 2014 
1.4.5.1 His8IFNα-2a used for conjugation 
His8IFNα-2a has been used previously to prepare both monoPEGylated and di-
PEGylated conjugates to explore histidine PEGylation (Cong et al., 2012). An 8-
polyhistidine tag was prepared recombinantly, which prepared higher yields, 
compared to 4 and 6-polyhistidine tags, which were expressed at lower yields. 
Further an 8-histidine tag was thought to allow the conjugation of two PEG 
molecules of moderate MW, to give a conjugate with good activity and long half-life. 
 To explore a recombinant-chemical approach, IFN α-2a with an 8-
polyhistidine tag was prepared recombinantly to explore the preparation of IFN 
homodimers (IFN-PEG-IFN) and heterodimers (IFN-PEG-Fab) using PEG 
di(bis)sulfone 4. These novel homodimers and heterodimers will be prepared using 
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either histidine conjugation or disulfide conjugation, as His8IFNα-2a has both the 
polyhistidine tag and two disulfides (Figure 1-18), which could be conjugated to. 
Disulfide conjugation on His8IFNα-2a has not been conducted before.  
1.4.6 Multifunctional protein therapeutics using PEG as a linker 
1.4.6.1 Approach 1: IFN-PEG-IFN as a therapeutic antiviral agent 
 Interferons were first described as antiviral agents in 1957 by Isaacs and 
Lindenmann (Isaacs and Lindenmann, 1957). They have been of particular 
therapeutic interest as they act on the target cell (not the virus) to inhibit replication 
and the lifecycle of a wide variety of viruses, thus conferring a state of resistance 
within the cell to viral infection (Brassard et al., 2002). There are a number of 
pharmaceutical forms of Type I IFNs, namely Infergen
®
, Intron A
®
, PEG-INTRON
®
 
and PEGASYS
®
 for the treatment of viral diseases such as Hepatitis B and Hepatitis 
C (Bell et al., 2008).  
 IFN α-2a (Intron A®) is comprised of five helical barrel structures with two 
disulfide bonds between residues Cys1-98 and Cys29- Cys138. The ribbon structure 
of IFN α-2a can be seen in Figure 1-18 (Klaus et al., 1997). IFN is approximately 20 
kDa, thus has a short circulation half-life of about six hours. Resulting in patients 
requiring an injection every other day in an attempt to keep blood concentration of 
IFN at an efficacious level (Glue et al., 2000; Luxon et al., 2002a). However, in 
reality patients are only being exposed to significant drug levels for approximately 
36 hours per week (21%), as drug levels peak and trough (Ahad et al., 2009). Hence, 
more frequent administration of IFN α is required; however this is inconvenient and 
debilitating for patients. In an attempt to improve the therapeutic properties of the 
native protein, whilst trying to retain the biological activity of IFN α, IFN α has been 
conjugated to PEG in order to increase its PK properties. 
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Figure 1-18. Ribbon structure of His8IFNα-2a prepared using Pymol software. The α-helices 
(in green) of His8IFN α-2a, with the two disulfide bridges shown as yellow spheres, with the 
8-polyhistidine tag shown in red. The α-helicies (in green) are marked with labels A to E 
close to their N-terminal end. His8IFN was used to prepare homodimeric and heterodimeric 
molecules using PEG di(bis)sulfone 4 in conjunction with site-specific conjugation 
approaches. The conjugation approaches used to prepare the homo- and hetero-dimeric 
molecules were either histidine or disulfide-bond conjugation; the sites His8IFNα-2a 
conjugation are labelled.  
 The two most commonly used treatments for Hepatitis C are PEGASYS
®
 and 
PEG-INTRON
®
 (Figure 1-17). As discussed in §1.2.1, these current treatments have 
several drawbacks, namely, heterogeneity of the final products from random 
conjugation, reduced IFN activity due to PEG-positional isomers binding near or at 
the binding site and side effects from IFN treatment. Therefore, how to can we 
improve upon these current IFN treatments?  
 Fundamentally, proteins are complex and as discussed in §1.3.5 the majority 
of protein self-interact, very few proteins act alone to prepare a biological response. 
As in the case with Type I IFNs, the signalling cascade for producing an antiviral 
response alone is prepared by a series of at least three separate complexes of two or 
more proteins interacting Figure 1-17. IFN α dimers are well documented within 
literature, where under the influence of zinc IFN α-2b forms dimers, these have been 
found to have similar crystal structures to IL-10 and IFN γ, which interact with their 
receptors in the dimer form (Nagabhushan, TL, Reichert P, 2002; Radhakrishnan et 
al., 1996). The DNL method has been used to create homodimeric PEGylated 
Interferon α molecules, which showed enhanced and prolonged efficacy in vivo 
(Chang, 2010; Chang et al., 2009b). However, protein fusion methods such as DNL 
N 
C 
C A 
B 
D 
E 
B’ 
conjugation of disulfide bond 
conjugation of the poly histidine tag 
conjugation of disulfide bond 
  
69 
may incur difficulties such as incompatible manufacturing properties of fusion 
partners, immunogenicity and reduced functionality as highlighted in §1.3.4.  
 Therefore, a recombinant-chemical approach will be adopted to prepare a 
His8IFN-PEG-His8IFN dimer. This approach combines the advantages of 
conjugation, such as reduced immunogenicity, increased body resistance time and 
protection from proteolytic digestion (Veronese and Morpurgo, 1999) with 
recombinant protein technology. IFN was expressed recombinantly with an 8-
polyhistidine tag (Figure 1-18), the polyhistidine tag and the natural disulfides could 
both be conjugated to with the PEG di(bis)sulfone reagent 4. Thus, site-specific his-
tag and disulfide conjugation was conducted on the His8IFN α-2a to create IFN 
homodimers. It is hypothesised that these His8IFN α2a dimers would have greater 
activity than PEG-IFN conjugates, due to i) the site-specific nature of conjugation, 
reducing conjugation near or at the binding sites and ii) the greater number of IFNs 
present within the molecule which are able to bind to IFNAR complex.  
1.4.6.2 Approach 2: IFN-PEG20-Fabalb heterodimer 
Current treatments based on IFN focused on utilising PEGylated versions of IFN to 
improve the short serum half-life of IFN. This approach has been successful in 
prolonging the circulation half-life of native IFN from 7-9 h to 48-72 h or 96 h for 
PEG-INTRON
®
 and PEGASYS
®
 respectively, thus both treatments can support 
once-weekly administration (Table 1–3) (Glue et al., 2000; Luxon et al., 2002a). 
These constant serum concentrations are able to reduce the side effects caused by 
multiple dosing (Figure 1-4). Furthermore, sustained PEG-IFN concentrations help to 
prevent viral rebound and continued viral replication (Harris et al., 2001). However, 
the current approach is dependent on patient adherence to treatment. Therefore, there 
is a pharmacological rationale to prepare a longer acting IFN treatment, which 
provides sustained viral suppression, thus minimum side-effects, with enhanced 
convenience of an improved dosing regimen and may reduce viral rebounds. This 
was attempted in the creation of Albinterferon (Albumin-IFN α-2b fusion), which 
could be support a 2-4 week dosing regimen. Yet, as discussed in §1.2.2, 
Albinterferon only possessed ~1% activity compared to native Interferon α-2b (Ahad 
et al., 2009; Bell et al., 2008; Osborn et al., 2002). The reduced activity of IFN 
within Albinterferon highlights in crucial balance between PK and PD.  
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 Understanding the important balance between PK and PD, whilst exploring 
approaches to improve the half-life of IFN beyond that of current treatments. It was 
thought that an anti-albumin Fab (Fabalb) could be used to ‘piggy-back’ upon 
circulating albumin. Where the PEG di(bis)sulfone reagent 4 could be used to 
conjugate both IFN and anti-albumin Fab. The rationales of this approach are firstly; 
anti-albumin Fab has a single disulfide, which can be easily reduced using mild 
reductants to allow for site-specific disulfide PEGylation. As stated previously, site-
specific PEGylation of Fabs with bis-alkylation PEG reagents has shown to retain the 
binding specificity (Khalili et al., 2012). Secondly, this novel approach conjugating 
His8IFN α-2a and anti-albumin Fab together using the PEG20 (20 kDa PEG) 
di(bis)sulfone as a ‘linker’, the complex (~110 kDa) will be above the renal filtration 
threshold (~70 kDa), thus enabling the complex to stay in circulation for longer. 
Further, the anti-albumin Fab can also bind to circulating albumin. Thirdly, by 
utilising the PEG di(bis)sulfone 4 as a ‘linker’ for protein-protein conjugation in 
conjunction with site-specific conjugation, it is hypothesised that the functional 
activity of both proteins will be retained as; i) conjugation is taking place away from 
the binding sites and ii) it is hoped that the PEG di(bis)sulfone 4 will act as a ‘spacer’ 
keeping the proteins from impeding the action of one another. Forth, anti-rat albumin 
IgG can be digested utilising immobilised papain to prepare anti-albumin Fabs. For 
future investigation, anti-rat albumin Fabs were used as to assess the in vivo half-life 
of the complex within a relevant model where it can be assessed if the anti-albumin 
Fab can extend the half-life further. 
 
1.4.6.3 Approach 3: IFN-PEG20-Fabbeva a possible therapeutic for renal cell 
carcinoma 
As discussed in §1.3.4 cytokines have three major disadvantages with cancer therapy 
firstly; severe toxicities are frequently associated with systemic infusions of 
cytokines, thus limiting the amount which can be administered to achieve an 
effective dose. Secondly, for a therapeutic protein to be effective it must reach its 
biological target, however cytokines lack tumour specificity. Thirdly, the majority of 
cytokines have a MW below 30 kDa, thus suffer from short serum half-lives 
(Vazquez-Lombardi et al., 2013). Consequently, the ultimate challenge for 
developing improved cytokine therapeutics for cancer is to reduce unwanted side 
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effects of cytokine treatment while increasing the local concentration of cytokines to 
the tumour microenvironment. Direct cytokine injections have been trialled with 
cytokines, however the major downfall of this approach is that the tumour must be 
accessible and visualised however this is not always possible with micrometastatic 
lesions (Forni et al., 1985). An intuitive approach has been to fuse cytokines to HSA, 
Fc regions to increase their half-life however this approach does not specifically take 
the cytokine to the tumour site(s) thus not reducing unwanted side effects (Bitonti et 
al., 2004; Jazayeri and Carroll, 2008; Subramanian et al., 2007).  
 Therefore, the third recombinant-chemical approach is to chemically link 
His8IFN α-2a with Fab derived from bevacizumab (Fabbeva) using PEG di(bis)sulfone 
4 as a linker. Bevacizumab plus interferon α has is an approved treatment for 
metastatic renal cell carcinoma (RCC) (Rini et al., 2008). Vascular endothelial 
growth factor (VEGF) is continuously expressed on many tumour cells and its the 
only angiogenic factor known continually expressed throughout the entire tumour 
life-cycle (Folkman, 2007). VEGF is a key mediator angiogenesis in cancer 
(Carmeliet, 2005), as the binding of VEGF to its receptor causes increased vascular 
permeability, induces proliferation and migration of endothelial cells (angiogenesis) 
and inhibits apoptosis of immature endothelial cells (Escudier et al., 2008). 
Therefore, bevacizumab (Avastin
®
) a recombinant humanised monoclonal IgG1 was 
developed to inhibit VEGF (Escudier et al., 2008). Interferon α has one of the longest 
clinical records for use in oncology, and is used to treat over 14 types of cancer 
including hairy cell leukaemia, RCC and Kaposi’s sarcoma (Table 1–7) (Ferrantini et 
al., 2007). This is due to IFN α’s ability to directly inhibit the proliferation of normal 
or tumour cells and modulate immune responses (Bekisz et al., 2010; Ferrantini et 
al., 2007; Wu et al., 2005). Further it is thought IFN α-2a could suppress VEGF 
synthesis and secretion by inhibiting P13 kinase and MAP kinase signalling 
pathways. This targeted dual-action treatment has become the first-line treatment for 
RCC as significant improvement was observed over IFN alone in progression-free 
survival in Phase III clinical trials (Escudier et al., 2007). However, throughout 
clinical trials toxicity of the combination therapy was greater than IFN α-2a alone 
(Rini et al., 2008). Further, the combination therapy is not a tumour specific and the 
combination therapy requires bevacizumab to be administered once every two weeks 
and IFN to be administered three times a week (Escudier et al., 2007). Adverse 
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effects from IFN treatment where observed, this is most likely due to either toxicity 
or side effects caused by multiple dosing (Figure 1-4) (Escudier et al., 2007). 
 By conjugating Fabbeva to His8IFN α-2a, it is hoped that; i) severe toxicity 
associated with systemic infusion of IFN would be reduced, as the IFN-PEG20-
Fabbeva conjugate has tumour specificity from the Fabbeva that specifically binds to 
tumour expressing VEGF, thus delivering IFN to its biological target; ii) improved 
patient quality of life, as both Fabbeva and IFN alone have relatively short half-lives in 
vivo, however when conjugated together using the homobifunctional reagent the 
overall MW of the conjugate ~110 kDa which could improve half-life leading to 
fewer injections for the patient; iii) greater therapeutic efficacy by combining the 
tumour specificity and anti-angiogenic ability of Fabbeva with the antiproliferative, 
immunodulatory and VEGF suppression ability of IFN within one molecule; and iv) 
improved activity retained by the therapeutic proteins and greater homogenicity of 
the final product, by thiol conjugation site-specificity. 
1.5 PhD hypothesis 
The main hypotheses of this PhD research are: 
 His8IFN-PEG-His8IFN homodimers can be made by selective conjugation to 
the N-terminal 8-polyhisitidine tag on the protein and that the homodimer 
will have retained in vitro activity.  
 Disulfide-bridging conjugation can be conducted on His8IFN with PEG 
di(bis)sulfone 4 to make IFN-PEG-IFN and this homodimer will have 
retained in vitro activity.  
 The IFN-PEG-IFN dimers will have greater activity than the corresponding 
PEG-IFN conjugates because the IFN-PEG-IFN dimer will provide a higher 
concentration of IFNs at the binding site able to bind to the IFNAR complex. 
 Heterodimeric protein-protein conjugates can be prepared using a 
homobifunctional PEG reagent 4 to make Fab-PEG-IFN conjugates. These 
heterodimeric conjugates will display biological properties that are associated 
with both of the conjugated proteins.   
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Chapter 2 Materials and Methods 
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2.1 Materials 
Table 2–1: PEG reagent names, structures, previous work and purpose of the reagent used within this thesis.  
PEG 
reagent 
number 
PEG reagent 
name 
PEG structure 
Previous work Purpose of reagents 
1 PEG bis-sulfone 
 
(Cong et al., 2012) 
(Shaunak et al., 2006) 
(Balan et al., 2007) 
PEG-protein controls 
2 
PEG mono-
sulfone 
 
(Shaunak et al., 2006) 
(Balan et al., 2007) 
(Khalili et al., 2012) 
 
4 
PEG di(bis)-
sulfone 
 
(Khalili et al., 2013) Homo-/hetero-protein dimers  
5 
PEG 
di(mono)sulfone 
 
(Khalili et al., 2013)  
PEG bis-sulfone PEG mono-sulfone 
PEG bis-sulfone PEG mono-sulfone 
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2.1.1 Preparation of PEG20 di(bis)sulfone 4 
For the synthesis of the homodimer (IFN-PEG-IFN) the PEG20 di(bis) sulfone 4 was 
made using PEG20 di(amine) 6 from NOF (DE-200PA) and bis-sulfone linker 7 was 
made by Martin Fisher and Farzad Khayrzad. 4-Dimethylaminopyridine (DMAP, 
148270050), dry-dichloromethane (DCM, 326851000) and dry-toluene (326980010) 
were all supplied by Acros Organics. Oxone
®
 (STBB229V) was brought from Sigma 
Aldrich. Methanol (H/4000/17) was supplied from Fisher Scientific and purified 
water was supplied in house at PolyTherics Ltd.  
 For the improved synthesis route of PEG20 di(bis) sulfone 4 which is used for 
the heterodimer synthesis (IFN-PEG-Fab), PEG20 di-amine 6 was supplied by NOF 
(DE-200PA) and bis-sulfide linker 9 was made by Gaidad Tekle. 4-
Dimethylaminopyridine (DMAP, 148270050), dry-dichloromethane (DCM, 
326851000) and dry-toluene (326980010) were all supplied by Acros Organics. 4-
Methylbenzene thiol (1001233199) and Oxone
®
 (STBB229V) was brought from 
Sigma Aldrich. Methanol (H/4000/17) was supplied from Fisher Scientific and 
purified water was supplied in house at Warwick Effect Polymers. 
2.1.2 His8IFN α-2a fermentation and production 
For the fermentation of His8IFN α-2a, Lysogeny Broth Miller (L3152-1KG) and 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (I6758-5G) were both supplied from 
Sigma Aldrich. Ampicillin sodium salt (BPE1760-25), tryptone (BPE-1421-2), 
glycerol (G/0650/17/F), potassium phosphate monobasic (BP362-500) and potassium 
phosphate dibasic (BP363-1) were all purchased from Fisher Scientific. Yeast extract 
(92144) was supplied from Fluka analytical. 
For the purification of His8IFN α-2a, phosphate buffer saline (PBS) (BP399-
20), imidazole (30187-0010), tris-hydrochloride (T/3710/60), sodium chloride 
(S/3710/60), EDTA (BP120-500F) and sodium azide (S/2360/48) were all supplied 
from Fisher Scientific. Protease inhibitor cocktail (P8465) was supplied from Sigma 
Aldrich. The following immobilised metal ion affinity chromatography (IMAC) and 
anion exchange chromatography (AIEC) columns were used, HisPrep™ FF 16/10 
(20 mL) (28-9365-51) and HiPrep™ Q FF 16/10 (20 mL) (28-9365-43) respectively 
were brought from GE healthcare. For large scale lysis the QuixStand Benchtop 
system and pre-static pump (56-4107-78) with a hollow fibre cartridge (UFP-500-C-
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4MA) were all brought from GE Healthcare. Lysozyme (L7651), protease inhibitor 
cocktail for His-tagged proteins, dimethyl sulfoxide solution (P8849), and 
deoxyribonuclease I from bovine pancreases (DN25) were supplied from Sigma 
Aldrich. Triton X-100 (BP151-500) was brought from Fisher Scientific. 
2.1.3 Digestion and purification of Rabbit anti-rat albumin (IgGalb) and 
Bevacizumab (IgGbeva)  
IgGbeva (Avastin
®
, 25 mg/mL, Genentech/Roche) and IgGalb (Genway Biotech Inc, 
GWB-E3EEDA) were digested using immobilised papain from Thermo Scientific 
(20341). The digestion buffer was made using di-sodium hydrogen orthophosphate, 
dodecahydrate (S/4400/53) and sodium hydrogen orthophosphate dehydrate 
(S/3760/60) were supplied from Fisher Scientific, ethylene-diamine-tetraacetic acid 
(EDTA) was supplied from Apollo Scientific Ltd. (BIE0729) and L-cysteine was 
from Sigma Aldrich (168149_2.5g). 
Purification of IgGalb and IgGbeva was conducted using HiTrap™ Protein A HP 
column (1 mL) from GE healthcare (17-0402-01). Glycine (G/P460/53) and di-
sodium hydrogen orthophosphate, dodecahydrate (S/4400/53) and sodium hydrogen 
orthophosphate dehydrate (S/3760/60) were supplied from Fisher Scientific. 
2.1.4 Protein desalting and conjugate purification columns 
For protein desalting, PD-10 and NAP-5/10 desalting columns were used from GE 
Healthcare (17-0851-01, 17-0853-01, 17-0854-01). For cation exchange 
chromatography (CIEC) HiTrap Macrocap SP HP columns (5 mL) were brought 
purchased from GE Healthcare (28-9508-59). Buffers A (100 mM sodium acetate, 
pH 4) and B (100 mM sodium acetate, 1 M sodium chloride pH 4) were made using 
acetic acid (A/0360/PB15), 1 M sodium hydroxide (J/7620/15), sodium chloride 
(BP358 212) and 1 M hydrochloric acid (J/4340/15) were brought from Fisher 
Scientific. For size exclusion chromatography (SEC), a HiLoad 16/60 Superdex™ 
200 prep grade column from GE Healthcare (28/9893-35) column was used. The 
buffer used for SEC was made using di-sodium hydrogen orthophosphate, 
dodecahydrate (S/4400/53), sodium hydrogen orthophosphate dehydrate (S/3760/60) 
and sodium chloride (BP358 212) were all supplied from Fisher Scientific. Zeba
™
 
spin desalting columns >7000 Da (2,5,10 mL) were brought from Thermo Scientific.  
  
77 
2.1.5 SDS-PAGE analysis  
SDS-PAGE was conducted using 4-12% Bis-Tris polyacrylamide gels (NuPAGE
®
; 
NP0323BOX). Every gel was loaded with Novex
®
 sharp pre-stained standards 
(Novex; P/ N 57318) and samples were loaded using an appropriately diluted 4×SDS 
sample buffer (NuPAGE
®
; NP0007). Gels were run in Xcell SureLock
™
 gel 
electrophoresis tanks (Invitrogen; EI0001) and run in MES SDS-PAGE running 
buffer (×20) from NuPAGE
® 
(NP0002-02). Gels were stained using InstantBlue™ 
gel stain (Expedeon; ISB01L) and PEG stain (barium chloride and 0.05 M iodide 
were both from Fisher Scientific (B/0500/53; J/4410/15). Alternatively, silver stain 
(SilverXpress
® 
Silver staining kit) was used from Invitrogen (LC6100). Densimetric 
analysis was conducted using ImageQuant™ LAS 4010 instrument (GE Healthcare, 
28-9558-10). 
2.1.6 PEGylation reagents and reactions  
PEG20 bis-sulfone 1 was supplied by BioVectra Inc (6237). Acetic acid 
(A/0360/PB15), 1 M sodium hydroxide (J/7620/15), disodium hydrogen 
orthophosphate, dodecahydrate (S/4400/3), sodium dihydrogen phosphate 
(S/3760/60), sodium chloride (BP358 212), 1 M hydrochloric acid (J/4340/15), 
ammonium bicarbonate (BP2413-500) and 100 mM dithiothreitol (DTT, BP172-5) 
were brought from Fisher Scientific. Hydroquinone (24,012-5) and 95% sodium 
triacetoxyborohydride (STAB) (316393-25G) were from Sigma Aldrich. Reduced 
and oxidised glutathione (A0279520 and A0288123 respectively) were supplied from 
Acros organics. Ethylene-diamine-tetraacetic acid (EDTA) was supplied from Apollo 
Scientific Ltd. (BIE0729), whilst tris(2-carboxyethyl)phosphine hydrochloride 
solution (TCEP) was supplied from Sigma Aldrich (646547-10X1ML). Tween-20 
was supplied from Fluka analytical (44112-100GF). 
2.1.7 Characterisation materials  
To determine His8IFN α-2a concentration the MicroBCA™ Protein Assay Kit 
(Thermo Scientific, 23235) was used. Additionally for quantification of proteins in 
small volumes (<900 µL), the Nanodrop 2000 spectrophotometer from Thermo 
Scientific (SPR-700-310L) was used. BradfordUltra™ reagent from Expedeon 
(BFU1L) was used for the quantification of Fab concentration, where the standard 
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curve of bevacizumab was used to quantify unknown Fab concentrations. Sequence 
grade modified Trypsin was brought from Promega (100 μL; V5111). 
Western blotting for assessing His-tag IFN, Fabbeva and Fabalb was conducted 
using Xcell™ II blot module gel transfer apparatus (Invitrogen, EI9051). Gel 
contents were transferred onto nitrocellulose membrane Hybond-C that was supplied 
from GE Healthcare (sandwiched between 1mm thick blotting paper). Transfer 
buffer stock (×12.5, 1 L) consisted tris-base (Fisher Scientific), glycine (Fisher 
Scientific; G/460/53) in purified water (in house). The transfer buffer (1×) was made 
from 12.5× transfer buffer stock, methanol (laboratory grade, Fisher Scientific) and 
was diluted with purified water (in house). Blocking solution was made using dried 
skimmed milk and PBST (1× solution prepared using 10× PBS stock from Fisher 
Scientific (M5401) and Tween-20 from Fluka analytical).  
Mouse anti-6×His monoclonal antibody (Clontech, 631212) and anti-mouse 
AP-conjugated antibody (Promega, S3721) were used to detect the His-tag. Samples 
were detected using a colorimetric detections method. Using, NBT/ BCIP (SIGMA 
FAST™, B5655-25TAB) alkaline phosphatase substrate tablets.  
For detecting IFN, rabbit anti-IFN α polyclonal antibody (RnD Systems, 
31101-1) and goat anti-rabbit HRP-conjugated antibody (AbCam, ab6721) were 
used. 
 To detect rat albumin (Sigma Aldrich, A6414-10 mg), anti-rat albumin IgG 
(Genway Biotech Inc, GWB-E3EEDA) and goat anti-rabbit HRP-conjugated 
antibody (AbCam, ab6721) were used. 
For detecting bevacizumab compounds goat anti-human κ-chain (Fab’2) (HRP-
conjugated) was used (Fitzgerald, 43C-CJ0132). Pierce ECL (enhanced 
chemiluminescence) Western blotting substrate kit supplied from Thermo Scientific 
(32106) was used with the ImageQuant™ for the detection of HRP enzyme activity.  
2.1.8 In vitro Antiviral assay  
The human lung fibroblast cell line (A549) (HPACC; 86012804) was cultured in 
Dulbecco’s Modified Eagles medium (DMEM) (Gibco/Fisher Scientific; 
VX21969035) and Foetal Bovine Serum (FBS) (Gibco/Fisher Scientific; 
VX25030024). The DMEM contained penicillin streptomycin (PAA; P11-101) and 
L-glutamine (Sigma; G7513-100 mL). Trypsin-EDTA (PAA; L11-004) was used for 
subculture. For a cell count trypan blue (Sigma Aldrich; T8154-100 mL), KOVA 
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glassic slide 10-grids (Hycor; FGK01) and an inverted microscope (Ceti, Jencons) 
were used. All cell culture work was conducted in a Bio-safety cabinet (class 2) 
(Biomat2), cells were kept in a CO2 air-jacket incubator (Binder; CB15) and all 
reagents were warmed using a water-bath (JB series, Grant) before use. For the 
antiviral assay A549 cells were infected using Encephalomyocarditis Virus (EMCV) 
(ATCC; VR-129B). Sample controls were NIBSC IFN α-2a standard (HPACC; 
95/650) and PEGASYS
® 
(Roche). Phosphate buffered saline (PBS) pH 7.4 (BPE399-
20); formaldehyde (40%) (F/145/PB17) and SDS (10%) (BPE 2436-1) were supplied 
from Fisher Scientific. Methyl violet 2B was from Sigma Aldrich (198099). The 
microplate reader was supplied from Dynex Technologies/Opsys MR and the 
microplate shaker was supplied from VWR/VWR (444-7094). 
2.1.9 In vitro Antiproliferative assay  
Human Negroid Burkitt lymphoma (Daudi) cell line was supplied from HPACC 
(85011437) and was cultured using RPMI 1960 (1×) liquid with L-glutamine from 
Fisher Scientific (VX21875-091). Control samples NIBSC IFN β-1b was supplied 
from NIBSC (00/574) and Betaferon
®
 (250 µg/mL) was supplied from Bayer 
Schering Pharma (Lot No: 01062A). Dimethyl sulfoxide (DMSO) (sterile filtered) 
was from Sigma Aldrich, tissue culture microplate 96 well U-bottom plates were 
from Thermo Scientific (FB56412) and thiazolyl blue tetra-zolium bromide (MTT) 
was supplied by Sigma.  
2.1.10 BIAcore 
All BIAcore consumables were purchased from GE healthcare Ltd. (Amersham). All 
affinity assays were conducted using the BIAcore X-100 instrument. For essential 
weekly and monthly maintenance, the BIAcore Maintenance kit was used (BR-1006-
66). For immobilisation the amine coupling kit (BR-1000-50) containing N-
hydroxysuccinimide (NHS), 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide 
(EDC), ethanolamine-HCl (1.0 M, pH 8.5), glycine buffer (10 mM, pH range of 1.5 
to 2.5, 22053613) and the Regeneration scouting kit (BR-1005-56) were used 
(including 10 mM glycine-HCl pH 2.0 and 2.5). For immobilisation, CM3 sensor 
chips were used (BR-1005-41). Sodium acetate pH 4.0 (BR-1003-49), 4.5 (BR-1003-
50), 5.0 (BR-1003-51) and 5.5 (BR-1003-52) were used for the pH scouting 
experiment with 50 mM sodium hydroxide (BR-1003-58) for regeneration. For all 
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runs HBS-EP buffer was used (BR-1006-6) (including HEPES (0.1 M), NaCl (1.5 
M), EDTA (30 mM), 0.5% V/V surfactant P20, pH 7.4). The test compounds were 
prepared in 1.5 mL plastic vials (BR-1002-87) and rubber caps (Type 2, BR-1004-
11) were used to close the vials. The two ligands used were human vascular 
endothelial growth factor (VEGF165, V7259-10 µg) were purchased from Sigma 
Aldrich and rat albumin (Sigma Aldrich, A6414-10 mg).  
2.2 Methods 
2.2.1 SDS-PAGE analysis 
 SDS-PAGE analysis of proteins was conducted with Novex
®
 4-12% Bis-Tris gels 
(10 or 15 wells) in an electrophoresis cell. Samples were prepared with NuPAGE
®
 
LDS sample buffer (in a 1:3 ratio) with the amount of sample loaded on the gel being 
approximately 1 μg. The protein molecular weight (MW) standard used was Novex® 
Sharp Protein Standard. NuPAGE
®
 MES SDS running buffer (×20) was used as 
running buffer. The voltage applied for electrophoresis was 200 V and the run time 
was 35-40 min. Gels were stained by; InstantBlue™, PEG stain or SilverStain 
(Kurfürst, 1992).  
2.2.2 Determination of protein concentration  
2.2.2.1 MicroBCA assay for protein concentration  
MicroBCA™ Protein Assay kit containing a solution of albumin standard (2 mg/mL) 
was diluted in appropriate buffer (dependent on sample buffer) to 200 μg/mL, 50 
μg/mL, 25 μg/mL, 12.5 μg/mL, 6.25 μg/mL, 3.125 μg/mL and 0.0 μg/mL (blank). 
The samples (75-150 μL) were incubated respectively with 75-150 μL MicroBCA™ 
solution (prepared by mixing solutions A:B:C in the ration of 25:24:1) at 37 °C for 2 
h. The absorbance was then measured at 570 nm and a standard curve was generated 
by plotting the absorbance values against their respective albumin concentrations. 
For His8IFN α-2a samples, appropriate dilutions (~40-60 μg/mL) were made to a 
concentration within the linear part of the standard curve and the above steps 
followed. The concentration of samples was calculated based on the standard curve 
obtained (6.1 Appendix I). 
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2.2.2.2 Bradford assay for determining Fab concentration 
Bevacizumab (Avastin
®
, 25 mg/mL, Genentech/Roche) was used as standard. 
Bevacizumab was first diluted in an appropriate buffer (dependent on sample buffer) 
to 625 μg/mL, which was then used to prepare a dilution series of 100 μg/mL, 80 
μg/mL, 60 μg/mL, 50 μg/mL, 40 μg/mL, 30 μg/mL, 20 μg/mL, 9 μg/mL and 0.0 
μg/mL (blank) for the standard curve. Similarly, samples were diluted to 60, 50 and 
40 μg/mL in the same buffer. The standard and the samples (80 µL) were pipetted 
into a 96 well plate and mixed with BradfordUltra
™
 reagent (220 µL). The plate was 
then left for 10 min at RT and the absorbance read at 590 nm. The concentration of 
samples was then calculated based on the standard curve obtained (6.1 Appendix I). 
2.2.3 Fermentation and purification of His8IFN α-2a 
2.2.3.1 Fermentation of His8IFN α-2a 
Terrific Broth (TB) was prepared using tryptone (12 g), yeast extract (24 g), glycerol 
(0.4% v/v), potassium phosphate dibasic (12.54 g, 0.072 M) and potassium 
phosphate monobasic (2.31 g, 0.017 M) per L and was supplemented with ampicillin 
(100 µg/mL). Lysogeny broth (LB) broth (25 g/L) was also supplemented with 
ampicillin (100 µg/mL). In a 0.5 L baffle flask, a pre-culture was prepared containing 
LB (90 mL), TB (10 mL) and glycerol stock (0.01 mL). The pre-culture was left to 
grow overnight at 37 °C in a shaking incubator rotating at 220 rpm. TB (500 mL) 
and pre-culture (50 mL) were then poured into two 2 L baffle flasks and were left to 
grow at 37 °C in a shaking incubator rotating at 180 rpm. The bacterial growth was 
monitored every hour until the absorbance reached 5.5–6.0. At this point a 1 mL 
aliquot from each baffled flask was taken and centrifuged for 2 min at 20,000 ×g. 
The supernatant from each aliquot was discarded and the pellet was stored at –20 °C. 
To each baffled flask, IPTG (1 mM) was added and further incubated at 30 °C for an 
additional 2.5 h shaking at 180 rpm. After this time, a 1 mL aliquot from each baffled 
flask was taken, centrifuged and stored as described previously. The fermentation in 
each baffled flask was then pipetted into 50 mL tubes and centrifuged at 3,500 ×g. 
The supernatant from all 50 mL tubes was discarded and the pellets stored at –80 °C. 
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2.2.3.2 Mini lysis  
Cell pellets harvested before and after IPTG induction were mixed with 0.5 mL lysis 
buffer (lysozyme (0.4% v/v), protease inhibitor (for his-tagged proteins with no 
metal chelator that might inhibit binding to affinity resin (IMAC)) (0.2% v/v), DNase 
(0.2% v/v) in 1× PBS). The resulting mixtures were incubated at 4 °C for 30 min, 
then an equal volume of PBS/1% Triton X-100 was added to each mixture, vortexed 
until the pellet was solubilised and left to incubate for a further 30 min at 4 °C. A 
crude extract aliquot (100 µL) was taken from each tube to perform the mini lysis 
with to assess the expression and then each tube was centrifuged for 30 min, 3.5 ×g, 
4 °C. The supernatant from each tube was then carefully transferred to pre-labelled 
Eppendorf tubes and the pellets were re-suspended with PBST. SDS-PAGE analysis 
was conducted on crude extracts, pellet and supernatant prior to and after induction 
with IPTG. 
2.2.3.3 Large-scale lysis  
Each of the pellets stored at -80 °C were weighed, and for each 1 g of pellet, 20 mL 
of lysis buffer was added (as in method 2.2.3.2). The pellets were vortexed until 
homogeneous, pooled and then sonicated for 5 min. The solution containing lysed 
cells was then left shaking at 4 °C for 1 h, rocking gently. Afterwards, equal volume 
of PBS/ 1% Triton X-100 was added and the mixture sonicated for 5 min at 100%. 
The mixture was then left for 1 h at 4 °C, rocking gently. His8IFN α-2a was then 
purified from cell debris by cross flow filtration using the QuixStand
™
 System with a 
hollow fibre cartridge, where the flow through contained the soluble protein. SDS-
PAGE analysis was conducted on crude extracts, pellet and supernatant prior to and 
after induction with IPTG.  
2.2.3.4 Immobilised metal ion affinity (IMAC) and anion exchange 
chromatography (AIEC) purification of His8IFN α-2a 
Prior to IMAC purification, the supernatant from the hollow fibre purification was 
supplemented with 20 mM imidazole. A HisPrep
™
 FF 16/60 column was pre-
equilibrated with buffer A (PBS pH 7.4) and the supernatant obtained from the 
hollow fibre purification was loaded onto the column overnight at 1 mL/min. The 
column was then washed with 2% buffer B (PBS, 1 M imidazole pH 7.4) at a flow 
rate of 5 mL/min for approximately 80 mL. A linear gradient of 2–25% buffer B was 
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set to flow for 25 min whilst 10 mL fractions were collected. SDS-PAGE analysis 
was conducted on the flow-through, loading and elution fractions.  
 Prior to AIEC purification, fractions containing His8IFN α-2a were pooled 
and diluted 4-fold using buffer C (20 mM Tris-HCl, pH 8.0). The HiPrep
™
 Q FF 
16/60 column was pre-equilibrated with buffer C; following this the protein was 
loaded onto the column at 1 mL/min. The column was then washed with ~80 mL of 
2% buffer D (20 mM tris-HCl, 1 M sodium chloride, pH 8.0) at 5 mL/min. A linear 
gradient of 2-30% buffer D was set to flow for 30 min whilst collecting 10 mL 
fractions. SDS-PAGE analysis was conducted on the flow-through, loading and 
elution fractions.  
Following SDS-PAGE analysis, the fractions containing pure His8IFN α-2a 
were pooled and the concentration measured by UV absorbance at 280 nm (ε=0.914, 
0.9 mg/mL, 70 mL). The concentration was made to 0.5 mg/mL and the solution 
supplemented with 100 mM sodium chloride, 10% glycerol, protease inhibitor 
(dilution 1/5000), 1 mM EDTA and 1 mM sodium azide. His8IFN α-2a was then 
aliquoted into 5 mL cryovials and snap-frozen in liquid nitrogen and stored at -80 °C. 
The production of His8IFN α-2a was conducted three times with the yields achieved 
being between 60-70 mg.  
2.2.4 Digestion and purification of IgGalb and IgGbeva 
2.2.4.1 Protein A purification of IgGalb 
Purification of IgGalb was performed using Protein A to separate IgGalb from albumin 
impurities. The IgGalb mixture was loaded onto a 1 mL HiTrap Protein A HP column 
using an ÄKTA prime plus which had been pre-equilibrated with buffer A (20 mM 
sodium phosphate pH 6.5). The IgGalb was eluted with 100% buffer B:0.1 M glycine 
pH 2.0. The IgGalb mixture was manually loaded onto the column (ca.=10 mL), and 
the system was washed for 30 mL with buffer A and then 100% B was used to elute 
the IgGalb. Throughout the manual run, 2 mL fractions were collected and for the 
IgGalb eluted with buffer B, 200 μL of neutralising buffer (1 M Tris, 1 mM EDTA, 
pH 8.0) was added. SDS-PAGE was used to characterise the peak fractions and the 
resulting gel was stained by InstantBlue
™
 stain. The purest IgGalb fractions were 
combined and buffer exchanged using a pre-equilibrated 10 mL Zeba
™
 spin column 
(1000 ×g, 2 min, 4 °C). The IgGalb concentration was estimated by UV absorbance at 
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280 nm, the concentration and yield were calculated using the extinction coefficient 
of IgGalb (ε=1.4, 0.95 mg/mL, 4.75 mg, final yield=47.5%). 
2.2.4.2 Optimisation of IgGalb digestion using papain 
Immobilised papain was mixed by inversion to obtain an even suspension, then 1 mL 
of the immobilised papain was pipetted into a 15 mL tube. The Immobilised papain 
was resuspended into 20 mM cysteine, 2 mM EDTA, sodium phosphate pH 7.0 
(digestion buffer) and centrifuged for 2 min at 4000 ×g. The supernatant was 
discarded and the step was repeated. After this, the Immobilised papain was re-
suspended into 0.9 mL of the digestion buffer. Three enzyme:IgG ratios were 
investigated, 1:10, 1:20 and 1:50. The enzyme was pipetted into the three Eppendorf 
tubes containing 0.2 mg/mL of anti-rat albumin IgG. The mixtures were left to shake 
at speed 200 at 37 °C. Aliquots were taken at 0,1,2,3,4,5,6,8 h and 16 h. SDS-PAGE 
analysis was conducted on these aliquots with the resulting gels stained by 
InstantBlue™ and silver stain. Further, SEC analysis was conducted at 0,2,4,6 and 8 
h following the method outlined by Zhao et al. 2009.  
2.2.4.3 Digestion of IgGalb 
Immobilised papain was mixed by inversion-shaking to obtain an even suspension, 
then 2 mL of 50% immobilized papain was transferred into a 15 mL falcon. The gel 
slurry was equilibrated with digestion buffer (8 mL) (20 mM sodium phosphate, 2 
mM EDTA, 20 mM cysteine, pH 7.0) and centrifuged (4 min, 400 ×g at RT), where 
the supernatant was discarded. This wash procedure was repeated, after this the gel 
slurry was re-suspended in 2.0 mL of digestion buffer. The digestion was conducted 
for 4 h at 37 °C (210 speed of shaking) in a shaker incubator and a ratio of 1:20 
(w/w) of papain:purified IgGalb (237.5 μg papain:4750 μg IgGalb). After 4 h, the 
immobilised papain was removed by filtering the digestion mixture through a 
polypropylene barrel with polyethylene frit (left after removing medium from PD-10 
column). The visible amount of papain captured by the frit was washed four times 
with 2 mL with buffer A (20 mM sodium phosphate pH 6.5). SDS-PAGE was 
carried on the digestion IgGalb mixture; the resulting gel was stained using 
InstantBlue
™
. 
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2.2.4.4 Purification of digested IgGalb 
A protein A column was used to purify the Fabalb from undigested IgGalb and Fcalb. 
The HiTrap Protein A HP 1 mL column was pre-equilibrated with buffer A (20 mM 
sodium phosphate pH 6.5); following this the digested mixture was loaded onto the 
column at 1 mL/min. The column was then washed with ~30 mL of buffer A and 
then IgGalb/Fcalb was eluted from the column with 100% buffer B (0.1 M glycine pH 
2.0). Throughout the manual run, 2 mL fractions were collected and for the Fcalb 
eluted with buffer B, 200 μL of neutralising buffer (1 M Tris, 1 mM EDTA, pH 8.0) 
was added. SDS-PAGE analysis was conducted on the flow-through, loading and 
elution fractions, with the resulting gel analysed by InstantBlue
™
. The Fabalb 
fractions were combined and concentrated in a pre-equilibrated Vivaspin 10,000 
MWCO (3000 ×g, 30 min, 4 °C). Once the Fabalb is concentrated to ca.=2 mL, the 
Fabalb was diluted to 20 mL with reaction buffer (50 mM sodium phosphate, 20 mM 
EDTA, 150 mM sodium chloride, 0.01% Tween-20, pH 8.2). This was repeated 
thrice, until the Fabalb (2 mL) was buffer exchanged into the reaction buffer. The 
Fabalb concentration was estimated by UV absorbance at 280 nm, the concentration 
and yield were calculated using the extinction coefficient of Fabalb (ε=1.4, 0.67 
mg/mL, 1.99 mg, final yield=41.9%). SDS-PAGE was conducted on the Fabalb and 
the resulting gel was stained with InstantBlue
™
.  
2.2.4.5 Digestion of IgGbeva 
Immobilised papain was mixed by inversion-shaking to obtain an even suspension, 
then 1 mL of 50% immobilized papain was transferred into a 15 mL falcon. The gel 
slurry was equilibrated with digestion buffer (9 mL) (20 mM sodium phosphate, 2 
mM EDTA, 20 mM cysteine, pH 7.0) and centrifuged (4 min, 400 ×g at RT), where 
the supernatant was discarded. This wash procedure was repeated, after this the gel 
slurry was re-suspended in 1.0 mL of digestion buffer. The digestion was conducted 
for 5.5 h at 37 °C (210 speed of shaking) in a shaker incubator and a ratio of 1:100 
(w/w) of papain: IgGbeva (250 μg papain:25,000 μg IgGbeva). After 5.5 h, the 
immobilised papain was removed by filtering the digestion mixture through a 
polypropylene barrel with polyethylene frit (left after removing medium from PD-10 
column). The visible amount of papain captured by the frit was washed four times 
with 2 mL with buffer A (100 mM Tris, 1 mM EDTA, pH 8.0). SDS-PAGE was 
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carried on the digestion mixture of IgGbeva (1 μg) and the gel was then stained using 
InstantBlue
™
. 
2.2.4.6 Purification of digested IgGbeva 
The digested IgGbeva was loaded onto two 1 mL HiTrap Protein A HP column using 
an ÄKTA prime plus fitted with two 5 mL loops which had been pre-equilibrated 
with buffer A (100 mM Tris, 1 mM EDTA, pH 8.0). The IgGbeva was eluted with 
100% buffer B: 100 mM glycine pH 2.8. The digested IgGbeva was manually loaded 
onto the column (~10 mL), and the system was washed for 30 mL with buffer A and 
then 100% buffer B was used to elute the Fcbeva. Throughout the manual run, 2 mL 
fractions were collected and for the Fcbeva eluted with buffer B, 200 μL of 
neutralising buffer (1 M Tris, 1 mM EDTA, pH 8.0) was added. SDS-PAGE was 
used to characterise the peak fractions and the resulting gel was stained by 
InstantBlue
™
 stain. The Fabbeva fractions were combined and concentrated in a pre-
equilibrated Vivaspin 10,000 MWCO (3000 ×g, 30 min, 4 °C). Once the Fabbeva is 
concentrated to ~2 mL, the Fabbeva was diluted to 20 mL with reaction buffer (50 mM 
sodium phosphate, 20 mM EDTA, 150 mM sodium chloride, 0.05% Tween-20, pH 
8.2). This was repeated thrice, until the Fabbeva (2 mL) was buffer exchanged into the 
reaction buffer. The Fabbeva concentration was estimated by UV absorbance at 280 
nm, the concentration and yield were calculated using the extinction coefficient of 
Fabbeva (ε=1.4, 4.89 mg/mL, 9.77 mg, final yield=39%). SDS-PAGE was conducted 
on the Fabbeva and the resulting gel was stained with InstantBlue
™
.  
2.2.5 Synthesis and activation of PEG reagents  
2.2.5.1 Activation of PEG20 bis-sulfone 1 for his-tag conjugation 
To obtain an improved yield of PEG20-His8IFN and (PEG20)2-His8IFN conjugates, 
the PEG bis-sulfone reagent 1 (Table 2–1) was pre-incubated for 8 h at 37 °C in 50 
mM sodium phosphate buffer pH 7.4 containing 150 mM sodium chloride. These 
conditions allow for the elimination of one of the β-sulfonyl groups generating a 
reactive PEG20 mono-sulfone 2 (Figure 2-1). In a similar manner, PEG20 di(bis)-
sulfone 4 can be activated to PEG20 di(mono)sulfone 4. The activation of PEG mono-
sulfone 2 does not go to completion, thus leaving a mixture of both un-activated bis-
sulfone and activated mono-sulfone PEG reagents.  
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Figure 2-1. Activation of PEG bis-sulfone 1 reagent by the elimination of one β-sulfonyl 
group 3 to PEG mono-sulfone 2.  
2.2.5.2 Synthesis of PEG20 di(bis) sulfone 4 for homodimer production 
PEG20 di(amine) 6 (20 mg, 0.001 mmol) was added to a single-neck Schlenk flask 
(50 mL) along with toluene (2.5 mL). The PEG was dried by azeotropic distillation 
by use of toluene at RT. In another single neck Schlenk flask, bis-sulfone linker 7 (7 
mg, 5 mg/mL) was weighed and dissolved in dichloromethane. The bis-sulfone 
linker 7 was then added to the dried PEG20 di(amine) 6 and a magnetic stirring bar 
added to the mixture. The mixture was then purged with argon and the reaction 
mixture was left stirring for 48 h at RT. After this time, volatiles were removed by 
rotary evaporation at RT and the crude mixture was placed under vacuum for 15 min. 
The crude product was re-dissolved in acetone (5-10 mL) and filtered through a 
cotton-wool filled pipette into a pre-weighed centrifuge tube. The dissolved PEG was 
placed in dry ice for precipitation to occur and centrifuged for 30 min, at -9 °C, 4000 
rpm. The supernatant was discarded and the white precipitant was re-dissolved in 
fresh acetone, allowed to precipitate and centrifuged as before. This procedure was 
repeated three times, discarding the supernatant each time. After the last round, the 
white precipitate was allowed to dry in vacuum at ambient temperature to afford a 
white solid product. The product (~7 mg) was weighed and analysed by 
1
H-NMR 
(400/300 MHz).  
2.2.5.3 Synthesis of PEG20 di(bis) sulfone 4 for heterodimer production 
PEG20 di(amine) 6 (20 kDa, 1.09 mg, 54.5 μmol, 1 eq.) was dissolved in warm dry 
toluene (100 mL) in a round bottom flask. Residual water trapped in the PEG was 
removed through azeotropic distillation, and the solid was then dissolved in dry-
DCM (114 mL). Bis-sulfide linker 9 (349 mg, 654 μmol, 12 eq.) was then added to 
the solution and the mixture was left stirring at RT, overnight. The mixture was then 
passed through a glass wool plug to filter off particulates before removing the solvent 
under pressure for 1 h to yield a white solid. This was then dissolved in warm 
PEG bis-sulfone PEG mono-sulfone 
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acetone (109 mL) and cooled down on dry-ice to form a white precipitate. After 
cooling, the sample was then centrifuged at -78 °C, 7800 rpm for 15 min and the 
supernatant was then decanted off. This acetone precipitation procedure was repeated 
twice using fresh acetone each time. Once completed, the solid was re-suspended in 
DCM in a round bottom flask and the solution was then dried under reduced pressure 
and subsequently on high vacuum, 1.1 mg of clean product (PEG20 di(bis) sulfide 8) 
was recovered (96.2 % yield).  
 PEG20 di(bis) sulfide 8 (1.480 g, 70.5 μmol, 1 eq.) was dissolved in dry-DCM 
(20.5 mL) with 4-methylbenzene thiol (87.5 mg, 705 μmol, 200 eq.) in a sealed-
round bottom flask and the solution as left stirring at RT, overnight. After this, the 
solvent was removed under reduced pressure and the resulting solid was dissolved in 
warm acetone (150 mL). The solution was then cooled using dry ice and precipitated 
by centrifugation at 7800 rpm at -78 °C for 15 min. Following this the supernatant 
was removed. This acetone precipitation was repeated thrice, each time using fresh 
acetone. The solid was then dissolved in DCM in a round bottom flask. Subsequently 
the solvent was removed under reduced pressure before being exposed to high 
vacuum for 3 h, 1.4 g of the final deactivated PEG20 di(bis) sulfide 8 product was 
recovered (94.6 % yield). 
 Following the deactivation of PEG20 di(bis) sulfide 8, is the oxidation to 
di(bis)-sulfone PEG 4. PEG20 di(bis) sulfide 8 (1.4 mg, 66 μmol, 1 eq.) was dissolved 
in a 50/50 mixture of water/methanol (50 mL) in a round bottom flask. To this 
solution, 246 mg of Oxone
®
 (800 μmol, 1 eq.) was added and the reaction was 
allowed to proceed overnight. Methanol was removed under reduced pressure and 
the remaining solution was frozen after the addition of 15 mL of water. The frozen 
solution was then freeze dried overnight. The dried solid was then dissolved in DCM 
and filtered using 3 μm and 0.22 μm hydrophobic membranes successively to 
remove Oxone
®
 and afford a clear solution. The DCM was the removed under high 
pressure and the resulting solid dried under high vacuum to give 1.38 g of PEG20 
di(bis)sulfone 4 (98% yield).  
2.2.5.4 Purity assessment of PEG20 di(bis)sulfone 4 by RP-HPLC 
Buffer A (94% filtered water, 5% HPLC grade acetonitrile and 1% TFA) and buffer 
B (99% HPLC grade acetonitrile, 1% TFA) were freshly prepared. RP-HPLC was 
conducted using a PLRP-S (1000 Å, C3) RP column, which had been pre-
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equilibrated with buffer B then buffer A. The PEG20 di(bis)sulfone 4 was injected 
(50 μL) onto the column and a gradient of 0% to 100% buffer B was conducted 
assessing the chromatogram at both 214 nm and 280 nm.  
2.2.5.5 Purity assessment of PEG20 di(bis)sulfone 4 by SDS-PAGE 
MES (1×; 1 L) running buffer was freshly prepared with 75 μL of antioxidant. PEG20 
di(bis)sulfone 4 from synthesis routes 1 and 2 was weighed and made into a 1 
mg/mL solution with purified water. A Bis-Tris (4-12 %) was then loaded with 1 and 
5 μg of PEG20 di(bis)sulfone 4 from synthesis routes 1 and 2. The gel was then run 
for 35 min at 200 V, 500 mA. The resulting gel was stained for 1 h with 
InstantBlue™ and then washed for 1 h with purified water. The gel was stained with 
PEG stain (25 mL barium chloride, 5 mL iodine) for 5 min and rinsed for 10 min 
with purified water and the resulting gel was then scanned.  
2.2.6 Protein reduction and re-oxidation 
2.2.6.1 His8IFN α-2a reduction using Dithiothreitol (DTT) 
Dithiothreitol (0.15425 g, 1 M) was diluted in purified water (1 mL). For the 
complete reduction of His8IFN α-2a, 25 mM DTT for 30 min at RT was found to be 
optimum. Desalting columns were used to remove the DTT from His8IFN α-2a, and 
reduction was confirmed using SDS-PAGE analysis. 
2.2.6.2 Glutathione re-oxidising of His8IFN α-2a 
A glutathione reoxiding solution (GSH) of 50 mM oxidized glutathione (GSSG, 30.6 
mg): 50 mM reduced glutathione (GSH, 15.4 mg) was made in purified water (1 mL) 
and stored at -80 °C as 150 µL aliquots. Reduced His8IFN α-2a once reacted with 
PEG, the un-reacted disulfide bond of His8IFN α-2a was re-oxidised using 0.5 mM 
oxidised glutathione: 0.5 mM reduced glutathione for 16 h at RT. Re-oxidation of 
His8IFN α-2a was confirmed using SDS-PAGE analysis. 
2.2.6.3 Reduction of Fabbeva with Tris(2-carboxyethyl)phosphine (TCEP) 
The optimum conditions established for the full reduction of Fabbeva were 1.4 
equivalents (eq.) TCEP (0.5 M, 1 mL) for 2 h at 37 °C. After 1.5 h, SDS-PAGE 
analysis was conducted on the TCEP-Fabbeva mixture to confirm reduction. 
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2.2.6.4 Reduction of Fabalb with DTT 
DTT (0.15425 g, 1 M) was diluted in purified water (1 mL). For the complete 
reduction of Fabalb 5 mM DTT for 30 min at RT was found be optimum. After 
reduction, DTT was removed using a pre-equilibrated PD-10 desalting column. SDS-
PAGE analysis was used to confirm the reduction of Fabalb. 
2.2.7 Preparation of his-tag PEGylated His8IFN α-2a conjugates 
2.2.7.1 PEGylation of His8IFN α-2a using PEG20 reagent 2 to prepare PEG20-
His8IFN and (PEG20)2-His8IFN  
The activated PEG20 reagent 2 (0.502 mL, 2.5 eq.) was added to the His8IFN α-2a 
solution (2.837 mL at 1.41 mg/mL) and incubated at 20 °C for 16 h. The reaction 
mixture was then analysed by SDS-PAGE, the gel was stained with InstantBlue
™
 
followed by PEG stain. The conjugated His8IFN α-2a conjugate was stabilised by the 
addition of 50 mM sodium triacetoxyborohydride (STAB) dissolved in DMSO at 4 
°C for 1.5 h (Figure 2-2). The crude mixture (2× 2.5 mL) was then buffer exchanged 
into 100 mM sodium acetate pH 4.0 using a pre-equilibrated PD-10 desalting 
column.  
 
Figure 2-2. Reduction of PEG linker ketone group by STAB 
2.2.7.2 Purification of the PEG20 mono-sulfone 2-His8IFN α-2a reaction mixture 
Purification of the reaction mixture was performed using CIEC to separate (PEG20)2-
His8IFN, unreacted PEG20 reagent 2, PEG20-His8IFN and unconjugated His8IFN α-
2a. The reaction mixture was loaded into a 5 mL HiTrap
 
Macrocap SP cation 
exchange column using an ÄKTA prime plus fitted with a 5 mL loop which had been 
pre-equilibrated with buffer A (100 mM sodium acetate pH 4.0). The His8IFN α-2a 
species were eluted using a step gradient of buffer B (1.0 M sodium chloride in 100 
mM sodium acetate pH 4.0) with the following steps 27, 36, 55 and 100%, with each 
step eluting over six column volumes. Fractions (2 mL) collected over the step 
gradient were then analysed by SDS-PAGE and stained using InstantBlue
™
 and PEG 
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stain. Fractions containing the desired conjugates were combined and centrifugally 
concentrated using a VivaSpin column with 10,000 MWCO at 3000 ×g, 4 °C until 
>1.5 mL. Once concentrated the PEG20-His8IFN and (PEG20)2-His8IFN conjugates 
were buffer exchanged into buffer A, to decrease the salt concentration and enable 
the conjugates to bind to the column during the further purification. Protein 
concentration and yield was estimated by measuring UV absorbance at 280 nm for 
both PEG20-His8IFN and (PEG20)2-His8IFN conjugates (1.054 mg, 26% and 0.483 mg, 
12% respectively). 
2.2.7.3 Further CIEC purification of PEG20-His8IFN and (PEG20)2-His8IFN  
PEG20-His8IFN and (PEG20)2-His8IFN conjugates were further purified using a 
buffering CIEC step using the same column and buffers as in method 2.2.7.2. For 
PEG20-His8IFN the step gradient of buffer B was 40, 55 and 100%, with each step 
eluting over six column volumes, whilst for (PEG20)2-His8IFN the step gradient was 
27, 36, 55 and 100% buffer B with each step also eluting over six column volumes. 
Analysis of the collected fractions was performed by SDS-PAGE, with the gels being 
stained with InstantBlue
™
, PEG stain and silver stain. Once analysed, the purest and 
most concentrated fractions were combined and centrifugally concentrated in a 
VivaSpin (10,000 MWCO) at 3000 ×g, 4 °C until ~1.5 mL. The concentrated PEG-
His8IFN and PEG2-His8IFN products (1× 2.5 mL) were then buffer exchanged into 
50 mM sodium phosphate pH 7.4 containing 150 mM sodium chloride using pre-
equilibrated PD-10 desalting columns. SDS-PAGE analysis was conducted on both 
PEG-His8IFN and PEG2-His8IFN products and InstantBlue
™
, PEG stain and silver 
stain were conducted on the gels. UV absorbance at 280 nm and MicroBCA™ assay 
were conducted to quantify protein concentration and final yields of PEG20-His8IFN 
and (PEG20)2-His8IFN conjugates (0.7 mg, 17.6% and 0.29 mg, 7.13% respectively). 
2.2.7.4 Conjugation of His8IFN α-2a with PEG20 di(mono)sulfone 5 to prepare 
His8IFN-PEG20-His8IFN  
Pre-activated PEG20 di(bis)sulfone 5 (0.515 mL,1 eq.) was added to His8 IFN α-2a 
solution (0.5 mL at 3 mg/mL) and incubated overnight (16 h) at 20 °C. Analysis of 
the reaction mixture was performed by SDS-PAGE, with the resulting gels initially 
stained by InstantBlue
™
 followed by PEG stain. To prevent de-PEGylation the 
conjugated His8IFN α-2a conjugates were stabilised by the addition of 100 mM 
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STAB dissolved in DMSO at 4 °C for 1.5 h. The crude mixture was then buffer 
exchanged into 100 mM sodium acetate pH 4.0 using a pre-equilibrated PD-10 
desalting column. 
2.2.7.5 Purification of His8IFN-PEG20-His8IFN using CIEC 
Purification of PEG20 di(mono)sulfone-His8IFN α-2a reaction mixture was 
performed using CIEC to separate PEG20-His8IFN, His8IFN-PEG20-His8IIFN, 
unreacted PEG di(mono)sulfone 5 and unconjugated His8IFN α-2a. The reaction 
mixture was loaded into a 5 mL HiTrap Macrocap SP CIEC column using an ÄKTA 
prime plus fitted with a 5 mL loop which had been pre-equilibrated with buffer A 
(100 mM sodium acetate pH 4.0). A buffer B (1 M sodium chloride, 100 mM sodium 
acetate pH 4.0) step gradient of 27, 36, 55, 80 and 100 % was used to elute the 
different His8IFN α-2a species. Fractions collected were then analysed by SDS-
PAGE and stained using silver stain. Fractions containing PEG20-His8IFN and 
His8IFN-PEG20-His8IFN were combined and centrifugally concentrated using a 
VivaSpin column with 10,000 MWCO at 3000 ×g, 4 °C until ~1.5 mL. Once 
concentrated PEG20-His8IFN and His8IFN-PEG20-His8IFN conjugates were buffer 
exchanged into 50 mM sodium phosphate containing 150 mM sodium chloride pH 
7.4 for size exclusion chromatography (SEC). The protein concentration and yield 
was estimated by measuring UV (abs= 280 nm) for the PEG20-His8IFN and His8IFN-
PEG20-His8IFN (0.092 mg/mL, 3% yield and 0.407 mg/mL, 13.5% yield 
respectively). 
2.2.7.6 Further purification of His8IFN-PEG20-His8IFN using SEC 
SEC was used to separate His8IFN-PEG20-His8IFN from native His8IFN α-2a. The 
mixture was loaded into a 120 mL Superdex
™
 200 prep grade column 16/60 using an 
ÄKTA prime plus fitted with a 2 mL loop which had been pre-equilibrated with 50 
mM sodium phosphate containing 150 mM sodium chloride pH 7.4. The protein 
conjugates were eluted according size over one column volume (120 mL), and the 
fractions collected (2 mL) analysed using SDS-PAGE. The resulting gel was stained 
using silver stain and the purest fractions of His8IFN-PEG20-His8IFN were combined 
and centrifugally concentrated using pre-equilibrated VivaSpin column with 10,000 
MWCO at 3000 ×g, 4 °C until ~1.5 mL. The His8IFN-PEG20-His8IFN concentration 
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and yield (0.030 mg/mL, ~1.5%) was estimated by UV absorbance (280 nm) and 
MicroBCA™ assay.  
2.2.8 Preparation of disulfide conjugated IFN conjugates 
2.2.8.1 Optimisation of PEG20 bis-sulfone 1 molar equivalents for PEG20-IFN and 
(PEG20)2-IFN preparation 
His8IFNα-2a (0.438 mg/mL, 0.1 mL) was reduced using 20 mM DTT for 30 min at 
RT. After reduction DTT was removed by PD-10 buffer exchange using a pre-
equilibrated PD-10 column. Scouting experiments were conducted with increasing 
molar equivalents (eq.) of PEG20 bis-sulfone 1 ranging from 0.8 to 2.5 eq. (Table 2–
2). The reactions were allowed to proceed for 4 h at 4 °C, then 1 mM GRS solution 
(2 µL) was added and the reaction mixture as allowed to react for a further 16 h at 4 
°C. After the incubation period the reaction mixture was assessed using SDS-PAGE 
analysis. 
Table 2–2: Molar equivalents of PEG20 bis-sulfone 1 tested to prepare disulfide conjugated 
PEG20-IFN and (PEG20)2-IFN 
Reagent Molar equivalent Volume (μL) 
PEG20 bis-sulfone 1 
(20 mg/mL) 
0.8 
1.0 
1.5 
2.0 
2.5 
0.85 
1.0 
1.6 
2.0 
2.7 
 
2.2.8.2 Disulfide conjugation of IFN with PEG20 bis-sulfone 1 
His8IFN α-2a (5 mg; 4.875 mL) was reduced using DTT (1 M, 15.4 mg, 125 μL) for 
30 min at RT. Once reduced, DTT was removed from the His8IFN α-2a solution by 
buffer exchange using two pre-equilibrated PD-10 columns. The concentration was 
quantified using UV at absorbance 280 nm (0.797 mg/mL, 6.5 mL) and was diluted 
to 0.5 mg/mL (10 mL). PEG20 bis-sulfone 1 was weighed (5.9 mg) and added to the 
reduced His8IFN α-2a (250 μL) in a 1:1 ratio (PEG20 bis-sulfone 1:IFN). The PEG20-
IFN reaction mixture was left to react for 3 h at RT, then 1 mM GRS (50 μL of 50 
mM GSH:50 mM GSSG in 50 mM sodium acetate pH 4.0) was added, and the 
reaction allowed to proceed for a further 16 h at 20 °C. SDS-PAGE analysis was 
conducted the reaction mixture prior to CIEC purification.  
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2.2.8.3 CIEC purification of PEG20 bis-sulfone 1- IFN reactions mixture 
CIEC purification of the reaction mixture was performed to separate (PEG20)2-IFN, 
unreacted PEG20 reagent 1, PEG20-IFN and unconjugated His8IFN α-2a. The reaction 
mixture was loaded onto a 5 mL HiTrap Macrocap SP column using an ÄKTA prime 
which had been pre-equilibrated with buffer A (100 mM sodium acetate pH 4.0). The 
protein conjugates were eluted with a step gradient of buffer B (1.0 M sodium 
chloride in 100 mM sodium acetate pH 4.0) where the reaction mixture was loaded 
manually onto the column (ca.=10 mL), and the system was washed for 30 mL, then 
the method in Table 2–3 was conducted.  
Table 2–3. CIEC purification method for PEG20 bis-sulfone 1-IFN reaction mixture 
Volume 
(mL) 
% Buffer 
B 
Flow Rate 
(mL/ min) 
Fraction 
Size (mL) 
Position Auto zero 
0.0 0 2.0 0 Load No 
2.0 0 2.0 0.0 Load Yes 
20.0 0 2.0 1.5 Load No 
20.1 40 2.0 1.5 Load No 
60.1 40 2.0 1.5 Load No 
60.2 45 2.0 1.5 Load No 
100.2 45 2.0 1.5 Load No 
100.3 55 2.0 1.5 Load No 
140.3 55 2.0 1.5 Load No 
140.4 100 2.0 1.5 Load No 
180.4 100 2.0 1.5 Load No 
180.5 0 2.0 0.0 Load No 
220.5 0 2.0 0.0 Load No 
 
Fractions collected were then analysed by SDS-PAGE and stained using 
InstantBlue
™
 and PEG stain. Fractions containing the desired conjugates were 
combined and centrifugally concentrated using a VivaSpin column with 10,000 
MWCO at 3000 ×g, 4 °C until ~1.5 mL. Once concentrated the PEG20-IFN and 
(PEG20)2-IFN conjugates were buffer exchanged into 50 mM sodium phosphate 
containing 20 mM EDTA pH 7.8. Protein concentration was estimated by measuring 
UV absorbance at 280 nm and was confirmed by MicroBCA assay for both PEG20-
IFN and (PEG20)2-IFN conjugates (330 μg/mL, 147.5 μg/mL respectively). Then 
approximate yield was calculated for both PEG20-IFN and (PEG20)2-IFN conjugates 
(28.8% and 12% respectively). 
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2.2.8.4 Disulfide conjugation of IFN with PEG10 bis-sulfone 1 
His8IFN α-2a (3 mg; 4.875 mL) was reduced using DTT (1 M, 15.4 mg, 125 μL) for 
30 min at RT. Once reduced, DTT was removed from the His8IFN α-2a solution by 
buffer exchange using two pre-equilibrated PD-10 columns. The concentration was 
quantified using UV at absorbance 280 nm (0.480 mg/mL, 7 mL) and was diluted to 
0.5 mg/mL (10 mL). PEG10 bis-sulfone 1 was weighed (2.2 mg) and added to the 
reduced His8IFN α-2a (220 μL) in a 1:1 ratio (PEG10 bis-sulfone 1:IFN). The PEG10 
bis-sulfone 1-IFN reaction mixture was left to react for 3 h at RT, then 1 mM GRS 
(204.1 μL of 50 mM GSH:50 mM GSSG in 50 mM sodium acetate pH 4.0) was 
added, and the reaction was allowed to proceed for a further 16 h at 20 °C. SDS-
PAGE analysis was conducted the reaction mixture prior to CIEC purification.  
2.2.8.5 CIEC purification of PEG10 bis-sulfone 1-IFN reaction mixture 
Purification of the PEG10 bis-sulfone 1-IFN reaction mixture was performed in the 
same procedure outlined in method 2.2.8.3, however the ÄKTA prime method used 
was optimised to the following percentages of buffer B: 0, 50, 55, 60 and 100. The 
protein concentration was estimated by measuring UV absorbance at 280 nm for both 
PEG20-IFN and (PEG20)2-IFN conjugates (1 mg/mL = 0.130 and 0.261 Abs=280 nm 
respectively) and then approximate yield was calculated (14% and 16% 
respectively). 
2.2.8.6 Disulfide conjugation of His8IFN α-2a with PEG5 bis-sulfone 1 
His8IFN α-2a (4.18 mg/mL; 4 mL) was reduced using DTT (1 M, 15.4 mg, 80 μL) 
for 30 min at RT. Once reduced, DTT was removed from the His8IFN α-2a solution 
by buffer exchange using two pre-equilibrated PD-10 columns. The concentration 
was quantified using UV at absorbance 280 nm (0.523 mg/mL, 7 mL). PEG 5 kDa 
bis-sulfone 1 was weighed (2.1 mg) and added to the reduced His8IFN α-2a (430 μL) 
in a 1:1 ratio (PEG5 bis-sulfone 1:IFN). The PEG5 bis-sulfone 1-His8IFN α-2a 
reaction mixture was left to react for 3 h at RT, then 1 mM GRS (142.9 μL of 50 mM 
GSH:50 mM GSSG in 50 mM sodium acetate pH 4.0) was added, and the reaction 
was allowed to proceed for a further 16 h at 20 °C. SDS-PAGE analysis was 
conducted the reaction mixture prior to CIEC purification.  
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2.2.8.7 CIEC purification of PEG5 bis-sulfone 1-IFN reaction mixture 
Purification of the PEG5 bis-sulfone 1- His8IFN α-2a reaction mixture was performed 
in the same procedure outlined in method 2.2.8.3, however the ÄKTA prime method 
used was optimised to the following percentages of buffer B: 0, 48, 55, 60 and 100. 
The protein concentration was estimated by measuring UV absorbance at 280 nm for 
both PEG5-IFN and (PEG5)2-IFN conjugates (0.304 mg/mL and 0.36 mg/mL 
respectively) and the approximate yield was calculated (29% and 34.5% 
respectively). 
2.2.8.8 Disulfide conjugation of IFN with PEG20 di(bis)sulfone 4 to prepare IFN-
PEG20-IFN 
His8IFN α-2a (2 mg/mL, 5 mL) was buffer exchanged into 50 mM sodium phosphate 
20 mM EDTA pH 7.8 using two pre-equilibrated PD-10 columns. His8IFN α-2a was 
reduced using 25 mM DTT (1 M, 15.8 mg, 180 µL) for 30 min. The reduced His8IFN 
α-2a was buffer exchanged into 50 mM sodium phosphate 20 mM EDTA pH 7.8 
using three pre-equilibrated PD-10 columns. The concentration was quantified using 
UV at absorbance 280 nm (0.752 mg/mL, 11 mL) and was diluted to 0.5 mg/mL (15 
mL), where half (7.5 mL, 4.1 mg) of this reduced His8IFN α-2a was used for the 
synthesis of IFN-PEG10-IFN. PEG20 di(bis)sulfone 4 was weighed (2.5 mg) and 
added to the reduced His8IFN α-2a (106 μL) in a 2:1 ratio (PEG20 di(bis)sulfone 
4:IFN). The PEG20 di(bis)sulfone-His8-IFN α-2a reaction mixture was left to react 
for 5 h at 20 °C, then 1 mM GRS (153.1 µL of 50 mM GSH:50 mM GSSG in 50 
mM sodium acetate pH 4.0) was added, and the reaction was allowed to proceed for 
a further 16 h at 20 °C. SDS-PAGE analysis was conducted the reaction mixture 
prior to and after GRS addition. The IFN-PEG20-IFN conjugate was then stabilized 
by the addition of 100 mM STAB dissolved in DMSO at 4 °C for 1.5 h. The reaction 
mixture (7.5 mL) was then buffer exchanged into 100 mM sodium acetate pH 4.0 
using three pre-equilibrated PD-10 desalting columns.  
2.2.8.9 Disulfide conjugation of IFN with PEG10 di(bis)sulfone 4 to prepare IFN-
PEG10-IFN 
Reduced His8IFN α-2a (7.5 mL, 4.1 mg) from method 2.2.8.8 was used for this 
reaction. PEG10 di(bis)sulfone 4 was weighed (2.9 mg) and added to the reduced 
His8IFN α-2a (110 μL) in a 2:1 ratio (PEG20 di(bis)sulfone 4:IFN). The PEG10 
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di(bis)sulfone 4-IFN mixture was left to react for 5 h at 20 °C, then 1 mM GRS 
(153.1 µL of 50 mM GSH:50 mM GSSG in 50 mM sodium acetate pH 4.0) was 
added, and the reaction was allowed to proceed for a further 16 h at 20 °C. SDS-
PAGE analysis was conducted the reaction mixture prior to and after GRS addition. 
The IFN-PEG10-IFN conjugate was then stabilized by the addition of 100 mM STAB 
dissolved in DMSO at 4 °C for 1.5 h. The reaction mixture (7.5 mL) was then buffer 
exchanged into 100 mM sodium acetate pH 4.0 using three pre-equilibrated PD-10 
desalting columns.  
2.2.8.10 CIEC purification of IFN-PEG20-IFN and IFN-PEG10-IFN reaction mixtures 
CIEC purification of the reaction mixtures was performed to separate unreacted PEG 
reagent 4, PEG-IFN from IFN-PEG-IFN and unconjugated His8IFN α-2a, which 
would be separated using SEC (method 2.2.8.11). The reaction mixture was loaded 
onto a 5 mL Macrocap SP ion exchange column using an ÄKTA prime plus fitted 
with two 5 mL loops which had been pre-equilibrated with buffer A (100 mM 
sodium acetate pH 4.0). The protein conjugates were eluted with a step gradient of 
buffer B: 1.0 M sodium chloride in 100 mM sodium acetate pH 4.0 of 45,55 and 
100%. Fractions collected were then analysed by SDS-PAGE and stained using 
InstantBlue
™
 and silver stain. Fractions (57-63 and 60-62) containing IFN-PEG20-
IFN+His8IFN α-2a, IFN-PEG10-IFN+His8IFN α-2a mixtures respectively were 
combined and centrifugally concentrated using a VivaSpin column with 10,000 
MWCO at 3000 ×g, 4 °C until >1.5 mL. The mixtures were buffer exchanged using 
pre-equilibrated NAP-10 columns into 50 mM sodium phosphate containing 150 mM 
sodium chloride pH 7.8. Protein concentration and yield was calculated by measuring 
UV absorbance at 280 nm for both IFN-PEG20-IFN+His8IFN α-2a, IFN-PEG10-
IFN+His8IFN α-2a mixtures (0.682 mg/mL, 27.3% and 1.12 mg/mL, 27.3% 
respectively).  
2.2.8.11 SEC purification of IFN-PEG20-IFN and IFN-PEG10-IFN mixtures 
SEC purification of IFN-PEG20-IFN + His8IFN α-2a and IFN-PEG10-IFN + His8IFN 
α-2a mixtures was performed to separate His8IFN α-2a from IFN-PEG20-IFN and 
IFN-PEG10-IFN. The mixtures were loaded separately onto the Superdex 200 Prep 
Grade Column 16/60 120 mL column, which had been pre-equilibrated with 50 mM 
sodium phosphate containing 20 mM EDTA pH 7.8 using an ÄKTA prime, plus 
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fitted with a 2 mL loop. The protein conjugates were eluted over 120 mL and the 
fractions collected were then analysed by SDS-PAGE and stained using silver stain. 
Fractions (26-29 and 22-28) containing IFN-PEG20-IFN or IFN-PEG10-IFN were 
combined and centrifugally concentrated using a VivaSpin column with 10,000 
MWCO at 3000 ×g, 4 °C until >1.5 mL. Protein concentration for both IFN-PEG20-
IFN and IFN-PEG10-IFN were estimated by measuring UV absorbance at 280 nm 
and confirmed by MicroBCA assay (0.035 and 0.046 mg/mL respectively). Final 
yields for IFN-PEG20-IFN and IFN-PEG10-IFN conjugates were 1.4% and 1.12% 
respectively. SDS-PAGE analysis was carried on the final conjugates. 
2.2.9 Preparation of disulfide PEGylated IFN-PEG-Fab heterodimer 
conjugates and PEG-Fab controls  
2.2.9.1 Optimisation of TCEP equivalents for Fabbeva reduction 
Fabbeva (0.38 mg/mL, 0.19 mg) in reaction buffer (50 mM sodium phosphate, 150 
mM sodium chloride, 40 mM EDTA, 0.05% Tween-20 pH 8.2) was pipetted into 
five 0.1 mL aliquots. TCEP (0.5 mM) was then diluted using purified water. The 
ratios of TCEP were then added to the Fabbeva aliquots following Table 2–4 volumes. 
All TCEP eq. volumes were made up to 2.74 μL by the addition of extra reaction 
buffer, to keep the concentration of Fabbeva the same throughout. The aliquots were 
then left for 2 h at 37 °C. After 1.5 h, SDS-PAGE analysis was conducted on the 
TCEP-Fabbeva mixtures to determine the optimum eq. for full reduction of Fabbeva. It 
was determined that 1.4 eq. of TCEP enough to reduce Fabbeva after 2 h incubation at 
37 °C. 
Table 2–4. Fabbeva reduction optimisation with TCEP: molar equivalents and volumes 
Reagent Molar equivalent Volume (μL) 
TCEP  
(2.1 mM) 
1 
1.2 
1.4 
1.8 
1.52 
1.82 
2.12 
2.74 
2.2.9.2 Optimisation of PEG20 bis-sulfone 1 equivalents for PEG20-Fabbeva 
A 100 μL aliquot of Fabbeva at 3.02 mg/mL was defrosted at RT. From a stock of 0.5 
M TCEP a 2.1 mM TCEP stock was prepared using purified water. Fabbeva (150 μg) 
was reduced using 2 μL of 2.1 mM TCEP stock, resulting in the final molar 
equivalents of TCEP being 1.4. The mixture was then incubated at 37 °C for 2 h. 
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After 1.5 h SDS-PAGE analysis was conducted on the TCEP-Fabbeva mixture to 
confirm reduction. 
 Following completion of reduction of Fabbeva with TCEP, different molar 
equivalents (1,1.2, 1.5,1.7, 2 eq.) of PEG20 bis-sulfone 1 were trialled to optimise 
yield of PEG20-Fabbeva.Fabbeva (20 μg, 6.9 μL) was pipetted into five 0.5 tubes and 
Table 2–5 was followed for the addition of PEG20 bis-sulfone 1. All PEG20 bis-
sulfone 1 eq. volumes were made up to 3.2 μL by the addition of extra reaction 
buffer, to keep the concentration of Fabbeva the same throughout. The reactions were 
allowed to proceed for 16 h at 25 °C. 
Table 2–5. Conjugation of Fabbeva to PEG20 bis-sulfone 1 optimisation: amounts and 
volumes used of reagent. 
Reagent Molar equivalent Volume (μL) 
PEG20 bis-sulfone 1 
(5 mg/mL) 
1 
1.2 
1.5 
1.7 
2 
1.59 
1.92 
2.4 
2.72 
3.2 
 
 After 16 h, SDS-PAGE analysis was conducted on all reactions and 
densimetric analysis was conducted on the InstantBlue™ stained gel using 
ImageQuant™. It was found that 2 eq. of PEG20 bis-sulfone 1 was optimum for 
PEG20-Fabbeva production. 
2.2.9.3 Disulfide conjugation of Fabbeva with PEG20 bis-sulfone 1 to prepare PEG20-
Fabbeva 
Three 100 μL aliquots of Fabbeva at 3.02 mg/mL was defrosted at RT and pooled. 
From a stock of 0.5 M TCEP a 14 mM TCEP stock was prepared using purified 
water. Fabbeva (1 mg, ca.=331 μL) was reduced using 2 μL of 14 mM TCEP stock, 
resulting in the final molar equivalents of TCEP being 1.4. The mixture was then 
incubated at 37 °C for 2 h. After 1.5 h SDS-PAGE analysis was conducted on the 
TCEP-Fabbeva mixture to confirm reduction. 
 Following completion of reduction of Fabbeva with TCEP, 2.0 eq PEG20 bis-
sulfone 1 (40 mg/mL, 20 μL) was added and the reaction allowed to proceed for 16 h 
at 25 °C. After 16 h, SDS-PAGE analysis was conducted on the reaction mixture. 
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2.2.9.4 Optimisation of CIEC purification of PEG20-Fabbeva reaction mixture 
The reaction mixture from method 2.2.9.3 (ca. 353 μL) was diluted 8.3× in buffer A 
(100 mM sodium acetate pH 4.0, 0.01% Tween-20 (ca.=2.9 mL). The reaction 
mixture was purified by CIEC using a HiTrap Macrocap SP column connected to an 
AKTA prime plus purifier, which had been pre-equilibrated with buffer A. To 
determine the percentage of buffer B (100 mM sodium acetate, 1 M sodium chloride, 
0.01% Tween-20 pH 4.0) at which the conjugates elute a linear gradient was 
performed from 0-100 % buffer B over 30 mL. The peak fractions (27-45) collected 
were then analysed by SDS-PAGE and stained using InstantBlue
™
 and PEG stain. 
 Fractions 29 to 45 were pooled and diluted 10× with buffer A (ca.=340 mL). 
The diluted protein was then re-loaded onto the pre-equilibrated HiTrap Macrocap 
SP column at 5 mL/min. The CIEC step gradient shown in Table 2–6 was then used 
to purity PEG20 bis-sulfone 1-Fabbeva reaction mixture. The peak fractions (5-32) 
were then analysed by SDS-PAGE. 
Table 2–6. Details of first CIEC step gradient used to purity PEG20 bis-sulfone 1-Fabbeva 
Volume 
(mL) 
% Buffer 
B 
Flow Rate 
(mL/ min) 
Fraction 
Size (mL) 
Position Auto zero 
0.0 0 5.0 0 Load No 
2.0 0 5.0 0.0 Load Yes 
10.0 0 5.0 2.0 Load No 
10.1 14 5.0 2.0 Load No 
30.1 14 5.0 2.0 Load No 
30.2 20 5.0 2.0 Load No 
60.2 20 5.0 2.0 Load No 
60.3 100 5.0 2.0 Load No 
65.3 100 5.0 2.0 Load No 
65.4 0 5.0 0.0 Load No 
95.4 0 5.0 0.0 Load No 
2.2.9.5 CIEC purification of PEG20 bis-sulfone 1-Fabbeva 
From the first CIEC in method 2.2.9.5, no separation was between PEG20-Fabbeva and 
Fabbeva was observed in the SDS-PAGE analysis. Therefore, fractions 6-31 were 
pooled and diluted 10× with buffer A (ca.=468 mL). The diluted mixture was re-
loaded onto the pre-equilibrated HiTrap Macrocap SP column at 5 mL/min. The 
second step gradient method shown in Table 2–7 was followed.  
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Table 2–7. Second CIEC step gradient method for purifying PEG20 bis-sulfone 1-Fabbeva 
Volume 
(mL) 
% Buffer 
B 
Flow Rate 
(mL/ min) 
Fraction 
Size (mL) 
Position Auto zero 
0.0 0 5.0 0 Load No 
2.0 0 5.0 0.0 Load Yes 
10.0 0 5.0 2.0 Load No 
10.1 17 5.0 2.0 Load No 
30.1 17 5.0 2.0 Load No 
30.2 30 5.0 2.0 Load No 
60.2 30 5.0 2.0 Load No 
60.3 100 5.0 2.0 Load No 
90.3 100 5.0 2.0 Load No 
90.4 0 5.0 0.0 Load No 
120.4 0 5.0 0.0 Load No 
 
The peak fractions (5-14, 15-25, 29-35) were then analysed by SDS-PAGE and the 
resulting gel was stained by InstantBlue™ and PEG stain. Fractions 5-13 were 
pooled (ca.=18 mL) and centrifugally concentrated in a pre-equilibrated Vivaspin 
MWCO 10,000 at 4 °C, 3000 ×g. The concentrated PEG20-Fabbeva (ca.=1 mL) was 
then buffer exchanged into 1×PBS using a pre-equilibrated NAP-10 column; 1 mL of 
conjugate was loaded onto the column and eluted. PSB (1×, 1.5 mL) was loaded onto 
the column and the conjugate eluted and collected in a 2 mL tube. Protein 
concentration for both PEG20-Fabbeva was estimated by measuring UV absorbance at 
280 nm (0.440 mg/mL). The final yield for PEG20-Fabbeva was 44% and then SDS-
PAGE analysis was conducted on the final conjugate were the resulting gel was 
stained by InstantBlue™ and PEG stain. 
2.2.9.6 Disulfide conjugation of Fabbeva with PEG20 di(bis)sulfone 4 to prepare 
Fabbeva-PEG20-X 
Fabbeva was reduced following method 2.2.6.3, the reduced Fabbeva (4 mg, 2 mL) in 
50 mM sodium phosphate, 150 mM sodium chloride, 20 mM EDTA, 0.005% 
Tween-20 pH 8.2 was allowed to react with 2 eq. PEG20 di(bis)sulfone 4. PEG20 
di(bis)-sulfone 4 was solubilised in 50 mM sodium phosphate, 150 mM sodium 
chloride, and 20 mM EDTA pH 7.4. The reaction was allowed to proceed for 2 h at 
25 ̊C. After this time, SDS-PAGE analysis of the reaction mixture was conducted and 
the subsequent gel was stained by InstantBlue
™
 and PEG stain (BaI2).  
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2.2.9.7 CIEC purification of PEG20 di(bis)sulfone 4-Fabbeva (Fabbeva-PEG20-X) 
The PEG20 di(bis)sulfone 4-Fabbeva reaction mixture (ca.=5 mL) was diluted 10× 
(ca.=50 mL) in buffer A (100 mM sodium acetate pH 4.0) and was manually loaded 
onto a 5 mL Macrocap SP ion exchange column using an ÄKTA prime plus which 
had been pre-equilibrated with buffer A. The protein conjugates were eluted with a 
linear gradient over 30 mL with a target of 100% buffer B:100 mM sodium acetate, 1 
M sodium chloride pH 4.0. Fractions collected were then analysed by SDS-PAGE 
and stained using InstantBlue
™
 and PEG stain (BaI2). Fractions (3-27) containing X-
PEG20-Fabbeva were combined, centrifugally concentrated and buffer exchanged into 
50 mM sodium phosphate, 150 mM sodium chloride, 20 mM EDTA pH 7.8 using a 
pre-equilibrated VivaSpin column with 10,000 MWCO at 3000 ×g, 4 °C until >1.5 
mL. The protein concentration of Fabbeva-PEG20-X was estimated using UV 
absorbance 280 nm (4.35 mg/mL, ε=1.4).  
2.2.9.8 Conjugation of IFN with Fabbeva-PEG-X to prepare IFN-PEG20-Fabbeva 
IFN was reduced according to method 2.2.6.1, the reduced IFN (2 eq, 3.55 mg) was 
then added to Fabbeva-PEG20-X (1 eq.) and the reaction allowed to proceed for 5 h at 
25 °C. After this time, glutathione re-oxidising solution was added the reaction 
mixture and the re-oxidising of IFN was allowed to proceed for 16 h at 25 °C. The 
IFN-PEG20-Fabbeva reaction mixture was then stabilised by the addition of 100 mM 
STAB dissolved in DMSO at 4 °C for 1.5 h (Figure 2-2). The crude mixture (ca.= 6 
mL) was then diluted 10-fold in 100 mM sodium acetate pH 4.0 for CIEC.  
2.2.9.9 CIEC purification of the IFN-PEG20-Fabbeva reaction mixture 
The IFN-PEG20-Fabbeva reaction mixture (ca.=60 mL) was manually loaded onto a 5 
mL Macrocap SP cation exchange column using an ÄKTA prime plus which had 
been pre-equilibrated with buffer A (100 mM sodium acetate pH 4.0). The protein 
conjugates were eluted with a step gradient of buffer B:1.0 M sodium chloride in 100 
mM sodium acetate pH 4.0 of 30,60, 80 and 100%. Fractions collected were then 
analysed by SDS-PAGE and stained using InstantBlue
™
 and PEG stain. Fractions 
(27-31) containing IFN-PEG20-Fabbeva were combined, centrifugally concentrated 
and buffer exchanged into 50 mM sodium phosphate containing 150 mM sodium 
chloride pH 7.8 using a pre-equilibrated VivaSpin column with 10,000 MWCO at 
3000 ×g, 4 until ~2 mL. Protein concentration was estimated by measuring UV 
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absorbance at 280 nm for IFN-PEG20-Fabbeva (Fab: ε=1.4 0.489 mg/mL, yield=12%; 
IFN: ε=0.914, 0.749 mg/mL, yield=21%).  
2.2.9.10 Optimisation of Fabalb reduction using DTT 
Fabalb (0.736 mg/mL; 10 μL aliquots) was reduced using 2.5, 5, 10 mM DTT for 1 h 
at RT. The reduced Fabalb mixtures were then analysed using SDS-PAGE. The 
resulting SDS-PAGE gel was stained using InstantBlue
™
. It was observed that 5 mM 
was required to fully reduce Fabalb. 
2.2.9.11 Control Fabalb-PEG20 bis-sulfone reaction 
To confirm site-specific disulfide conjugation of Fabalb, a control reaction was 
conducted. Fabalb (10 μg; 0.15 mL) (in 50 mM sodium phosphate, 20 mM EDTA, 50 
mM sodium chloride) was not reduced and incubated for 5 h at RT with PEG20 bis-
sulfone 1 in a ratio of 1:1 PEG:Fab. The mixture was analysed by SDS-PAGE, with 
the resulting gel stained with InstantBlue™ and PEG stain. PEG bis-sulfone 1 was 
also run on the gel for comparison.  
2.2.9.12 Optimisation of reaction buffer pH to prepare PEG20-Fabalb 
Fabalb (0.736 mg/mL, 1.0 mL) was reduced with 5 mM DTT for 1 h at RT. 
Confirmation of reduction was conducted by SDS-PAGE. To remove the DTT the 
reduced Fabalb was buffer exchanged into 50 mM sodium phosphate, 40 mM EDTA, 
150 mM sodium chloride (reaction buffer) pH 6.5, pH 7.0 and pH 7.4 by pre-
equilibrated PD-10 columns. Fabalb (1 eq., 1 mL) was reacted with PEG20 bis-sulfone 
1 (1 eq., 20 mg/mL) for 1,3,16 h at 25 °C at each pH (Table 2–8). SDS-PAGE 
analysis was conducted at each time point to monitor the reactions. The optimum 
reaction conditions to prepare PEG20-Fabalb were found to be pH 6.5 for 3 h. 
Table 2–8: Conjugation of Fabalb to PEG20 bis-sulfone 1 optimum pH determination, 
conditions and volumes used for reactions 
Reaction buffer pH Fabalb concentration (mg) 
Volume (μL) of PEG20 bis-
sulfone 1 
6.5 0.171 3.41 
7.0 0.197 3.94 
7.4 0.196 3.90 
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2.2.9.13 Disulfide conjugation of Fabalb with PEG20 bis-sulfone 1-Fabalb to prepare 
PEG20-Fabalb 
Fabalb (0.3 mg/mL, 1.0 mL) was defrosted at RT, and then reduced using 20 mM 
DTT for 1 h at RT. Confirmation of reduction was conducted by SDS-PAGE. To 
remove the DTT, the reduced Fabalb was buffer exchanged into 50 mM sodium 
phosphate, 20 mM EDTA, 150 mM sodium chloride and 0.01% Tween-20 pH 6.5 
(reaction buffer) by pre-equilibrated PD-10 column. The reduced Fabalb concentration 
was assessed by UV absorbance (280 nm, 0.285 mg/mL, 2 mL). PEG20 bis-sulfone 1 
was weighed out (3.4 mg) and solubilised in reaction buffer (20 mg/mL, 170 μL). 
The PEG20 bis-sulfone 1 (0.163 mg, 8.15 μL) was then added in a 1:1 eq. ratio to the 
reduced Fabalb and the reaction allowed to proceed for 4 h at 25 °C. After overnight 
incubation, SDS-PAGE was conducted on the reaction mixture and the resulting gel 
was stained by InstantBlue™ and PEG stain. 
2.2.9.14 SEC purification of PEG20 bis-sulfone 1-Fabalb reaction mixture 
The PEG20 bis-sulfone 1-Fabalb reaction mixture from method 2.2.9.12 was purified 
by SEC purification in an effort to separate PEG20-Fabalb from Fabalb and high MW 
impurities ((PEGn)-Fabalb). The mixture was loaded onto the Superdex 200 Prep 
Grade Column 16/60 120 mL column, which had been pre-equilibrated with 50 mM 
sodium phosphate containing 20 mM EDTA pH 7.8 using an ÄKTA prime, plus 
fitted with a 2 mL loop. The protein conjugates were eluted over 120 mL and the 
fractions collected were then analysed by SDS-PAGE and stained using silver stain. 
Fractions (23-28) containing PEG20-Fabalb were combined and centrifugally 
concentrated using a VivaSpin column with 10,000 MWCO at 3000 ×g, 4 °C until 
>2 mL. Protein concentration for PEG20-Fabalb was estimated by measuring UV 
absorbance at 280 nm (41 μg/mL, 2 mL). The final yield of PEG20-Fabalb was 
calculated to be 28.8%. SDS-PAGE analysis of the final product was conducted and 
the resulting gel stained with InstantBlue™ and PEG stain. 
2.2.9.15 Disulfide conjugation of Fabalb with PEG20 di(bis)sulfone 4 to prepare 
Fabalb-PEG20-X 
Fabalb (0.37 mg, 1 mL) was reduced according to method 2.2.6.4 in 50 mM sodium 
phosphate, 150 mM sodium chloride, 20 mM EDTA, and 0.005% Tween-20 pH 7.0 
and was subsequently reacted with 5 eq PEG20 di(bis) sulfone 4 (0.732 mg, 36.6 μL). 
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The PEG20 di(bis)sulfone 4 was solubilised in 50 mM sodium phosphate, 150 mM 
sodium chloride, and 20 mM EDTA pH 7.4. The reaction was allowed to proceed for 
3 h at 25 ̊C. After this time, SDS-PAGE analysis of the reaction mixture was 
conducted and the subsequent gel was stained by InstantBlue
™
 and PEG stain. 
2.2.9.16 CIEC purification of PEG20 di(bis)sulfone 4-Fabalb (Fabalb-PEG20-X) 
To remove excess PEG20 di(bis)sulfone 4, a linear CIEC was performed. The PEG20 
di(bis)-sulfone-Fabalb reaction mixture (ca.=1 mL) was diluted 10-fold in buffer A 
(100 mM sodium acetate pH 4.0). The diluted mixture was then manually loaded 
onto the 5 mL Macrocap SP column using an ÄKTA prime plus which had been pre-
equilibrated with buffer A. The protein conjugates were eluted with a linear gradient 
over 30 mL with a target of 100% buffer B (100 mM sodium acetate, 1 M sodium 
chloride pH 4.0). Fractions collected were then analysed by SDS-PAGE and stained 
using InstantBlue
™
 stain. Fractions (29-39) containing PEG20-Fabalb were combined, 
centrifugally concentrated and buffer exchanged into 50 mM sodium phosphate, 150 
mM sodium chloride, 20 mM EDTA pH 7.4 using a pre-equilibrated VivaSpin 
column with 10,000 MWCO at 3000 ×g, 4 °C until ca.=6 mL. The concentration of 
X-PEG20-Fabalb was estimated to be 0.17 mg using UV absorbance 280 nm (Fabalb 
ε=1.4) with a resulting yield of 46.7%.  
2.2.9.17 Disulfide conjugation of IFN with PEG20 di(bis)sulfone 4-Fabalb (Fabalb-
PEG20-X) 
IFN was reduced following method 2.2.6.1. Reduced IFN (2 eq, 0.25 mg) was then 
added to X-PEG20-Fabalb (1 eq, 0.17 mg) and the reaction allowed to proceed for 4 h 
at 25 °C. After this time, glutathione re-oxidising solution (40 μL) was added the 
reaction mixture and re-oxidising of IFN was allowed to proceed for 16 h a 25 °C. 
The IFN-PEG20-Fabalb conjugate was then stabilised by two additions (80 μL) of 100 
mM STAB dissolved in DMSO at 4 °C for 1.5 h (Figure 2-2). The crude mixture 
(ca.=2 mL) was then diluted 10-fold in 100 mM sodium acetate pH 4.0 for CIEC to 
reduce the salt concentration and allow the proteins to bind to the column.  
2.2.9.18 CIEC purification of the IFN-PEG20-Fabalb reaction mixture 
The IFN-PEG-Fabalb reaction mixture (ca.=2 mL) was manually loaded at a flow rate 
of 2 mL/min onto a pre-equilibrated (buffer A:100 mM sodium acetate pH 4.0) 5 mL 
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Macrocap SP cation exchange column using an ÄKTA prime plus. The protein 
conjugates were eluted with a step gradient of buffer B:1.0 M sodium chloride in 100 
mM sodium acetate pH 4.0 of 30,60,80 and 100 %. Fractions collected (2 mL) were 
then analysed by SDS-PAGE and stained using InstantBlue
™
 and silver stain. 
Fractions (4-24) containing IFN-PEG20-Fabalb were combined, centrifugally 
concentrated and buffer exchanged into 50 mM sodium phosphate containing 150 
mM sodium chloride pH 7.8 using a pre-equilibrated VivaSpin column with 10,000 
MWCO at 3000 ×g, 4 °C until ~1.5 mL. Protein concentration was estimated by 
measuring UV absorbance (280 nm) for IFN-PEG20-Fabalb (IFN ε=0.914, 0.11 
mg/mL, yield=44%; Fabalb ε=1.4, 0.0725 mg/mL, yield=20.5%).  
2.2.10 Characterisation of protein species 
2.2.10.1 Western blot for protein species characterisation  
Protein species were loaded (1 μg protein) and run on SDS-PAGE gels (35 min, 200 
V, 500 mA). The transfer buffer stock (12.5×) was made in advance; it consisted of 
tris-base (37.8 g), glycine (181.7 g) and was made up to 1 L with purified water. 
Transfer buffer (1×) was prepared by diluting 100 mL of transfer stock (12.5×) with 
methanol (250 mL) and 900 mL of purified water. The gels and transfer equipment 
were soaked for 10 min in transfer buffer (1×) and the protein samples in the SDS-
PAGE gel were transferred to a nitrocellulose membrane for 1 h, 30 V. After the 
transfer, the membrane was blocked with 20 mL PBST (1×PBS, 0.01% Tween-20) 
containing 5% skimmed milk for 1 h at RT. 
For His8IFN α-2a detection, the membrane was washed briefly with PBST and 
then left overnight at 4 °C with a ratio of 1:5000 antibody:PBST. The primary 
antibody used was anti-IFN α-2 rabbit polyclonal antibody, followed by anti-rabbit 
AP-conjugated (H&L) antibody in a ratio of 1:10000 in PBST for 1 h at RT. The 
membrane was washed trice with PBST. The samples were detected by a 
colorimetric detection method. Therefore, one Sigma Fast™ NBT/BCIP alkaline 
phosphatase substrate tablet was dissolved in 10 mL deionized water and poured 
over the membrane. Incubation was conducted in the dark for 20 min and stopped by 
washing the membrane with water. 
For detecting the his-tag only PEGylation, mouse anti-6×His monoclonal 
antibody was used and was conjugated to by anti-mouse AP-conjugated antibody at 
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1:5000 in PBST for 1 h at RT. The membrane was washed trice with PBST and was 
detected by a colorimetric detection method. Therefore, one Sigma Fast™ 
NBT/BCIP alkaline phosphatase substrate tablet was dissolved in 10 mL deionized 
water and poured over the membrane. Incubation was conducted in the dark for 20 
min and stopped by washing the membrane with water. 
For detecting the rabbit anti-rat albumin species a polyclonal anti-rabbit IgG 
(H&L) AP-conjugated IgG was used. The membrane was used thrice with PBST and 
was developed by a colorimetric method. One Sigma Fast™ NBT/BCIP alkaline 
phosphatase substrate tablet was dissolved in 10 mL deionized water and poured 
over the membrane. Incubation was conducted in the dark for 20 min and stopped by 
washing the membrane with water. 
For detecting bevacizumab species goat anti-human κ-chain HRP-conjugated 
Fab’2 was used in a 1:10,000 ratio of antibody:PBST. The membrane was briefly 
washed with PBST and left overnight at 4 °C with the antibody. Following this, the 
membrane was washed 6 times with PBST. The samples were detected using 
Enhanced Chemiluminescence (ECL) and visualised by a digital imaging system 
(ImageQuant
™ 
LAS 4000). Detecting substrates A and B were mixed in a 40:1 ratio 
(2 mL), poured on the membrane and left to incubate for 1 min in the dark. After 
this, the ECL solution was poured off the membrane and with the ImageQuant
™
 set 
to chemiluminescence, pictures of the developed membrane were taken at 5,10,30 
sec, 1 and 3 min.  
2.2.10.2 NMR analysis of PEG20 di(mono)sulfone 5 
To investigate how the PEG20 di(mono)sulfone 5 and buffer interact, PEG20 
di(mono)sulfone 5 was left for 16 h at 20 °C in 50 mM sodium phosphate pH 6.5. 
This sample was then buffer exchanged using a PD-10 column into purified water 
and then freeze dried for 24 h. The freeze-dried PEG20 di(mono)sulfone 5 was re-
suspended in 200 μL deuterated water. The sample was then pipetted into an NMR 
tube and analysed by NMR. 
2.2.10.3 Matrix-Assisted Laser Desorption Ionisation Time of Flight (MALDI-TOF) 
Mass Spectrometry of analysis of IFN conjugates 
Mass spectra were acquired using an Applied Biosystems Voyager DE-PRO 
Biospectrometry workstation MALDI-TOF mass spectrometer using a nitrogen laser 
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(345-347 nm). Two matrix solution were used, firstly 25-dihydroxbenzoic acid 
(DHB) and secondly, sinapinic acid (SA) (3-(4-hydroxy-3-5-dimethoxyphenyl) pro2-
enoic). The matrix was a solution of either DHB or SA in a 50:50 mixture of 
acetonitrile and water containing 0.01% trifluoroacetic acid. The sample and matrix 
were mixed in a 1:1 ratio and 1 µL was spotted onto a 100-well stainless steel plate. 
All spectra were acquired in positive mode over a range of 2-100 kDa under linear 
conditions (25 kV accelerating voltage, 750 ns extraction time delay).  
2.2.10.4 7 day stability study of conjugated protein species 
To assess the stability of all PEGylated proteins prepared a 7-day stability study was 
conducted. Samples were incubated at 4 °C for 7 days and SDS-PAGE analysis was 
conducted on the incubated samples, with the resulting gels stained by InstantBlue™ 
and PEG stain. For conjugated proteins with a low concentration, silver stain was 
used to detect the conjugate and determine if there was any free protein.  
2.2.10.5 Accelerated stability assessment of PEGylated products  
PD-10 desalting columns were used to buffer exchange PEGylated protein samples 
into 10 mM ammonium bicarbonate pH 8.0 and the protein concentration quantified 
by UV absorbance at 280 nm. The protein concentrations were then diluted to 50 
μg/mL, and for each protein concentration, 27 μL was transferred into 4×0.5mL 
sample vials. For each of the protein products two of the sample vials were made up 
to 30 μL with the addition of 3 μL of 10 mM ammonium bicarbonate pH 8.0 while 
the two remaining sample vials are made up to 30 μL with 100 mM DTT solution. 
For each protein product, two sample vials (one with DTT and one without) were 
heated on a metal heating block to 90 °C for 10 min. The two remaining sample vials 
(one with DTT and one without) were then heated in the metal heating block for 1 h 
at 50 °C. Once all sample vials for each protein product were cooled to RT, 22 μL 
was taken from each sample vial and transferred into new labelled sample vials 
containing 11 μL loading dye. The sample/loading dye mixtures were subsequently 
analysed by SDS-PAGE and stained with InstantBlue™ and PEG stain, to identify if 
the protein conjugates are stable by the absence of unreacted His8IFN α-2a.  
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2.2.10.6 Assessment of EMCV titre (50 % Tissue Culture Infective dose (TCID50) 
assay) in A549 cells 
For the TCID50 assay, A549 cells (9×10
5
 cells/mL) were added at 0.1 mL/well in 96 
well microtitre plates (assay plates) and incubated for 24 h at 37 °C, 5% CO2 to 
allow the cells to adhere. Serial dilutions (10-fold, 10
-1
 to 10
-9
) of EMCV stock were 
prepared in 2 mL tubes using DMEM/2% FBS, serial dilutions (10
-2
 to 10
-9
, 150 
μL/well) were transferred into V-bottom microtitre assay plates (sample plates) in 
rows A to H and columns 2 to 11 (Figure 2-3). Columns 1 and 12 were the negative 
control wells where 150 μL DMEM/2% FBS was added (Figure 2-3). Media in the 
assay plates was aspirated and replaced with 0.1 mL of the EMCV dilutions. Sample 
transfer was rapidly performed using a multichannel pipette. Assay plates were then 
incubated for 72 h in 37 °C, 5% CO2. From 72 h to 120 h the numbers of wells 
showing a cytopathic effect (CPE) was monitored using an inverted microscope and 
pictures were taken of the positive and negative control wells. After 120 h, 50 μL of 
MTT (5 mg/mL) was added to all wells in the assay plates and incubated for 3 h at 
37 °C, 5 % CO2. MTT is metabolised by live cells to insoluble purple formazan 
crystals. The plates were then centrifuged for 5 min at 1500 ×g to sediment formazan 
crystals and the medium carefully aspirated. The crystals were then solubilised using 
0.1 mL/well of dimethyl sulfoxide (DMSO) for 20 min at RT and the absorbance at 
570 nm determined using a microplate reader. The plaque forming units (PFU) were 
determined from the TCID50/mL (6.3 Appendix III). Plaque forming units are the 
measure of the number of viruses capable of causing cell lysis from viral replication 
and forming a plaque. 
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Figure 2-3. Plate layout for the EMCV titre TCID50 assay. Negative controls (media and 
A549 cells) are in columns 1 and 12 seen in the black boxes. EMCV serial dilutions (10
-2
 to 
10
-9
) were conducted in columns 2-11 seen in the orange box. 
2.2.10.7 In vitro antiviral assay for potency testing of IFN species 
The human lung fibroblast cell line A549 was maintained in DMEM media 
supplemented with 10% foetal bovine serum (FBS), 50 units/mL penicillin, 2 mM L-
glutamine and 50 µg/mL streptomycin. For the antiviral assay, A549 cells were 
plated (1.7×10
5 
cells/mL at 50 μL/well) in 96 well flat-bottomed tissue culture plates, 
then incubated at 37 °C, 5% CO2 overnight until the cells were 80% confluent. Serial 
dilutions (2-fold) of the His8IFN α-2a samples were prepared in DMEM/10% FBS in 
96 well V-bottom plates. Fifty µL of the diluted samples was transferred to flat-
bottom plates and incubated for 24 h at 37 °C, 5% CO2. Protein samples were tested 
in triplicate (Figure 2-4). Control wells contained only cells (negative control) or 
cells with virus (positive control) (Figure 2-4). After incubation, the sample and 
media were discarded. Following this, 50 μL/well of EMCV, pre-titrated to achieve 
complete killing in 24 h in control wells, was added to all wells except for the 
negative control wells where, 50 μL/well of DMEM/2% FCS was added. The plate 
was then incubated for 21 h at 37 °C after which ~80% cell death occurred in the 
control wells. Media was then discarded and the wells were washed with 300 
μL/well of PBS added. Plates were then incubated for 30 min at RT with 50 μL/well 
of 4% formaldehyde/0.5% methyl violet. After incubation the plates were washed 
Virus serial dilutions 
 
10-2 
 
10-3 
 
10-4 
 
10-5 
 
10-6 
 
10-7 
 
10-8 
 
10-9 
Negative control Negative control 
  
111 
twice with PBS (200 µL/well) and tap-dried. Dye was solubilised by 20 min agitation 
in 50 μL/well of 2% SDS and the absorbance measured at 570 nm. 
 
Figure 2-4. Antiviral assay plate layout. Negative control (A549 cells and media) can be 
seen in the black boxes (columns 1 and 12), whilst the positive controls (A549 cells plus 
virus) can be seen in the red boxes (columns 1 and 12). The serial dilutions were conducted 
in columns 2-11 from high to low sample concentration. NIBSC IFN α was conducted on 
every plate as an internal control in duplicate (orange box). Samples 1 and 2 were conducted 
in triplicate (purple and green box).  
2.2.11 Resuscitation and growth profile assay for the A549 cell line 
A549 cells previously stored in liquid nitrogen were thawed at 37 °C in a water bath, 
then immediately re-suspended in 10 mL of DMEM/20% FBS. Thawed cells were 
centrifuged for 5 min at 1500 ×g and the supernatant was carefully removed. The 
cells were then re-suspended in 20 mL of DMEM/20% FBS and transferred to a T75 
tissue culture flask and incubated at 37 °C, 5% CO2. A549 cell growth was 
monitored daily by visual inspection every 4 days and photography of the cells under 
an inverted microscope.  
2.2.11.1 Effect of different EMCV concentrations on NIBSC IFN α-2a 
A549 cells were re-suspended in DMEM/10% FBS at 1.7×10
5
 cells/mL and seeded 
at 8,500 cells/well (50 μL/well) in four 96 well microtitre plates (assay plates) for 24 
h. A serial dilution (2-fold) of NIBSC IFN α-2a was prepared in DMEM/10% FBS in 
96 V-bottom microtitre plates (sample plates, 300 μL). Fifty μL was then transferred 
to the four assay plates using a multichannel pipette and the assay plates incubated 
for a further 24 h. Four EMCV titres were prepared (1×10
5
, 2 ×10
5
, 3 ×10
5
 and 4×10
5
 
PFU/mL) in DMEM/2% FBS. The IFN-containing media was aspirated from the 
assay plates and was replaced with media containing EMCV titres (50 μL/well) in 
Negative control 
Negative control 
Sample 2 
Sample 1 
Sample serial dilutions 
Positive control 
Positive control 
NIBSC IFN α 
Low High 
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duplicate. Viral inoculation was allowed to occur for 19 h. The plates were then 
washed once with PBS (200 μL/well), 0.1% methyl violet in 4% formaldehyde-PBS 
added (50 μL/well) and incubated for 20 min at RT. The staining solution was 
aspirated and the plates washed thrice with PBS (200 μL/well). The dye was then 
solubilised in 2% SDS (50 μL/well) for 20 min on a plate shaker at RT and the 
absorbance measured at 570 nm using a microplate reader.  
2.2.11.2  Effect on EMCV incubation time on A549 cell death 
A549 cells were re-suspended in DMEM/10% FBS and diluted to 1.7×10
5
 cells/mL 
then 50 μL of the cell suspension seeded into the wells of a 96 well flat-bottom plate. 
Cells were then allowed to adhere to the plate surface overnight at 37 °C until they 
reach ~80 % confluency. After 24 h, 50 μL of DMEM/10% FBS was added to all 
wells and the plates incubated for a further 24 h. EMCV stock was diluted to 1×10
5
 
PFU/mL in DMEM/2% FBS, and 50 μL added to all wells except the control 
columns (columns 1 and 12) where only medium was added. The plates (2 per 
incubation time) were then incubated with the virus for different lengths of time (4, 
8, 16, 20, 24 and 28 hour). Pictures of the A549 cells controls with and without virus 
were taken prior to harvesting, to observe how cell death is affected by EMCV 
incubation time. Plates were then washed once with PBS (150 μL) and the viable 
adherent cells detected by staining with 50 μL of 4.0 % formaldehyde/0.5 % methyl 
violet for 20 min at RT. Plates were then washed twice with 200 μL of PBS and 
remaining dye solubilised by the addition of 50 μL of 2 % SDS. Plates were agitated 
on a plate shaker for 20 min before the absorbance was read at 570 nm using a 
spectrometer. 
2.2.11.3 Data analysis of Antiviral assay results 
In line with the British pharmacopoeia, the interferon concentration (the log 
reciprocal of the interferon dilution) was plotted against the absorbance achieved. 
The reduction in cell viability fits a sigmoidal dose-response curve, thus the distance 
between the linear portions of the curves is used to compare the response and relative 
potencies of the standards and samples tested. Data was only considered valid under 
two criterion, i) the variation between the straight part of the sigmoidal curve and the 
data points was small enough to be accurately represented by a straight line (absolute 
sum of squares (r value)) and ii) the ED50 for the internal control, NIBSC IFN α, is 
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within the expected range. If the data achieved was not in line with this criterion, the 
data was not used. Accepted potency data was then turned into international units 
(IU) to allow for direct comparisons to be made to literature data. GraphPad Prism 5 
was used for all data analysis. 
2.2.11.4  In vitro antiproliferative assay for the potency testing of IFN species 
The human Negroid Burkitt’s lymphoma (Daudi) cell line was maintained in RPMI 
1640 media supplemented with 10 % foetal bovine serum (FBS), 50 units/mL 
penicillin and 50 µg/mL streptomycin. For the antiproliferative assay Daudi cells 
were plated (1.7×10
5 
cells/mL at 100 μL/well) in a 96 well round-bottomed tissue 
culture plates and these were incubated at 37 °C, 5% CO2 whilst the sample serial 
dilutions were being conducted. Serial dilutions (three-fold) of IFN α controls 
(NIBSC IFN α-2a and Pegasys®) were conducted in 1.5 mL centrifuge tubes using 
RPMI 1640/10% FBS. IFN α controls were pipetted into the plate (100 µL/well) 
from low to high dilutions in duplicates, with each well having a final volume of 200 
µL/well. Control wells contained only media without cells (negative control) or cells 
with media (as positive control). The plate layout was the same as with the antiviral 
assay (Figure 2-4). The plates were then incubated for 72 h at 37 °C, 5% CO2. 
Methyl thiazolyl tetrazolium (MTT), a soluble metabolic substrate which is 
converted into formazan salt, was used to determine the Daudi cell viability (Wang et 
al., 1996). MTT solution (5 mg/mL) was dissolved in PBS and was prepared 10 min 
before addition to the wells. MTT solution was filtered through a 0.2 µm syringe 
filter. Twenty µL/well MTT was added to each well and the plates incubated for 3 h 
at 37 °C, 5% CO2. Plates were then centrifuged at 1500 ×g for 10 min, allowing 
formazan crystals to sediment. Using a multichannel pipette, the supernatant was 
carefully removed and 100 µL/well non-sterile DMSO was added to solubilise the 
crystals by agitation. Absorbance was then measured at 570 nm.  
2.2.11.5 Growth characteristics of Daudi cells 
A marked antiproliferative effect typically requires an incubation period of several 
days, thus a growth curve for Daudi cells was conducted to determine the stage of 
growth the Daudi cells are in typically when carrying out the antiproliferative assay. 
Daudi cells were seeded (250,000 cells/flask) in four T25 flasks, these were then 
incubated at 37 °C, 5% CO2, whilst recording the time. At the same time 24 h later, a 
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manual cell count was conducted on one of the T25 flasks, and the cell number 
recorded. This procedure was conducted for 7 days. 
2.2.11.6  Daudi cell density optimisation by MTT colorimetric response 
Daudi cells were diluted in RPMI/10% FBS to 200,000 cells/well, 100,000 
cells/well, 50,000 cells/well, 25,000 cells/well and 12,500 cells/well. Five U-bottom 
microtitre assay plates were seeded with each cell density (100 μL/well) in duplicate 
with the 96 well plates, 100 μL/well of media was then added to replace sample 
volume. Control wells were included in each experiment to serve as positive control 
(media without cells). The plates were incubated at 37 °C, 5% CO2 and harvested 
after 0,1,2,3 and 4 days. A 5 mg/mL solution of MTT in PBS was prepared and 
filter-sterilised. MTT was added at 20 μL/ well and the plates incubated for 3 h at 37 
°C, 5% CO2. Plates were then centrifuged at 1500 ×g for 10 min, allowing formazan 
crystals to sediment. Using a multichannel pipette, supernatant was carefully 
removed and 100 µL/well of non-sterile DMSO was added to solubilise the crystals 
by agitation. Absorbance was then measured at 570 nm.   
2.2.11.7  Effect of cell seeding density on IFN response 
A variation on method 2.2.11.4 was conducted whereby standards were prepared in a 
two-fold serial dilution in assay media instead of a three-fold dilution. Incubation 
periods of 72 h and 96 h were also conducted. 
2.2.11.8  Effect of sample incubation time on cell viability 
Following method 2.2.11.4, plates were incubated for 72 h, 96 or 120 h at 37 °C in a 
humidified atmosphere of 5% CO2.  
2.2.11.9 Data analysis for the antiproliferative assay 
GraphPad Prism 5 was used for all data analysis. For optimisation work, cell viability 
(%) was plotted against control wells using site-specific binding with Hill slope on a 
semi-log graph. For sample potency testing, as with the antiviral assay, the interferon 
concentration (the log reciprocal of the interferon dilution) was plotted against the 
absorbance achieved. The reduction in cell viability fits a sigmoidal dose-response 
curve, thus the distance between the linear portions of the curves is used to compare 
the response and relative potencies of the standards and samples tested. Data was 
only accepted if the variation between the straight part of the sigmoidal curve and the 
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data points was small enough to be accurately represented by a straight line (absolute 
sum of squares (r value)). 
2.2.11.10 BIAcore kinetic and affinity assay of Fab species  
Binding affinity assays were conducted for a) anti-albumin and b) bevacizumab 
compounds. For the anti-rat albumin species, rat albumin (~65 kDa) was 
immobilised on a CM3 chip as the ligand whilst for bevacizumab compounds VEGF 
(~38 kDa) was immobilised as on another CM3 chip. Three steps were optimised for 
the two chips preparations; 1) pH scouting, 2) immobilisation and 3) regeneration 
prior to kinetic and affinity analysis of the compounds. 
2.2.11.11  pH scouting assay 
To find the best electrostatic interaction between the rat albumin with the dextran 
chip, a pH scouting assay was performed. Rat albumin (1 μg/mL) was dissolved in 
10 mM sodium acetate buffer at pH (4, 4.5, 5 and 5.5) and run through flow channel 
2 (Fc=2). A contact time of 200 sec was applied. To regenerate the CM3 chip 
surface, 50 mM sodium hydroxide was used to remove any bound rat albumin. It was 
found that Rat albumin (1 μg/mL) in 10 mM sodium acetate pH 5.0 was the optimum 
pH for the binding of the rat albumin to the dextran matrix on the chip.  
2.2.11.12  Immobilisation optimisation assay 
Rat albumin and VEGF were immobilised by carbodiimide mediated coupling onto 
separate CM3 chips. VEGF165 (38 kDa, 0.2 μg/mL) was immobilised to a level of 
110 RU and rat albumin (65 kDa, 0.2 μg/mL) was immobilised to a level of 72 RU. 
Ligand immobilisation was conducted by firstly docking the new CM3 chip inside 
the BIAcore. A manual run was conducted as because it was possible to better con-
trol contact time and ligand immobilisation level. The flow rate was set to 5 μL/min 
through Fc=2 and the chip was washed for 60 sec with 50 mM sodium hydroxide. 
The chip dextrin carboxyl groups were activated by an injection of NHS:EDC (1:1 
ratio) solution for 200 sec to give reactive succinimides esters. After this, the HBS-
ES buffer was allowed to wash over the chip surface for ~200 sec. The ligand, rat 
albumin or VEGF, was then injected for 180 or 150 sec respectively. Lastly, 1.0 M 
ethanolamine-HCL solution was injected for 180 sec to inactivate any remaining 
succinimides esters on the chip surface and remove non-covalent bound ligand.  
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2.2.12  Regeneration optimisation assay 
A regeneration scouting experiment was performed to find the potential conditions 
for the regeneration of the rat albumin immobilised chip, where the ligand level of 
the chip stays the same and only bound analyte was removed. Scouting was 
performed by testing repeated cycles (5 cycles) of rat albumin binding and 
regeneration with differing 10 mM glycine-HCL conditions (pH 2.25, pH 2.5) and 
examining the response levels within each condition. To avoid complicating the 
interpretation, a new CM3 bound with rat albumin was made and the high pH was 
tested first. It was found that using 10 mM glycine-HCL pH 2.25 achieved the 
baseline. Only a slight increase in analyte/baseline response was observed a pH 2.25, 
which is due to the dextran matrix taking longer to equilibrate at lower pHs.  
2.2.12.1  Kinetics and affinity assay analysis 
All analyte samples were freshly prepared in the standard HBS-EP running buffer 
(10 mM HEPES pH 7.4, 150 mM sodium chloride, 3 mM EDTA and 0.005% P20) 
before the run. All kinetic measurements were conducted at 25 °C at a flow rate of 
30 μL/min with an association time of 180 sec and a dissociation time of 1200 sec 
for bevacizumab compounds and 1600 sec for anti-albumin compounds. Double-
referencing (buffer blanks) was conducted in every analyte kinetic run as a control to 
account for bulk effects caused by changes in buffer composition or non-specific 
binding (Myszka, 2000; Rich and Myszka, 2000). Further it improves the quality and 
reproducibility of data achieved at low RUs, by subtracting the average response of 
the blank injections from the entire data set (Myszka, 2000; Rich and Myszka, 2000). 
2.2.12.2  Data analysis 
All kinetic data was analysed with the BIAevaluation software (version 2.1) and the 
best fit (lowest Chi
2
) was obtained using a 1:1 binding model. Kinetics and affinity 
analysis was performed by fitting the 1:1 binding model, globally over five 
sensogram association and dissociation curves of varying analyte concentrations. 
Equilibrium dissociation constants (KD) were calculated from the rate constants 
(KD=koff/kon). koff is also known as kd or the dissociation rate constant, whilst kon is 
also known as ka or the association constant. 
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Chapter 3 Preparation and functional activity studies of IFN-PEG-
IFN homodimers 
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3.1 Introduction 
As discussed, proteins rarely act alone to prepare a biological response. Instead, 
proteins bind to other biomolecules, often self-associating to form dimers within a 
network to prepare a biological response (Marianayagam et al., 2004). For example, 
the active form of interleukin-12 (IL-12) is a heterodimer comprised of p35 and p40. 
IL-12 is responsible for triggering the production of interferon γ (IFN γ) during acute 
inflammation (Marianayagam et al., 2004). However, the activity of IL-12 is 
regulated by the production of p40 homodimers, where p40 homodimers can bind to 
the IL-12 receptor and inhibit the production of IFN γ (Heinzel et al., 1997). This 
example shows that within a biological network, both homodimers and heterodimers 
can be involved and that the same protein can associate to different proteins 
depending on the function required. The ability to self-associate to prepare homo- or 
hetero-dimers allows the genome size to stay small whilst maintaining the 
advantages associated with protein complex formation (Ispolatov et al., 2005; 
Marianayagam et al., 2004).  
 There are many approaches being investigated to prepare multifunctional 
proteins (§ 1.3). The PEG di(bis)sulfone 4 reagent has been used to prepare dimers of 
Fabs, Fab-PEG-Fab homo- and hetro-dimers (Khalili et al., 2013) and peptides, 
specifically Octreotide. The aim of the work described in this chapter was to explore 
methods to make IFN dimers (IFN-PEG-IFN) utilising site-specific bis-alkylation 
conjugation using PEG as a linker to dimerise IFN. A recombinant-chemical 
approach was investigated to prepare IFN dimers. Where, IFN was expressed 
recombinantly with an 8-polyhistidine tag (Figure 1-18). Both the polyhistidine tag 
and the natural disulfides can both be conjugated to with the PEG di(bis)sulfone 
reagent 4. Firstly, site-specific his-tag conjugation was conducted to take advantage 
of the 8-polyhistidine tag to create novel His8IFN-PEG20-His8IFN dimers using 
PEG20 di(mono)sulfone 5. His-tag conjugation has been investigated previously with 
His8IFN to prepare the monomeric variants of His8IFN (PEG-His8IFN) (Cong et al., 
2012). It was hypothesised that the novel IFN dimers would retain their biological 
activity, due to the site-specific conjugation used.  
 His8IFN-PEG20-His8IFN dimers were prepared by his-tag conjugation by 
reacting His8IFN α-2a with PEG20 di(bis)sulfone 4 (Figure 3-1). While for disulfide 
conjugation, His8IFN α-2a was reduced with DTT prior to conjugation with PEG20 
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di(bis)sulfone 4 (Figure 3-1). The IFN dimers were then isolated in a two-step 
purification process. The IFN dimers were isolated from X-PEG20-IFN (X being the 
unconjugated linker end) by CIEC. The IFN dimers were then isolated from 
unconjugated His8IFN α-2a and higher MW impurities by SEC purification. The IFN 
dimers were then characterised in terms of purity, identity, stability and activity. 
Anti-IFN Western blot was used to determine the purity and identity of the 
conjugates. The activity of the IFN dimers was assessed by two cell-based assays: 
antiviral and antiproliferative assays. These assays examined two aspects of the 
pleiotropic nature of IFN.  
 As previously discussed, Type I IFNs are a group of heterogenous group of 
pleiotropic cytokines with antiviral, antiproliferative, antitumour and 
immunodulatory activities (Anguille et al., 2011; Goodbourn, 2000; Nanus et al., 
1990). The antiviral activity of IFN is currently being used to treat Hepatitis B and C 
with treatments such as PEGASYS
®
 and PEG-INTRON
®
. However, these 
PEGylated forms of IFN have several drawbacks, namely, heterogeneity of the final 
products from random conjugation, reduced IFN activity due to PEG-positional 
isomers binding near or at the binding site and side effects from IFN treatment. In an 
attempt to improve upon these treatments for Hepatitis B and C, a recombinant-
chemical approach was used to prepare IFN dimers. His8IFN α-2a was used to 
prepare the IFN dimers. His8IFN α-2a has been previously used to prepare 
monoPEGylated and diPEGylated conjugates to explore histidine PEGylation, while 
disulfide conjugation has not been conducted on His8IFN α-2a before. 
Advantageously, His8IFN α-2a has both a polyhistidine-tag and two disulfide bonds, 
therefore both histidine and disulfide conjugation can therefore be conducted to 
prepare the IFN homodimers. It was found that PEG di(bis)sulfone 4 can be used as a 
linker and prepare IFN dimers. These IFN-PEG-IFN dimers were prepared utilising 
both histidine and thiol conjugation strategies. It was found that His8IFN-PEG20-
His8IFN retained greater activity than IFN-PEG20-IFN within the antiviral assay, 
where both conjugates demonstrated higher activity than PEGASYS
®
 (Table 3–6). 
This shows that the PEG di(bis)sulfone 4 reagent in conjunction with site-specific 
conjugation could be used to prepared multifunctional proteins, such as IFN dimers. 
However the PEG di(bis)sulfone 4 reagent needs further investigation regarding 
purity, conjugation process and final yield to make the approach scalable.  
 
  
120 
 
Figure 3-1: Experimental plan of the IFN homodimers and controls prepared in this chapter. 
The His8IFN-PEG20-His8IFN dimer was prepared by his-tag conjugation by reacting His8IFN 
with PEG20 di(bis)sulfone 4. The PEG20-His8IFN, (PEG20)2-His8IFN controls were prepared 
by reacting His8IFN with PEG20 bis-sulfone 1. For preparing the IFN-PEG-IFN dimers by 
disulfide conjugation, His8IFN was first reduced before being allowed to react with PEG 
di(bis)sulfone 4. Whilst for preparing PEG-IFN and (PEG)2-IFN controls by disulfide 
conjugation, His8IFN was reduced with DTT and then allowed to react with PEG bis-sulfone 
1. A two-step chromatography process of CIEC and SEC was used to purify the IFN dimers 
whereas the mono- and di-PEGylated IFN controls were purified by CIEC only. All 
conjugates prepared where characterised in terms of their purity, identity, stability and 
biological activity by SDS-PAGE, anti-IFN Western blot, stability studies and antiviral and 
antiproliferative assays respectively.  
3.2 Results and Discussion 
3.2.1 Synthesis of 10 kDa and 20 kDa PEG di(bis)sulfone 4 
The 10 and 20 kDa PEG di(bis)sulfone 4 reagents were prepared by F Khayrzad 
(Figure 3-2) and donated by PolyTherics for use in this PhD project. The PEG 
di(bis)sulfones 4 were prepared following method 2.2.5.2.  
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Figure 3-2. Synthesis route for PEG di(bis)sulfone 4 used in the IFN-PEG-IFN homodimer 
production. PEG di(amine) 6 was reacted with the bis-sulfone linker 7 at RT with DCM to 
prepare PEG di(bis)sulfone 4. Acetone precipitation purification was used to purify the PEG 
di(bis)sulfone 4, the purified homobifunctional reagent 4 was analysed by 
1
H-NMR.  
 
Prior to conjugation to prepare the IFN-PEG-IFN dimer, 
1
H-NMR (400/300 
MHz) was used to analyse the final 10 and 20 kDa PEG di(bis)sulfone 4 reagents in 
deuterated chloroform (Figure 3-3). The PEG20 can be seen between 3.25-4.5 ppm. 
Theoretically the integration value should be ~1900 relative to 12 protons for the 4 
aryl methyl groups (2.49 ppm) indicate there was excess PEG species within the 
sample. There did not appear to be any elimination of the tolyl sulfinic acid groups. It 
is possible that unreacted PEG bis-amine was carried through the purification, which 
was addition of the crude reaction mixture to cold acetone to precipitate the PEG 
di(bis)sulfone 4 reagents. Protons labelled number 4 the PEG di(bis)sulfone 4  have a 
similar chemical shift as the methylene proteins in PEG, so cannot be seen in the 
1
H-
NMR spectrum. The aromatic compounds (labelled 2, 3, 6, 7) can be seen at ~7 ppm.  
Bis-sulfone linker 7 PEG di(amine) 6 PEG di(bis)sulfone  4 
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Figure 3-3. 
1
H-NMR of PEG20 di(bis)sulfone 4 in deuterated chloroform. Analysis by 
1
H-
NMR has revealed that PEG20 di(bis)sulfone 4 was successfully made, however it contains 
excess PEG revealed from the integration, possibly unreacted PEG bis-amine 6. Conjugation 
with His8IFN α-2a was then conducted to prepare the IFN homodimer using the 
homobifunctional reagent 4. 
 For his-tag conjugation to proceed, the PEG di(mono)sulfone 5 was expected 
to be a better reagent to use (Figure 3-4). This is due to the his-tag conjugation taking 
place at slightly acidic conditions, meaning the generation of PEG di(mono)sulfone 5 
which would normally happen in situ at neutral or slightly basic conditions is unable 
to occur (Brocchini et al., 2006). Therefore, PEG di(mono)sulfone 5 was prepared 
following method 2.2.5.1. 
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Figure 3-4. Activation of PEG20 di(bis)sulfone 4 reagent by the elimination of two β-
sulfonyl groups 3 to prepare PEG20 di(mono)sulfone 5. PEG20 di(mono)sulfone 5 was used to 
prepare the His8IFN-PEG20-His8IFN dimers, due to his-tag conjugation taking place at lower 
pHs. Thus, the generation of PEG20 di(mono)sulfone 5 is unable to occur in situ.  
 
It was observed during the preparation of the His8IFN-PEG20-His8IFN dimer 
that there was low conversion to the His8IFN-PEG20-His8IFN dimer, when compared 
to the preparation of the monomeric PEG20-His8IFN with PEG20 bis-sulfone 1. One 
reason for low conversion to His8IFN-PEG20-His8IFN may have been due to 
competitive addition of water to the PEG20 di(mono)sulfone 5 reagent. Addition of 
water would lead to the formation of allylic alcohol adducts (Figure 3-5) that would 
undergo subsequent elimination of hydroxide to allow addition to occur at the β-
carbon.  
 The 
1
H-NMR analysis of PEG20 di(mono)sulfone 5 after eight months storage 
at -20ºC under argon (Figure 3-6 B) was the same as the 
1
H-NMR obtained when the 
reagent was prepared (Figure 3-6 A). However, when the PEG20 di(mono)sulfone 
reagent 5 was incubated for 16 h in 50 mM sodium phosphate containing 150 mM 
sodium chloride pH 6.5 (Figure 3-6 C) the 
1
H-NMR spectrum changed with the 
presence of new peaks (black circle). 
 Peak integration (Figure 3-6 C) indicated that approximately a third of the 
PEG20 di(mono)sulfone 5 had changed, presumably having undergone addition of 
water or hydrolysis. This hydrolysis can occur at one of the 4 reactive β-carbons, 
PEG di(bis)sulfone 4 
PEG di(mono)sulfone 5 
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where conjugation is designed to occur on the PEG20 di(mono)sulfone 5 (Figure 3-5). 
Because of the slow addition of the imidazole amine in the his-tag and the fact that a 
reactive form of the reagent is present in high concentration throughout the 
conjugation period, it is not surprising that hydrolysis was observed.  
 
Figure 3-5. Possible mixtures of hydrolysed PEG20 di(mono)sulfone 5. A) one third of the 
bi-functional PEG reagent 4 is hydrolysed at one linker end, B) one third of the bi-functional 
PEG reagent 4 mixture is hydrolysed at both ends of the linker. As 
1
H-NMR analysis 
revealed one third of the PEG20 di(mono)sulfone 5 mixture had hydrolysed.  
  
A 
B 
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Figure 3-6. NMR analysis of PEG20 di(mono)sulfone 5 A) immediately after preparation, B) 
after eight months at -20 °C under argon and C) after 16 h at 20 °C in 50 mM sodium 
phosphate containing 150 mM sodium chloride pH 6.5. 
1
H-NMR analysis reveals some 
changes have occurred (black circle) to PEG20 di(mono)sulfone 5 presumably from water 
addition or hydrolysis. Peak integration suggests one third of the PEG20 di(mono)sulfone 5 
mixture has changed. 
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 Alternatively, PEG20 di(bis)sulfone 4 purity or purity of the starting reagents 
could also be a reasons for the low conversion of the His8IFN-PEG20-His8IFN dimer. 
Therefore, to investigate the purity of the PEG20 di(bis)sulfone 4, SDS-PAGE of the 
PEG20 di(bis)sulfone 4 was conducted. SDS-PAGE of the PEG20 di(bis)sulfone 4 
reveals 2 impurities at 80-110 kDa and 110-160 kDa, which could affect the 
conversion of IFN dimers.  
 
Figure 3-7. SDS-PAGE analysis of PEG20 di(bis)sulfone 4. Lane 1: Novex pre-stained 
markers, Lane 2: PEG20 di(bis)sulfone 4, Lane 3: PEG20 bis-sulfone 1. Two impurities can be 
seen in at 160 and 110 kDa (Impurity 1 and 2), which could affect the conversion and yield 
of homodimer production. 
The SDS-PAGE (Lane 2, Figure 3-7) shows that PEG20 di(bis)sulfone 4 is a mixture, 
as three bands at 40-50 kDa, 80-110 kDa and 110-160 kDa. The main band at 
between 40-50 kDa is the PEG20 di(bis)sulfone 4. However the two bands above are 
impurities (impurities 1 and 2), which could be multi-PEG derivatives, whereby the 
PEG20 di(bis)sulfone has undergone a reaction with the starting PEG bis-amine. 
Furthermore, it can be observed that the purity of PEG20 bis-sulfone 1 (Lane 3, 
Figure 3-7) is greater than that of PEG20 di(bis)sulfone 4, as there are fewer impurity 
bands observed for PEG20 bis-sulfone 1. These differences could be the cause of the 
low yields observed for the IFN dimer and also explain the differences in conversion 
observed between the PEG20-His8IFN, (PEG20)2-His8IFN and that of the His8IFN-
PEG20-His8IFN dimer.  
 Moreover, the behaviour of the PEG20 di(bis)sulfone 4 in solution could 
affect the conversion of the His8IFN-PEG20-His8IFN. As it has been reported that by 
260 kDa 
160 kDa 
 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
Impurity 2  
20 kDa PEG di(bis)sulfone 4  
1                2            3  
Impurity 1  
20 kDa PEG bis-sulfone 1  
  
127 
dynamic light scattering, the solution size of PEG20-Fab was 21.2 ± 1.8 nm, whilst 
for solution size for Fab-PEG20-Fab was 11.6 ± 0.2 nm, which is half the PEG20-Fab 
molecule size (Khalili et al., 2013). This data suggests that in solution the PEG20 
di(bis)sulfone 4 could be more compact in nature than that of the PEG20 bis-sulfone 
1. This behaviour could impede the conjugation of the PEG20 di(bis)sulfone with 
His8IFN, thus explaining the low conversions.  
 It was hoped that by improving the purity of the PEG20 di(bis)sulfone 4, a 
higher conversion of His8IFN-PEG20-His8IFN would be achieved. First, F Khayrzad 
conducted RP-HPLC purification of the PEG20 di(bis)sulfone 4 mixture (10 mg) 
using a gradient of 0-100% acetonitrile (§2.2.5.4).  
 As can be seen in Figure 3-8 there are three peaks at min 20.69, 21.87 and 
22.2. The most intense peak, 1000 absorbance (mAu) being that of PEG20 
di(bis)sulfone 4 at 22.2 minutes. The three peaks observed by RP-HPLC were also 
observed in the SDS-PAGE analysis (Figure 3-7). As the small-scale separation was 
successful, the scale was then increased to 90 mg. This scale was conducted in the 
hope that enough PEG20 di(bis)sulfone 4 could be successfully purified and used for 
further conjugation studies. This conjugation could determine if the purified PEG20 
di(bis)sulfone 4 would improve the conversions and yields of the homodimer.  
 The 90 mg RP-HPLC chromatogram at both 214 and 280 nm showed no 
separation of the three peaks. This is due to the absorbance being above the 
maximum intensity levels detectable by the HPLC. Therefore, an alternative 
synthesis route for the PEG20 di(bis)sulfone 4 was examined in an effort to improve 
the purity of the reagent. It is important that each terminus on the PEG is 
appropriately functionalised to ensure that protein conjugation can occur.  
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Figure 3-8. Reverse phase-HPLC analysis of PEG20 di(bis)sulfone 4 at A280 nm A) 10 mg 
scale and B) 90 mg scale. PEG20 di(bis)sulfone 4 was purified at the 10 mg scale, but no 
separation occurred at the 90 mg scale. 
A 
B 
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An alternative synthesis route for the PEG20 di(bis)sulfone 4 was used to improve the 
purity of the reagent. The PEG20 di(bis)sulfone 4 was prepared by G. Tekle (Figure 
3-9) and donated by PolyTherics for use in this PhD project following method 
2.2.5.3. The final PEG20 di(bis)sulfone 4 prepared by synthesis route 2 was 
characterised by 
1
H-NMR, SDS-PAGE and RP-HPLC.  
 
Figure 3-9. PEG20 di(bis) sulfone 4 synthesis route 2 for heterodimer preparation. PEG20 
di(amine) 6 was reacted with the bis-sulfide linker 9 with DMAP to prepare PEG20 
di(bis)sulfide 8. PEG20 di(bis)sulfide 8 was reacted with Oxone
®
 to prepare PEG20 
di(bis)sulfone 4. Acetone precipitation purification was used to purify the PEG20 
di(bis)sulfone 4, the purified homobifunctional reagent 4 was analysed by 
1
H-NMR.  
The 
1
H-NMR (Figure 3-10) was obtained for PEG20 di(bis)sulfone 4 synthesised by 
route 2. The integration of the 4 methyl peaks (~2.5 ppm) was set to 12 protons 
(Figure 3-10). The PEG protons appear between ~3.4-4.5 ppm with an integration of 
2400.12. The theoretical integration value for PEG20 is ~1900, therefore there was 
excess PEG within the mixture, which cannot be removed by acetone precipitation 
explaining the higher integration value. However, it can be observed that the PEG20 
integration is lower in Figure 3-10 than in Figure 3-3, showing improved quality of 
the PEG20 di(bis)sulfone 4. 
Bis-sulfide linker 9 
PEG di(amine) 6 
PEG di(bis)sulfide 8 
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Figure 3-10. 
1
H-NMR analysis of the PEG20 di(bis)sulfone 4 prepared using synthesis route 
2 (Figure 3-9). Analysis by 
1
H-NMR has revealed that PEG20 di(bis)sulfone 4 was 
successfully made. Integration revealed excess PEG (3.4-4 ppm), possibly from the starting 
material. Disulfide conjugation with His8IFN α-2a was then conducted to prepare the IFN-
PEG20-Fab heterodimers using PEG20 di(bis)sulfone 4.
 
RP-HPLC (method 2.2.5.4) was conducted on the PEG20 di(bis)sulfone 4 prepared 
using synthesis route 2. RP-HPLC allows for the separation of components within 
the PEG20 di(bis)sulfone 4 mixture and to identify and quantify each separated 
component/peak. The RP-HPLC chromatograms (Figure 3-11) at 214 nm and 280 
nm showed two peaks. The first peak eluted at 28.68 min (15% relative area) and the 
second peak eluted at 29.89 min (84.9% relative area). The smaller peak could be an 
impurity from the synthesis route or starting PEG material. The larger peak was 
deduced to be PEG20 di(bis)sulfone 4 as this has a longer retention time compared to 
the impurity. The amount of peaks observed in the RP-HPLC chromatogram (Figure 
3-11) also correlates with the amount of bands observed in the SDS-PAGE analysis 
for PEG20 di(bis)sulfone 4 synthesised by route 2 (Figure 3-12). When the RP-HPLC 
chromatograms of the two synthesised PEG20 di(bis)sulfone 4 were compared, the 
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second synthesis route has a higher purity (84% relative area, Figure 3-11) of the 
PEG20 di(bis)sulfone 4 than synthesis route 1 where there are two impurity peaks.  
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Figure 3-11. RP-HPLC purity analysis of PEG20 di(bis)sulfone 4 prepared by synthesis route 
2 at A) 214 nm and B) 280 nm. Peak 1 is an impurity possibly from the PEG starting 
material or synthesis and Peak 2 is the PEG20 di(bis)sulfone 4. Purity is assessed to be 84% 
by RP-HPLC. 
Peak No.  Retention Time (min) Area  
(mAU* min) 
Height (mAU) Relative Area (%) Resolution 
1 28.673 29.965 33.321 15.16 1.41 
2 29.89 167.6779 285.725 84.84 n.a. 
Total: 197.6429 319.046 100 
A 
Peak	No.	 Reten on	Time	(min) Area		
(mAU*	min) 
Height	(mAU) Rela ve	Area	(%) Resolu on 
1 28.677 7.9104 8.776 15.4 1.4 
2 29.89 43.4482 74.467 84.6 n.a. 
Total: 51.3586 83.243 100 
B 
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SDS-PAGE analysis (Figure 3-12) showed that PEG20 di(bis)sulfone 4 prepared from 
route 2 (Lane 3) was more pure than when prepared by route 1 (Lanes 2). The PEG20 
di(bis)sulfone 4 was observed between 40-50 kDa on the Bis-Tris gel (Figure 3-12) , 
this is due to PEG20 running on the SDS-PAGE gel at double its MW, as the PEG 
binds 2-3 water molecules (Roberts et al., 2002). In Lane 2 (Figure 3-12) there was a 
laddering effect of the PEG20 di(bis)sulfone 4 and two impurity bands could be seen 
at 80 and 100 kDa; where the band at 80 kDa could be seen in Lane 3.  
 The SDS-PAGE results agree with the RP-HPLC analysis results on the 
PEG20 di(bis)sulfone 4 prepared from routes 1 and 2. For synthesis route 1 three 
peaks were seen on the chromatogram (Figure 3-8) whilst two peaks could be seen 
on the chromatogram (Figure 3-11) for synthesis route 2. It can be observed Figure 
3-8 and Figure 3-11 the HPLC retention times vary. This can be due to variations in 
the SEC column used, small changes in mobile phase composition, flow rate and 
temperature (Brocchini et al., 2006).  
 For the preparation of His8IFN-PEG20-His8IFN and IFN-PEG-IFN, PEG20 
di(bis)sulfone 4 synthesised using synthesis route 1 was used. As knowledge of the 
homobifunctional reagent 4 and preparation of the IFN dimers grew through the 
project, it was decided to use PEG20 di(bis)sulfone 4 prepared by synthesis route 2 
for the preparation of the IFN-PEG20-Fab heterodimers. As this was the purest 
reagent prepared, thus it was hoped that a greater yield of the final IFN-PEG20-Fab 
heterodimers would be prepared.  
 
Figure 3-12. SDS-PAGE (PEG stain) analysis (InstantBlue™ and PEG stain) of PEG20 
di(bis)sulfone 4 prepared by synthesis route 1 (Lanes 2) and synthesis route 2 (Lanes 3). 
Lane 1: Novex pre-stained makers, Lane 2: synthesis route 1 PEG20 di(bis)sulfone 4 (5 μg), 
Lane 3: synthesis route 1 PEG20 di(bis)sulfone 4 (5 μg). 
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3.2.2 Production of His8IFN α-2a 
 The aim here was to prepare a good yield of active recombinant IFN α-2a in 
fusion with an eight-histidine tag (His8) in Escherichia coli (E.coli) for conjugation 
to PEG di(bis)sulfone 4 to prepare novel IFN dimers (His8IFN-PEG-His8IFN). The 
eight-histidine tag was attached between the cysteine and methionine at the N-
terminus end of IFN α-2a (Cong et al., 2012). The His8IFN α-2a gene was cloned 
into an expression vector utilising a T7 promotor inducible by isopropyl-β-D-1-
thiogalactopyranoside (IPTG) on an ampicillin resistance backbone. PolyTherics 
kindly donated the clone for expression in E. coli. 
 The SHuffle™ T7 Express strain of E.coli was selected as the expression host 
for His8IFN α-2a. The SHuffle™ T7 Express system prepares correctly disulfide 
bonded active proteins in high yields within the cytoplasm of E.coli (Lobstein et al., 
2012). Additionally, the SHuffle™ E.coli have also been engineered to express 
DsbC, which promotes the correction of mis-oxidised proteins into their correctly 
folded form (Lobstein et al., 2012). A preculture (method 2.2.3.1) was set up 
overnight with a chunk of glycerol stock and then the next day the culture was added 
to the optimised fermentation buffer and the growth of the E.coli followed by optical 
density (OD) readings taken once an hour (Figure 3-13). Once an OD of 5 was 
reached, IPTG was added to allow the transcription of the lac operon which was 
stopped at an OD of ca.=9 by the centrifuging of the solution to obtain the bacterial 
pellets. 
 
Figure 3-13. Representative growth curve of SHuffle™ Express expressing His8IFN when 
grown at 30 °C and induced with 1 mM IPTG after an OD of ca.=9 (red line). His8IFN α-2a 
successfully expressed in SHuffle™ express system, the His8IFN α-2a was purified by 
IMAC. His8IFN was expressed twice (n=2) within the SHuffle™ Express system. 
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 Prior to and after IPTG induction an aliquot of the SHuffle
™
 T7 expression 
strain E.coli growth was taken and frozen at -80 °C. The non-induced and induced 
samples were lysed (method 2.2.3.2). The crude extract, supernatant and pellet from 
each sample (non-induced/induced) were evaluated by SDS-PAGE to compare the 
expression of soluble His8IFN.  
 
Figure 3-14. Example SDS-PAGE analysis (InstantBlue™ stain) of prior to and after 
induction effect on His8IFN expression in SHuffle™ T7 Express system (n=2). Lane 1: 
Novex pre-stained markers, Lane 2: non-induced crude extract, Lane 3: non-induced pellet, 
Lane 4: non-induced supernatant, Lane 5: IPTG induced crude extract, Lane 6: IPTG 
induced pellet and Lane 7: IPTG induced supernatant. High yield of soluble recombinant 
His8IFN expressed after IPTG induction.  
 It can be observed (Figure 3-14) that a high yield of soluble recombinant 
His8IFN was expressed after IPTG induction in the SHuffle
™ 
T7 express E.coli. The 
His8IFN can be seen at between 15-20 kDa in the crude extract and supernatant when 
IPTG induced. A small amount can also be seen in the pellet fraction, but this could 
be due to some protein that had remained after pipetting off the supernatant. The 
band below His8IFN (between 10-15 kDa) could be lysozyme as it can be seen in 
both the crude extract and pellet.  
 After confirmation of recombinant His8IFN expression with the small-scale 
lysis, a larger scale lysis was conducted firstly by sonication and then cross flow-
filtration to remove the soluble His8IFN from the cell debris. The soluble protein was 
then collected for purification. 
 His8IFN was purified by an optimised two-step purification method 2.2.3.4. 
First, IMAC purification was conducted to take advantage of the poly-histidine tag of 
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His8IFN. As His8IFN was expressed as a soluble protein, an optimised purification 
method working at physiological pH was chosen to maintain the stability/activity of 
the protein. Firstly, the HisPrep™ FF 16/60 column was pre-equilibrated with buffer 
A (PBS, 20 mM imidazole), then the supernatant was loaded onto the column and the 
column was then washed with 2% buffer A; this was to elute non-specific 
interactions and improve the purity of His8IFN. His8IFN was then eluted with a 
linear gradient of 2-25% buffer B (PBS, 1 M imidazole) (Figure 3-15). The fractions 
from purification were then analysed using SDS-PAGE (Figure 3-15) and the 
fractions containing His8IFN were then diluted 4-fold in 20 mM Tris pH 8.0 to allow 
the proteins to bind to the anion column for further purification.  
 
Figure 3-15. Example IMAC purification of His8IFN bacterial lysis mixture. A) IMAC 
purification chromatogram, B) SDS-PAGE analysis (InstantBlue™ stain) of IMAC 
purification fractions, Lane 1: Novex pre-stained markers, Lane 2: pellet (17.5× diluted), 
Lane 3: supernatant after filtration, Lane 4: flow through, Lane 5: fraction B4, Lane 6-14: 
fractions C1-12 and Lane 15: fraction D4. His8IFN was successfully purified by IMAC from 
bacterial lysis mixture (n=2); a polishing AIEC purification step was next used on the IMAC 
purified His8IFN. 
 In the second purification step, His8IFN was passed through an AIEC column 
(Figure 3-16). The HiTrap Q HP column was first equilibrated in 20 mM Tris pH 8.0 
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and the diluted protein was loaded onto the column and as before the column was 
washed with buffer C (20 mM Tris, pH 8.0) to elute molecules with non-specific 
interactions. His8IFN was then eluted by a 2-20% gradient over 30 min of buffer D 
(20 mM Tris, 1 M sodium chloride pH 8.0). Fractions from purification were 
collected and analysed by SDS-PAGE (Figure 3-16 B). 
 
Figure 3-16. Representative AIEC purification of IMAC purified His8IFN, A) AIEC 
purification chromatogram, B) SDS-PAGE analysis of AIEC purification fractions, Lane 1: 
Novex pre-stained markers, Lane 2: IMAC purified His8IFN, Lane 3-6: fractions B8-12, 
Lane 7-8: fractions C1-2, Lane 9: C4, Lane 10: C6, Lane 11: C8, Lane 12: C9, Lane 13: D1, 
Lane 14: D2 and Lane 15: flow through. Pure His8IFN was prepared from a polishing AIEC 
step was successfully conducted twice, the His8IFN was then characterised. 
Fractions B8-C9 (Figure 3-16) containing pure His8IFN were pooled and 
quantified by UV (abs=280 nm) and MicroBCA™ assay to be 62.8 mg. His8IFN was 
prepared two times, each as a 500 mL culture with a yield of between 60-70 mg of 
His8IFN being prepared each time. This shows that the production of His8IFN was 
quite reproducible as loss of material could be due to i) variations in expression 
levels, ii) loss during purification process. His8IFN was stored at a concentration of 
0.5 mg/mL, which was suitable for conjugation reactions. The purified His8IFN 
buffer was then supplemented with 1 mM EDTA, protease inhibitor cocktail, 1 mM 
A 
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 090712 IEX run large scale his8IFNalpha purification:10_UV  090712 IEX run large scale his8IFNalpha purification:10_Cond
 090712 IEX run large scale his8IFNalpha purification:10_Conc  090712 IEX run large scale his8IFNalpha purification:10_Fractions
 090712 IEX run large scale his8IFNalpha purification:10_Logbook
  0
100
200
300
400
500
600
700
mAU
450 500 550 600 650 700 750 ml
A4 A5 A6 A7 A8 A9 A10 A11 A12 B1 B2 B3 B4 B5 B6 B7 B8 B9 B10 B11 B12 C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 D1 D2 D3 D4 D5
160 kDa 
110 kDa 
80 kDa 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
His8IFNα-2a 
B 	1    2   3    4    5    6    7    8     9   10  1 1  12  13  14  15 
  
138 
sodium azide and 10% glycerol for long-term storage at -80 °C. The final His8IFN 
product was then characterised in terms of its identity, purity (SDS-PAGE, MALDI-
TOF, Western blot) and biological activity (antiviral assay).  
Figure 3-17. Characterisation of final His8IFN product by A) SDS-PAGE (n=2), B) anti-IFN 
western blot (n=1) and C) MALDI-TOF spectrum (n=1), Lane 1: Novex pre-stained markers, 
Lane 2: His8IFN. Purity characterisation identifies the His8IFN α-2a prepared is pure and ~20 
kDa. 
 SDS-PAGE analysis was conducted to assess the purity of His8IFN. For this 
1 μg of the final His8IFN product was loaded into a 4-12% Bis-Tris gel and stained 
using InstantBlue™. His8IFN migrates at ~16 kDa (Cong et al., 2012) and has no 
visible impurities (Figure 3-17 A). His8IFN was expression was conducted twice and 
for each expression, SDS-PAGE was conducted. His8IFN was found to consistently 
migrate at ~16 kDa on the Bis-Tris gel. 
 To further corroborate the identity and purity of His8IFN an anti-IFN α-2a 
Western blot was conducted. The purified final His8IFN (1 μg) product was loaded 
into a SDS-PAGE 4-12% Bis-Tris gel and the gel was transferred onto nitrocellulose 
membrane which was subject to rabbit anti-IFN α antibody followed by anti-rabbit-
AP conjugated antibody (method 2.2.10.1). First to load 1 μg of His8IFN required the 
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concentration of His8IFN to be quantified and then dilutions (i.e. 10×) were made for 
the final loading of 1 μg onto the SDS-PAGE. His8IFN was successfully identified 
by the anti-IFN α antibody, as a band can be observed at approximately ~15 kDa 
(Figure 3-17 B). Other bands were observed in Figure 3-17 B, could be due to i) 
over-sensitivity of the primary or secondary antibody or ii) over-development of the 
membrane with the alkaline phosphatase tablet and/or iii) insufficient time in the 
blocking step that leads to high background signals. To improve the Western blot, 
increasing the washing time could help to reduce the background signal. Further too 
high of an exposure can lead to increased background; therefore reducing/optimising 
the development time can help to reduce the background signal. Additionally, a 
lower concentration of IFN could be used to help reduce the high background signal. 
Some of the bands in Figure 3-17 B, can be seen to be blurry, this is caused by air 
bubbles present during transfer, this can be avoided by rolling a tube across the gel 
and nitrocellulose membrane to remove air bubbles (Mahmood and Yang, 2012).  
 MALDI-TOF analysis was conducted to determine the molecular weight 
(MW) and further characterise the identity of the expressed His8IFN α-2a. His8IFN 
was buffer exchanged into water using a PD-10 column (method 2.2.10.2). Prior to 
MALDI-TOF analysis, His8IFN was freeze-dried and subsequently re-suspended into 
ammonium bicarbonate pH 8.0. The MALDI-TOF spectrum for His8IFN showed a 
peak molecular weight of ≈20405.2 Da (Figure 3-17 C), this is comparable to that 
stated in literature of 20 kDa (Ahad et al., 2009; Vanden Broecke and Pfeffer, 1988). 
However, the MW may be slightly higher taking into account the eight-histidine tag 
(1.2 kDa) (Cong et al., 2012).  
 The biological potency of His8IFN was assessed in vitro by the prevention of 
infection of human lung carcinoma (A549) cells by encephalomyocarditis virus 
(EMCV) (Grace et al., 2005). The His8IFN displayed a specific activity of 231 ± 
10.95
 
MIU/mg (Table 3–3), whilst the positive control of NIBSC (non-his-tagged) 
IFN α-2a displayed an activity of 254 MIU/mg. In literature His8IFN has been 
reported to display an ED50 of 7 pg/mL (Cong et al., 2012). The activity of non-his-
tagged interferon α is reported to be 1.4×108 IU/mg (British pharmacopoeia 7.0).  
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3.2.3 Preparation of His8IFN-PEG20-His8IFN using his-tag conjugation 
3.2.3.1 Preparation of His8IFN-PEG20-His8IFN 
Novel His8IFN-PEG20-His8IFN dimers were prepared using PEG20 di(mono)sulfone 
5 (1 eq. in 200 mM sodium phosphate containing 150 mM sodium chloride) and 
three molar equivalents of His8IFN in 50 mM sodium acetate pH 5.3 containing 35 
µM hydroquinone. Hydroquinone was added to all of the his-tag conjugation reaction 
buffers. Due to PEG20 di(bis)sulfone 4 undergoing conjugation by addition reactions 
to a double bond, it is possible that radical induced side-reactions can occur. Previous 
investigations in house have shown that the addition of hydroquinone to conjugation 
buffers prevents the polymerisation of bis-alkylating PEG reagents. As fewer side 
reactions occur, resulting in better conversion of the his-tag conjugated protein.  
 The pH of the reaction mixture was ≈ pH 6.5. The high IFN concentration 
(3.3 mg/mL, 0.5 mL) and stoichiometry were used to promote the formation of 
His8IFN-PEG20-His8IFN. The reaction mixture was for 16 h at 20 °C, which is 
similar to what is used to prepare PEG20-His8IFN (§ 2.2.7.4). The reaction mixture 
was analysed by SDS-PAGE (Figure 3-18) where a band (Lane 4) at 50-60 kDa 
consistent for the formation of His8IFN-PEG20-His8IFN was evident. However 
conversion was low as there was a significant amount of un-conjugated IFN still 
present. 
 
Figure 3-18. Example SDS-PAGE analysis (InstantBlue™ and PEG (BaI2 stain) of His8IFN 
reaction with PEG20 di(mono)sulfone 5 (n=2), Lane 1: Novex pre-stained markers, Lane 2: 
PEG20 di(mono)sulfone 5, Lane 3: His8IFN, Lane 4: PEG20 di(mono)sulfone 5-His8IFN 
reaction mixture. SDS-PAGE analysis shows the formation of His8IFN-PEG20-His8IFN. 
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 After SDS-PAGE analysis the reaction mixture was stabilised using an excess 
of 100 mM sodium triacetoxyborohydride (STAB). STAB, a mild reducing agent, 
reduces the electron withdrawing ketone group located on the PEG reagent to an 
alcohol group to stabilise His8IFN-PEG20-His8IFN by preventing de-PEGylation 
(Figure 2-2). The reaction mixture was then buffer exchanged into 100 mM sodium 
acetate pH 4.0 for CIEC purification.  
 Initially a single His8IFN CIEC purification step was used to separate the 
His8IFN-PEG20-His8IFN from un-conjugated PEG20 di(mono)sulfone 5 species, 
unreacted His8IFN and low and high MW impurities (§ 2.2.7.5). However, as seen in 
Figure 3-19 (Lane 3), a single CIEC step was unable to separate the His8IFN-PEG20-
His8IFN from high and low MW impurities. A polishing second CIEC step was 
conducted, but the impurities remained (Figure 3-19, Lane 4).  
 
Figure 3-19. SDS-PAGE (silver stain) of CIEC purified His8IFN-PEG20-His8IFN. Lane 1: 
Novex pre-stained markers, Lane 2: His8IFN α-2a, Lane 3: one-step CIEC purified His8IFN-
PEG20-His8IFN, Lane 4: two-step CIEC purified His8IFN-PEG20-His8IFN. One and two step 
CIEC unable to purity His8IFN-PEG20-His8IFN from high and lower MW impurities.  
 Seeley J.E and colleagues have reported different methods to purity PEG 
dimers (one PEG conjugated to two proteins) made using PEG20 bis-vinyl sulfone 
(Seely and Richey, 2001). Cation exchange purification was successful for purify the 
PEG dimer from PEG monomer (one protein with one PEG conjugated) and 
unconjugated protein. Size exclusion chromatography (SEC) characterises proteins 
according to size (Tayyab et al., 1991). SEC was successful in separating the 
unPEGylated from the PEGylated proteins, but could not purify the PEG dimer from 
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the PEG monomer (James E Seely et al., 2005). Therefore, the reaction was repeated 
and CIEC used to remove unconjugated PEG20 di(bis)sulfone 4 and PEG20-His8IFN 
from His8IFN-PEG20-His8IFN. SEC purification was then used in an attempt to 
separate His8IFN-PEG20-His8IFN dimer from low and high MW impurities (method 
2.2.7.6). The SEC chromatogram (Figure 3-20 A), shows that low and high MW 
impurities were separated with the first peak (Figure 3-20 C) being the high MW 
impurities (22% of the purified reaction mixture, SEC analysis), then the His8IFN-
PEG20-His8IFN (38% of the purified reaction mixture, SEC analysis) and then the 
unreacted His8IFN α-2a (40% of the purified reaction mixture, SEC) (Figure 3-20 B).  
 To determine the best purification method, the final His8IFN-PEG20-His8IFN 
from the different purification methods was compared by SDS-PAGE analysis 
(Figure 3-20 D). Each His8IFN-PEG20-His8IFN sample was stored at 4 °C in 50 mM 
sodium phosphate containing 150 mM sodium chloride pH 7.8 for approximately 2 
months. Silver stain was used, as it is a highly sensitive and quick method of 
detecting low concentrations (very low nanogram detection level) of protein 
(Chevallet et al., 2006). The best method to obtain a pure His8IFN-PEG20-His8IFN 
conjugate was after one cycle of CIEC and SEC, as seen in Figure 3-20 D (Lane 4). 
Low and high MW can be seen in Lanes 2 and 3 (Figure 3-20 D) after one or two 
cycles of CIEC, thus the His8IFN-PEG20-His8IFN dimer could not be obtained in 
high enough purity without using SEC. The high MW impurities observed (Lane 3-7, 
Figure 3-20 C) could be (PEG)n-His8IFN, where the polyhistidine tag has two or 
more PEG di(bis)sulfone 4 conjugated to it, producing (PEG)n-His8IFN. No free 
His8IFN α-2a can be seen in any homodimer samples, indicating that the His8IFN-
PEG20-His8IFN dimer is stable for 2 months at 4 °C.  
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Figure 3-20. SEC purification of His8IFN-PEG20-His8IFN fractions. A) SEC purification 
chromatogram and B) peak information table, C) SDS-PAGE (Silver stain) of fractions from 
SEC purification, Lane 1: Novex markers, Lane 2: CIEC purified mixture, Lane 3-7: high 
MW species, Lane 8-12: His8IFN-PEG20-His8IFN, Lane 13-15: low MW impurities, Lane 
16-17: unreacted His8IFN α-2a. D) SDS-PAGE analysis of different purification methods, 
Lane 1: Novex pre-stained markers, Lane 2: His8IFN-PEG20-His8IFN after two CIEC steps, 
Lane 3: His8IFN-PEG20-His8IFN after one CIEC step, Lane 4: His8IFN-PEG20-His8IFN after 
one CIEC and one SEC step. The best method to obtain a pure His8IFN-PEG20-His8IFN 
conjugate was one cycle of CIEC and SEC.  
 The yield of His8IFN-PEG20-His8IFN dimer (0.030 mg/mL, from 3 mg/mL) 
after one cycle of CIEC followed by one cycle of SEC purification was found to be 
≈1.5 % after UV and MicroBCA™ assay to ascertain the His8IFN α-2a 
concentration. This is a very low yield compared to that obtained for PEG20-His8IFN 
and (PEG20)2-His8IFN, 0.7 mg, 17.6% yield and 0.29 mg, 7.1 % yield respectively (§ 
3.2.4). The preparation of His8IFN-PEG20-His8IFN dimer was conducted twice 
where the low conversion was consistently observed. 
 The low yield for the His8IFN-PEG20-His8IFN dimer results from a low 
conversion, which could be due to the impure PEG20 di(mono)sulfone 5 as can 
observed in Lane 2 (Figure 3-18) and/or long reaction time (16 h), which may be 
causing hydrolysis of the PEG reagent 5. Histidine is less reactive as a nucleophile 
than a free thiol, so there was concern about the His8IFN-PEG20-His8IFN dimer 
could be improved with purer reagents and possibly with reagent that had different 
leaving groups (Cong et al., 2012). However, the aim was to prepare the His8IFN-
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PEG20-His8IFN dimer and to characterise the dimer in terms of activity, purity and 
identity. Thus, the His8IFN dimer was prepared in enough quantity to characterise it 
in terms of purity, identity and activity along with the PEG20-His8IFN and (PEG20)2-
His8IFN controls.  
3.2.4 Preparation of PEG20-His8IFN and (PEG20)2-His8IFN using his-tag 
conjugation 
His-tag conjugation of His8IFN was conducted with PEG20 mono-sulfone 2. The 
PEG20-His8IFN and (PEG20)2-His8IFN were prepared to evaluate the different 
properties of the His8IFN-PEG20-His8IFN dimer to that of both mono- and di-
PEGylated His8IFN. In an effort to increase the yield of PEG20-His8IFN and 
(PEG20)2-His8IFN, the PEG20 bis-sulfone reagent 1 was activated by the elimination 
of one of the β-sulfonyl groups generating a reactive PEG mono-sulfone 2 (§ 
2.2.5.1). As a slightly acid pH is required for conjugation to one of the amines in the 
imidazole ring of histidine, preparation of PEG bis-sulfone 1 to PEG mono-sulfone 2 
was conducted prior to the reaction, as the elimination reaction of β-sulfonyl groups 
would be very slow (Brocchini et al., 2008).  
 His-tag conjugation was conducted using 2.5 eq. of PEG20 mono-sulfone 2 to 
1 eq. of His8IFN, the reaction was left for 16 h at 20 °C. The slight excess of PEG 
reagent and the longer incubation time are required to maximise the conjugation 
yields, as histidine is less reactive as a nucleophile than a free thiol (Brocchini et al., 
2006; Cong et al., 2012). Factors also affecting the conjugation include, protein 
concentration and pH (Brocchini et al., 2008). SDS-PAGE analysis was then 
conducted on the reaction mixture (Figure 3-21). The conditions for PEG20 bis-
sulfone 1 reaction with IFN were taken from Cong et al. (Cong et al., 2012), which 
was based on extensive optimisation. Due to the his-tag having eight-histidine’s, two 
molecules of PEG can conjugate to the his-tag, producing a (PEG20)2-His8IFN 
species. The conjugation of His8IFN was successful with (PEG20)2-His8IFN 
migrating to between ~80-110 kDa. PEG20-His8IFN α-2a migrated on the gel 
between ~50-60 kDa and native His8IFN is seen at ~16 kDa (Figure 3-21). 
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Figure 3-21. Representative SDS-PAGE (left: InstantBlue™ stain, right: InstantBlue™ and 
PEG (BaI2) stain) analysis of PEG20 mono-sulfone 2 reaction with His8IFN (n=4), Lane 1: 
Novex markers, Lane 2: His8IFN and Lane 3: His8IFN incubated with 2.5 eq. of PEG20 
mono-sulfone 2. SDS-PAGE shows successful his-tag conjugation of His8IFN, to prepare 
PEG20-His8IFN and (PEG20)2-His8IFN. 
After the reaction incubation period, the solution containing the reaction mixture (in 
pH 7.4 buffer) was buffer exchanged into 50 mM sodium acetate buffer, pH 4.0. This 
was done due to the pI of IFN being ~6.0, meaning the His8IFN would be positively 
charged at pH 4.0 to bind efficiently to the CIEC column. The recommended buffer 
for CIEC at pH 4.0 was sodium acetate with the HiTrap™ sulphopropyl (SP) 
MacroCap™ column (GE Healthcare HiTrap™ SP MacroCap™ product literature). 
The reaction mixture was purified by the different positively charged His8IFN 
species having different affinities to the column, which were eluted with a step 
gradient (method 2.2.7.2). Collected fractions, were analysed for each peak by gel 
electrophoresis (Figure 3-22).  
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Figure 3-22. Example analysis of CIEC purification of PEG20 mono-sulfone 2-His8IFN 
reaction mixture (n=4). A) CIEC chromatogram and B) SDS-PAGE (InstantBlue™ and PEG 
stain) analysis of CIEC fractions, Lane 1: Novex markers, Lane 3: reaction mixture prior to 
CIEC, Lane 3-4: PEG20 mono-sulfone 2, Lane 5-6: (PEG20)2-His8IFN, Lane 7-8: PEG20-
His8IFN and Lane 9: His8IFN. CIEC successfully purified (PEG20)2-His8IFN and PEG20-
His8IFN from His8IFN. 
Analysis of the chromatogram showed the major peak maxima were at 20.92, 22.21, 
36.08, 52.90 and 66.77 min (Figure 3-22 A). The first peak corresponds to 
unconjugated PEG20 reagent 2, which does not bind to the CIEC column, this can be 
seen in lanes 3-4 (Figure 3-22 B) at ~40 kDa. The second peak corresponds to 
multimers or (PEG)n-His8IFN, which bind loosely to the column due to steric 
hinderance from the conjugated PEGs. (PEG20)2-His8IFN and PEG20-His8IFN elute 
prior to unconjugated His8IFN, which bound strongest to the column and therefore 
required the highest concentration of buffer B to elute from the column (Figure 
3-22). Purification was found to be very reproducible, where the elution pattern was 
consistent for each of the four separate occasions it was conducted.  
 PEG20-His8IFN and (PEG20)2-His8IFN fractions (52-60 and 35-44 
respectively) were subsequently centrifugally concentrated  using VivaSpin column 
10,000 MWCO, combined and purified further by CIEC separately (§ 2.2.7.3). The 
CIEC chromatogram peaks and SDS-PAGE analysis of the CIEC peak fractions for 
PEG20-His8IFN and (PEG20)2-His8IFN respectively are shown in Figure 3-23. PEG20-
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His8IFN was observed as single peak (Figure 3-23 A) and can be seen between 50-60 
kDa by SDS-PAGE analysis (Figure 3-23 B). The chromatogram of (PEG20)2-
His8IFN CIEC purification showed two peaks (Figure 3-23 C), the larger peak 
between 30-40 min was confirmed to be (PEG20)2-His8IFN by SDS-PAGE (~110 
kDa, Figure 3-23 D), whilst the smaller peak at 50 min was confirmed to be PEG20-
His8IFN (50-60 kDa) (Lanes 7-9, Figure 3-23 D).  
 
Figure 3-23. Example of further CIEC purification analysis of A) PEG20-His8IFN, C) 
(PEG20)2-His8IFN and SDS-PAGE (silver stain) analysis of peak fractions of B) PEG20-
His8IFN and D) (PEG20)2-His8IFN. Further purification of PEG20-His8IFN and (PEG20)2-
His8IFN was consistently successful at isolating the final PEG20-His8IFN and (PEG20)2-
His8IFN conjugates (n=4). 
Fractions containing pure PEG20-His8IFN and (PEG20)2-His8IFN were then combined 
and centrifugally concentrated until approximately 2.5 mL remained so the 
conjugates could be buffer exchanged into storage buffer (§ 2.2.7.3). The storage 
buffer was 50 mM sodium phosphate containing 150 mM sodium chloride pH 7.4 
and was chosen as this buffer is often used for the storage of proteins (Cong et al., 
2012). A final SDS-PAGE analysis was conducted on the final conjugates to confirm 
their purity, as seen in Figure 3-24. Quantification of protein concentration was 
conducted by MicroBCA™ assay and UV absorbance at 280nm (§ 2.2.2.1). The final 
yields for PEG20-His8IFN and (PEG20)2-His8IFN were calculated by MicroBCA™ 
quantification of protein concentration were 0.7 mg, 17.6% yield for PEG20-His8IFN 
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and 0.29 mg, 7.1 % yield for (PEG20)2-His8IFN. The preparation of PEG20-His8IFN 
and (PEG20)2-His8IFN was conducted four times, with yields were found to be 
reproducible at ~17% and 7-9% for PEG20-His8IFN and (PEG20)2-His8IFN 
respectively. Samples were then aliquoted into cryovials, and flash frozen using 
liquid nitrogen, and stored at -80 ºC ready for identity, purity, stability and activity 
characterisation tests to be conducted with the His8IFN-PEG20-His8IFN dimer.  
 The His8IFN-PEG20-His8IFN (~1.5%) was prepared along with controls 
PEG20-His8IFN (17.6%) and (PEG20)2-His8IFN (7.1%). The yields were lower than 
those reported for thiol-conjugation of non-his-tagged IFN, where a 65% yield of 
PEG10-IFN was reported (Balan et al., 2007). This could be due to histidine being a 
less reactive nucleophile than thiol. Further, investigations (§3.2.1) into the PEG 
di(bis)sulfone 4 revealed that the reagent purity was low, which could have impeded 
on the yield/conversion of the His8IFN-PEG20-His8IFN.  
 
Figure 3-24. SDS-PAGE (InstantBlue™ stain) analysis of final PEG20-His8IFN and 
(PEG20)2-His8IFN, Lane 1: Novex pre-stained markers, Lane 2: His8IFN, Lane 3: PEG20-
His8IFN, Lane 4: (PEG20)2-His8IFN. PEG20-His8IFN and (PEG20)2-His8IFN successfully 
prepared for identity, purity and activity characterisation for comparison to the His8IFN-
PEG20-His8IFN. 
3.2.5 Characterisation of His8IFN-PEG20-His8IFN dimer 
3.2.5.1 Accelerated stability study of His8IFN-PEG20-His8IFN dimer 
An accelerated stability study was conducted on the His8IFN-PEG20-His8IFN dimer 
in comparison to the PEG20-His8IFN and (PEG20)2-His8IFN conjugates in order to 
assess the STAB treatment on the conjugates using DTT and high temperatures (50 
260 kDa 
 
160 kDa 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
			1         2    3            4          
PEG20-His8IFN α-2a  
(PEG20)2-His8IFN α-2a  
His8IFN α-2a 
  
149 
°C and 90 ºC). DTT was used to act as a nucleophile. De-conjugation of the 
conjugate may occur by DTT reacting with the linker, but STAB would prevent this 
as the amide/ester bonds within the linker are already reduced. 
 The His8IFN-PEG20-His8IFN dimer, PEG20-His8IFN and (PEG20)2-His8IFN 
conjugates were shown to be stable (Figure 3-25) as no free His8IFN α-2a from de-
conjugation was observed in those samples subject to DTT reduction. In addition, 
this accelerated stability study showed that the His8IFN-PEG20-His8IFN dimer, 
PEG20-His8IFN and (PEG20)2-His8IFN remain conjugated to PEG up to 90 ºC, as no 
free or aggregated His8IFN was observed.  
 
Figure 3-25. A) SDS-PAGE (InstantBlue™ and PEG stain) analysis of PEG20-His8IFN 
(Lanes 6-9) and (PEG20)2-His8IFN (Lanes 2-5) stressed with ± DTT at 50 and 90 °C. Lane 1: 
Novex pre-stained markers, Lane 2: -DTT 50 °C, Lane 3: +DTT 50 °C, Lane 4: -DTT 90 °C, 
Lane 5: +DTT 90 °C, Lane 6: -DTT 50 °C, Lane 7: +DTT 50 °C, Lane 8: -DTT 90 °C, Lane 
9: +DTT 90 °C. B) SDS-PAGE (InstantBlue™ and PEG stain) analysis of His8IFN-PEG20-
His8IFN dimer stressed with ± DTT at 50 and 90 °C, Lane 1: Novex pre-stained markers, 
Lane 2: -DTT 50 °C, Lane 3: +DTT 50 °C, Lane 4: -DTT 90 °C, Lane 5: +DTT 90 °C. 
His8IFN-PEG20-His8IFN, PEG20-His8IFN and (PEG20)2-His8IFN found stable when reduced 
± DTT at 50 °C and 90 °C, as no free His8IFN was observed by SDS-PAGE.  
3.2.5.2 Anti-IFN α-2a Western blot of his-tag conjugated His8IFN α-2a conjugates 
To confirm the identity of His8IFN-PEG20-His8IFN dimer, PEG20-His8IFN and 
(PEG20)2-His8IFN, an anti-IFN α-2a Western blot was conducted to confirm the 
presence of IFN. Samples were loaded (1 μg) into a SDS-PAGE 4-12% Bis-Tris gel. 
The resulting gel was transferred onto nitrocellulose membrane, which was subject to 
rabbit anti-IFN α-2a antibody followed by anti-rabbit-AP conjugated antibody 
(method 2.2.10.1).  
260 kDa 
 
160 kDa 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
			1      2      3      4      5               6       7       8       9          
PEG20-His8IFN α-2a  
(PEG20)2-His8IFN α-2a  
			1      2      3     4      5  
260 kDa 
 
160 kDa 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
B A 
His8IFN-PEG20-His8IFN  
  
150 
 
Figure 3-26. Anti-IFN α-2a Western blot of His8IFN-PEG20-His8IFN dimer, PEG20-His8IFN 
and (PEG20)2-His8IFN. Lane 1: Novex markers, Lane 2: His8IFN α-2a, Lane 3: PEG20-
His8IFN, Lane 4: (PEG20)2-His8IFN, Lane 5: His8IFN-PEG20-His8IFN. Anti-IFN α-2a 
antibody identifies all His8IFN α-2a species confirming their identities.  
 The anti-IFN α-2a identifies His8IFN-PEG20-His8IFN dimer, which can be 
clearly observed at ~80 kDa (Lane 5, Figure 3-26). This is 20 kDa larger than that 
observed for PEG20-His8IFN, which can be seen at ~60 kDa (Lane 3, Figure 3-26). 
This 20 kDa difference could be explained by the conjugation of one more His8IFN 
molecule within His8IFN-PEG20-His8IFN dimer compared to that of PEG20-His8IFN. 
Interestingly, the MW of the His8IFN-PEG20-His8IFN dimer is similar to that of 
(PEG20)2-His8IFN, where (PEG20)2-His8IFN can be seen at ~80 kDa in lane 4 (Figure 
3-26). Unconjugated His8IFN was analysed as a control, which is seen at ~15 kDa in 
Lane 1 (Figure 3-26). This anti-IFN Western blot therefore confirms the identity of 
His8IFN-PEG20-His8IFN dimer, PEG20-His8IFN and (PEG20)2-His8IFN as they were 
successfully detected.  
 The Western blot (Figure 3-26) has a high background signal, with some 
smearing of His8IFN α-2a (Lane 2), PEG20-His8IFN (Lane 3), (PEG20)2-His8IFN 
(Lane 4). Optimising the development time of the membrane could reduce the 
background signal. Additionally, longer washing steps would also help to reduce the 
background signal, however, too long a washing steps can also reduce the signal. An 
optimised lower concentration of IFN species could be used to help reduce the high 
background signal. The patchiness of the Western blot could be prevented by rolling 
a tube across the gel and nitrocellulose membrane to remove air bubbles (Mahmood 
and Yang, 2012).  
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3.2.5.3 MALDI-TOF analysis of his-tag PEGylated His8IFN α-2a conjugates 
To confirm the MW and thus identity of His8IFN-PEG20-His8IFN dimer in 
comparison to controls (His8IFN, PEG20-His8IFN and (PEG20)2-His8IFN) MALDI-
TOF analysis was conducted. MALDI-TOF mass spectrometry (MS) is widely used 
technique for the precise mass determination of proteins, peptides or glycan’s and 
has also been used for the analysis of post-translational modifications (Fenselau, 
1997). MALDI-TOF can ionise molecules with molecular masses of 100-1,000,000 
Da for analysis and can be a highly sensitive technique. As MALDI-TOF was 
conducted n=1 for His8IFN-PEG20-His8IFN, His8IFN, PEG20-His8IFN and (PEG20)2-
His8IFN, the achieved MS data was analysed to one significant figure since the 
accuracy of MS is often between 0.1-0.01% (Fenselau, 1997). One significant figure 
was used as no repeats were conducted to determine the reproducibility of the 
MALDI-TOF data. 
 Typically, for MALDI-TOF analysis, the amount of salts in the samples 
should be as low as possible. Thus, the samples (His8IFN-PEG20-His8IFN, His8IFN, 
PEG20-His8IFN and (PEG20)2-His8IFN) were concentrated by freeze-drying. Prior to 
freeze-drying the samples were desalted using a PD-10 column to buffer exchange 
the samples into deionised water. These freeze-dried samples were then re-suspended 
in ammonium bicarbonate pH 8.0. PEG20 di(mono)sulfone 2 was re-suspended into 
ammonium bicarbonate pH 8.0; then all the samples were then analysed by MALDI-
TOF MS (method 2.2.10.2).  
 As discussed previously (§ 3.2.2), the MALDI-TOF spectrum for His8IFN α-
2a showed a peak MW of ≈20405.2 Da (Figure 3-27 A), this was found to be 
comparable to that stated in literature (Ahad et al., 2009; Vanden Broecke and 
Pfeffer, 1988), but the MW was slightly larger taking into account the eight-histidine 
tag (1.2 kDa) (Cong et al., 2012). The PEG20 di(mono)sulfone 2 MALDI-TOF 
spectrum showed a peak at ≈22940.6 Da (E). The MALDI-TOF spectrum of 
His8IFN-PEG20-His8IFN dimer showed a peak MW of ≈63106.7 (Figure 3-27 D), 
suggesting the conjugate obtained was His8IFN-PEG20-His8IFN (2× His8IFN α-2a’s 
≈20405.2 Da each + PEG20 ≈22940.6 Da). SDS-PAGE analysis of His8IFN-PEG20-
His8IFN dimer was observed on the gel at ≈70 kDa such as observed for the anti-IFN 
Western blot (Figure 3-26).  
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 The His8IFN-PEG20-His8IFN dimer was found to be difficult to prepare pure 
and in good yield (n=2). Optimisation reactions investigating PEG20 di(bis)sulfone 4 
vs. PEG20 di(mono)sulfone 5, incorporating DMSO, PEG:IFN equivalents and 
reaction times were all investigated. The purity of the His8IFN-PEG20-His8IFN was 
improved with optimisation of the purification procedure, whereby CIEC followed 
by SEC was used. 
 Whereas, the PEG20-His8IFN MALDI-TOF spectrum showed a peak of 
≈40686.0 Da (Figure 3-27 B), confirming the conjugate’s identity as PEG20-His8IFN 
(His8IFN α-2a≈20405.2 Da + PEG≈20 kDa). Comparing the MW of the PEG20-
His8IFN (≈40686.0 Da) to His8IFN-PEG20-His8IFN (≈63106.7 Da) there is a 20 kDa 
difference in MW between the two molecules. As the His8IFN-PEG20-His8IFN is 
conjugated to one more His8IFN molecule compared to that of the dimer, thus 
confirming the identity of both the PEG20-His8IFN and His8IFN-PEG20-His8IFN. 
Whilst for (PEG20)2-His8IFN, the MALDI-TOF spectrum (Figure 3-27 C) of 
≈60688.3 Da, this confirms the identity of (PEG20)2-His8IFN (His8IFN α-2a≈20405.2 
Da + PEG≈40 kDa). Compared to PEG20-His8IFN, the MW of (PEG20)2-His8IFN is 
20 kDa larger, taking into account the conjugation of the second PEG bis-sulfone 1. 
Whilst compared to the His8IFN-PEG20-His8IFN the MW is similar, however the 
slightly larger for the His8IFN-PEG20-Hi8IFN dimer, taking into account the 
polyhistidine tags attached to IFN.  
 To conclude, the aim was to prepare His8IFN-PEG20-His8IFN utilising a 
recombinant-chemical approach, taking advantage of the 8-polyhistidine-tag on the 
recombinantly prepared IFN. However, it was found that pure His8IFN-PEG20-
His8IFN, were more difficult to prepare than thought in a good yield, even after 
numerous optimisation experiments and attempts. Enough was prepared to test the 
activity of the His8IFN-PEG20-His8IFN within the in vitro assays. However, to 
investigate whether pure IFN-PEG-IFN could be prepared and possibly in higher 
yields, disulfide conjugation was used due to free thiols being a better nucleophile 
than free histidines (Cong et al., 2012). Therefore, it was hoped that the free thiols 
would be more reactive with the PEG di(bis)sulfone 4 and prepare IFN-PEG-IFN 
dimers. Disulfide conjugation on His8IFN was conducted with PEG di(bis)sulfone 4 
to make IFN-PEG-IFN dimers to evaluate the different properties of the IFN-PEG-
IFN dimers.  
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Figure 3-27. MALDI-TOF spectrum for His8IFN α-2a species and PEG20 di(mono)sulfone 
5. A) His8IFN α-2a B) PEG20-His8IFN, C) (PEG20)2-His8IFN, D) His8IFN-PEG20-His8IFN, E) 
PEG20 di(mono)sulfone 5. MALDI-TOF confirmed the MW of the his-tag conjugates. 
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3.3 Disulfide-bridging conjugation to prepare IFN-PEG-IFN 
3.3.1 Optimisation of reduction conditions for His8IFN α-2a using DTT 
The most commonly used thiol reductant is dithiothreitol (DTT) (Hansen and 
Winther, 2009). Disulfide reduction with requires only one molecule of DTT for 
each disulfide to be reduced. DTT is converted into a stable cyclic disulfide which 
drives the reduction of the accessible protein disulfides (Getz et al., 1999; Hansen 
and Winther, 2009). Scouting experiments were conducted with increasing 
concentrations of DTT to evaluate the conditions to reduce the disulfides in His8IFN 
α-2a. His8IFN α-2a (0.1 mg/mL; 0.1 mL) was reduced using DTT concentrations 
ranging from 10-100 mM for 30 min and 1 h at RT (Figure 3-28). The reduction was 
conducted at pH 7.8 (method 2.2.6.1) as DTT has been shown to be most effective at 
pH values above pH 7.0 (protonated sulfurs have lowered nucleophilicities) (Cleland, 
1964; Hermanson, 2008).  
 
Figure 3-28. DTT (10-100 mM) reduction study of His8IFNα-2a (0.1 mg/mL) for A) 30 min 
and B) 1 h. Lane 1: Novex pre-stained markers, Lane 2: 10 mM DTT, Lane 3: 20 mM DTT, 
Lane 4: 50 mM DTT and Lane 5: 100 mM DTT. His8IFN α-2a was completely reduced by 
20 mM DTT after 30 min. The reduced disulfides in His8IFN α-2a are then able to undergo 
bis-alkylation reactions with PEG di(bis)sulfone 4 to prepare IFN-PEG-IFN homodimers.  
 SDS-PAGE analysis (Figure 3-28) indicated that His8IFN is completely 
reduced at DTT concentrations above 20 mM from 30 min (Lanes 3-5,Figure 3-28). 
Fully reduced protein (Lanes 2-5, Figure 3-28) migrated more slowly compared to 
native His8IFN α-2a with its two disulfides oxidised. This is due to the disulfide 
reduced IFN being able to be completely unfolded in the presence of SDS to have a 
larger solution structure than the oxidised IFN. His8IFN α-2a was not fully reduced 
using 10 mM DTT (Lane 2, Figure 3-28) even after 1 h, therefore 20 mM DTT for 30 
min was considered best for reducing His8IFN α-2a.  
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 Another common method to reduce disulfide bonds in proteins is to use tris 
(2-carboxyethyl) phosphine (TCEP). TCEP has been shown to be significantly more 
stable over a wider pH range (1.5-8.5) than DTT (Getz et al. 1999). However, there 
are two main disadvantages of using TCEP. Firstly, TCEP does not have a long shelf 
life (Getz et al., 1999); hence its reducing efficiency declines over time as it 
degrades. Secondly, DTT is more stable in buffers containing a metal chelator 
whereas the stability of TCEP can be affected for example by the presence of 
phosphates (Getz et al., 1999). Therefore, DTT was used for reduction. 
 Removal of the reductant (TCEP or DTT) from the reduced protein, elution 
over a PD-10 column is necessary. As, the reductant (TCEP or DTT) could react 
with the bis-sulfone linker, reducing the yield of the desired PEGylated conjugate. 
However, as the protein is within the reduced state, it is more amenable to 
precipitation or dimerisation. No precipitation was observed when eluting reduced 
IFN from the PD-10 column during preparation of the IFN-PEG-IFN dimers.  
3.3.2 Glutathione re-oxidation of His8IFN α-2a 
IFN has two disulfide bonds that are amenable to reduction by DTT. To prepare the 
mono-PEG IFN conjugate, only one disulfide bond was conjugated by PEG bis-
sulfone 1. Upon conjugation it is necessary to ensure the unconjugated disulfide is 
reoxidised.  
 Glutathione is one of the most abundant thiol compounds found in cells, and 
plays a major role in the formation of disulfide bonds in proteins in the endoplasmic 
reticulum (Okumura et al., 2011). Glutathione is widely used to assist protein 
reoxidation in vitro with proteins containing disulfide bond(s) (Okumura et al., 
2011).  
 The formation of a disulfide bond in a protein in the presence of glutathione 
occurs via ‘oxido-shuffling’ (thiol/disulfide exchange reaction) process. Initially, a 
mixed disulfide of the reduced protein and glutathione forms (Figure 3-29). 
However, this mixed disulfide is often less stable than the protein disulfide which 
then forms. Fahey et al (2000) have shown the effect of GSH:GSSG on the 
reoxidation of the reduced disulfides and recovery of activity of serine protease 
domain of urokinase plasminogen activator (Fahey et al., 2000). They found that the 
optimum ratio of GSH:GSSG for efficient reoxidation to be 0.5:0.5 mM (Fahey et 
al., 2000). Further, glutathione has been described to reoxidise IFN α-2b after 
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conjugation with PEG bis-sulfone 1. This work demonstrated glutathione could be 
utilised in the reoxidation of IFN after disulfide conjugation (Balan et al., 2007). As 
disulfide-conjugation was to be conducted on His8IFN, the optimum reoxidation 
conditions for His8IFN were investigated.  
 
Figure 3-29. The process of protein disulfide bond formation via thiol/disulfide exchange 
process initiated by small MW disulfide compounds (R) such as glutathione. His8IFN has 
two disulfide bonds, which can be conjugated to. Conjugation to one reduced disulfide was 
required, therefore, once conjugated to, the other disulfide bond needs to be reoxidised, for 
this glutathione was used.  
To determine the optimum incubation time and temperature for the complete 
reoxidation of the reduced cysteine-thiols of His8IFN, an investigation was 
undertaken using glutathione at RT and 4 °C over time points (0, 1, 3, 5, 8 and 16 h). 
This is due to the reduced disulfide to take time to reoxidise, as the disulfide-
exchange reactions are the rate-determining step (Okumura et al., 2011). His8IFN 
(0.5 mg/mL, 2 mL) was reduced with DTT (20 mM), the DTT was removed and the 
reduced His8IFN α-2a was aliquoted into two 1 mL fractions. Glutathione (50 mM 
GSH:50 mM GSSG) was added to each aliquot, where one was placed at RT and the 
other at 4 °C, and SDS-PAGE analysis run at the determined time points (method 
2.2.6.2). Densimetric analysis of the InstantBlue™ stained gels was conducted, as 
InstantBlue™ is a quantitative stain. 
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Figure 3-30. Glutathione reoxidisation of DTT reduced His8IFN α-2a time point 
(0,1,3,5,8,16 h) studies, A) 0 h, B) 3 h, C) 8 h, D) 16 h. Lane 1: Novex pre-stained markers, 
Lane 2: His8IFN α-2a, Lane 3: reduced His8IFN α-2a, Lane 4: 4 °C glutathione-His8IFN α-2a 
mixture, Lane 5: RT glutathione-His8IFN α-2a mixture. Complete reoxidation of reduced 
His8IFN α-2a was observed when His8IFN α-2a was incubated with glutathione at RT for 16 
h. 
From the results (Figure 3-30) it was deduced that the most favourable conditions for 
glutathione reoxidisation of the reduced His8IFN was to allow incubation to proceed 
for 16 h at RT, which led to complete reoxidation of His8IFN. In contrast, the 
reactions at 4 °C did not go to full conversion to prepare oxidised His8IFN, as ~23% 
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of the mixture was His8IFN-His8IFN. Similarly, at 8 h at RT had a 94% yield of 
oxidised His8IFN as some of the mixture had formed His8IFN-His8IFN. To conclude, 
it was chosen to combine the conjugation reaction time and after this add the GRS 
(50 mM GSH:50 mM GSSG) and allow the reoxidising of the reduced His8IFN to be 
conducted for 16 h at RT. Balan and colleagues reported using a 1 mM solution of 
glutathione (50 mM oxidised glutathione: 50 mM reduced glutathione) for 24 h at 4 
°C (Balan et al., 2007).  
3.3.3 Preparation of IFN-PEG20-IFN and IFN-PEG10-IFN 
To investigate whether pure IFN-PEG-IFN could be made and possibly in higher 
yields, disulfide conjugation was used. Disulfide conjugation had not previously 
been conducted on His8IFN. Disulfide conjugation was conducted on His8IFN with 
PEG di(bis)sulfone 4 to make IFN-PEG-IFN dimers to evaluate the different 
properties of the IFN-PEG-IFN dimers. IFN-PEG10-IFN was prepared to determine i) 
how varying the PEG di(bis)sulfone 4 size (20 kDa vs. 10 kDa) affects the reaction 
conversion/yield and ii) how varying the PEG di(bis)sulfone 4 sizes affect the 
bioactivity of IFN in comparison to their mono- or di-PEGylated counterparts. 
Further, PEG di(bis)sulfone 4 had been previously used to prepare Fab-PEG-Fab 
dimers using disulfide-conjugation (Khalili et al., 2013). When tested in vitro, the 
Fab-PEG-Fab dimers binding activity mimicked that of mAbs (§1.4.1.4) (Khalili et 
al., 2013), therefore it was thought that the PEG di(bis)sulfone 4 with disulfide 
conjugation could be used sucessfully to prepare IFN-PEG-IFN dimers.  
 For conjugation with the 10 and 20 kDa PEG di(bis)sulfone 4, His8IFN α-2a 
(4.1 mg) was first reduced using 20 mM DTT (Figure 3-31). Reduced His8IFN was 
buffer exchanged into 50 mM sodium phosphate 20 mM EDTA pH 7.8 for 
conjugation, as thiols are nucleophilic at neutral pH, therefore thiol-specific 
conjugation can take place (Brocchini et al., 2008).  
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Figure 3-31. SDS-PAGE of His8IFN α-2a reduced using DTT for 10 and 20 kDa PEG 
di(bis)sulfone 4 conjugation. Lane 1: Novex pre-stained markers, Lane 2: His8IFN α-2a and 
Lane 3: reduced His8IFN α-2a. Successful reduction of His8IFN α-2a with 20 mM DTT for 
10 and 20 kDa PEG di(bis)sulfone 4 conjugation. 
The reduced His8IFN was conjugated to using PEG20 di(bis)sulfone 4 in a 2:1 ratio. 
This stoichiometry was selected to promote the formation of IFN-PEG20-IFN, as 
there was excess of His8IFNα-2a to PEG to minimise the formation of X-PEG20-IFN 
(§ 2.2.8.8). The same ratio was used of PEG10 di(bis)sulfone 4 to promote the 
formation of IFN-PEG10-IFN (§ 2.2.8.9). To reduce the risk of hydrolysis, the PEG 
reagent was activated in situ by the elimination of two β sulfonyl groups generating 
reactive PEG di(mono)sulfone 4 (Figure 2-1). Reduced His8IFN α-2a (0.5 mg/mL, 
7.5 mL) was allowed to incubate for 5 h at 20 °C separately with the 10 kDa and 20 
kDa PEG di(bis)sulfone 3. To re-oxidise the unconjugated thiol of the remaining 
disulfide, GRS was added (50 mM, 153.1 μL) and left to reaction for a further 16 h at 
20 °C. Confirmation of re-oxidisation was conducted by SDS-PAGE analysis (Figure 
3-32).  
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Figure 3-32. Example Glutathione reoxidation of His8IFN α-2a unconjugated thiols in A) 
PEG20 di(bis)sulfone 4-His8IFN α-2a reaction mixture, Lane 1: Novex pre-stained markers, 
Lane 2: His8IFNα-2a, Lane 3: PEG20 di(bis)sulfone 4-His8IFNα-2a reaction mixture, Lane 4: 
PEG20 di(bis)sulfone 4-His8IFNα-2a reaction mixture with GRS solution. B) PEG10 
di(bis)sulfone 4-His8IFN α-2a reaction mixture. Lane 1: Novex pre-stained markers, Lane 2: 
His8IFNα-2a, Lane 3: PEG10 di(bis)sulfone 4-His8IFNα-2a reaction mixture, Lane 4: PEG10 
di(bis)sulfone 4-His8IFNα-2a reaction mixture with GRS solution. Complete re-oxidation of 
reduced His8IFNα-2a by glutathione after 16 h. Low conversion of IFN-PEG-IFN dimers 
observed when using both 10 and 20 kDa PEG di(bis)sulfone 4 and was observed for each of 
the three repeats conducted. 
Prior to purification, two additions (0.15 mL) of STAB were added to ‘lock’ the 
IFNs in place (Figure 2-2) by preventing de-conjugation. Cation exchange 
chromatography (CIEC) was used to purify X-PEG-IFN from His8IFNα-2a and IFN-
PEG-IFN. CIEC was unable to purify His8IFN from IFN-PEG-IFN; due to the later 
having the same affinity to the column as native His8IFN. CIEC was successful in 
purifying X-PEG-IFN from both His8IFN and IFN-PEG-IFN, which could be 
separated by SEC (§ 2.2.8.10 and 2.2.8.11). One step of SEC was tried but it was 
unable to separate X-PEG-IFN from His8IFN and IFN-PEG-IFN.  
 The reactions to prepare IFN-PEG20-IFN and IFN-PEG10-IFN were repeated 
three times, with low conversions observed each time to the homodimers. These low 
conversions suggest that the reactivity or purity of the PEG di(bis)sulfone 4 maybe 
impeding the conversion to the homodimer product rather than the conjugation 
chemistry, as conversion to the homodimer was low for both disulfide and his-tag 
conjugation. 
 A CIEC step gradient of 0, 45, 55, 100% was used to purify the PEG20 
di(bis)sulfone 4-His8IFN reaction mixture, with aim of purifying X-PEG20-IFN from 
His8IFN and IFN-PEG20-IFN (Figure 3-33 A). Fractions were collected and analysed 
using SDS-PAGE (Figure 3-33 B) following method 2.2.8.10.  
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Figure 3-33. A) CIEC chromatogram and B) SDS-PAGE analysis (InstantBlue™) of CIEC 
purification of PEG20 di(bis)sulfone 4-His8IFNα-2a reaction mixture. Lane 1: Novex pre-
stained markers, Lane 2-7: X-PEG20-IFN fractions 7-19, Lane 9-10: His8IFN α-2a and IFN-
PEG20-IFN fractions 57-63. His8IFN α-2a and IFN-PEG20-IFN were successfully purified 
from X-PEG20-IFN by CIEC. 
 Analysis of the chromatogram shows the major peaks at 2.58, 14.63, 35.52 
and 60.38 min (Figure 3-33 A). The first peak corresponds to PEG20 di(bis)sulfone 4, 
which is flowing straight through the column as it does not bind. The next peak at 
14.63 min (Figure 3-33 A) corresponds to X-PEG20-IFN which can be seen between 
50-60 kDa in Lanes 2-8 in Figure 3-33 B. The peak at 60.38 min corresponds to 
His8IFN α-2a (15-20 kDa) and IFN-PEG20-IFN (between 60-80 kDa) which bind 
tightly to the column eluting at ~80% buffer B, the mixture can be seen in Lane 9 
(Figure 3-33 B).  
  To purify X-PEG10-IFN from IFN-PEG10-IFN and some His8IFN, an 
optimised CIEC step gradient of 0, 45, 55, 100% was used. This was developed by 
carrying out a linear gradient from 0-100% buffer B, the fractions where collected 
and analysed by SDS-PAGE. Using the chromatogram and SDS-PAGE results, the 
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percentage of buffer B where each conjugate elutes is calculated, to develop the draft 
step gradient-this is then further adjusted for optimum separation.  
 Analysis of the chromatogram (Figure 3-34 A) shows the major peaks at 
4.33, 16.98, 39.10 and 62.91 min. The first two peaks correspond to PEG10 
di(bis)sulfone 4, which has flowed straight through the CIEC column as it does not 
bind. The next peak at 39.10 min (Figure 3-34 A) corresponds to X-PEG10-IFN, 
which can be seen between 30-40 kDa in Lanes 8-11 in Figure 3-34 B and His8IFN 
α-2a between 15-20 kDa that co-eluted with X-PEG10-IFN. The peak at 62.91 min 
corresponds to His8IFN α-2a (15-20 kDa) and IFN-PEG10-IFN (~50 kDa) which bind 
tightly to the column eluting at ~80% buffer B, the mixture can be seen in Lane 12 
(Figure 3-34 B).  
 
Figure 3-34. A) CIEC chromatogram and B) SDS-PAGE analysis of PEG10 di(bis)sulfone 4-
His8IFN α-2a reaction mixture purification. Lane 1: Novex pre-stained markers, Lane 2-7: 
PEG10 di(bis)sulfone 4, Lane 8-11: X-PEG10-IFN+ His8IFN α-2a, Lane 12-13: IFN-PEG10-
IFN and His8IFN α-2a. His8IFN α-2a and IFN-PEG10-IFN successfully purified from X-
PEG10-IFN. 
 For SEC purification, CIEC fractions 57-63 were pooled of His8IFN α-2a and 
IFN-PEG20-IFN and CIEC fractions 61-64 were pooled of His8IFN and IFN-PEG10-
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IFN. The pooled fractions were diluted into 50 mM sodium phosphate pH 7.8 for 
SEC purification (method 2.2.8.11).  
 SEC successfully purified IFN-PEG20-IFN from His8IFN α-2a (Figure 3-35), 
therefore fractions 26-30 were centrifugally concentrated until <~1 mL. No buffer 
exchanged was necessary due to the SEC running buffer being 50 mM sodium 
phosphate pH 7.8.  
 
Figure 3-35. SEC purification A) chromatogram and B) SDS-PAGE analysis (silver stain) of 
peak fractions of PEG20 di(bis)sulfone 4-His8IFNα-2a CIEC purified mixture. Lane 1: Novex 
pre-stained markers, Lane 2-5: (PEG)n-IFN fractions 18-24, Lane 6-9: IFN-PEG20-IFN 
fractions 26-30, Lane 10-11: low MW impurities fractions 32-36, Lane 12-18: His8IFN α-2a. 
SEC purification successfully purified IFN-PEG20-IFN from His8IFN α-2a, for further 
characterisation in terms of activity, identity and purity. 
 Analysis of the SEC chromatogram obtained (Figure 3-36 A) shows three 
major peaks at 47.58, 67.73 and 86.23 min. The first peak could possibly be (PEG)n-
IFN where two or more PEGs have linked to one IFN and/or where more than two 
IFNs have conjugated to one PEG in which mis-bridging has allowed more than one 
IFN to bind at either linker end. The second peak at 67.73 min is IFN-PEG10-IFN, 
this can be seen on the gel between 50-60 kDa, lanes 7-10 (Figure 3-36 B). His8IFN 
is the smallest and therefore last to elute from the SEC column at 86.23 min (Figure 
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3-36 A) and can be observed on the gel in lanes 11-17 (Figure 3-36 B). Further, the 
two chromatograms Figure 3-35, Figure 3-36, show the same trend in elution, 
showing how reproducible the purification process is for PEG di(bis)sulfone 4-
His8IFN.  
 
Figure 3-36. SEC purification A) chromatogram and B) SDS-PAGE analysis (silver stain) of 
peak fractions of PEG10 di(bis)sulfone 4-His8IFN α-2a CIEC purified reaction mixture. Lane 
1: Novex pre-stained markers, Lane 2-6: (PEG)n-IFN fractions 19-34, Lane 7-10: IFN-
PEG10-IFN fractions 31-43, Lane 11-17: His8IFN α-2a fractions 49-70. SEC purification 
successfully purified IFN-PEG10-IFN from His8IFN α-2a for further characterisation studies. 
 From the SDS-PAGE analysis it can be observed that SEC (Figure 3-36 B) 
successfully purified IFN-PEG10-IFN from His8IFN α-2a, therefore fractions 31-43 
were centrifugally concentrated until ~1 mL remained. For IFN-PEG20-IFN fractions 
26-30 were pooled and also concentrated until ~1 mL. No buffer exchanged was 
necessary because SEC running buffer (50 mM sodium phosphate pH 7.8) was 
compatible with the biological assay media which is used to test potency.  
 UV and BCA quantification was conducted and the yields obtained for IFN-
PEG20-IFN and IFN-PEG10-IFN were 0.85% (35 μg/mL) and 1.1% (46 μg/mL) 
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respectively. The yields of the IFN-PEG-IFN dimers were very low, this was also 
found for the His8IFN-PEG20-His8IFN dimer (§ 3.2.3.1), where the yield achieved 
was ~1.5%. These low yields could be due to i) a two-step purification which 
involves SEC which causes reduced yields and ii) the PEG di(bis)sulfone 4 reagent 
which causes low conversion. The IFN-PEG-IFN were prepared n=2, however the 
low yield was reproducible. It was found upon investigation into the PEG 
di(bis)sulfone 4 that the reagent was impure, this was thought to be the cause of the 
low yields. Thus, a different synthesis route (2) was developed to prepare a pure PEG 
di(bis)sulfone 4 for heterodimer preparation. The PEG di(bis)sulfone 4 has been used 
to prepare Fab-PEG-Fab dimers (§1.4.1.4). However, the aim was to prepare IFN-
PEG-IFN dimers, which were pure to investigate their properties.  
 SDS-PAGE of the final IFN-PEG10-IFN and IFN-PEG20-IFN conjugates can 
be seen in Figure 3-37 where it can be seen that the conjugates was made to high 
purity. Purity assessment of the IFN-PEG-IFN dimers was confirmed by Western 
blotting.  
 
Figure 3-37. SDS-PAGE (InstantBlue™ and PEG stain) analysis of final IFN-PEG10-IFN 
and IFN-PEG20-IFN conjugates. Lane 1: pre-stained Novex markers, Lane 2: His8IFN α-2a, 
Lane 3: IFN-PEG20-IFN, Lane 4: IFN-PEG10-IFN. IFN-PEG10-IFN and IFN-PEG20-IFN 
conjugates successfully prepared using disulfide-bridging conjugation of His8IFN and 
purified. 
3.3.4 Preparation of 5, 10 and 20 kDa PEG-IFN α-2a and (PEG)2-IFN α-2a 
Disulfide conjugation was conducted on His8IFN α-2a, this had not been explored 
previously. As His8IFN has two disulfide bonds (Figure 1-18), a PEG molecule can 
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conjugate to each of the disulfide bonds, producing the (PEG20)2-IFN species. To 
evaluate the IFN-PEG-IFN dimers to see if they have different properties of PEG-
IFN and (PEG)2-IFN, PEG-IFN and (PEG)2-IFN were prepared. For preparing the 
PEG-IFN and (PEG)2-IFN, PEG bis-sulfone 1 was used, with PEG MW of 5, 10 and 
20 kDa. These PEG MW were used to evaluate how the PEG MW affects the activity 
of His8IFN and how this compares to that of the IFN-PEG-IFN dimers.  
3.3.4.1 Optimisation of PEGylation conditions for the synthesis of PEG20-IFN α-2a 
and (PEG20)2-IFN α-2a 
After it was determined that 20 mM DTT was sufficient to reduce completely the 
two disulfides in His8IFN α-2a, PEG20 bis-sulfone 1 was used to optimise the molar 
equivalents required to prepare PEG20-IFN and (PEG20)2-IFN. Scouting experiments 
were conducted with increasing molar equivalents (eq.) of PEG20 bis-sulfone 1 
ranging from 0.8 to 2.5 eq., the reactions were incubated for 4 h at 4 °C (method 
2.2.8.1). The glutathione solution (1 mM) was added and the reaction was allowed to 
proceed for a further 16 h at 4 °C. The GRS was added to reoxidise the reduced 
disulfide bond, which had not been PEGylated. After reoxidation the reaction 
mixture was assessed using SDS-PAGE analysis. 
 
Figure 3-38. Optimisation of PEG:IFN ratios for disulfide-conjugation of His8IFN with 
PEG20 bis-sulfone 1. Lane 1) Novex pre-stained markers, Lane 2) His8IFN α-2a, Lanes 3-7) 
0.8-2.5 eq PEG-His8IFN α-2a reaction mixture. Optimum ratio for preparing PEG20-IFN and 
(PEG20)2-IFN, was found to be 1:1 PEG: His8IFN α-2a for thiol PEGylation.  
It was observed (Figure 3-38) that with increasing PEG eq. more PEG molecules 
conjugate to one IFN molecule creating (PEG)n-IFN species. Therefore, a balance is 
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required between PEG stoichiometry and the conversion of PEG20-IFN and 
(PEG20)2-IFN and limiting the conversion of (PEG)n-IFN. To achieve the highest 
conversion of PEG20-IFN and (PEG20)2-IFN, 1 eq. (Lane 4, Figure 3-38) of PEG20 
bis-sulfone 1 was chosen. One eq. was observed to prepare both PEG20-IFN and 
(PEG20)2-IFN, but only trace amounts of (PEG)n-IFN species, thus maximising 
conversion of PEG20-IFN and (PEG20)2-IFN. In comparison, 2.5 eq. PEG yielded 
more high MW impurities of (PEG)n-IFN as seen in lane 7 (Figure 3-38). The use of 
1 eq. PEG for disulfide-bridging conjugation of non-his-tagged IFN α-2 has also 
been described for the preparation of PEG-IFN (Brocchini et al., 2008). Interestingly, 
the non-his-tagged IFN is not reported to dimerise during disulfide-conjugation 
(Balan et al., 2007). Suggesting the presence of the his-tag within His8IFN increases 
the propensity of His8IFN to dimerise, as seen at 35 kDa in Figure 3-38.  
3.3.4.2 Preparation of 5, 10 and 20 kDa PEG-IFN and (PEG)2-IFN 
Prior to the disulfide-bridging conjugation of the his-tag IFN, 20 mM DTT (1.0 M, 
0.15 g) was used to reduce the two disulfides in His8IFN α-2a (1.0 mg/mL, 3.13 mL) 
(Figure 3-39). Disulfide-bridging conjugation was conducted (method 2.2.8.1) using 
1 eq. of PEG bis-sulfone 1 to 1 eq. of reduced His8IFN α-2a, the reaction was 
conducted for 20 h at 20 °C.  
 
Figure 3-39. Example SDS-PAGE (InstantBlue™ stain) analysis of reduced His8IFN -2a 
with 20 mM DTT for 30 min, Lane 1: Novex pre-stained markers, Lane 2: reduced His8IFN 
α-2a for conjugation to PEG bis-sulfone 1, Lane 4: oxidised His8IFN α-2a. His8IFN α-2a was 
fully reduced to react with PEG bis-sulfone 1. Reduction was conducted six times (2 times 
per PEG size used) as conjugation was conducted twice (n=2) for each PEG size (20, 10 and 
5 kDa).  
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As the free thiol is more reactive as a nucleophile than the histidine residue, less 
equivalents of PEG can be used than in his-tag conjugation. As discussed previously, 
due to His8IFN α-2a having two disulfide bonds, it is possible to prepare both PEG-
IFN and (PEG)2-IFN in one reaction (Figure 3-40). The reaction mixture for 20, 10 
and 5 kDa PEG bis-sulfone 1-His8IFN α-2a were analysed using SDS-PAGE (Figure 
3-40).  
 
Figure 3-40. Representative SDS-PAGE (InstantBlue™ and PEG stain) of the A) 20, B)10 
and C) 5 kDa PEG bis-sulfone 1-IFN reaction mixtures. A) Lane 1: Novex pre-stained 
markers, Lane 2: His8IFN α-2a and Lane 3: PEG20 bis-sulfone 1-IFN reaction mixture. B) A) 
Lane 1: Novex pre-stained markers, Lane 2: His8IFN α-2a and Lane 3: PEG10 bis-sulfone 1-
IFN reaction mixture. C) A) Lane 1: Novex pre-stained markers, Lane 2:PEG5 bis-sulfone 1-
IFN reaction mixture. Successfully disulfide-bridging conjugation of His8IFN α-2a with 20, 
10 and 5 kDa bis-sulfone PEG 1 to prepare PEG-IFN and (PEG)2-IFN. Conjugation was 
conducted twice for each PEG size; the SDS-PAGE shown is an example for each PEG size 
reaction. 
After the incubation period, the solution was diluted 3- to 4- fold with 50 mM 
sodium acetate pH 4.0. The pI of IFN is ~6.0, thus to bind to the cation exchange 
column resin, His8IFN would be positively charged at ~ pH 4.0. The recommended 
buffer for CIEC at pH 4.0 was sodium acetate with the HiTrap™ sulphopropyl (SP) 
MacroCap™ column (GE Healthcare HiTrap™ SP MacroCap™ product literature). 
The PEG20 bis-sulfone 1-IFN reaction mixture was purified by the different 
positively charged His8IFN species having different affinities to the column, which 
were eluted with a step gradient of 0, 40, 45, 55 and 100% sodium chloride (§ 
2.2.8.3). For each peak the fractions were collected and analysed by SDS-PAGE 
(Figure 3-41 B).  
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Figure 3-41. Representative CIEC chromatogram of A) PEG20 bis-sulfone 1-His8IFNα -2a 
reaction mixture (n=2) and B) SDS-PAGE analysis (InstantBlue™ and PEG stain) of CIEC 
peak fractions, Lane 1: Novex pre-stained markers, Lane 2-9: fractions 16-37 of (PEG20)2-
IFN, Lane 11-20: fractions 46-75 of PEG20-IFN, Lane 21: His8IFN α-2a. PEG20-IFN and 
(PEG20)2-IFN were successfully purified by CIEC using a sodium chloride step gradient of 0, 
40, 45, 55 and 100%. 
 For PEG10 bis-sulfone 1-IFN, reaction mixture was purified using a step 
gradient of 0, 50, 55, 60 and 100% sodium chloride (method 2.2.8.5). While the 
PEG5 bis-sulfone 1-IFN reaction mixture was purified using a step gradient of 0, 48, 
55, 60 and 100% sodium chloride (method 2.2.8.7).  
 Analysis of the chromatogram obtained shows the major peaks at 25.46, 
35.09, 58.56 and 76.00 min (Figure 3-41 A). The first two peaks correspond to 
(PEG20)2-IFN, which binds least strongly due to steric hindrance from the two PEGs 
conjugated to the two disulfide bonds of His8IFN. The next peak (58.56 min, Figure 
3-41 A) corresponds to PEG20-IFN, which can be seen in Lanes 11-20 (Figure 3-41 
B). His8IFN α-2a binds strongest to the column and elutes at approximately 80% 
buffer B, this can be seen in Lane 21 (Figure 3-41 B).  
 The CIEC chromatograms for both 10 kDa (Figure 3-42 A) and 5 kDa PEG 
(Figure 3-43 A) bis-sulfone 1-His8IFN α-2a reaction mixtures showed the same 
elution trend as observed with PEG20 bis-sulfone 1-His8IFN α-2a reaction mixture, 
where (PEG)2-IFN eluted first followed by PEG-IFN and then His8IFN α-2a eluted 
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last. However, the percentage of sodium chloride required to elute the different 
conjugated species differed with PEG MW and required optimisation to elute pure 
conjugates. For example, 40% sodium chloride was required to elute PEG20-IFN, 
while ~50% sodium chloride was required to elute PEG10-IFN and PEG5-IFN. This is 
due to the smaller PEG MW having less of a steric shielding effect over His8IFN α-
2a. Interestingly, PEG-positional isomers have been described with PEG-INTRON
®
 
and PEGASYS
®
 where by the PEG conjugates to different lysine residues and it has 
been described that each PEG-positional isomers retained different levels of activity 
(§1.2.1.1). Therefore, different potencies may be found for each of the disulfide 
PEG-positional isomers in Figure 3-42. However, this has not been described before 
using disulfide conjugation of non-his-tagged IFN. Possibly this could be due to the 
sensitivity of the AKTA, where the purification is monitored by UV, compared to the 
use of a pre-static pump for purification as described by Balan and co-workers 
(Balan et al., 2007). 
 
Figure 3-42. A) Representative CIEC chromatogram and peak information table of PEG10 
bis-sulfone 1-His8IFNα -2a reaction mixture and B) SDS-PAGE analysis (InstantBlue™ and 
PEG stain) of CIEC peak fractions (n=2), Lane 1: Novex pre-stained markers, Lane 3-4: 
fractions 18-20 of (PEG10)2-IFN, Lane 5-13: fractions 22-32 of PEG10-IFN, Lanes 11-15: 
His8IFN α-2a. PEG10-IFN and (PEG10)2-IFN were successfully purified by CIEC using a 
sodium chloride step gradient of 0, 50, 55, 60 and 100%. 
PEG20-IFN and (PEG20)2-IFN fractions (16-37 and 46-75 respectively) were pooled, 
concentrated using a VivaSpin column and buffer exchanged into 50 mM sodium 
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phosphate pH 7.8 (method 2.2.8.3). While for PEG10-IFN and (PEG10)2-IFN and 
PEG5-IFN and (PEG5)2-IFN fractions 17-21, 22-39 and 11-18, 23-43 respectively 
were each pooled and buffer exchanged (methods 2.2.8.5 and 2.2.8.7 respectively). 
Final SDS-PAGE analysis (Figure 3-44) was conducted on the final disulfide 
conjugated IFN samples. Interestingly, it was observed that the yields for 10 kDa 
PEG bis-sulfone 1 samples were lower than when using the 20 and 5 kDa bis-sulfone 
1 (Table 3–1). However, the yields obtained for PEG-IFN and (PEG)2-IFN samples 
where greater than those achieved for IFN-PEG-IFN dimers. These yields highlight 
there are obvious differences between the PEG bis-sulfone 1 and PEG di(bis)sulfone 
4.  
 
Figure 3-43. A) Representative CIEC chromatogram of PEG5 bis-sulfone 1-His8IFNα -2a 
reaction mixture and B) SDS-PAGE analysis (InstantBlue™ and PEG stain) of CIEC peak 
fractions (n=2), Lane 1: Novex pre-stained markers, Lane 3-4: fractions 10-19 of (PEG5)2-
IFN, Lane 5-13: fractions 22-44 of PEG5-IFN, Lanes 11-15: His8IFN α-2a. PEG5-IFN and 
(PEG5)2-IFN were successfully purified by CIEC using a sodium chloride step gradient of 0, 
48, 55, 60 and 100%. 
 The differences in yields between the PEG bis-sulfone 1 and PEG 
di(bis)sulfone 4, is the same even when using different conjugation strategies (his-tag 
vs. disulfide conjugation). As the IFN dimer has a reduced yield when using both 
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conjugation strategies, as for IFN-PEG10-IFN a 1.1% yield was achieved. While for 
IFN-PEG10-IFN a 0.85% yield was achieved compared to the 1.5% yield of His8IFN-
PEG20-His8IFN. The low yields were thought to be due to the PEG di(bis)sulfone 4 
being an impure mixture compared to the pure PEG bis-sulfone 1 (Figure 3-12), thus 
a purer homobifunctional reagent 4 was prepared using synthesis route 2 in an 
attempt to improve the conversion and yields products prepared (§3.2.1).  
 Interestingly, higher yields were achieved for the disulfide-conjugated 
(PEG20)2-IFN (12%) compared to that of his-tag conjugated (PEG20)-His8IFN (7.1% 
yield). This could possibly due to the greater reactivity of the thiols than the amines 
or could it be due to steric shielding of one PEG conjugated to the his-tag reducing 
the conjugation of a second PEG molecule to the histidine tag. Overall, the yields 
achieved for PEG-IFN (Table 3–1) where quite similar to that achieved for PEG20-
His8IFN (17.1%). The yields achieved of the disulfide-conjugated his-tag IFN were 
lower than that reported for non-his-tagged IFN (56% PEG-IFN) (Balan et al., 2007). 
This could be due to variations in conjugation procedure such as using PEG mono-
sulfone 2 for conjugation, rather than PEG bis-sulfone 1 and using different 
purification columns (Balan et al., 2007). 
 As is stated in Table 3–1, the reactions for each PEG size (i.e. 20, 10 and 5 
kDa) were repeated twice. The yields achieved for each of the thiol-conjugates 
His8IFN being found consistent for each replicate, showing the reproducibility of the 
conjugate and purification processes developed.  
 
Table 3–1. Summary of thiol-conjugates His8IFN α-2a samples and the achieved yields 
Thiol conjugated His8IFN 
α-2a species 
Average Yield (%) n 
PEG20-IFN 29 2 
(PEG20)2-IFN 12 2 
PEG10-IFN 14 2 
(PEG10)2-IFN 16 2 
PEG5-IFN 29 2 
(PEG5)2-IFN 35 2 
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Figure 3-44. Final SDS-PAGE analysis (InstantBlue™ and PEG stain) of disulfide-
conjugated His8IFN α-2a species. Lane 1: Novex pre-stained markers, Lane 2: His8IFN α-2a, 
Lane 3: PEG20-IFN, Lane 4: (PEG20)2-IFN, Lane 5: PEG10-IFN, Lane 6: (PEG10)2-IFN, Lane 
7: PEG5-IFN, Lane 8: (PEG5)2-IFN. Novel disulfide-conjugated his-tagged IFN species 
successfully prepared.  
3.3.5 Characterisation of thiol conjugated IFN-PEG-IFN dimers  
3.3.5.1 Stability study of thiol PEGylated IFN α-2a conjugates 
Stability studies were performed for all bis-thiol selective PEG conjugated IFN α-2a 
species. First the purity of the thiol conjugated IFN α-2a species was first determined 
to confirm the absence of free IFN α-2a before starting the stability studies (Figure 
3-45). For that reason, the products were analysed by SDS-PAGE and the resulting 
gels were stained with InstantBlue™ and PEG stain followed by Western blotting 
using anti-IFN α-2a antibody (1 μg of protein/well, Figure 3-45, method 2.2.10.1). 
The results revealed no free IFN α-2a was present in any of the thiol conjugated IFN 
α-2a species prepared.  
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Figure 3-45. SDS-PAGE (InstantBlue™ and PEG stain) analysis of thiol PEGylated IFN α-
2a species. Lane 1: Novex pre-stained markers, Lane 2: His8IFN α-2a, Lane 3: PEG20-IFN, 
Lane 4: (PEG20)2-IFN, Lane 5: IFN-PEG20-IFN, Lane 6: PEG10-IFN, Lane 7: (PEG10)2-IFN, 
Lane 8: PEG5-IFN, Lane 9: (PEG5)2-IFN, Lane 10: IFN-PEG10-IFN. No un-conjugated 
His8IFN α-2a is observed from any of the thiol PEGylated IFN α-2a species.  
In addition, longer term stability studies were conducted by incubating the 
compounds in 50 mM sodium phosphate buffer, 150 mM NaCl pH 7.8 for 7 days at 4 
°C. The results showed no evidence of aggregation or free protein being released 
when analysed by SDS-PAGE (Figure 3-46).  
 
Figure 3-46. Thiol conjugated IFNα-2a conjugates incubated at 4 °C for 7 days. Lane 1: 
Novex pre-stained markers, Lane 2: His8IFN α-2a, Lane 3: PEG20-IFN, Lane 4: (PEG20)2-
IFN, Lane 5: PEG10-IFN, Lane 6: (PEG10)2-IFN, Lane 7: PEG5-IFN, Lane 8: (PEG5)2-IFN, 
Lane 9: IFN-PEG20-IFN, Lane 10: IFN-PEG10-IFN. No evidence of free or aggregated 
protein was observed by SDS-PAGE analysis using InstantBlue™ and PEG stain. 
Accelerated stability studies were also performed by incubating the thiol PEGylated 
IFN α-2a compounds (~40 μg/mL) at 90 ºC (10 min) with or without 20 mM DTT 
(method 2.2.10.5). Sample analysis was conducted by SDS-PAGE with the resulting 
gel stained using silver stain (Figure 3-37).  
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Figure 3-47. SDS-PAGE (silver stain) analysis of disulfide-conjugated IFN conjugates 
stressed with ± DTT for 10 min at 90 °C. A) Lane 1: Novex pre-stained markers, Lane 2: 
IFN-PEG20-IFN +DTT, Lane 3: IFN-PEG20-IFN -DTT, Lane 4: PEG20-IFN +DTT, Lane 5: 
PEG20-IFN -DTT, Lane 6: (PEG20)2-IFN +DTT, Lane 7: (PEG20)2-IFN -DTT. B) Lane 1: 
Novex pre-stained markers, Lane 2: IFN-PEG10-IFN +DTT, Lane 3: IFN-PEG10-IFN -DTT, 
Lane 4: PEG10-IFN +DTT, Lane 5: PEG10-IFN –DTT , Lane 6: (PEG10)2-IFN +DTT, Lane 7: 
(PEG10)2-IFN -DTT. C) Lane 1: Novex pre-stained markers, Lane 2: PEG5-IFN +DTT, Lane 
3: PEG5-IFN -DTT, Lane 4: (PEG5)2-IFN +DTT (InstantBlue™ and PEG stain), Lane 5: 
(PEG5)2-IFN –DTT (InstantBlue™ and PEG stain). The conjugates were shown to be stable 
when stressed with DTT for 10 min at 90 °C. 
The results indicated that when the thiol conjugated IFN α-2a were visualised on the 
gel by silver stain, no free protein was observed for the IFN-PEG20-IFN, PEG20-IFN, 
IFN-PEG10-IFN and (PEG5)2-IFN in the presence or absence of DTT, showing the 
conjugates to be stable even when stressed under reducing conditions and high 
temperatures (90 °C). A trace amount of free protein was observed for the PEG10-
IFN, (PEG10)2-IFN and PEG5-IFN conjugates when incubated for 10 min with DTT. 
Considering the acutely high sensitivity of the silver stain technique and the artificial 
design of the condition tested, this observation is unlikely to represent their stability 
under physiological conditions. Overall, these results suggest that the conjugates are 
stable. This shows that the 3-carbon bridge is highly thermodynamically stable, as 
the disulfide-conjugated IFN samples were not treated with STAB. 
260 kDa 
160 kDa 
 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
PEG20-IFN 
His8IFN α-2a 
1      2       3      4      5      6       7  
IFN-PEG20-IFN 
/(PEG20)2-IFN 
IFN-PEG10-IFN 
/(PEG10)2-IFN 
PEG10-IFN 
260 kDa 
160 kDa 
 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
1      2        3        4      5       6       7  A B 
260 kDa 
160 kDa 
 
110 kDa 
80 kDa 
 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
1           2       3      4     5  C 
(PEG5)2-IFN 
PEG5-IFN 
  
176 
3.3.5.2 Anti IFN α Western blot of thiol PEGylated IFN conjugates 
To assess the purity and to prove the identity of the conjugates in terms of IFN α-2a 
content, an anti-IFN α Western blot was conducted. One μg of His8IFN α-2a and 
thiol conjugated IFN α-2a species were loaded onto a SDS-PAGE 4-12 % Bis-Tris 
gel. The resulting gel was transferred onto nitrocellulose membrane, which was 
subject to rabbit anti-IFN α antibody followed by anti-rabbit-AP conjugated antibody 
(method 2.2.10.1).  
 
Figure 3-48. Anti IFN α western blot of A) His8IFN, IFN-PEG20-IFN and IFN-PEG10-IFN, 
B) PEG20-IFN and (PEG20)2-IFN, C) PEG10-IFN, (PEG10)2-IFN, PEG5-IFN and (PEG5)2-IFN. 
A) Lane 1: Novex pre-stained markers, Lane 2: His8IFN α-2a, Lane 3: IFN-PEG20-IFN, Lane 
4: IFN-PEG10-IFN, B) Lane 1: Novex pre-stained markers, Lane 2: PEG20-IFN, Lane 3: 
(PEG20)2-IFN, C) Lane 1: Novex pre-stained markers, Lane 2: PEG10-IFN, Lane 3: (PEG10)2-
IFN, Lane 4: PEG5-IFN, Lane 5: (PEG5)2-IFN. Anti-IFNα Western blot identified all the 
thiol conjugated species.  
All thiol-conjugates IFN α-2a species were observed by anti-IFN α Western blot. 
First, His8IFN was seen in Lane 2 (Figure 3-48 A) between 15-20 kDa. IFN-PEG20-
IFN (Lane 3) and IFN-PEG10-IFN (Lane 4, Figure 3-48 A) were observed at 80 kDa 
and 60 kDa respectively. PEG20-IFN conjugate was identified and was observed at 
~60 kDa (Lane 2, Figure 3-48 B), where as (PEG20)2-IFN was observed at ~100 kDa. 
This is 40 kDa larger than PEG20-IFN, and 20 kDa larger than IFN-PEG20-IFN, this 
is due to the (PEG20)2-IFN having two PEG molecules conjugated, which are 40 kDa, 
each in solution. IFN-PEG10-IFN is 20 kDa larger than PEG10-IFN (~40 kDa) (Lane 
2, Figure 3-48 C), due to the addition of an extra IFN molecule. While (PEG10)2-IFN 
was seen at ~60 kDa in Lane 3 (Figure 3-48 C). (PEG5)2-IFN (Lane 4, Figure 3-48 
C) can be seen at 40 kDa, the same MW as PEG10-IFN. While PEG5-IFN was 
observed at 30 kDa in Lane 5, Figure 3-48 C.  
 Trace amounts of (PEG)n-IFN can be seen in many of the conjugated species 
in Figure 3-48. Interesting, no un-conjugated His8IFN was observed in any of the 
thiol-conjugated samples. The blurry bands observed in the anti-IFN Western blot 
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could be caused by high voltage or air bubbles present during the transfer process. 
These could be avoided by ensuring that the gel is run using a lower voltage and that 
the transfer is rollered to remove air bubbles prior to transfer. Considering the 
acutely high sensitively of the detection antibodies and Western blot technique, these 
observations are unlikely to represent the actual purity of the samples. Overall, the 
results confirm the identity of the thiol-conjugated conjugates. 
3.3.6 In vitro biological potency of IFN-PEG-IFN dimers 
3.3.6.1 Antiviral activity testing of his-tag conjugated His8IFN-PEG20-His8IFN 
dimer 
IFN α-2a has numerous distinct biological properties; one of these is antiviral 
activity. This can be assessed in vitro, by the prevention of infection of human lung 
carcinoma (A549) cells by encephalomyocarditis virus (EMCV) (Grace et al., 2005) 
(Figure 3-49). The relative activity of the PEGylated His8IFN α-2a conjugates was 
determined by comparing the dose (concentration) of the sample, which displays 50 
% prevention of infection in cells or (50 % effective dose- ED50) in vitro to the dose 
of the National Institute for Biological Standards and Control (NIBSC) reference 
standard IFN α-2a. The ED50 was then used to calculate the specific activity of each 
of the His8IFN α-2a compounds (6.1 Appendix I). 
 
Figure 3-49. Microscope pictures of antiviral assay positive and negative controls, A) A549 
cells incubated without virus (negative), B) A549 cells incubated with EMCV virus 
(positive). 
 Cell-based assays are inherently variable (Meager, 2006). The use of 
international standards can significantly reduce inter-assay and even inter-laboratory 
variability. However, even optimised assays can lead to different specific activities 
being achieved by different laboratories (Giard and Fleischaker, 1984). The activity 
A) B) 
  
178 
of an IFN product is usually compared against the WHO international standard (IS) 
matching subtype, which is assigned an agreed specific activity per milligram 
(Meager, 2006). The WHO IS for IFNs are a homogenous standard of individual 
subtypes with separate unitage (Meager et al., 2001). The use of IS allows for 
comparisons to be made between different IFN preparations in a variety of biological 
assays including antiviral assays (Meager, 2002; Meager et al., 2001; Mire-Sluis et 
al., 1996).  
  Within this antiviral assay, two controls were used to ensure the data 
achieved was ‘real’ and not an artefact of the cell-based assay. First, on each plate an 
International standard was used, NIBSC IFN α-2a, which allows IFN potency to be 
reported in universally accepted International Units (IU) (Meager, 2006). Thus, 
direct comparisons can be made between IFN samples from different laboratories. 
Secondly, PEGASYS
®
 was also used concomitantly as a PEGylated IFN α control. 
As discussed (§ 1.2.1.1), PEGASYS
®
, a 40 kDa branched PEG-IFN α-2a, is a 
marketed product for the treatment of HCV. To further ensure the data achieved was 
accurate the assay was optimised as outlined in 6.3 Appendix III. 
 First, His8IFN α-2a, PEG20-His8IFN, (PEG20)2-His8IFN and His8IFN-PEG20-
His8IFN were subject to antiviral assay testing (§ 2.2.10.7). The raw data was plotted 
as shown for His8IFN-PEG20-His8IFN (Figure 3-50). The effective dose at 50% 
(ED50) was calculated into specific activity (MIU/mg) using the calculations in 6.1 
Appendix I.  
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Figure 3-50. Representative graph of His8IFN-PEG20-His8IFN with the ED50 for calculating 
the specific activity (MIU/mg). The Kd value in the table is the EC50 on the graph. The 
His8IFN-PEG20-His8IFN was tested twice within the antiviral assay. 
 The specific activity for NIBSC IFN is 63,000 IU/mL. Given that the vial 
contains ca. 250 ng of IFN, the specific activity would be ca. 254 MIU/mg. As stated 
cell based assays are inherently variable, therefore the inclusion of the NIBSC 
standard allows for any drifts in the values achieved for specific activity but may also 
indicate any negative changes within the assay or its components. Therefore a range 
for NIBSC IFNα-2a was set to 200-300 MIU/mg allowing for 20% variation or 
%CV. This 20% CV of specific activity for compounds would be taking this drift of 
NIBSC standard into account. 
 The mean specific activity achieved for PEGASYS
®
 (n=6) was 2.75 ± 0.37 
MIU/mg (Table 3–2). For His8IFN α-2a, the specific activity achieved was 195.5 ± 
66.8 MIU/mg (n=3) (Table 3–3). The specific activity achieved for PEG20-His8IFN 
was 9.84 ± 2.08 MIU/mg (5% retained activity, n=3) (Table 3–2). The novel 
His8IFN-PEG20-His8IFN dimer achieved a specific activity of 5.78 ± 1.62 MIU/ mg 
(2.95% retained activity, n=2, Table 3–2), whereas, (PEG20)2-His8IFN achieved a 
specific activity of 0.38 ± 0.16 MIU/mg (0.19% retained activity, n=3, Table 3–2). 
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Despite having a reduced antiviral activity all of the his-tag conjugates achieved 
complete inhibition of cell death from EMCV infection at saturating doses.  
Table 3–2. Summary of in vitro specific activity values achieved and n numbers for his-tag 
conjugated His8IFN-PEG20-His8IFN and controls. His8IFN-PEG20-His8IFN retained greater 
activity than PEGASYS and all his-tag conjugates achieved complete inhibition of cell 
death, thus retaining biological activity.  
Value His8IFN α-2a PEGASYS
®
 
PEG20-
His8IFN 
(PEG20)2-
His8IFN 
His8IFN-
PEG20-
His8IFN 
Mean specific 
activity 
(MIU/mg) 
195.50 2.75 9.84 0.38 5.78 
ST.DEV of 
specific 
activity 
(MIU/mg) 
66.83 0.37 2.08 0.16 1.62 
retained 
activity (%)  
100 - 5 0.19 2.95 
n 3 6 3 3 2 
 
 Specific activities achieved for the novel His8IFN-PEG20-His8IFN and the 
controls were plotted onto a bar graph and a one-way analysis of variance (ANOVA) 
was conducted. The one-way ANOVA was used to test that the null hypothesis that 
the sets of bioactivity data have the same mean (Dytham, 2011). One-way ANOVA 
was used in conjunction with a post hoc test, the Tukey’s test. The Tukey’s test is a 
multiple comparison test, which compares all possible pairs of means to find which 
are statistically different from one another and is based on studentised range of 
distribution (q). The assumption of the Tukey’s test are that i) the observations being 
tested are independent and ii) there is equal variation across the sets of data (Dytham, 
2011). 
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Figure 3-51. One-way ANOVA analysis of the specific activity (MIU/mg) data achieved for 
the novel His8IFN-PEG20-His8IFN and controls. Statistically different (P < 0.05) conjugates 
are marked (*). 
  The one-way ANOVA in conjunction with the Tukey test showed that all the 
conjugated His8IFN species were significantly different (P < 0.05) when compared to 
un-conjugated His8IFN α-2a (Figure 3-51). Interestingly, there is not a significant 
difference (P < 0.05) between any of the conjugated His8IFN α-2a conjugates made. 
This was an unexpected result for the His8IFN-PEG20-His8IFN, as the make up of the 
conjugate is quite different compared to that of PEG20-His8IFN and (PEG20)2-
His8IFN. Perhaps this difference in activity and statistical difference could be due to 
the presence of the PEG attached to the homobifunctional linkers as the difference is 
between native His8IFN and not vs. the controls (PEG20-His8IFN and (PEG20)2-
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His8IFN). It is well documented in literature that the conjugation of PEGs to proteins 
reduces the activity of the protein (Bailon et al., 2001; Monkarsh et al., 1997; Wang 
et al., 2002). However, as discussed (§ 1.2.1.1) conjugation is used to improve the 
PK of the proteins, so reduction in activity is not always detrimental if the proteins 
effect in vivo is prolonged. Further the reduction in activity can be overcome by 
increasing the dose. Therefore, the reduction in activity of the His8IFN-PEG20-
His8IFN is not detrimental if there is prolonged half-life, which could be assumed 
due to the MW of the conjugate (~80 kDa). 
 To better compare the specific activity achieved between the novel His8IFN-
PEG20-His8IFN and the controls. The achieved specific activities of all his-tag 
conjugated His8IFN species were plotted onto a scatter graph (Figure 3-51). It is 
observed that the order of activity is His8IFN with 100% retained activity, followed 
by PEG20-His8IFN (5%), His8IFN-PEG20-His8IFN (2.95%), (PEG20)2-His8IFN 
(0.19%). It was unexpected that the His8IFN-PEG20-His8IFN dimer activity was less 
than that of PEG20-His8IFN (Figure 3-51). The data achieved suggests that may be 
the second His8IFN molecule within the His8IFN-PEG20-His8IFN is impeding the 
activity of the other His8IFN molecule. His8IFN-PEG20-His8IFN was shown to have 
~2-fold greater activity than PEGASYS
®
. The reduction in IFN dimer activity has 
also been reported with DNL IFN α-2b dimers (§1.3.5). It was reported that a DNL 
monoPEGylated (20 kDa PEG) IFN α-2b dimer (10×1012 IU/mmol) had greater in 
vitro activity compared to PEGASYS
® 
when tested within the antiviral assay (Chang 
et al., 2009b). They accounted that site-specific PEGylation may preserve biological 
better, when using larger PEG MW (Chang et al., 2009b). The specific activity data 
achieved is in agreement with this, as the his-tag conjugates, PEG20-His8IFN and 
His8IFN-PEG20-His8IFN, achieved greater retained activity than that PEGASYS
®
, 
which is prepared using random conjugation. However, (PEG20)2-His8IFN retained 
less activity than PEGASYS
®
, this is most likely due to the conjugation of two PEG 
molecules masking the binding site or impeding the IFN binding to the 
IFNAR1/AR2 (Bailon and Won, 2009).  
 It is well documented in literature that conjugating proteins to PEG results in 
a reduction in protein activity, there is a directly proportional trend of reduced 
protein activity with increasing PEG MW (Grace et al., 2005). This trend can be seen 
when comparing the activity of the activity of PEG20-IFN to (PEG20)2-IFN or PEG20-
IFN to PEGASYS
®
. In both cases, the PEG20-IFN has a greater activity of 25- and 4-
  
183 
fold respectively. When compared to His8IFN-PEG20-His8IFN, PEG20-IFN has a 1.7-
fold better activity.  
3.3.6.2 Antiviral activity assessment of thiol conjugated IFN conjugates  
Antiviral assay was also performed on the disulfide-conjugated IFN-PEG20-IFN 
dimers and control conjugates, to compare the effect of the PEG MW on the IFN-
PEG-IFN in vitro activity and how the activity of the IFN-PEG-IFN dimers 
compares to the conjugated controls.  
 As with the his-tag conjugated samples, ED50 values were used to calculate 
specific activity (MIU/mg) according to the method described in 6.1 Appendix I. The 
specific activity achieved for His8IFN was 231.31 ± 10.95 (n=3, Table 3–2), while 
for PEGASYS® was 2.43 ± 0.06 MIU/mg (n=3, Table 3–2). PEG5-IFN and (PEG5)2-
IFN achieved specific activities of 51.89 ± 10.45 MIU/mg (n=2, 22.4% retained 
activity, Table 3–2) and 0.84 ± 0.03 MIU/mg (n=3, 0.36% retained activity, Table 3–
2) respectively. Specific activities of 4.86 ± 1.77 MIU/mg (2.1% specific activity, 
n=5, Table 3–2) and 0.12 ± 0.04 MIU/mg (0.05% retained activity, n=3, Table 3–2) 
for PEG10-IFN and (PEG10)2-IFN respectively. IFN-PEG10-IFN achieved a specific 
activity of 5.99 MIU/mg (2.59% retained activity, n=3, Table 3–2). The specific 
activities of PEG20-IFN and (PEG20)2-IFN were 3.95 ± 1.69 MIU/mg (1.7% retained 
activity, n=5, Table 3–2) and 0.55 ± 0.04 MIU/mg (0.24% retained activity, n=3, 
Table 3–2), respectively. A specific activity of 2.12 ± 0.64 MIU/mg (0.95% retained 
activity, n=4, Table 3–2) was achieved for IFN-PEG20-IFN.  
 To better compare the specific activities of the IFN-PEG-IFN dimers with the 
controls, the specific activities of all the thiol-conjugated IFN species were plotted on 
a graph (Figure 3-52). The graph shows that both the IFN-PEG-IFN dimers have 
retained activity. The IFN-PEG10-IFN dimer (2.59% retained activity, Figure 3-52) 
has greater activity than both PEG10-IFN (2.1%, Table 3–3) and (PEG10)2-IFN 
(0.05%, Table 3–3). This could possibly be the smaller homobifunctional PEG 4 
allowing both the IFN molecules to bind to the IFNAR1/AR2 on the cell surface. 
Interestingly, IFN-PEG20-IFN achieved a specific lower activity (2.12 ± 0.64 
MIU/mg, Table 3–3) compared to IFN-PEG10-IFN (5.99 ± 2.08 MIU/mg, Figure 
3-52). This could be due to the increasing PEG size affecting the IFN binding to 
IFNA receptors. Even so, both the IFN-PEG20-IFN and IFN-PEG10-IFN dimers were 
found to be more active that PEGASYS
®
 (Figure 3-52). IFN-PEG20-IFN (2.12 ± 0.64 
  
184 
MIU/mg, Figure 3-52) had a greater specific activity than (PEG20)2-IFN (0.55 ± 0.04 
MIU/mg) but a slightly lower activity than PEG20-IFN (3.95 ± 1.69 MIU/mg, Table 
3–3). Suggesting the addition a second PEG molecule has greater detriment to 
retained activity than a second protein. The only thiol-conjugate to have a greater 
specific activity than IFN-PEG10-IFN (5.99 ± 2.08 MIU/mg) was PEG5-IFN (51.89 ± 
10.45 MIU/mg, Figure 3-52). This observation highlights the correlation that with 
increasing PEG MW a decrease in specific activity is observed with the IFN-PEG-
IFN dimers and controls (Figure 3-52). The trend of decreasing activity of PEGylated 
proteins with increasing PEG MW trend is well documented in literature (Grace et 
al., 2005). It was also observed that all (PEG)2-IFN molecules had a much lower 
activity than IFN-PEG-IFN dimers and mono-PEGylated-IFNs, suggesting the 
conjugation of two PEG molecules must reduce the ability of IFN to bind to the 
IFNA receptors, thus reducing the activity of IFN (Figure 3-52).  
 
 
Figure 3-52. Specific Activities achieved for IFN-PEG-IFN dimers and control prepared 
using thiol-conjugation.  
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Table 3–3. Antiviral specific activity achieved for disulfide conjugated IFN-PEG-IFN dimers and controls (PEG-IFN and (PEG)2-IFN). All disulfide 
conjugates have retained biological potency. 
Value 
His8IFN α-
2a 
PEGASYS
®
 PEG5-IFN 
(PEG5)2-
IFN 
PEG10-IFN 
(PEG10)2-
IFN 
IFN-
PEG10-IFN 
PEG20-
IFN 
(PEG20)2-
IFN 
IFN-
PEG20-
IFN 
Mean 
specific 
activity 
(MIU/mg) 
231.31 2.43 51.89 0.84 4.86 0.12 5.99 3.95 0.55 2.12 
ST.DEV of 
specific 
activity 
(MIU/mg) 
10.95 0.06 10.45 0.03 1.77 0.04 2.08 1.69 0.04 0.64 
Percentage 
(%) retained 
activity  
100 - 22.4 0.36 2.1 0.05 2.59 1.7 0.24 0.92 
n 3 3 2 3 5 3 3 5 3 4 
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3.3.6.3 Comparison between the specific activities of thiol and his-tag IFN-PEG-
IFN dimers and controls 
As IFN-PEG-IFN dimers prepared using both his-tag and thiol conjugation of 
His8IFN. To observe if there were any differences within the specific activities 
achieved between the IFN dimer samples and their controls, their specific activity 
data and percentage retained activity data was summarised in Table 3–4. 
Interestingly, His8IFN-PEG20-His8IFN had a greater specific activity compared to 
both IFN-PEG10-IFN and IFN-PEG20-IFN (Table 3–4). Further PEG20-His8IFN 
retained greater specific activity than PEG20-IFN. This data suggests the conjugation 
at the his-tag has a higher retained activity compared to thiol conjugation of His8IFN. 
The IFN α-2a domains thought to interact with the IFNA receptors are A (Met16-
Ser28), AB (Cys29-Phe36), C (Glu78-Asp95) and DE (Tyr122-Ala139) (Figure 
3-53) (Fish, 1992; Mitsui et al., 1993; Uzé et al., 1994; Waine et al., 1992). Figure 
3-53 of the binding domains shows that one disulfide bond is between binding 
domains A and B, therefore conjugation at this disulfide bond (Cys29-Cys138) 
would drastically reduce the specific activity of His8IFN. It is understood that the 
disulfide conjugation reaction mixture of IFN is a mixture of two ‘PEG position 
isomers’ where the PEG conjugated at Cys1-CC[PEG]-C-Cys98 and Cys29-
CC[PEG]C-Cys138 (Balan et al., 2007). CIEC purification of PEG-IFN reaction 
mixtures showed two peaks of PEG-IFN, these are thought to be the two disulfide 
PEG positional isomers (§ 3.3.4.2). While, the higher specific activity of His8IFN-
PEG20-His8IFN and controls could be due to location of the polyhistidine-tag away 
from the binding domains, thus there is less steric hinderance from the conjugated 
PEG. Interestingly, (PEG20)2-His8IFN (0.38 ± 0.16 MIU/mg, Table 3–4) retained 
similar activity to (PEG20)2-IFN (0.55 ± 0.04 MIU/mg, Table 3–4) suggesting steric 
hinderance of two conjugated PEGs effect the binding of IFN in a similar way. 
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Table 3–4. Summary of specific activities and percentage retained activity achieved for IFN-
PEG-IFN dimers and the controls prepared. Grey colour indicates His-tag conjugated 
species, while white shows thiol-conjugated species. All site-specifically conjugated IFN 
conjugates retained biological activity, with His8IFN-PEG20-His8IFN retaining the highest 
biological activity of the IFN dimers prepared.  
Sample Specific Activity 
(MIU/mg) 
Percentage (%) retained 
activity 
His8IFN-PEG-20-His8IFN 5.78 ± 1.62 2.95 
PEG20-His8IFN 9.84 ± 2.08 5 
(PEG20)2-His8IFN 0.38 ± 0.16 0.19 
IFN-PEG20-IFN 2.12 ± 0.64 0.92 
PEG20-IFN 3.95 ± 1.69 1.7 
(PEG20)2-IFN 0.55 ± 0.04 0.24 
IFN-PEG10-IFN 5.99 ± 2.08 2.59 
PEG10-IFN 4.86 ± 1.77 2.1 
(PEG10)2-IFN 0.12 ± 0.04 0.05 
 
 
Figure 3-53. A) Receptor binding sites located on IFN α-2a, with binding domains A, AB, C 
and D labelled, sulphur atoms are coloured yellow and carbon atoms in grey (adapted from 
Klaus et al. 1997) to show the conjugation sites used for preparing the homo- and hetero-
dimeric molecules of IFN. The disulfide and histidine conjugation sites are labelled, taking 
into account where the location of the histidine tag would be located within His8IFN α-2a. 
Conjugation between Cys29-Cys138 would result in reduced IFN activity due to conjugation 
being located within the binding domains, whereas conjugation at Cys1-98 or on the 
histidine tag would result in higher retained activity of IFN due to the conjugation being 
away from the binding domains.  
three patches of conserved residues implicated in
interacting with the receptor(s) were found on the
AB loop (Cys29-Phe36, termed AB domain), on
helix C (Glu78-Asp95, C domain) and on helix D
including the adjacent DE loop (Tyr122-Ala139, D
domain) (Waineet al., 1992; Fish, 1992; Mitsui et al.,
1993). Uze¬ and co-workers proposed one more
receptor binding epitope located on helix A,
namely Met16-Ser28, i.e. the last two turns of helix
A and the proximal part of the AB loop (A
domain) (Uze¬et al., 1994). They also suggested a
sequential two-step model for the binding of an
IFN-a molecule to its cellular receptors where all
four domains would be involved. To learn more
about the role of conserved residues, a sequence
alignment of 35 IFN-a speciesshowsthat 25amino
acid residues are absolutely conserved (Table 3).
Sixteen of these invariant residuesare found in the
helical regions of IFN-a, four are cysteines (of
which two are also part of helices), and Æve map
to the AB loop (including Cys29). Threeconserved
residuesarelocated in Øexibleelementswhilenone
is found in helix A. However, there are clear pre-
ferencesfor certain typesof amino acidsat position
13 (Arg), 17, 18 (both Leu) and 21 (Met). Due to
their location within the three-dimensional struc-
turethey play an important rolein maintaining the
integrity of the helix-bundle. Interestingly, no resi-
due on that helix has been identiÆed as important
for binding by mutagenesis studies. The clustering
of important amino acidsin theABloop isremark-
able. Almost conserved sites are found at position
23 (Arg), 24 (Leu, Ileor Val) and 30 (Leu). The lat-
ter site is also substantially accessible to solvent as
is position 27, although it is less strictly conserved,
and they may well be important in mediating
hydrophobic interactions with the receptor mol-
ecules. The adjacent segment from Lys31 to Asp35
of theABdomain comprises exclusively polar resi-
dues which, with the exception of Asp32, show a
high degree of solvent accessibility. Furthermore,
they exhibit a slightly higher mobility than the
other well-deÆned parts of the protein structure.
Taken together these features make them ideally
suited for electrostatic interactions with oppositely
charged regionsof thereceptor molecules. Further-
more, their Øexibility would allow for structural
adaptations upon intermolecular contacts. This
polar interfaceisnicely extended upon inclusion of
the charged residues Lys131, Glu132, Lys133, and
Lys134 located at the C-terminal end of helix D
and of the absolutely conserved residues Cys138-
Glu141 which together make up the D domain.
Their locations in the three-dimensional structure
of IFN a-2a imply that they together might form
onebipartite epitope for binding of one of the two
Figure 6. Location of putative
receptor binding domains (A, AB,
C, and D) of interferon a-2a. Seg-
ments that have been implicated
are colored in orange. The two dis-
ulÆde bridges are shown in a ball-
and-stick representation with the
sulfur atoms in yellow, and thecar-
bon atoms in gray. The Figure was
prepared using the program Rib-
bons 2.0 (Carson, 1991).
670 The 3D Structure of Human Interferon ↵ -2a
Disulfide conjugation 
site (Cys29-Cys138) 
Disulfide conjugation 
site (Cys1-Cys98) 
Histidine conjugation 
site 
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3.3.6.4 Antiproliferative assay to assess the biological potency of thiol PEGylated 
IFN conjugates 
IFN is a pleiotropic protein, therefore to better judge the specific activity of the IFN-
PEG-IFN dimers and controls, the disulfide-conjugates were subject to an 
antiproliferative assay. The antiproliferative activity of IFNs was first described by 
Paucker in 1962 and colleagues who demonstrated that a 24 h exposure of L-cells to 
either UV-irradiated Newcastle disease virus or to IFN led to a temporary decline in 
cell growth. Interferons exert antiproliferative effects though cell cycle arrest 
particularly of the G0 and G1 phases (Sangfelt et al., 1997; Tiefenbrun et al., 1996).  
 The antiproliferative assay used to Daudi (human Burkitts Lymphoma) cells, 
the most widely utilised cell line, to assess the antiproliferative activity of the IFN-
PEG-IFN conjugates and mono-PEGylated controls. Due to the large quantity of 
sample required to run the assay, di-PEGylated samples as well as PEG5-IFN could 
not be assayed. The antiproliferative assay was optimised as outlined in 6.2 
Appendix II to ensure the data achieved was accurate and reproducible. As in the 
antiviral assay, NIBSC IFN α-2a was run on every plate as a control.  
 Raw data was plotted as shown for IFN-PEG10-IFN. The effective dose at 
50% (ED50) was calculated from the normalised graph (Figure 3-54) into specific 
activity (MIU/mg) using the calculations in 6.1 Appendix I.  
 
Figure 3-54. Representative Left) plotted data for IFN-PEG10-IFN and right) transformed 
data plot for IFN-PEG10-IFN with analysis tables (n=3). In the analysis table, the Kd is the 
EC50. 
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The specific activity achieved for His8IFN was 329.36 ± 97.98 MIU/mg (n=5, Table 
3–5). PEG10-IFN achieved a specific activity of 2.95 ± 0.21 MIU/mg (0.90% retained 
activity, n=2, Table 3–5). IFN-PEG10-IFN achieved a specific activity of 1.52 ± 0.47 
MIU/mg (0.46% retained activity, n=3, Table 3–5). The specific activity of PEG20-
IFN was 5.13 ± 1.44 MIU/mg (1.56% retained activity, n=4, Table 3–5). Specific 
activity of 0.81 ± 0.09 MIU/mg (0.25% retained activity, n=3, Table 3–5) was 
achieved for IFN-PEG20-IFN.  
Table 3–5. Summary of antiproliferative activity (MIU/mg) achieved for IFN-PEG-IFN 
dimers and controls (PEG-IFN and (PEG)2-IFN). All tested samples retained biological 
activity. 
Sample Specific Activity 
(MIU/mg) 
Percentage (%) 
retained activity 
n number 
His8IFN α-2a 329.36 ± 87.98 100 5 
IFN-PEG20-IFN 0.81 ± 0.09 0.25 3 
PEG20-IFN 5.13 ± 1.44 1.56 4 
IFN-PEG10-IFN 1.52 ± 0.47 0.46 3 
PEG10-IFN 2.95 ± 0.21 0.90 2 
 
 The specific activity and the percentage retained activity achieved for IFN-
PEG10-IFN in the antiproliferative assay was higher than that for IFN-PEG20-IFN. 
This shows that the PEG size affects the activity of the conjugated IFN molecule, 
where the larger PEG20 has reduced activity compared to the smaller PEG10 version 
of the dimer. However, the contrary is true for the mono-PEGylated controls. The 
PEG10-IFN has a lower activity than the PEG20-IFN control. This is not the same 
trend observed within literature or previous antiviral assay results as it is well 
documented that the larger PEG MW correlates with a reduction in protein activity 
(Grace et al., 2005). Thus, it is thought that further experiments should be conducted 
to increase the number of replicates on both PEG20-IFN and PEG10-IFN to better 
assess the true antiproliferative activity of these conjugates.  
 IFN-PEG10-IFN in both the antiviral and antiproliferative assays was shown 
to be more active than IFN-PEG20-IFN (Table 3–6). This could be due to the smaller 
PEG MW having less steric hinderance on the functional binding of IFN to its 
IFNAR receptors. This trend has also been reported in literature with IFN, where 
larger PEG sizes correlates with reduced activity (Grace et al., 2005). This trend was 
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also seen for the PEG-IFN controls within the antiviral assay, where PEG10-IFN had 
greater activity compared to PEG20-IFN (Table 3–6). However, for the 
antiproliferative data, PEG10-IFN achieved a lower specific activity than PEG20-IFN 
(Table 3–6). This is against the trend observed seen in the antiviral assay and in the 
literature, thus the data is questionable. Thus, it is difficult to ascertain whether the 
IFN-PEG10-IFN is more active than the PEG10-IFN as seen in the antiviral assay. 
However, both assays showed that the IFN-PEG-IFN dimers had retained activity.  
Table 3–6. Summary table of antiviral and antiproliferative specific activity data achieved 
for IFN-PEG-IFN dimers and monoPEGylated controls  
Sample Antiviral specific 
activity (MIU/mg) 
Antiproliferative 
specific activity 
(MIU/mg) 
His8IFN α-2a 231.31 ± 10.95 329.36 ± 87.98 
IFN-PEG20-IFN 2.17 ± 0.77 0.81 ± 0.09 
PEG20-IFN 3.95 ± 1.69 5.13 ± 1.44 
IFN-PEG10-IFN 5.99 ± 2.08 1.52 ± 0.47 
PEG10-IFN 4.86 ± 1.76 2.95 ± 0.21 
3.4 Conclusion 
This work has shown that PEG di(bis)sulfone 4 can be used as a linker to make IFN-
PEG-IFN dimers. These IFN-PEG-IFN dimers were prepared utilising both histidine 
and thiol conjugation strategies. It was found that His8IFN-PEG20-His8IFN retained 
greater activity than IFN-PEG20-IFN (Table 3–6). This is thought to be due to the 
conjugation site. The polyhistidine tag is thought to be further away from the protein-
binding site than the thiols from the disulfides.  
 Interestingly, it was found that the IFN-PEG10-IFN dimer was found to be 
more active than PEG10-IFN in the anti-viral assay (Table 3–6). This could be due to 
the presence of the second IFN molecule and the lower MW PEG used. However, 
this observation was reversed for IFN-PEG20-IFN, where PEG20-IFN displayed a 
higher specific activity in both the antiviral and antiproliferative assays. These results 
indicate that each conjugate should each be evaluated. 
 The trend where smaller PEG MW have greater retained activity was 
observed for the novel IFN-PEG-IFN dimers, PEG-IFN and (PEG)2-IFN, where 
increasing PEG size correlates with greater reductions in protein activity. This was 
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shown where IFN-PEG10-IFN had greater retained activity compared to IFN-PEG20-
IFN (Table 3–6). To further develop the IFN-PEG10-IFN homodimer into a possible 
treatment for hepatitis C, two areas need to be further investigated: i) experimental 
process and i) pharmacokinetics (PK). First, the experimental process to make the 
IFN-PEG10-IFN dimers would need to be improved to give higher conversions and 
yields of IFN-PEG10-IFN dimer to make the process scalable. Regarding purification, 
a SEC purification step that is readily scalable would need to be replaced by a CIEC 
step. Additionally, investigations into improving the purity of the PEG10 
di(bis)sulfone 4 would need to be conducted in an effort to improve the conversion 
of IFN-PEG10-IFN. As for in vivo studies, larger quantities of the IFN-PEG10-IFN 
heterodimer made from a single batch would be required. Second, investigations into 
the dosing and pharmacokinetic properties of the homodimer would be necessary. 
For the IFN-PEG10-IFN dimer to become a possible treatment for hepatitis C, it 
would need to have more favourable PK properties than current treatments 
PEGASYS
®
 and PEG-INTRON
®
 resulting in less frequent injections and greater 
patient compliance.  
 It was observed that the conversion and yield of the IFN-PEG-IFN dimers 
were much lower than those observed when preparing the PEG-IFN conjugates 
(Table 3–6), using either the polyhistidine or thiol conjugation strategies. One reason 
for this difference is the PEG di(bis)sulfone 4 used for conjugation was found to be 
less pure (§ 3.2.1) than the mono PEGylation reagents used to prepare the PEG-IFN 
conjugates. Utilising an alternative synthesis route (synthesis route 2, § 3.2.1), PEG 
di(bis)sulfone 4 was used to investigate producing multifunctional proteins (IFN-
PEG-Fab) using PEG di(bis)sulfone 4 as a linker.  
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Table 3–7. Summary of all the prepared conjugates, demonstrating reaction conditions, yields and biological activities. ND=not determined 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PEGylated 
conjugate 
PEG eq. 
in 
reaction 
Purification 
method 
Conversion 
(%) 
Yield 
(%) 
AV mean 
Specific 
activity 
(MIU/mg) 
Percentage 
retained 
activity 
(%) 
AP mean 
Specific 
activity 
(MIU/mg) 
Percentage 
retained 
activity (%) 
His-tag conjugated conjugates  
PEG20-His8IFN 2.5 2x CIEC 17.6 17.6 9.84 ± 2.08 5 ND ND 
 (PEG20)2-His8IFN 2.5 2x CIEC 7.1 7.1 0.38 ± 0.16 0.19 ND ND 
His8IFN-PEG20-
His8IFN 
1 CIEC, SEC 1.5 ~1.5 5.78 ± 1.62 2.95 ND ND 
Disulfide conjugated conjugates  
PEG20-IFN 1 CIEC 28.8 29 3.95 ± 1.69 1.7 5.13 ± 1.44  
(PEG20)2-IFN 1 CIEC 12.0 12 0.55 ± 0.04 0.24 ND ND 
IFN-PEG20-IFN 1 CIEC, SEC 0.8 0.85 2.12 ± 0.64 0.92 0.81 ± 0.09 0.25 
PEG10-IFN 1 CIEC 14.0 14 4.86 ± 1.76 2.1 2.95 ± 0.21 0.25 
(PEG10)2-IFN 1 CIEC 16.0 12 0.12 ± 0.04 0.052 ND ND 
IFN-PEG10-IFN 1 CIEC, SEC 1.1 1.1 5.99 ± 2.08 2.59 1.52 ± 0.47 0.46 
PEG5-IFN 1 CIEC 29.0 29 32.31 ± 23.66 14.0 ND ND 
(PEG5)2-IFN 1 CIEC 34.5 34.5 0.84 ± 0.03 0.36 ND ND 
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Chapter 4 Preparation and in vitro functional activity  
studies of IFN-PEG-Fab heterodimers 
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4.1 Introduction to IFN-PEG-Fab heterodimers 
There are many approaches being investigated to prepare multifunctional proteins (§ 
1.3). The PEG di(bis)sulfone 4 reagent has been used to prepare dimers of IFN 
(Chapter 3), Fabs (Khalili et al., 2013) and peptides, specifically Octreotide. The aim 
of this chapter was to explore a recombinant-chemical method to make heterodimers. 
IFN-PEG20-Fab heterodimers were hoped to be prepared, utilising the 20 kDa PEG 
di(bis)sulfone 4 as a linker to conjugate the two proteins together by site-specific 
disulfide conjugation.  
 The aim to prepare and characterise IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb 
heterodimers required utilising the 20 kDa PEG di(bis)sulfone 4 as a linker to 
conjugate both IFN and Fabbeva or Fabalb by disulfide PEGylation (§1.4.1.1). A 20 
kDa PEG derived reagent was chosen because i) 20 kDa PEG-protein conjugates are 
easier to purify by CIEC, due to the greater size of the PEG ii) by using a 20 kDa 
PEG, the MW of the desired conjugate would be approximately ~90 kDa which is 
above the renal filtration cut-off of 50-60 kDa which could be useful to help achieve 
a prolonged half-life in vivo.  
 As discussed in §1.4.6.3 cytokines have three major disadvantages with 
cancer therapy firstly; severe toxicities are frequently associated with systemic 
infusions of cytokines, thus limiting the amount, which can be administered to 
achieve an effective dose. Secondly, for a therapeutic protein to be effective, it must 
reach its biological target, however cytokines lack tumour specificity. Thirdly, the 
majority of cytokines have a MW below 30 kDa, thus suffer from short serum half-
lives (Vazquez-Lombardi et al., 2013). Consequently, the ultimate challenge for 
developing improved cytokine therapeutics for cancer is to reduce unwanted side 
effects of cytokine treatment while increasing the local concentration of cytokines to 
the tumour microenvironment. Bevacizumab (Avastin) plus interferon α is an 
approved first-line dual-action treatment for metastatic renal cell carcinoma (RCC) 
(Escudier et al., 2007; Rini et al., 2008). In an attempt to overcome the shortcomings 
associated with cytokine treatment, a novel therapeutic IFN-PEG20-Fabbeva 
heterodimer using disulfide conjugation was made. The heterodimer was made by 
firstly conjugating Fabbeva to PEG20 di(bis)sulfone 4 to prepare Fabbeva-PEG-X 
(Figure 4-1). Fabbeva-PEG20-X was purified by a linear CIEC step to remove 
unreacted PEG20 di(bis)sulfone 4 and then was allowed to react with reduced IFN. 
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An optimised CIEC step gradient was used to isolate the IFN-PEG20-Fabbeva 
heterodimer (Figure 4-1). The IFN-PEG20-Fabbeva was then characterised in terms of 
purity (SDS-PAGE), identity (anti-IFN, anti-human Western blots) and stability prior 
to functionality testing.  
 Second, it was hoped a novel IFN-PEG20-Fabalb heterodimer could be 
prepared. It was thought that an anti-albumin Fab (Fabalb) could be used to ‘piggy-
back’ upon circulating albumin. This approach was explored in an attempt to 
improve the half-life of IFN beyond that of current treatments of hepatitis C. This 
approach used the PEG20 di(bis)sulfone 4 as a linker to conjugate IFN to Fabalb. A 
similar experimental process was used as for preparing the IFN-PEG20-Fabbeva 
heterodimer. Whereby, first the Fabalb was reduced using DTT, the reduced Fabalb 
was then allowed to react with PEG20 di(bis)sulfone 4 (Figure 4-1). The X-PEG20-
Fabalb conjugate was isolated from the unreacted PEG20 di(bis)sulfone 4 by CIEC. 
The purified X-PEG20-Fabalb conjugate was then allowed to react with reduced IFN 
to prepare IFN-PEG20-Fabalb. An optimised CIEC step gradient was used to isolate 
the IFN-PEG20-Fabalb heterodimer (Figure 4-1). The IFN-PEG20-Fabalb was then 
characterised in terms of purity (SDS-PAGE), identity (anti-IFN, anti-rat Western 
blots) and stability prior to functionality testing.  
 The purified IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb heterodimers were 
characterised in terms of functional activity. It was hoped that both IFN and 
Fabbeva/Fabalb would both retain activity within the heterodimer complex, as i) site-
specific disulfide conjugation was used and ii) the PEG20 di(bis)sulfone 4 was used a 
‘spacer’ as well as a ‘linker’ to conjugate the two proteins together.  
 Antiviral and antiproliferative assays were conducted to determine if IFN had 
retained activity within the heterodimers. Functionality testing determined that IFN 
within the IFN-PEG20-Fabbeva heterodimer had retained activity. It was found that the 
IFN-PEG20-Fabalb heterodimer bound to the FBS within the cell media, therefore it 
was difficult to determine the activity of the heterodimer, however the results 
obtained suggest that the IFN-PEG20-Fabalb heterodimer has retained some activity. 
BIAcore using a VEGF coated chip was used to determine if Fabbeva within the 
heterodimer had retained activity. While, BIAcore using a rat albumin coated chip 
was used to determine if Fabalb within the heterodimer had retained activity. 
Functionality testing determined that both Fabbeva and Fabalb within the heterodimers, 
IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb respectively, had retained activity.  
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Figure 4-1: Experimental plan for preparing the IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb 
heterodimers. The IFN-PEG20-Fabbeva heterodimer was prepared by a two-step disulfide 
conjugation process, first by reacting reduced Fabbeva with PEG20 di(bis)sulfone 4. The X-
PEG20-Fabbeva conjugate was purified from the unconjugated PEG20 di(bis)sulfone 4 by a 
linear CIEC purification step. The X-PEG20-Fabbeva was then allowed to react with reduced 
His8IFN, following this IFN-PEG20-Fabbeva was isolated by CIEC purification. For preparing 
IFN-PEG20-Fabalb, the same process was conducted by first reacting Fabalb with PEG20 
di(bis)sulfone 4, the X-PEG20-Fabalb conjugate was then isolated by CIEC. The X-PEG20-
Fabalb conjugate was then allowed to react with reduced IFN. A step gradient was then used 
to isolate the IFN-PEG20-Fabalb heterodimer. The controls, PEG20-Fabbeva and PEG20-Fabalb, 
were prepared by allowing reduced Fabbeva or Fabalb to react with PEG20 bis-sulfone 1 
respectively. PEG20-Fabbeva was purified using a single CIEC step, while PEG20-Fabalb was 
purified by SEC. All conjugates prepared where characterised in terms of their purity, 
identity, stability and biological activity by SDS-PAGE, Western blot, stability studies and 
antiviral/antiproliferative assays and BIAcore respectively. 
4.2 Results and discussion 
4.2.1 Digestion and purification of bevacizumab  
4.2.1.1 Digestion and purification of bevacizumab to prepare Fabbeva 
Bevacizumab was proteolytically digested with immobilised papain to obtain Fabbeva 
(method 2.2.4.5). Papain is a thiol protease, which has a sulfhydryl group in the 
active site, which must be reduced for enzymatic activity (Goding, 1996). Papain 
reduction by disulfide exchange is possible by the addition of free thiol to the 
digestion mixture. Cysteine is generally used. Papain digestion of an IgG generally 
prepares two Fab fragments and one Fc fragment by cleaving peptides in the hinge 
region (Figure 4-2). Unlike pepsin, papain can prepare Fab fragments from all IgG 
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subclasses from all species (Andrew and Titus, 2001; Mage, 1980), but it can be 
inactivated by heavy metals. Therefore, to ensure maximal activity of the enzyme, 
EDTA was incorporated into the digestion buffer as a metal chelator (Goding, 1996). 
Immobilised papain (i.e. papain agarose resin) was chosen over crystalline papain or 
mercuripapain, as it does not require an oxidant to end digestion. Additionally, 
immobilised papain is easy to remove by passing the digestion mixture over a PD-10 
frit, so there is no need to optimise an ion exchange method for papain removal 
(Mage, 1980).  
 
Figure 4-2: IgG antibody structure and the resulting products after enzyme (pepsin or 
papain) digestion (Arruebo et al., 2009). The antibody is made up a heavy chain (H) and a 
light chain (L). The heavy chain consists of four constant domains (CH1, CH2, CH3, CH4) 
and a variable region (VH), whilst the light chain is made up of two domains; variable and 
constant, VL and CL respectively. The complementary determining region (CDR) 
responsible for antigen binding is found on the VH and VL domains. 
Antibody to enzyme ratio, digestion time and purification of bevacizumab 
digestion was optimised. The optimised conditions (method 2.2.4.5) were a 5 h 
digestion period using a 1:100 papain:antibody ratio, which allows for the near 
complete digestion of bevacizumab (150 kDa) to Fab (~45 kDa) and Fc (~50 kDa) 
(25 mg scale, n=2) (Figure 4-3). Interestingly, it appeared by SDS-PAGE (Figure 
4-3) there were also bands of heavy chain of bevacizumab (~110 kDa), half a chain 
of bevacizumab (~80 kDa), reduced Fcbeva (~30 kDa) and reduced Fabbeva (~20 kDa). 
These could be the result of proteolytic cleavage and/or partial reduction by cysteine. 
Thiol exchange reducing agents such as cysteine have been reported for their ability 
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membranes.For instance,certainregionsof theTAT-peptide
known as protein transduction domains are able to pass
biological membranesbymechanismsthat areindependent
of transporters and receptor-mediated endocytosis. The
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and their short vascular circulation lifetimesaretheir main
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aptamers are also able to recognize speciﬁc proteins. The
main advantageof usingaptamerscompared to antibodies
istheir in vitroselection processwithout usinganimals, in
addition to their small size, lack of immunogenicity, and
easeof isolation. Themain disadvantagesof usingaptamers
compared to antibodiesarethehigh cost to generatethem
especially in large quantities and their susceptibility to
enzymaticdegradation.
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deservingitsown.
2.Antibodies:StructureandFunction
Immunoglobulinsor antibodiesareagroupof glycoproteins
that constituteoneof themost important speciﬁc defence
mechanismsin vertebrateanimals. All of them haveavery
similar structure in a Y form (Figure1) of bifunctional
moleculeswith two identical domainsfor antigen recogni-
tion(Fabfragment),andtwoidentical domainswitheffector
functions (Fc fragment). The antigen-binding region is
highlyspeciﬁc, andvariesamongtheantibodies. Thousands
of millionsof different antibodiescanbegenerated,eachone
withadistinct speciﬁcity.
Antibodieshave two identical light chainsof 24-25kD
(either, κor, λ) and twoheavychains, also identical, of 55–
70kD (γ, ε, δ, α, or µ) bound by disulphur bridges [3–
6]. Thetypeof immunoglobulin generated dependson the
type of heavy chain and, therefore, in vertebrate animals
ﬁveclassesor isotypesof immunoglobulins(IgG, IgE, IgD,
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functionality. In addition to thedisulphur bridgesbetween
the chains, there are intracatenary disulphur bridges that
provide stability to the molecule [7]. The light chain (L)
is formed by two domainsof around 100 residues, known
asthevariabledomain (VL), at itsaminoterminal end, and
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Figure1: Structureof an Igmoleculecarryingtwoheavyand two
light chains linked by disulphur bridges. The products resulting
fromtheactionof enzyme (papaina dpepsin) areshown.
theconstant domain (CL). Theheavy chain (H) containsa
variabledomain (VH) and threeor four constant domains
(CH1,CH2,CH3,CH4), depending on the isotype [8]. The
variable regonsare thezones f themole ule involved in
antigen bi ding, where the most divergent hypervariable
regions, or complementarydeterminingregions(CDR), are
three in the VL domain and three in the VH domain [9,
10]. Theseregionsareseparatedbystructural regionscalled
framework(FRW),whichhavehighlyconservedsequences.
Immunoglobulins(Igs) arefou d asmembranere ep-
torsi Blymphocytes, whichareasubpopulation f leuko-
cytes. After activation mediated by antigen (virus, bacteria,
parasite),andincollaborationwithother immunecells(such
asT lymphocytes), theBlymphocytesbecomeplasmacells
secreting antibodies. The antibodies can then be released
fromthecell andhavedifferent effector functions.
Among their most important functionsarethefollow-
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(1) neutralizationandblockingof pathogensandtoxins;
(2) activation of complement: theIgM and IgGactivate
aproteolytic cascade, which leadseventually to the
openingof poresin themembraneof thepathogens
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(3) opsonizationandPhagocytosis: theIgGarethemain
typeof antibodiescapableof facilitatingphagocytosis
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IgE is involved in allergic responses through the
activationof mastocytes, whichreleasetheir charged
granules(of histamine, prostaglandins, etc.). It also
participatesin theelimination of parasites, with the
helpof eosinophils;
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to cleave the interchain disulfide bonds of immunoglobulins (Andrew and Titus, 
2001; Goding, 1996).  
 
Figure 4-3. Representative SDS-PAGE analysis (InstantBlue™) of bevacizumab digestion 
with immobilised papain (n=2). Lane 1: Novex pre-stained markers, Lane 2: bevacizumab, 
Lane 3: bevacizumab digestion mixture. Successful immobilised papain digestion of 
bevacizumab to prepare Fabbeva and Fcbeva. 
Protein purification was used to isolate of the Fabbeva from the papain digested 
bevacizumab mixture, (method 2.2.4.6). Staphylococcal protein A is a single 
polypeptide chain of ~45 kDa (Goding, 1996; Verwey, 1940). The protein A 
molecule has four high affinity (Ka=10
8
/ M) binding sites within the Fc region 
capable of binding several species (Hjelm et al., 1975), which makes it ideal for the 
purification of Fab from Fc within digestion mixtures. Protein A was used 
successfully to isolate the Fabbeva from the undigested bevacizumab and Fcbeva 
(Figure 4-4) with a yield of 39% based on total starting IgG protein. Digestion of 
bevacizumab was conducted twice with the yields achieved being 39% and 33%. 
This could be due to incomplete digestion as previously discussed as well as some 
material loss during buffer exchange and papain removal steps.  
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Figure 4-4. Representative A) Chromatogram and B) SDS-PAGE analysis of Protein A 
purification of papain digested bevacizumab mixture (n=2). Lane 1: Novex pre-stained 
markers, Lane 2: papain digested bevacizumab mixture, Lanes 3-8: Fabbeva, Lanes 9-10: 
bevacizumab/Fcbeva. Protein A purification successfully isolates Fabbeva from the digestion 
mixture.  
4.2.1.2 Characterisation of Fabbeva  
Prior to conjugation, the Fabbeva prepared from bevacizumab digestion was 
characterised in terms of its identity (Western blot), purity (SDS-PAGE) and size 
(MALDI-TOF). SDS-PAGE (Figure 4-5) analysis showed one band at ~50 kDa, 
which is the Fabbeva. No other bands were observed. Since InstantBlue™ stain has a 
detection level of 5 ng, we deduce that the Fabbeva was essentially pure and certainly 
pure enough for conjugation (Expedeon product information).  
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Figure 4-5. Representative SDS-PAGE analysis (InstantBlue™) of Fabbeva prepared from 
bevacizumab digestion (n=2). Lane 1: Novex pre-stained markers, Lane 2: Fabbeva (1 μg). 
Fabbeva prepared by digestion of bevacizumab shows good purity.  
To confirm the identity of Fabbeva, an anti-human IgG Western blot was 
conducted (method 2.2.10.1). A goat anti-human κ-chain HRP-conjugated Fab´2 was 
used to detect the κ-light chains on bevacizumab and Fabbeva. As the anti-human IgG 
detection antibody is specific to the κ-light chain, it would not be able to detect the 
Fcbeva that is made up of heavy chains. The anti-human IgG detection antibody was 
HRP-conjugated hence enhanced chemiluminescence (ECL) was applied directly. 
The HRP enzyme catalyses the conversion of luminol to 3-aminophthalate via 
intermediates in the presence of chemicals to enhance the emitted light. The emitted 
light was detected by ImageQuant™ where both bevacizumab and Fabbeva were 
successfully visualised confirming the identities of the bevacizumab and Fabbeva 
(Figure 4-6).  
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Figure 4-6. Anti-human Western blot of bevacizumab and Fabbeva visualised by ECL. Lane 1 
and 2: bevacizumab, Lane 3: Fabbeva. The detection of bevacizumab and Fabbeva was 
successful using anti-human k-chain HRP-conjugated F(ab’)2.  
For accurate calculations of molar equivalents for conjugation, MALDI-TOF 
(method 2.2.10.3) was used to quantify the size of Fabbeva once (n=1). The MW 
achieved for Fabbeva was 48204.1 Da (Figure 4-7), which is in agreement with the 
theoretical MW for digested Fabs (Andrew and Titus, 2001). The spectra (Figure 
4-7) shows three other peaks at 23419.8, 23601.2 and 24141.6 Da, which are doubly 
(+2) charged species of Fabbeva. Therefore, the MW based on singly (+1) charged 
Fabbeva was 48.2 kDa, the MW is expressed to one significant figure due reported 
sensitivity of MS (Fenselau, 1997).  
 
Figure 4-7. MALDI-TOF spectra achieved for Fabbeva. MALDI-TOF shows the MW of 
Fabbeva to be 48.2 kDa (n=1).  
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4.2.2 Preparation of IFN-PEG20-Fabbeva heterodimer 
The IFN-PEG20-Fabbeva synthesis is summarised in Figure 4-8. Firstly, the interchain 
disulfide of Fabbeva is reduced and then the TCEP is removed. The reduced Fabbeva is 
then allowed to react with PEG20 di(bis)sulfone 4 to prepare Fabbeva-PEG20-X (X 
being the unconjugated linker end). After the incubation of PEG20 di(bis)sulfone 4 
with Fabbeva this reaction mixture is purified by CIEC purification to remove 
unreacted PEG20. The second conjugation reaction is then conducted by allowing 
reduced IFN to react with Fabbeva-PEG20-X to prepare IFN-PEG20-Fabbeva. The 
reaction mixture is then purified by CIEC to isolate the IFN-PEG20-Fabbeva conjugate. 
 
Figure 4-8. Summary of IFN-PEG20-Fabbeva preparation. First, Fabbeva is reduced using mild 
reductants, then the Fabbeva is reacted with PEG20 di(bis)sulfone 4. The purified Fabbeva-
PEG20-X conjugate is then reacted with reduced IFN to prepare the IFN-PEG20-Fabbeva 
heterodimer. 
4.2.2.1 Fabbeva reduction using tris(2-carboxyethyl)phosphine (TCEP) 
For conjugation, mild reduction of the accessible native disulfide bond within Fabbeva 
is necessary to liberate the cysteine thiols for the conjugation of PEG di(bis)sulfone 4 
(Balan et al., 2007). Optimisation of reduction of Fabbeva with TCEP was conducted 
(method 2.2.9.1). TCEP was introduced in 1992 as an alternative to DTT. TCEP was 
chosen for the mild reduction of Fabbeva because it is more stable over a wider pH 
range (1.5-8.5) than DTT (Getz et al., 1999; Hansen and Winther, 2009). TCEP can 
be used quite accurately in stoichiometric amount to avoid eluting the reduction 
mixture over a PD-10 column. However care must be taken because TCEP can 
  
203 
undergo reaction with the bis-alkylating PEG reagents, reducing the yield of the 
desired PEGylated conjugate. 
As shown in Figure 4-9, increasing molar equivalents of TCEP resulted in 
more of the Fabbeva to have been reduced. The reduced Fabbeva can be seen on the gel 
at ~25 kDa due to the dissociation of the two heavy and light chain polypeptides in 
the presence of SDS. As unreacted TCEP can impede conjugation by reacting with 
the PEG bis-sulfone 1, a slightly longer reduction period with a lower TCEP 
stoichiometry would ensure all the TCEP has undergone reaction. Therefore, 
reduction of Fabbeva was conducted with 1.4 eq TCEP for 2 h. This ensured complete 
reduction of Fabbeva, with only a trace amount of unreduced Fabbeva present after 1.5 
h (Lane 5, Figure 4-9). 
 
Figure 4-9. SDS-PAGE analysis (InstantBlue
™
) of the optimisation of TCEP molar 
equivalents (eq.) for the complete reduction of Fabbeva after 1.5 h. Lane 1: Novex pre-stained 
markers, Lane 2: Fabbeva, Lane 3: Fabbeva + 1 eq TCEP, Lane 4: Fabbeva + 1.2 eq TCEP, Lane 
5: Fabbeva + 1.4 eq TCEP, Lane 6: Fabbeva + 1.8 eq TCEP. Optimum reduction conditions for 
Fabbeva are 1.4 eq. TCEP for 2 h. 
4.2.2.2 Preparation of Fabbeva-PEG20-X 
First the Fabbeva (1 eq.) was reduced with TCEP (as optimised in §4.2.2.1) and then 
reacted with PEG20 di(bis)sulfone 4 (2 eq.) for 2 h at 25 °C. These conditions were 
optimised to promote the formation of Fabbeva-PEG20-X, as by using excess PEG than 
Fabbeva the reaction is more driven to prepare Fabbeva-PEG20-X rather than Fabbeva-
PEG20-Fabbeva. No TCEP was removed prior to conjugation.  
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In a 16 h hydrolysis study of the PEG20 di(mono)sulfone 5, 
1
H-NMR results 
indicated that approximately a third of the PEG20 di(mono)sulfone 5 had changed (§ 
3.2.1), presumably having undergone addition of water to the double bond in the 
linker moiety. In an effort to maximise yield and conversion of Fabbeva-PEG20-IFN, 
short reaction times were conducted. Further conjugation and purification was 
conducted quickly (less than 12 h) to reduce the risk of hydrolysis to the PEG20 
di(bis)sulfone 4.  
On SDS-PAGE analysis, for a given molecular weight of PEG, it will run at 
double the molecular weight of the marker protein due to the hydrophilic and flexible 
nature of PEG. This can be seen in Lane 4 (Figure 4-10) where PEG20 di(bis)sulfone 
4 is stained orange from barium iodide and has migrated to ~40 kDa. Fabbeva-PEG20-
X can be seen on the gel in Lane 3 (Figure 4-10) at ~90 kDa (50 kDa=Fabbeva + 40 
kDa=PEG20). Fabbeva-PEG20-X is stained a green colour from a mixture of protein 
being stained blue from the InstantBlue™ stain and the orange colour from the PEG 
stained with barium iodide. A faint band of oxidised Fabbeva (50 kDa) can be seen. 
The oxidation of Fabbeva could be prevented by argon purging buffers and the use 
EDTA. PEG reagent and protein stoichiometry is important and although only a ratio 
of 2:1 was used, some high MW impurities of Fabbeva-PEG20-Fabbeva or (Fabbeva)n-
(PEG)n appeared to be present. Future optimisation could be conducted to optimise 
PEG:protein stoichiometry and time of conjugation, as fewer protein eq. and a 
shorter time of conjugation may improve the conversion to Fabbeva-PEG20-X. 
 
Figure 4-10. Representative SDS-PAGE analysis of reduced Fabbeva (InstantBlue™) and 20 
kDa PEG di(bis)sulfone 4-Fabbeva reaction mixture (IntantBlue™ + PEG stain, n=2). Lane 1: 
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Novex pre-stained markers, Lane 2: Fabbeva, Lane 3: TCEP reduced Fabbeva, Lane 4: PEG20 
di(bis)sulfone 4-Fabbeva reaction mixture. Successful conjugation of Fabbeva with PEG20 
di(bis)sulfone 4 to prepare Fabbeva-PEG20-X. 
4.2.2.3 CIEC purification of the Fabbeva-PEG20-X reaction mixture 
CIEC purification (§ 2.2.9.7) was used to purify Fabbeva-PEG20-X from the 
unconjugated PEG20 di(bis)sulfone 4. This was a necessary step to prepare the 
heterodimer, as the presence of excess PEG20 di(bis)sulfone 4 would compete with 
Fabbeva-PEG20-X for conjugating the reduced IFN. Therefore CIEC was used to 
purify the PEG20 di(bis)sulfone 4. PEG is a neutral water soluble organic polymer, so 
will not bind to the column (Molineux, 2002), whilst the Fabbeva-PEG20-X conjugates 
will bind to the column. The chromatogram (Figure 4-11 A) shows a single peak 
which is a mixture of Fabbeva-PEG20-X (~90 kDa), Fabbeva-PEG-Fabbeva (160 kDa) 
and (Fabbeva)n-(PEG20)n (>160 kDa) (Figure 4-11 B).  
 
Figure 4-11. Representative A) Chromatogram and B) SDS-PAGE analysis of Fabbeva-
PEG20-X CIEC purification (n=2). Lane 1: Novex pre-stained markers, Lane 2-9: fractions 3-
13. Successful isolation of Fabbeva-PEG20-X by CIEC purification from unconjugated PEG20 
di(bis)sulfone 4. 
There is an absence of an orange band at 40 kDa on the SDS-PAGE (Figure 4-11 B) 
of the PEG20 di(bis)sulfone 4 showing that it has been successfully removed by CIEC 
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purification. The HiTrap Macrocap SP column used is designed for the CIEC 
purification of large PEGylated proteins as it is a strong cation exchanger and is 
made of a highly porous base matrix, which allow for the binding of large proteins. 
Bevacizumab has a pI of 7.6, so pH 4.0 was used where Fabbeva would have a net 
positive charge to bind tightly to the CIEC column. 
4.2.2.4 Conjugation of IFN with Fabbeva-PEG20-X 
Following the successful isolation of the Fabbeva-PEG20-X conjugate from unreacted 
20 kDa PEG di(bis)sulfone 4 by CIEC; the fractions containing Fabbeva-PEG-X were 
pooled and quantified by UV ready for conjugation to IFN (§ 2.2.9.7). The two 
disulfides in IFN were first reduced using DTT (25 mM) and then IFN (2 eq.) was 
allowed to undergo reaction with Fabbeva-PEG20-X (1 eq.) to form IFN-PEG20-Fabbeva 
(§ 2.2.9.8). Conjugation of the reduced IFN to the remaining linker group (X) within 
Fabbeva-PEG20-X may be difficult due to the hydrophilic nature of the PEG. The end 
groups on PEG comprise the Fab and the remaining linker. While the PEG is 
hydrophilic, it is not miscible with proteins. So it is possible the end groups of the 
intermediate conjugate Fabbeva-PEG20-X can self associate and become less 
accessible to solvent. This could result in a slower second conjugation step, with 
hydrolysis becoming more competitive. The net result being the second conjugation 
step becomes much less efficient than the first conjugation step. Therefore, a high 
concentration of IFN was used to promote the reaction with the remaining linker.  
As IFN as two disulfide bonds (Figure 1-18), once reduced by DTT, both 
reduced disulfides are accessible for conjugation as shown in §3.3.4. However, 
within the Fabbeva-PEG20-X conjugate only one linker group (X) is available for 
conjugating to IFN. Once formed the IFN within the IFN-PEG20-Fabbeva conjugate 
has one reduced unconjugated disulfide. For IFN to retain its activity this disulfide 
bond must be oxidised and this was done using glutathione (§2.2.9.8). As discussed 
in §3.3.2, reduced and oxidised glutathione has been shown to re-oxidise and 
maintain the activity of proteins (Fahey et al., 2000). No reduced unconjugated IFN 
can be seen in Lane 3 at between 10-15 kDa (Figure 4-12) after glutathione 
treatment; oxidised unconjugated IFN can be seen between 15-20 kDa. IFN-PEG20-
Fabbeva conjugate can be seen in Lane 3 (Figure 4-12) at 110 kDa. This was inferred 
because i) the MW corresponds to what is expected (50 kDa=Fabbeva + PEG20=40 
kDa + oxidised IFN=~20 kDa) and ii) this band is not observed in the reaction 
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mixture prior to IFN conjugation i.e. Fabbeva-PEG20-X reaction mixture which can be 
seen in Lane 2 (Figure 4-12). Interestingly, there is still a band of Fabbeva-PEG20-X, 
meaning the reaction has not gone to completion even though excess reduced IFN 
was within the reaction mixture. This could be due to i) some of the di(bis)sulfone 
linker may have hydrolysed due to the long synthesis route or ii) a longer incubation 
time is required with the IFN, as a 4 h incubation time may not have been sufficient 
time for all the IFN to react with the Fabbeva-PEG20-X. The purity of the starting 
PEG20 di(bis)sulfone 4 is also important to ensure there are no dead chain ends in 
Fabbeva-PEG20-X. 
Following glutathione re-oxidisation of the IFN in the IFN-PEG20-Fabbeva 
conjugate, the reaction mixture was then subjected to STAB treatment (§ 2.2.9.8). 
This was conducted to ‘lock’ the linker into place by reducing the linker ends.  
 
Figure 4-12. Example SDS-PAGE (InstantBlue™ and PEG stain) of the IFN-PEG20-Fabbeva 
reaction mixture. Lane 1: Novex pre-stain markers, Lane 2: Fabbeva-PEG20-X reaction 
mixture prior to CIEC purification, Lane 3: IFN-PEG20-Fabbeva reaction mixture prior to 
CIEC purification. Successful conjugation of reduced IFN to Fabbeva-PEG20-X to prepare 
IFN-PEG20-Fabbeva, this was conducted twice to ensure conjugation was reproducible. 
4.2.2.5 CIEC purification of the IFN-PEG20-Fabbeva reaction mixture 
A step CIEC gradient was used to purify the IFN-PEG20-Fabbeva conjugate from the 
unreacted IFN and Fabbeva-PEG20-X, and higher MW impurities of (Fabbeva)n-
(PEG20)n (Figure 4-13 A). This step gradient of 30, 60, 80 and 100% buffer B (§ 
2.2.9.9) was optimised to isolate the IFN-PEG20-Fabbeva conjugate by CIEC 
purification in an effort to maximise yield. SDS-PAGE analysis (Figure 4-13 B) 
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shows that the step gradient CIEC was successful to isolate the IFN-PEG20-Fabbeva 
(Lane 6), conjugate from the unreacted IFN (Lanes 7-10) and Fabbeva-PEG20-X (Lane 
3), and higher MW impurities of (Fabbeva)n-(PEG20)n (Lane 3). It can be seen that the 
mAu (absorbance at 280 nm) of the Fabbeva-PEG20-X peak (Figure 4-13 A) is greater 
than that of the IFN-PEG20-Fabbeva peak, this is due to Fabbeva-PEG20-X, and higher 
MW impurities of (Fabbeva)n-(PEG20)n co-eluting as can be seen on the SDS-PAGE 
analysis.  
 
Figure 4-13. Example A) Chromatogram and B) SDS-PAGE of IFN-PEG20-Fabbeva reaction 
mixture CIEC purification. Lane 1: Novex pre-stained markers, Lane 3: Fabbeva-PEG20-
X/Fabbeva)n-(PEG20)n, Lane 6: IFN-PEG20-Fabbeva, Lanes 7-10: IFN. Successful step CIEC 
purification to purify out the IFN-PEG20-Fabbeva conjugate. Purification was found to be 
reproducible with each repeat (n=2).  
The fractions for IFN-PEG20-Fabbeva were pooled and the concentration of 
Fabbeva and IFN quantified by UV (Fabbeva: ε=1.4 0.489 mg/mL, yield=12%; IFN: 
ε=0.914, 0.749 mg/mL, yield=21%). The yields of the repeat were found be very 
reproducible, with the repeat yields being Fabbeva=19.4% and IFN=23.4%. The yields 
achieved for IFN-PEG20-Fabbeva were found to be comparable to that achieved for the 
PEG bis-sulfone 1. This shows that synthesis route 2 (Figure 3-9) for PEG20 
di(bis)sulfone 4 has a greater reactivity compared to the previously used PEG20 
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di(bis)sulfone 4 synthesised by route 1 (Figure 3-2). This could be due to i) the 
improved purity of the PEG20 di(bis)sulfone 4 which was quantified by RP-HPLC (§ 
2.2.5.4) and SDS-PAGE (§ 2.2.5.5); ii) the better understanding of hydrolysis and its 
effect on the PEG di(bis)sulfones, whereby the synthetic approach was conducted in 
under 12 hours, reducing the risk of hydrolysis to the di(bis)sulfone linkers.  
SDS-PAGE analysis was conducted with the final IFN-PEG20-Fabbeva 
conjugate to assess its purity. It can be seen in Lane 5 (Figure 4-14) that the IFN-
PEG20-Fabbeva conjugate at 110 kDa was prepared and purified in good purity as no 
other bands can be seen by InstantBlue™ or PEG stain.  
 
Figure 4-14. SDS-PAGE analysis of final IFN-PEG20-Fabbeva conjugate prepared. Lane 1: 
Novex pre-stained markers, Lane 2: Fabbeva, Lane 3: Fabbeva-PEG20-X reaction mixture, Lane 
4: IFN-PEG20-Fabbeva reaction mixture, Lane 5: final IFN-PEG20-Fabbeva conjugate. Final 
IFN-PEG20-Fabbeva conjugate successfully prepared and purified. 
4.2.3 Preparation of PEG20-Fabbeva 
4.2.3.1 Optimisation of PEG20 bis-sulfone 1 conjugation to Fabbeva 
It was necessary to prepare PEG20-Fabbeva as a control to compare the binding 
kinetics to that of IFN-PEG20-Fabbeva. To ensure the highest yield of PEG20 bis-
sulfone 1-Fabbeva was achieved, the stoichiometry for PEG20 bis-sulfone 1 was 
optimised (method 2.2.9.2). It has been shown that 1.4 eq. TCEP (§ 4.2.2) can 
successfully liberate the Fab cysteine thiols for the conjugation of PEG20 bis-sulfone 
to the Fabbeva. For the conjugation, 50 mM sodium phosphate buffer pH 7.8 was used 
as pH 7.8 allows the PEG bis-sulfone 1 to undergo elimination in situ to prepare PEG 
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mono-sulfone 2 (Figure 2-1) (Brocchini et al., 2006). It can be seen (Figure 4-15) 
that with increasing PEG eq. there is a directly proportional increase in the 
conversion of PEG20-Fabbeva being prepared. Within SDS-PAGE analysis PEG20 bis-
sulfone can be observed on the SDS-PAGE gel at ~40 kDa (Figure 4-15 A). PEG20-
Fabbeva can be seen at ~90 kDa by SDS-PAGE analysis (50 kDa=Fabbeva + 40 kDa 
=PEG20, Figure 4-15). The highest percentage conversion (66%) to PEG20-Fabbeva 
was observed at 2 eq (Figure 4-15 B). Therefore, a 2:1 molar ratio of PEG20 bis-
sulfone 1:Fabbeva was used to scale up the preparation of PEG20-Fabbeva.  
 
Figure 4-15. A) SDS-PAGE and B) ImageQuant™ analysis and C) Densimetric information 
table of Fabbeva conjugation with varying PEG20 bis-sulfone 1 equivalents (1, 1,2, 1,5, 1,7, 
and 2). Lane 1: Novex pre-stained markers, Lane 2: Fabbeva, Lane 3: TCEP reduced Fabbeva, 
Lane 4: Fabbeva + 1 eq PEG, Lane 5: Fabbeva + 1.2 eq. PEG, Lane 6: Fabbeva + 1.5 eq., Lane 7: 
Fabbeva + 1.7 eq., Lane 8: Fabbeva + 2.0 eq. PEG, Lane 9: PEG20 bis-sulfone 1. PEG20 bis-
sulfone 1 to PEG ratio found to be 2:1 eq. for 16 h at 25 °C. 
4.2.3.2 Optimisation of PEG20 bis-sulfone 1-Fabbeva purification  
To isolate the PEG20-Fabbeva from the unreacted PEG reagent species and Fabbeva, 
CIEC was used. Elution of the different molecules from the CIEC column occurs 
with different percentages of buffer. For use in the CIEC purification optimisation, a 
1 mg reaction of Fabbeva with PEG20 bis-sulfone 1-Fabbeva was conducted (§ 2.2.9.3). 
The reaction mixture of the PEG20 bis-sulfone 1-Fabbeva can be seen in Lane 10, 
Figure 4-16 A where PEG20-Fabbeva can be seen at ~90 kDa. To determine the 
different elution percentages for the PEG20-Fabbeva and Fabbeva a linear gradient from 
0 to 100% of salt was conducted (§ 2.2.9.4).  
 The percentage at which the PEG20-Fabbeva and Fabbeva eluted from the 
column was calculated by determining the delay in millilitres from when the linear 
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gradient started. The volume of the middle of the two peak columns was subtracted 
from the delayed linear gradient volume. This gave the accurate volume at which 
buffer B was eluting the PEG20-Fabbeva and Fabbeva, taking into account the volume 
delay. The percentage of buffer B at the calculated volume was then determined from 
the chromatogram. It was calculated that ~17% and ~30% buffer B were eluting 
PEG20-Fabbeva and Fabbeva respectively. A step gradient method was designed using 
17% and 30% buffer B to in an effort to elute PEG20-Fabbeva and Fabbeva in separate 
peaks and thus prepare pure PEG20-Fabbeva. 
 
Figure 4-16. Linear CIEC A) chromatogram and B) SDS-PAGE analysis of PEG20 bis-
sulfone 1-Fabbeva reaction mixture. Lane 1: Novex pre-stained markers, Lanes 2-6: PEG20-
Fabbeva + Fabbeva, Lanes 7-9: Fabbeva + PEG-Fabbeva, Lane 10: PEG20 bis-sulfone 1-Fabbeva 
reaction mixture prior to CIEC.  
4.2.3.3 Scaled up preparation of PEG20-Fabbeva  
Using the optimised conditions, PEG20-Fabbeva was prepared for kinetic and affinity 
binding studies. Reduced Fabbeva (1 mg) was allowed to react with PEG bis-sulfone 1 
as stated in §2.2.9.3. The reaction was then purified by a step gradient of 17, 30 and 
100% PBS with 1 M sodium chloride (buffer B) (§ 2.2.9.5). It can be observed 
(Figure 4-17 A) that at 17% buffer B, the salt dissociates the PEG20-Fabbeva conjugate 
from the column where as a higher salt concentration (30%) is required to dissociate 
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the Fabbeva from the column, as the PEG reduces the ability of the Fabbeva to bind to 
the cation exchange column. It can be observed that the step gradient has 
successfully purified out the PEG20-Fabbeva (Lanes 2-5) from the Fabbeva (Lanes 6-9, 
Figure 4-17 B).  
 The final PEG20-Fabbeva conjugate was then assessed regarding concentration 
(UV at A280 nm) and purity (SDS-PAGE). The final yield for the PEG20-Fabbeva 
conjugate was 44% (0.440 mg/mL, § 2.2.9.5), which can be seen in lane 3 at ~90 
kDa (Figure 4-17 C). No other bands were observed in lane 3 (Figure 4-17 C). 
 
Figure 4-17. Step CIEC gradient A) chromatogram, B) SDS-PAGE analysis (InstantBlue™ 
+ PEG stain) of PEG20 bis-sulfone 1-Fabbeva purification fractions and C) Final purified 
PEG20-Fabbeva. B) Lanes 1-5: PEG20-Fabbeva, Lanes 6-9: Fabbeva, Lane 10: aggregated Fabbeva, 
C) Lane 1: Novex pre-stained markers, Lane 2: Fabbeva, Lane 3: PEG20-Fabbeva. Step CIEC 
successfully purified PEG20-Fabbeva from Fabbeva.  
4.2.4 Characterisation and purification of anti-albumin IgG  
The aim of this section is to prepare an IFN-PEG20-Fabalb heterodimer, using Fab 
enzymatically generated from polyclonal rabbit anti-rat albumin IgG. The IFN-
PEG20-Fabalb heterodimer was prepared as a longer acting therapeutic for Hepatitis C 
virus. The heterodimer prepared was utilising disulfide conjugation of both Fabalb 
and His8IFN. The PEG20 di(bis)sulfone 4 was used which had been prepared using 
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synthesis route 2 (Figure 3-9). The synthesis route for preparing the IFN-PEG20-
Fabalb is outlined in Figure 4-8.  
4.2.4.1 Characterisation of anti-albumin IgG by SDS-PAGE and Western blotting 
Polyclonal anti-rat albumin IgG was purchased from GenWay Biotech. To ensure the 
anti-rat albumin IgG was pure for digestion and specific to rat albumin, the following 
studies were conducted. First, SDS-PAGE was conducted (§ 2.2.1) to determine if 
the anti rat albumin IgG was pure for papain digestion as impurities within the IgG 
may impede digestion or purification. InstantBlue™ and silver staining were both 
performed on the gel (Figure 4-18). Silver stain is more sensitive than InstantBlue™ 
(Chevallet et al., 2006).  
Two main bands could be identified in the SDS-PAGE analysis (Figure 4-18). 
One band between 110 kDa and 160 kDa is the polyclonal rabbit anti-rat albumin 
IgG of 150 kDa in size (Andrew and Titus, 2001). The band second was between 50 
kDa and 60 kDa, which could be a stabiliser such as bovine serum albumin (BSA) 
and gelatin, which is used in purified antibody stock solutions for long term storage. 
The presence of such stabilisers usually does not interfere with immunodetection 
methods, however its presence could interfere with antibody digestion. This problem 
is well understood so ‘antibody clean-up’ kits are available with Protein A or Protein 
G spin-columns. Thus, it was necessary to purify the anti-albumin IgG from the 
stabiliser for enzymatic digestion.  
 
Figure 4-18. SDS-PAGE of anti-rat albumin IgG stained with A) InstantBlue™ and B) 
silver stain. Lane 1: Novex pre-stained markers, Lane 2: anti-rat albumin IgG. SDS-PAGE 
analysis reveals anti-rat albumin has been stored with stabiliser protein. 
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Prior to further studies, it was important to determine if the commercially 
available anti-rat albumin IgG (from a rabbit host) would bind to the rat serum 
albumin. To determine this, the anti-rat albumin IgG was used as a primary antibody 
to detect rat serum albumin that had run on a SDS-PAGE gel. A secondary AP-
conjugated antibody against the rabbit anti-rat albumin IgG was used to visualise 
binding (§ 2.2.10.1).  
SDS-PAGE analysis (§ 2.2.1) was performed initially to assess the purity of 
the rat albumin and for comparison by western blot. Two bands can be seen in the 
SDS-PAGE analysis (Figure 4-19 A), the main band can be seen at ~60 kDa and the 
other band at ~120 kDa (Figure 4-19 A). According to the product information from 
Sigma-Aldrich, the main band is likely to be rat albumin, which is 65 kDa in size. 
The other high MW bands could be the dimer of rat albumin (130 kDa), as the 
second band is between 110 kDa and 160 kDa.  
The two bands of albumin (~60 kDa) and possible albumin dimer (~120 kDa) 
identified in the SDS-PAGE analysis (Figure 4-19 A) could also be observed by 
Western blot (Figure 4-19 B). As the rat albumin was visualised by Western blot, this 
suggests the anti-rat albumin IgG has bound to the rat albumin. Additionally, it also 
suggests that the high MW impurity is an albumin dimer for it to be detected by the 
anti-rat albumin IgG.  
 
Figure 4-19. A) SDS-PAGE and B) Western blot of rat albumin. Lane 1: Novex pre-stained 
markers, Lane 2: rat serum albumin (1 μg), Lane 3: rat serum albumin (5 μg). Detection of 
rat albumin by Western blot confirmed the anti-rat albumin IgG has bound to rat serum 
albumin.  
 In the Western blot of rat albumin (Figure 4-19 B) there is a band in all wells 
at ~50 kDa. This could be rat albumin that when the SDS-PAGE was loaded has 
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spilled into other wells and due to the sensitivity of the Western blot, has been 
detected by the primary and secondary antibodies. This shows that when loading the 
SDS-PAGE care must be taken to ensure all the sample is loaded carefully into the 
wells. Overspill can be avoided by reducing the volume loaded into the SDS-PAGE 
wells ensuring the sample stays within one well.  
4.2.4.2 Purification of anti-rat albumin IgG for digestion 
From the SDS-PAGE analysis of the rabbit anti-rat albumin IgG it was found that a 
protein stabiliser, most probably HSA, was in the IgG stock solution (§ 4.2.4.1). To 
remove BSA, we elected to use HiTrap Protein A columns. Protein A has been used 
to purity monoclonal or polyclonal IgG ascites, serum and tissue culture and 
bioreactor supernatants. However, variation in the strength of binding between 
species of animal and species of IgG subclasses has been reported. The polyclonal 
anti-rat albumin IgG was prepared in rabbits and the strength of binding of rabbit 
IgG or IgG fragments to Protein A is stronger than Protein G (Antibody purification 
handbook from GE-healthcare). Therefore, a HiTrap Protein A column was used to 
isolate the anti-rat albumin IgG from BSA and other potential impurities (§ 2.2.4.1).  
Following Protein purification, two peaks were observed (Figure 4-20 A). The 
first, small and wide peak (< 500 mAu, Figure 4-20 A) is the loading peak and any 
molecules not bound to the Protein A resin are eluted. The second, large and sharp 
peak (>2000 mAu, Figure 4-20 A) represents the elution peak where the pH is 
changed to pH 2.0 which caused the bound molecules to dissociate from the Protein 
A resin to then elude from the column. SDS-PAGE analysis, Lanes 2-6 (Figure 4-20 
B) of the peak fractions revealed that the first peak was a mixture of BSA (between 
50 kDa and 60 kDa) and anti-rat albumin IgG (between 110 kDa and 160 kDa). The 
anti-rat albumin IgG may have eluted during loading as the concentration of the IgG 
may have exceeded the capacity of the Protein A column.   
 In the second peak (Lanes 7-8,Figure 4-20 B) the main band was the anti-rat 
albumin IgG. Importantly, the band associated with BSA was not present. The bands 
above and below the ~150 kDa IgG band are most likely from the high concentration 
of IgG, as these were not observed in the SDS-PAGE analysis prior to Protein A 
purification (Figure 4-18).  
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Figure 4-20. Example A) Chromatogram and B) SDS-PAGE analysis of fractions collected 
from Protein A purification of anti-rat albumin IgG. Lane 1: Novex pre-stained markers, 
Lanes 2-6: stabilising protein + anti-rat albumin IgG, Lanes 7-8: anti-rat albumin IgG. 
Successful removal of stabilising protein from anti-rat albumin IgG by Protein purification. 
Purification of anti-rat albumin IgG from the stabiliser protein was found to be consistent in 
all four repeats conducted.  
 The yield of the purified anti-rat albumin IgG was found to be consistent in in 
all three purifications conducted, with the yields achieved of anti-albumin IgG being 
54.6%, 47.5% and 50.7%. These yields demonstrate the reproducibility of the Protein 
A purification process to isolate the anti-albumin IgG from the stabiliser protein, 
with the average recovery of IgGalb being 51%.  
4.2.5 Digestion and purification of anti-rat albumin IgG to prepare Fabalb 
4.2.5.1 Optimisation of enzymatic digestion of anti-rat albumin and purification to 
prepare Fabalb 
The aim was to optimise the digestion conditions of polyclonal anti-rat albumin IgG 
to obtain Fabalb. It was necessary to optimise the digestion conditions as i) individual 
IgG classes and species vary in their susceptibility to digestion and ii) the rate of 
digestion is influenced by papain concentration (Andrew and Titus, 2001; Goding, 
1996). The two variables that were examined for optimisation were the papain:IgG 
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ratio and the length of time to allow for papain digestion. Papain :IgG ratio for the 
rabbit anti-rat albumin IgG was conducted (§ 2.2.4.2) and the digestion mixture was 
analysed by SDS-PAGE. The cleavage of IgG by papain was then monitored by SE-
HPLC over an 8 h period (§ 2.2.4.2) to determine the optimum digestion time.  
The following papain:IgG concentrations were investigated: 1:10, 1:20 and 
1:50. Coulter reported a concentration of 1:10 for the digestion of rabbit IgG, whilst 
typical concentrations reported for mouse, rat, human are 1:20-1:100 (Andrew and 
Titus, 2001; Coulter and Harris, 1983; Mage, 1980; Zhao et al., 2009). Therefore 
experiments were conducted to find the optimum concentration for the polyclonal 
rabbit anti-rat albumin IgG. A concentration of 20 mM cysteine was used as 
previously reported (Goding, 1996; Zhao et al., 2009).  
SDS-PAGE analysis was performed on the anti-rat albumin IgG as a control 
(Figure 4-21 A) to compare the digestion mixture to over the time points (1-6 h). The 
SDS-PAGE analysis revealed two bands for anti-rat albumin IgG (~150 kDa) and 
BSA (~60 kDa) as previously observed. SDS-PAGE analysis revealed that with all 
concentrations of papain and digestion lengths (1-6 h) tested that the IgG was fully 
digested with no IgG visible at 150 kDa (Figure 4-21 B-E). Fabalb was observed at 
~40-50 kDa with a band that was interpreted to be the Fc at ~50 kDa (Figure 4-21 B-
E), which are in agreement with reported literature (Zhao et al., 2009).  
Due to the presence of the cysteine, some reduced Fabalb and Fc could be seen 
at 30 kDa and 25 kDa, respectively (Figure 4-21 B-E). As the incubation period 
increases, greater amounts of the Fabalb and Fc were seen. However, with higher 
ratios (1:10) more reduced species were observed at ~30 kDa and below with longer 
incubation time. On the contrary, at a lower papain concentration (1:50) some higher 
MW bands representing un-digested anti-rat albumin IgG were detected (Figure 4-21 
B-E), suggesting a longer incubation necessary. Therefore, the 1:20 papain:IgG 
appeared to be the best condition because there was little anti-rat albumin IgG 
observed in the incubation times and less reduced impurities below ~30 kDa (Figure 
4-21 B-E).  
To then define the optimum digestion period and in an effort to improve the 
yield of Fabalb, analytical SEC was conducted. SEC has been previously reported for 
a similar purpose and was employed to analyse the extent of papain digestion with 
time at the 1:20 papain to IgG ratio (Zhao et al., 2009).  
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Figure 4-21. SDS-PAGE analysis (silver stain) of A) anti-rat albumin IgG, B) 1 h, C) 2 h, D) 
4 h, E) 6 h incubation of anti-rat albumin IgG with varying papain concentrations 
(1:10,1:20,1:50). A) Lane 1: Novex pre-stained markers, Lane 2: anti-rat albumin IgG. B-E) 
Lane 1: Novex pre-stained markers, Lane 2: papain: IgG 1:10 ratio, Lane 3: papain: IgG 1: 
20 ratio, Lane 4: papain: IgG 1: 50 ratio. Optimum papain: anti-albumin IgG concentration 
was found to be 1:20.  
Zhao and colleagues demonstrated by using SEC, that papain digestion of IgG 
over time can be analysed by integrating the area under the curve of chromatograms 
at different incubation times, which can then compared (Zhao et al., 2009). The 
optimum incubation time was defined as the time in which the IgG peak area under 
the curve reaches or is close to zero absorbance (A280 nm). SE-HPLC analysis 
(Figure 4-22,Table 4–1) of the peaks was performed as detailed in § 2.2.4.2.  
The first two peaks seen in the chromatograms (Figure 4-22) at 8 and 9 min are 
the largest MW species as these have eluted first. These impurities were not 
visualised by SDS-PAGE analysis (Figure 4-22) by silver stain or InstantBlue™ thus 
the impurities must be in very low concentration, which the small peak area also 
confirms this. The impurity could be aggregates of IgG due to the MW being >150 
kDa. The peak at ~10.5 min corresponds to the undigested anti-rat albumin IgG 
molecule, and as the digestion time proceeds, the area under the curve (Table 4–1) 
can be seen to decrease in size (Figure 4-22). The Fabalb and Fc fragments are of 
similar size ~50 and 55 kDa respectively, there elution is seen as one peak at ~13 
min. This peak increases in size as the digestion time proceeds and can be seen to 
plateau at 4 h of digestion (Figure 4-22).  
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As previously discussed, the presence of cysteine is for papain activation, 
however cysteine can cleave the interchain disulfide of IgG (Andrew and Titus, 
2001; Goding, 1996). This was seen in SDS-PAGE analysis with bevacizumab where 
approximately half IgG molecules were observed (Figure 4-3) and has been observed 
in SE-HPLC analysis by Zhao and colleagues (Zhao et al., 2009). This would explain 
the peak observed at ~11 min on the SE-HPLC chromatograms (Figure 4-22) as the 
peak is after the elution of IgG (~150 kDa) but before the elution of Fabalb/Fc (~50 
kDa). 
As for bevacizumab, a band for approximately half IgG was seen at ~80 kDa 
(Figure 4-3). This strongly suggests the peak at ~11 min is the IgG heavy chain 
prepared by cysteine reduction. The peaks observed after 13 min are buffer 
components absorbed at 280 nm. The SE-HPLC results suggest that a digestion 
period 4 h using 1:20 papain to anti-rat albumin IgG ratio digestion is sufficient to 
prepare Fabalb. The SEC results achieved for the papain digestion of polyclonal anti-
albumin IgG are comparable to those achieved for the digestion of monoclonal 
antibodies reported by Zhao and colleagues (Zhao et al., 2009) confirming the 
reliability of the results achieved. 
 
Table 4–1. Area under the peak integrated from the SEC chromatograms in Figure 4-22. 
ND=could not be determined due to software failure. 
Time (h) Area under peak (% total area) 
10.5 min 11.3 min 13 min 
0 ND ND ND 
1 202.67 (22.13) 144.40 (157.77) 148.68 (16.24) 
2 108.45 (11.39) 144.73 (15.2) 248.46 (26.10) 
4 ND ND ND 
6 ND ND ND 
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Figure 4-22. Papain digestion of polyclonal anti-rat albumin IgG analysed by analytical 
SEC. The peak at ~10.5 min corresponds to the undigested anti-rat albumin IgG molecule. 
As the size of Fabalb/Fc are similar, these make up the peaks at ~13 min. The peak at ~11 min 
is from the partial reduction of the IgG (i.e. light chain falling off under cysteine reduction). 
Peaks before 10 min could be high MW impurities and the peaks after 13 min are due to 
buffer components absorbed at 280 nm.  
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4.2.5.2 Digestion and purification of anti-rat albumin IgG to isolate Fabalb 
Utilising the optimised papain concentration of 1:20 papain to anti-albumin IgG ratio 
and the optimum incubation time of 4 h (§ 2.2.4.2) Fabalb was prepared for 
conjugation studies. Digestion of anti-albumin IgG (4.75 mg) was complete as no 
whole IgG was observed at ~150 kDa. The fragments of Fabalb (~45 kDa) and Fc 
(~50 kDa) can be seen as well as there reduced forms at ~25 kDa and ~30 kDa, 
respectively (Figure 4-23 B). The reduced Fabalb and Fc migrate faster by SDS 
PAGE than their oxidised forms; this could be due to the structure being open and 
spread out in the reduced form.  
Prior to Protein purification, the digestion mixture was pipetted through a PD-
10 frit to remove the immobilised papain. This method is quicker and more accurate 
than using iodoacetamide to stop digestion or centrifugation (Goding, 1996; Zhao et 
al., 2009). This is due to the frit being washed five times with binding buffer or until 
no protein is detected by UV (A280 nm). 
Protein A purification was chosen over conventional methods of ion exchange, 
DEAE cellulose or Protein G because, i) the protein A molecule has a high binding 
affinity specifically for the Fc region (Hjelm et al., 1975), which makes it ideal for 
the purification of Fab from Fc within digestion mixtures, ii) the anti-rat albumin IgG 
is of rabbit origin, rabbit IgG binds strongly to Protein A, where it has week binding 
to Protein G, iii) Protein A columns were used for the purification of the anti-rat 
albumin IgG and could be easily used for digestion mixture purification (§4.2.4.2). 
Additionally, Protein A has been shown to be more efficient at purifying rabbit Fab 
fragments over conventional ion exchange procedures (Coulter and Harris, 1983).  
The chromatogram (Figure 4-23 A) shows a small peak from 20-80 min at 
~100 mAu, this is the loading peak, where any molecules not bound to the Protein A 
resin, namely Fabalb, elute. The eluting Fabalb can be seen in the SDS-PAGE analysis 
(Lanes 2-6, Figure 4-23 C) at ~40 kDa, reduced Fabalb can be also be observed 
between 20-30 kDa. The second large and sharp peak (>2000 mAu) is the elution 
peak where the pH was dropped to pH 2.0, causing bound Fc molecules to dissociate 
from the Protein A resin. As pH 2.0 was used to dissociate the anti-rat albumin 
IgG/Fc from the Protein A, a neutralising solution (1 M Tris) was pipetted into the 
collected fractions as they were eluted to increase the pH to ~pH 7 which is a more 
appropriate physiological pH (§ 2.2.4.4).  
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SDS-PAGE analysis (Lane 9, Figure 4-23 C) of the eluted peak fractions 
showed three bands. The first band is at ~110 kDa, this could be heavy chain of the 
anti-rat albumin molecule. The heavy chain molecule is most likely a product of 
cysteine reduction from digestion (Andrew and Titus, 2001). The ~50 kDa band 
(Lane 9, Figure 4-23 C) is the Fc fragment and the reduced Fc can be seen at ~30 
kDa. The digestion has gone to completion, as no whole anti-rat albumin IgG can be 
seen in Lane 9 at 150 kDa, indicating that the selected digestion conditions were 
successful. This method was utilised three times within the study to isolate Fabalb for 
conjugation, the average yield achieved was ~39% (yields achieved: 35%, 42% and 
39%). Some Fabalb may have been lost through the digestion and purification process 
or within other fragments such as heavy chain. The yields achieved of Fabalb are very 
similar to those achieved for Fabbeva (39% and 33%, §4.2.1.1), showing the 
consistency of the papain digestion and protein A purification process.  
 
Figure 4-23. Representative B) Papain digestion mixture of anti-rat albumin IgG, A) Protein 
A purification chromatogram of anti-rat albumin IgG digestion mixture and C) SDS-PAGE 
analysis of Protein A purification fractions. B) Lane 1: Novex pre-stained markers, Lane 2: 
anti-rat albumin IgG digestion mixture; C) Lane 1: Novex pre-stained markers, Lane 2-6: 
Fabalb, Lane 9: Fc. Successful papain digestion of anti-rat albumin IgG and isolation of Fabalb 
by Protein A purification. The purification process was found to be reproducible in all three 
repeats conducted.  
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4.2.5.3 Characterisation of Fabalb 
Prior to conjugation, the Fabalb was characterised. SDS-PAGE analysis (Figure 4-24) 
showed one band at ~45 kDa, which is the Fabalb. No other bands were observed.  
 
Figure 4-24. Example SDS-PAGE analysis (InstantBlue™ stain) of Fabalb prepared from 
anti-rat albumin IgG (n=3). Lane 1: Novex pre-stained markers, Lane 2: Fabalb. Fabalb 
prepared from anti-rat albumin IgG is pure to the 5 ng level.  
To confirm the identity of the Fabalb isolated from papain digestion of anti-rat 
albumin IgG an anti-rabbit Western blot was performed (§ 2.2.10.1). A polyclonal 
anti-rabbit IgG (H&L) AP-conjugated IgG was used and a colorimetric method of 
detection was used. The anti-rabbit IgG has positively identified the Fabalb prepared 
from anti-rat albumin IgG digestion, as a ~45 kDa band is visible by colorimetric 
detection (Figure 4-25). This MW is the same as that observed by other SDS-PAGE 
analysis, such as that seen in Figure 4-23 C, thus confirming the identity of Fabalb. A 
faint band is visible between 20-30 kDa; this is the reduced Fabalb, which is also 
observed on SDS-PAGE as in Figure 4-23 C.  
MALDI-TOF (§ 2.2.10.3) indicated the MW for Fabalb was 45883.8 Da (Figure 
4-26).  This is in agreement with the theoretical MW for digested rabbit Fabalb 
(Coulter and Harris, 1983). The MALDI-TOF spectra (Figure 4-26) show’s two other 
peaks at 22805.4 and 91914.7 Da. The peak at 22805.4 Da is a result of double 
charged species of Fabalb, whilst the other peak at 91914.7 Da is a result of Fabalb 
dimers
1+
. Therefore, the MW based on singly charged Fabalb was 45.9 kDa from n=1, 
this is expressed to one significant figure due to the reported accuracy of MS being 
0.1-0.01% (Fenselau, 1997).  
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Figure 4-25. Anti-rabbit Western blot of Fabalb. Lane 1: Novex pre-stained markers, Lane 2: 
Fabalb. Successful identification of Fabalb by anti-rabbit IgG by Western blotting. 
 
Figure 4-26. MALDI-TOF spectrum of Fabalb conducted once. Singley charged Fabalb can be 
seen at 45883.8 Da, whilst a double charged Fabalb was observed at 22805.4 Da. A singly 
charged Fabalb dimer can be seen at 91914.7 Da. 
4.2.6 Preparation of IFN-PEG20-Fabalb heterodimer 
The aim was to prepare an IFN-PEG20-Fabalb heterodimer utilising the PEG20 
di(bis)sulfone 4 as a linker to conjugate both IFN and Fabalb by disulfide PEGylation 
following the same strategy used to prepare IFN-PEG20-Fabbeva (Figure 4-8). The aim 
260 kDa 
160 kDa 
110 kDa 
80 kDa 
60 kDa 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
		1        2 
Fabalb 
Reduced Fabalb 
Fabalb
1+
 
Fabalb
2+
 
Fabalb dimer
1+ 
  
225 
was to prepare a therapeutic IFN-PEG20-Fabalb heterodimer in an effort to elongate 
the half-life of IFN, where the Fabalb would ‘piggy back’ on circulating albumin, thus 
elongating the half-life of IFN beyond that of monoPEGylated IFN.  
4.2.6.1 Optimisation of Fabalb reduction using DTT 
The aim was to optimise the mild reduction of Fabalb to liberate the accessible sulfur 
atoms, which in turn can be conjugated to by the bis-thiol alkylating reagent 
(Brocchini et al., 2006). For the mild reduction of Fabalb, TCEP was tested, however 
a large excess of TCEP (>4 eq.) was required to reduce the single disulfide bond. 
Further, when using 4 eq. of TCEP, Fabalb was not fully reduced. Thus, DTT was 
used to reduce the disulfide of Fabalb. Scouting experiments were conducted with 
increasing concentrations of DTT (2.5 mM-25 mM) to evaluate the optimum 
conditions for Fabalb reduction (§ 2.2.9.10). The reduction was conducted at pH 7.8 
(§ 2.2.9.10) as DTT has been shown to be most effective at pH values above pH 7.0 
(protonated sulfurs have lowered nucleophilicities) (Cleland, 1964; Hermanson, 
2008). 
A trend was observed where as the concentration of DTT increases, the amount 
of oxidised Fabalb was seen to decrease (Figure 4-27). Fabalb was observed to be 
completely reduced with 5 mM DTT, as no oxidised Fabalb was present at ~40 kDa 
(Lane 4, Figure 4-27). With 2.5 mM DTT, Fabalb, and both reduced and oxidised 
Fabalb were observed (Lane 3, Figure 4-27). When preparing the heterodimer (IFN-
PEG20-Fabalb) it was necessary to try to reduce the risk of hydrolysis to the PEG 
di(bis)sulfone 4. Therefore, by using a higher DTT concentration and a shorter 
incubation time, reduction is preferred. Thus, the minimum amount of DTT for 
reduction of Fabalb is 5 mM for 1 h at RT.  
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Figure 4-27. SDS-PAGE analysis of Fabalb reduction by varying DTT concentrations. Lane 
1: Novex pre-stained markers, Lane 2: Fabalb, Lane 3: 2.5 mM DTT+ Fabalb, Lane 4: 5 mM 
DTT + Fabalb, Lane 5: 10 mM DTT+ Fabalb, Lane 6: 25 mM DTT + Fabalb. Optimum DTT 
concentration for Fabalb reduction was found to be 5 mM. 
4.2.6.2 Conjugation of Fabalb with PEG20 di(bis)sulfone 4 to prepare Fabalb-PEG20-
X 
Analogous to the sequence of steps to prepare Fabbeva-PEG20-IFN, the initial step to 
prepare the IFN-PEG20-Fabalb heterodimer was first to reduce the accessible disulfide 
of Fabalb for conjugation to PEG20 di(bis)sulfone 4 to give Fabalb-PEG20-X. Fabalb (1 
eq., 0.37 mg Fabalb) was reduced with DTT and then allowed to react with PEG20 
di(bis)sulfone 4 (5 eq.) for 3 h at 25 °C (§2.2.9.15). As before (§ 4.2.2.2) excess PEG 
di(bis)sulfone 4 was used to cause the formation and efficient purification of Fabalb-
PEG20-X, while minimising the formation of Fabalb-PEG20-Fabalb.  
In an effort to maximise yield and conversion of the conjugation reactions to 
make Fabalb-PEG20-IFN, while avoiding the potential hydrolysis reactions to the 
reagent, short reaction times were conducted. Further conjugation and purification 
was conducted in one day to reduce the risk of changes to the PEG di(bis)sulfone 4, 
from the PEG di(bis)sulfone 4 being present in solution for long periods of time. 
Further, the purity of the reagent is also an important factor in producing good yields 
of Fabalb-PEG20-IFN heterodimers, as discussed in §3.2.1.  
Fabalb-PEG20-X was observed at ~80 kDa (~45 kDa=Fabalb+ 40 kDa=PEG20, 
Figure 4-28). Fabalb-PEG20-X is a green band, where the InstantBlue™ stains 
proteins blue, whilst PEG is stained orange. A clear blue band of un-conjugated 
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Fabalb can be seen between 20-30 kDa in Figure 4-28. The band at ~110 kDa could 
be Fabalb-PEG-Fabalb, as (2× Fabalb= ~60 kDa+ 40 kDa=PEG20). 
 
Figure 4-28. Example SDS-PAGE analysis of (InstantBlue™) A) reduced Fabalb and (PEG 
stain) B) PEG20 di(bis)sulfone 4-Fabalb reaction mixture. A) Lane 1: Novex pre-stained 
markers, Lane 2: reduced Fabalb. B) Lane 1: Novex pre-stain markers, Lane 2: PEG20 
di(bis)sulfone 4-Fabalb reaction mixture. Successful conjugation of Fabalb with di(bis)sulfone 
4 to prepare Fabalb-PEG20-X, this was conducted n=2.  
4.2.6.3 CIEC purification of the Fabalb-PEG20-X reaction mixture 
CIEC purification (§2.2.9.16) was used to purify the Fabalb-PEG20-X from the 
unreacted PEG20 di(bis)sulfone 4. This again was a necessary step for creating the 
heterodimer, as unreacted PEG20 di(bis)sulfone 4 would compete against the Fabalb-
PEG20-X for conjugating the reduced IFN.  
The CIEC chromatogram (Figure 4-29 A) shows two peaks at 20 min and 70 
min respectively. The first peak at 20 min is PEG20 di(bis)sulfone 4 which can be 
seen in Lane 2 (Figure 4-29 B), where the PEG stained orange from the barium 
chloride. The second peak at 70 min (~45 mAu) is the Fabalb species eluting from the 
column due to the salt gradient causing the Fabalb species to dissociate from the 
cation exchange resin. The SDS-PAGE analysis of the peak fractions shows both un-
conjugated Fabalb between 20-30 kDa and 20 kDa Fabalb-PEG20-X (~80 kDa) have 
co-eluted. However, this is of no consequence as the aim was to remove the un-
reacted PEG20 di(bis)sulfone 4, which would otherwise compete against the Fabbeva-
PEG20-X for conjugating the reduced IFN.  
260 kDa 
160 kDa 
110 kDa 
80 kDa 
60 kDa 
 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
 
10 kDa 
 
3.5 kDa 
		1    2 A B 
PEG20 di(bis)sulfone 4 
1               2  
Reduced Fabalb 
260 kDa 
160 kDa 
110 kDa 
80 kDa 
60 kDa 
50 kDa 
40 kDa 
 
30 kDa 
 
20 kDa 
 
15 kDa 
10 kDa 
 
3.5 kDa 
Fabalb-PEG20-X 
Reduced Fabalb 
Fabalb-PEG20-Fabalb 
  
228 
 
Figure 4-29. Representative A) Chromatogram and SDS-PAGE analysis (B) PEG stain, C) 
InstantBlue™ stain) of the linear CIEC purification of PEG20 di(bis)sulfone 4-Fabalb reaction 
mixture. Lane 1: Novex pre-stained markers, Lane 2: PEG20 di(bis)sulfone 4, Lane 6-9: 
Fabalb-PEG20-X mixture. Successful removal of un-reacted PEG20 di(bis)sulfone 4 from 
Fabalb-PEG20-X mixture, this was repeated n=2. 
4.2.6.4 Disulfide conjugation of IFN with Fabalb-PEG20-X  
In an effort to maximise the yield of Fabalb-PEG20-IFN, Fabalb-PEG20-X was in 
solution for as short as time as possible. Fabalb was reacted with PEG20 di(bis)sulfone 
4 for 3 h and purified at once. Once quantified the Fabalb-PEG20-X was reacted 
straight away with reduced IFN. Following the isolation of the Fabalb-PEG20-X 
conjugate from unreacted PEG20 di (bis)sulfone 4 by CIEC; the fractions containing 
Fabalb-PEG20-X were pooled and quantified by UV (0.17 mg, yield=46.7%) ready for 
conjugation to IFN (§ 2.2.9.16). The disulfide reduced IFN (2 eq., 0.25 mg) was then 
allowed to undergo conjugation with Fabalb-PEG20-X (1 eq.) in an effort to form IFN-
PEG20-Fabalb (§ 2.2.9.17). To promote the conjugation of IFN to Fabalb-PEG20-X an 
excess of reduced IFN were used.  
As before (§ 4.2.2.4), once the IFN-PEG20-Fabalb conjugate had been formed 
the unconjugated disulfide in IFN was oxidised using glutathione. Prior to 
glutathione treatment, SDS-PAGE analysis was conducted on the IFN-PEG20-Fabalb 
reaction mixture. The IFN-PEG20-Fabalb conjugate can be seen in Lane 2 (Figure 
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4-30) at a new band ~110 kDa, which is the expected MW (~50 kDa=Fabalb + 
PEG20=40 kDa + IFN=~20 kDa) (Figure 4-30). A faint band of Fabalb-PEG20-X can 
be observed in Lane 2 at ~80 kDa (Figure 4-30), meaning the reaction has not gone 
to completion or that some of the Fab-PEG-X had a dead chain end due to hydrolysis 
or because the reagent was not pure at the start of the conjugation sequence.  
Following glutathione re-oxidisation of IFN within the IFN-PEG20-Fabalb 
conjugate, the reaction mixture was then subject to STAB treatment (§ 2.2.9.17) to 
reduce the electron withdrawing carbonyl to stop de-conjugation.  
 
Figure 4-30. Example SDS-PAGE analysis A) InstantBlue™ B) PEG stain of the IFN-
PEG20-Fabalb reaction mixture. Lane 1: Novex pre-stained markers, Lane 2: IFN-PEG20-
Fabalb reaction mixture. Successful conjugation of reduced IFN to Fabalb-PEG20-X to prepare 
IFN-PEG20-Fabalb. This was repeated twice independently.  
4.2.6.5 CIEC purification of the IFN-PEG20-Fabalb reaction mixture  
A step CIEC gradient was used to purify the IFN-PEG20-Fabalb conjugate from the 
unreacted IFN and Fabalb-PEG20-X, and higher MW impurities of Fabalb-PEG20-
Fabalb (Figure 4-31 A). This step gradient of 30, 60, 80 and 100% buffer B (§ 
2.2.9.18) was optimised to isolate the IFN-PEG20-Fabalb conjugate in a single step 
CIEC purification in an effort to maximise yield. SDS-PAGE analysis (Figure 4-31 
B) shows that the step gradient CIEC was successful at isolating the IFN-PEG20-
Fabalb heterodimer (Lane 7) from the unreacted IFN (Lanes 8-9), Fabalb-PEG20-X and 
Fabalb (Lanes 3-5), plus higher MW impurities of Fabalb-PEG20-Fabalb (Lanes 3-5). As 
the Fabalb-PEG20-X (~80 kDa), Fabalb (~45 kDa), Fabalb-PEG20-Fabalb (~140 kDa) 
(Lanes 3-5) co-eluted this suggests that their binding affinity for the column is 
similar as they all required 30% salt to elute from the column.  
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Figure 4-31. Representative A) Chromatogram and B) SDS-PAGE analysis of IFN-PEG20-
Fabalb CIEC purification to isolate IFN-PEG-Fabalb. Lane 1: Novex pre-stained markers. 
Lanes 3-5: Fabalb-PEG20-X/Fabalb/Fabalb-PEG20-Fabalb mixture, Lanes 7: IFN-PEG20-Fabalb, 
Lane 8-9: IFN. Successful CIEC purification was conducted to isolate IFN-PEG20-Fabalb. 
Purification was found to be reproducible, as IFN-PEG20-Fabalb was successfully isolated 
twice.  
Whilst 60% salt was required to elute the IFN-PEG20-Fabalb (~110 kDa, Lane 
7, Figure 4-31) from the resin, as the binding affinity of the conjugate is an average 
of both proteins, thus it is in the middle of the Fabalb (~20 mAu) and IFN (5 mAu) 
peaks within the chromatogram. Interestingly, the Fabalb mixture peak (~20 mAu) is 
the largest of the three peaks; this peak is a mixture of Fabalb-PEG20-X (~ 80 kDa), 
Fabalb (~45 kDa) and Fabalb-PEG20-Fabalb (~140 kDa) explaining the higher 
absorbance. 
The fractions for IFN-PEG20-Fabalb were pooled and the concentration of Fabalb 
and IFN quantified by UV (IFN ε=0.914, 0.11 mg/ mL, yield=44%; Fabalb ε=1.4, 
0.0725 mg/ mL, yield=20.5%). The yields achieved for Fabalb and IFN are 
comparable to that achieved for the PEG20 bis-sulfone 1 and that achieved for the 
IFN-PEG20-Fabbeva heterodimer (§ 4.2.2.5). As discussed these results show that 
synthesis route 2 for PEG20 di(bis)sulfone 4 has a greater reactivity compared to the 
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PEG20 di(bis)sulfone 4 synthesised by route 1. This could be due to i) the improved 
purity of the PEG20 di(bis)sulfone 4 which was quantified by RP-HPLC (§ 2.2.5.4) 
and SDS-PAGE (§ 2.2.5.5); ii) the better understanding of hydrolysis and its effect 
on the di(bis)sulfones, whereby the synthesis approach was conducted in under 12 
hours, reducing the risk of hydrolysis to the di(bis)sulfone linkers.  
SDS-PAGE analysis was conducted on the final IFN-PEG20-Fabalb conjugate to 
assess its purity. It can be seen in Lane 2 (Figure 4-32) that the IFN-PEG20-Fabalb 
conjugate at ~110 kDa was prepared and purified in good purity as no other bands 
can be seen by InstantBlue™ stain.  
 
Figure 4-32: Example SDS-PAGE analysis (InstantBlue™ stain) of final IFN-PEG20-Fabalb 
conjugate (n=2). Lane 1: Novex pre-stained markers, Lane 2: IFN-PEG20-Fabalb. IFN-PEG20-
Fabalb was successful prepared and in good purity.  
4.2.7 Preparation of PEG20-Fabalb 
PEG20-Fabalb was prepared as a control for the binding studies, to compare the 
binding affinities of IFN-PEG20-Fabalb, PEG20-Fabalb and Fabalb to rat albumin, and 
how the conjugation of IFN and PEG20 affect the binding of Fabalb to rat albumin.  
4.2.7.1 Reaction optimisation of PEG20 bis-sulfone 1-Fabalb production 
As Fabalb had not been conjugated to PEG before, little was known about the 
optimised reaction conditions (pH and reaction time) to prepare PEG20-Fabalb. 
Therefore, to confirm the site-specific PEGylation of Fabalb, a control reaction was 
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conducted (§ 2.2.9.11) by allowing non-reduced Fabalb to incubate with PEG20 bis-
sulfone 1 in 1:1 molar ratio. This ratio was used as Fabalb only has one disulfide to 
which the PEG20 bis-sulfone 1 could generate the 3-carbon linkage and conjugate. 
The reaction was conducted at pH 7.8 for 5 h hours at RT. This allows for the PEG 
bis-sulfone 1 to generate PEG mono-sulfone 2 by an in situ elimination reaction as 
shown in Figure 2-1 (§2.2.9.11, Brocchini et al. 2006).  
 
Figure 4-33. SDS-PAGE analysis (InstantBlue™/PEG stain) of PEG20 bis-sulfone 1-Fabalb 
control reaction. Lane 1: Novex pre-stained markers, Lane 2: PEG20 bis-sulfone 1, Lane 3: 
PEG20 bis-sulfone 1-Fabalb control reaction. Unspecific conjugation of PEG20 bis-sulfone 1 to 
Fabalb was observed (~85 kDa). 
SDS-PAGE analysis was conducted on the PEG20 bis-sulfone 1-Fabalb mixture 
(Figure 4-33). Two PEG bands can be observed on the gel at ~40 kDa and ~80 kDa; 
the band at ~ 40 kDa is PEG bis-sulfone 1 (Lane 2, Figure 4-33). The band observed 
at ~80 kDa is most likely to be a PEG impurity. Oxidised Fabalb can be seen as a 
clear blue band at ~45 kDa (Lane 3, Figure 4-33). A PEG-protein band can be seen at 
~85 kDa (Lane 3, Figure 4-33). Additionally, due to the MW, it is most likely a 
Fabalb (45 kDa)-PEG20 (~40 kDa) conjugate prepared from unspecific binding of 
PEG20 bis-sulfone 1 to the Fabalb. This indicates that tailored reaction conditions, 
specifically pH, need to be found to reduce the likelihood of this taking place. 
As unspecific conjugation had occurred to a small extent at pH 7.8, lower pH 
values were evaluated in an effort to minimise unspecific conjugation to Fabalb. 
Reducing the pH was expected to protonate any nucleophilic residues available for 
conjugation. Bis-thiol alkylation occurs efficiently at slightly acidic pH (Brocchini et 
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al., 2006), therefore activation in situ to PEG mono-sulfone 2 would not be effected 
by reducing the pH (Figure 2-1).  
First, Fabalb was reduced using DTT; the reduced Fabalb can be seen in Lane 2 
at between 20 kDa-30 kDa (Figure 4-34 A). Varying pH’s (pH 6.5, 6.0, 7.8) were 
tested to prepare PEG20-Fabalb at 25 °C. After 1 h little conjugation of the reduced 
Fabalb was observed at of the pH values tested (Figure 4-34 A), this could be due to 
the in situ activation of the PEG20 bis-sulfone 1 occurring at this time. However, at 3 
h of reaction time, conjugation of Fabalb appeared to occur at all pH values tested as 
seen in Figure 4-34 B. The band of interest is PEG20-Fabalb, which can be seen at ~80 
kDa (~45 kDa=Fabalb + PEG20=40 kDa).  
Interestingly, it can be seen in Figure 4-34 B and C, that the higher the pH the 
more bands for conjugated Fabalb can be seen. The band observed at ~110 kDa could 
be (PEG20)2-Fabalb. This is unusual as Fabalb is thought to have only one accessible 
disulfide that could be reduce and to which the PEG reagent can conjugate. The 
starting antibody was polyclonal and it is possible that there are many Fab variants in 
the solution. However, non-specific binding or mis-bridging of PEG20 bis-sulfone 1 
cannot be ruled out.  
It was interesting that at pH 6.5 at 3 h (Lane 2, Figure 4-34 B), no (PEG20)2-
Fabalb is observed; only PEG20-Fabalb, suggesting this pH and reaction time is 
favourable for preparing PEG20-Fabalb. Also it can be seen that after 16 h, there was 
no remaining Fabalb at pH 7.0 and pH 7.4. There was excess PEG bis-sulfone 1, so 
this could explain why more (PEG20)2-Fabalb was prepared. However, at pH 6.5, 
(PEG20)2-Fabalb was also prepared yet there was still some reduced Fabalb remaining. 
This suggested conjugation of two PEG bis-sulfone 1 molecules is due to unspecific 
conjugation. 
The band at ~60 kDa is thought to be the heavy or light chains from Fabalb, 
from reduction of Fabalb, which has been conjugated by PEG20 bis-sulfone 1. It was 
observed as incubation time increased from 3 h to 16 h, the band of PEG20-heavy or 
light chain of Fabalb band was seen to reduce at pH 7.0 and pH 7.4 (Lanes 3-4, Figure 
4-34 B/C). The bands of (PEG20)2-Fabalb and PEG20-Fabalb were seen to be deeper in 
colour, suggesting more of these conjugates had been made. Possibly, conjugation of 
the heavy or light chain of Fabalb prepared PEG20-Fabalb or (PEG20)2-Fabalb 
explaining the increased prominence of these bands on the gel. However, the aim 
was to prepare PEG20-Fabalb, therefore the best conditions found where 3 h at pH 6.5, 
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as no higher MW impurities ((PEG20)2-Fabalb) were prepared (Lane 2, Figure 4-34 
C).  
 
Figure 4-34. SDS-PAGE of the PEG20 bis-sulfone 1-Fabalb reactions with pH (pH 6.5,7, 7.4) 
and reaction time, A) 1 h, B) 3 h, C) 16 h optimisation. A) Lane 1: Novex pre-stained 
markers, Lane 2: reduced Fabalb, Lane 3: pH 6.5, Lane 3: pH 7.0, Lane 4: pH 7.4. B/ C) Lane 
1: Novex pre-stained markers, Lane 2: pH 6.5, Lane 3: pH 7.0, Lane 4: pH 7.4. For the 
preparation of PEG20 bis-sulfone 1-Fabalb 1:1 ratio of 3 h conjugation pH 6.5 found to 
optimum at 25 °C.  
4.2.7.2 Conjugation of Fabalb with PEG bis-sulfone 1  
The optimum conditions to prepare PEG20-Fabalb and to avoid high MW impurities 
were pH 6.5 for 3 h. However it was observed that there was some unreacted reduced 
Fabalb (1:1 eq. PEG:Fabalb) so in an effort to increase the yield of PEG20-Fabalb the 
reaction time was increased to 4 h instead of 3 h (Figure 4-34).  
First, Fabalb (Lane 2, Figure 4-35) was reduced with DTT (§2.2.9.12). The 
reduced Fabalb was then allowed to react with PEG20 bis-sulfone 1 (~80 kDa, Lane 4-
5, Figure 4-35). Unreacted reduced Fabalb can be seen in Lanes 4 and 5 between 20-
30 kDa, however as discussed there was a balance between PEG20-Fabalb yield, pH 
and conjugation specificity. Therefore, as no high MW impurities of (PEG20)2-Fabalb 
were observed in the reaction mixture (Lane 4-5, Figure 4-35), conjugation was 
viewed as successful, as only the conjugate of interest was prepared.  
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Figure 4-35. SDS-PAGE analysis (InstantBlue™ stain) on PEG20 bis-sulfone 1 –Fabalb 
reaction mixture. Lane 1: Novex pre-stained markers, Lane 2: Fabalb, Lane 3: DTT reduced, 
Lane 4: PEG20 bis-sulfone 1-Fabalb reaction mixture, (PEG stain) Lane 5: PEG20 bis-sulfone 
1-Fabalb reaction mixture. Successful conjugation of reduced Fabalb to prepare PEG20-Fabalb. 
4.2.7.3 SEC purification of the PEG20 bis-sulfone 1 –Fabalb reaction mixture 
To purify PEG20-Fabalb from the reaction mixture, SEC purification was used 
(§2.2.9.14). CIEC was first tried twice however, but no separation of the PEG20-
Fabalb from the reaction mixture could be achieved. As CIEC is the purification is the 
separation of proteins by differences in binding affinity for the resin, this suggests 
the conjugation of PEG20 bis-sulfone 1 to Fabalb has not drastically changed the 
binding affinity of Fabalb due to CIEC not being able to purify PEG20-Fabalb from 
Fabalb. This was unexpected since PEGylation typically results in a conjugate that is 
less able to bind to the column than the unmodified protein.  
SDS-PAGE analysis (Figure 4-36 B) of the fractions collected from SEC 
purification (Figure 4-36 A) shows PEG20-Fabalb was purified from Fabalb. However, 
PEG20-Fabalb (Lane 3-4, Figure 4-36) could not be purified from PEG20-half Fabalb. 
The final yield of PEG20-Fabalb successfully purified from Fabalb was 28.8% (n=1). 
Although this was lower than that achieved for PEG20-Fabbeva (44%, 41μg/mL, 2 mL, 
§4.2.3.3), the yield was sufficient for the binding studies. Yields of ~65% have been 
stated in literature for disulfide-conjugated Fabs (Khalili et al., 2012), however, this 
was the first time polyclonal anti-rat albumin Fab had been conjugated to, thus more 
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optimisation regarding pH, reaction time, purification and equivalents could be 
conducted to improve the yield.  
 
Figure 4-36. A) Chromatogram and B) SDS-PAGE (silver stain) of fractions from SEC 
purification of PEG20 bis-sulfone 1-Fabalb reaction mixture, C) SDS-PAGE (InstantBlue™ 
and PEG stain) of final PEG20-Fabalb conjugate. B) Lane 1: Novex pre-stained markers, Lane 
2: (PEG20)2-Fabalb, Lanes 3-4: PEG20-Fabalb/PEG20-half Fabalb, Lanes 7-11: Fabalb and 
reduced Fabalb. C) Lane 1: Novex pre-stained markers, Lane 2: Fabalb, Lane 3: final PEG20-
Fabalb. SEC purified PEG20-Fabalb was used as a control in IFN-PEG20-Fabalb functionality 
testing.  
4.2.8 Characterisation of Fabbeva-PEG20-IFN and Fabalb-PEG20-IFN  
Characterisation in terms of purity (SDS-PAGE) and identity (Western blot) was 
conducted on the IFN-PEG20-Fab heterodimers and PEG20-Fab controls prior to 
functionality testing (binding affinity and in vitro activity assays).  
4.2.8.1 Characterisation of IFN-PEG20-Fab and PEG20-Fab conjugates 
SDS-PAGE analysis of the final bevacizumab compounds was performed, where 
after InstantBlue™ stain, densitometric analysis was conducted on the gel (§2.2.1). 
Bevacizumab and Fabbeva were also run for comparison (Figure 4-37 B), PEG20-
Fabbeva was present as a band at ~90 kDa (50 kDa for Fabbeva + 40 kDa for PEG20) 
(Lane 4, Figure 3-37). In Lane 5 (Figure 4-37 B), IFN-PEG-Fabbeva conjugate was 
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visible as being 110 kDa in size (20 kDa for IFN + 50 kDa for Fabbeva + 40 kDa for 
PEG20). It was also noted that on the SDS-PAGE gel (Figure 4-37 B) the bands for 
PEG20-Fabbeva and IFN-PEG20-Fabbeva had a green colour compared to those for 
bevacizumab and Fabbeva. This is due to the overlapping colours for the protein 
(stained blue) and the PEG moiety (stained orange). In addition, the band for IFN-
PEG20-Fabbeva was less green in colour in comparison to the PEG20-Fabbeva band due 
to the additional IFN conjugated to the PEG di(bis)sulfone 1. 
 
Figure 4-37. A) ImageQuant™ densimetric image and B) SDS-PAGE analysis 
(InstantBlue™ + PEG stain) of bevacizumab compounds. Lane 1: Novex pre-stained 
markers, Lane 2: bevacizumab, Lane 3: Fabbeva, Lane 4: PEG20-Fabbeva and Lane 5: IFN-
PEG20-Fabbeva. Densimetric analysis showed that the bevacizumab conjugates were prepared 
in good purity (>80%). 
ImageQuant™ LAS 4000 digital imaging system was used with the 
transillumination setting for densitometric analysis (Figure 4-37 A). The results 
showed that Fabbeva prepared from digested bevacizumab was 100% pure while 
PEG20-Fabbeva and IFN-PEG20-Fabbeva were 83% and 89% pure respectively. In Lane 
4 (Figure 4-37 A), several bands below ~90 kDa were observed which could be 
Fabbeva at 50 kDa and PEGylated single chain at ~80 kDa. In Lane 5 (Figure 3-37 A), 
two impurity bands above 110 kDa could be Fabbeva-PEG-Fabbeva (~140 kDa) or 
(PEG20)n-(Fabbeva)n (~170 kDa). However, as these bands were in trace amounts as 
they could not be visible with InstantBlue™ stain whose limit of detection is 5 ng. 
These impurities were considered to be due to the purification conditions used rather 
than product instability, thus stability studies were conducted to confirm this. 
SDS-PAGE analysis of IFN-PEG20-Fabalb showed the samples to be pure by 
silver stain analysis, as no other bands were visible (Figure 4-38, Lane 4). SDS-
PAGE PEG20-Fabalb showed some faint bands above and below the PEG20-Fabalb at 
~80 kDa. However, these are in very low concentration due to being only slightly 
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visible by silver stain (Lane 3, Figure 4-38). Fabalb was shown to be ~50 kDa and 
pure by InstantBlue™ stain (Lane 2, Figure 4-38). 
 
Figure 4-38. SDS-PAGE analysis of IFN-PEG20-Fabalb, PEG20-Fabalb (silver stain) and Fabalb 
(InstantBlue™ stain). Lane 1: Novex pre-stained markers, Lane 2: Fabalb, Lane 3: PEG20-
Fabalb and Lane 4: IFN-PEG20-Fabalb. SDS-PAGE analysis shows the samples to be pure, 
with light impurity bands visible for PEG20-Fabalb. 
4.2.8.2 Identity confirmation by Western blot of IFN-PEG20-Fab heterodimers and 
controls  
Western blot of anti-IFN α-2 and anti-human were used to identify the bevacizumab 
and IFN samples (§ 2.2.10.1.). Goat anti-human κ-chain HRP-conjugated Fab’2 was 
used to detect the κ-light chains on bevacizumab and Fabbeva samples. The anti-
human detection antibody is HRP-conjugated which can be detected by enhanced 
chemiluminescence (ECL). All the bevacizumab samples were visualised and thus 
the identities of bevacizumab, Fabbeva, PEG20-Fabbeva and IFN-PEG20-Fabbeva were 
confirmed by their detection and migration patterns (Figure 4-39 A). 
The anti-human IgG Western blot successfully detected the κ-light chain of 
Fabbeva within the IFN-PEG20-Fabbeva conjugate, but to confirm the identity of the 
IFN-PEG20-Fabbeva conjugate, IFN must also be identified. For this an anti-IFN α-2 
Western blot was conducted (§ 2.2.10.1.). Here, a colorimetric method of detection 
was used using a substrate for alkaline phosphatase, so the Novex pre-stained 
markers could also be observed. IFN was included as a positive control (Lane 2) and 
detected near the 15 kDa ladder (Figure 4-39 B). Similarly, IFN-PEG20-Fabbeva 
conjugate was also detected near the 110 kDa ladder and confirmed the presence of 
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IFN within the IFN-PEG20-Fabbeva conjugate. Impurities, also discussed previously 
(Figure 4-39 B), were more prominent in this study due to the greater sensitivity of 
the Western blot method. 
 
Figure 4-39. A) anti-human and B) anti-IFN α-2 Western blot of bevacizumab samples. A) 
Lane 1: bevacizumab, Lane 2: Fabbeva, Lane 3: PEG20-Fabbeva, Lane 4: IFN-PEG20-Fabbeva. B) 
Lane 1: Novex pre-stained markers, Lane 2: IFN, Lane 3: IFN-PEG20-Fabbeva. Anti-human 
and anti-IFN α-2 Western blots successfully identify all bevacizumab samples. 
To confirm the identity of the anti-rat albumin conjugates prepared, anti-IFN α-
2 and anti-rabbit Western blots were conducted (§ 2.2.10.1). For the detection of the 
rabbit anti-rat albumin species a polyclonal anti-rabbit IgG (H&L) AP-conjugated 
IgG was used. A colorimetric method of detection was used, so the Novex pre-
stained markers could also be observed. In the resulting Western blot (Figure 4-40 A) 
Fabalb, PEG20-Fabalb and IFN-PEG20-Fabalb were successfully identified, positively 
identifying the presence of the rabbit Fabalb within in the conjugates. Furthermore, as 
the ladder is present, the MW of the conjugates could be assessed. In Lane 2 (Figure 
4-40 A) Fabalb was visualised at ~45 kDa, this MW confirmed the identity of Fabalb, 
as this was the MW achieved in previous SDS-PAGE analysis (Figure 4-24). In Lane 
3 (Figure 4-40 A) PEG20-Fabalb can be seen at ~70 kDa, whilst in Lane 4, IFN-
PEG20-Fabalb was identified at ~90 kDa. The MW’s achieved in the Western blot for 
these conjugates, match those achieved in previous SDS-PAGE analysis (Figure 
4-38).  
However, to successfully identify the IFN-PEG-Fabalb conjugate, IFN must be 
identified, to confirm its presence within the conjugate. For this an anti-IFN α-2 
Western blot was performed (§ 2.2.10.1.). In Lane 2 (Figure 4-40 B) IFN was 
observed between 15-20 kDa, this MW is the same as that achieved in previous 
analysis (Figure 4-38). Whilst in Lane 3, the IFN-PEG20-Fabalb can be seen at ~110 
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kDa (Figure 4-40 B). This confirms the presence of IFN within the IFN-PEG20-Fabalb 
conjugate and its identity. Therefore, from the anti-rabbit and anti-IFN α-2 Western 
blots conducted, the identity of Fabalb, PEG20-Fabalb and IFN-PEG20-Fabalb were 
confirmed.  
 
Figure 4-40. A) anti-rabbit and B) anti-IFN α-2 Western blots of anti-rat albumin 
compounds. A) Lane 1: Novex pre-stained markers, Lane 2: Fabalb, Lane 3: PEG20-Fabalb, 
Lane 4: IFN-PEG20-Fabalb. B) Lane 1: Novex pre-stained markers, Lane 2: IFN, Lane 3: IFN-
PEG20-Fabalb. The anti-rabbit and anti-IFN α-2 Western blots conducted positively identified 
Fabalb, PEG20-Fabalb and IFN-PEG20-Fabalb. 
 It can be observed in Figure 4-39 and Figure 4-40 that there are two areas 
where the Western blots could be improved. First, there is a smearing of the protein 
bands; which is caused by high voltage or air bubbles present during transfer 
(Mahmood and Yang, 2012). This can be overcome by ensuring that a lower voltage 
and thus longer transfer is conducted. Further prior to transfer, the gel and 
nitrocellulose membrane are rollered to ensure no air bubbles are between them. 
Second, there is high background observed in some sample columns (e.g. Figure 
4-40 A, Lane 3), this could be avoided by using a lower sample concentration.  
4.2.8.3 Stability assessment of IFN-PEG20-Fab  
Stability studies were conducted with Fabbeva, PEG20-Fabbeva and IFN-PEG20-Fabbeva 
to determine if they underwent de-conjugation or non-reversible aggregation in 
simulated storage and in vitro assay conditions. As shown in §4.2.2.5, all samples 
were considered stable at the time they were made and at the start of the stability 
studies, with no changes observed by SDS PAGE. 
Firstly, one-week stability studies were conducted by incubating the 
compounds in 50 mM sodium phosphate buffer, 150 mM NaCl pH 7.8 for 7 days at 4 
°C. The results showed no evidence of free protein (IFN or Fabbeva) or de-PEGylation 
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when analysed by SDS-PAGE (Figure 4-41 A). This study indicates that Fabbeva, 
PEG20-Fabbeva and IFN-PEG20-Fabbeva were stable for at least 7 days at 4 °C. 
Accelerated stability studies were also performed by incubating IFN-PEG-
Fabbeva conjugate (40 μg/mL) at 50 ºC (1 h) with or without 20 mM DTT (§ 
2.2.10.5). DTT was added to induce de-PEGylation. Sample analysis was conducted 
by SDS-PAGE with the resulting gel stained using InstantBlue™ and PEG stain. The 
results showed no de-PEGylation from incubation with DTT, this demonstrates that 
STAB treatment has fully reduced the ketone group within the di(bis)sulfone linker 
(Figure 2-2) as the DTT could not react with the ketone group to induce de-
conjugation. 
 
Figure 4-41. SDS-PAGE analysis of Fabbeva samples stability studies at A) 4 °C for 7 days 
and B) 50 °C for 1 h. A) Lane 1: Novex pre-stained markers, Lane 2: Fabbeva, Lane 3: PEG20-
Fabbeva, Lane 4: IFN-PEG20-Fabbeva, B) Lane 1: Novex pre-stained markers, Lane 2: IFN-
PEG20-Fabbeva –DTT and Lane 3: IFN-PEG20-Fabbeva +DTT. All Fabbeva compounds were 
shown to be stable at 4 °C for 7 days and IFN-PEG20-Fabbeva shown to be stable for 1 h at 50 
°C ±DTT.  
A one-week stability study was then conducted with PEG20-Fabalb and IFN-
PEG20-Fabalb. As shown in §4.2.6.5, the Fabalb samples were stable at day 0, where 
no free IFN or Fabalb was observed in the conjugated compounds. The compounds 
were again stored in 50 mM sodium phosphate buffer, 150 mM NaCl pH 7.8 for 7 
days at 4 °C. Analysis by SDS-PAGE (Figure 4-42) indicated there was no free IFN 
(~20 kDa) or Fabalb (45 kDa) in either sample. In Lane 3 (Figure 4-42), PEG-Fabalb 
can be observed at ~80 kDa (Fabalb= ~45 kDa + PEG20=40 kDa), while in Lane 2 
(Figure 4-42), IFN-PEG20-Fabalb can be seen at ~110 kDa (IFN=20 kDa+ PEG20=40 
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kDa+ Fabalb=~45 kDa). These observations indicate that PEG20-Fabalb and IFN-
PEG20-Fabalb are stable for 7 days at 4 °C. 
 
Figure 4-42. 7 day at 4 °C stability study of PEG20-Fabalb and IFN-PEG20-Fabalb analysed by 
SDS-PAGE A) InstantBlue™, B) PEG stain. Lane 1: Novex pre-stained markers, Lane 2: 
IFN-PEG20-Fabalb, Lane 3: PEG20-Fabalb. No free protein (IFN or Fabalb) can be observed by 
SDS-PAGE analysis, therefore PEG20-Fabalb and IFN-PEG20-Fabalb are stable for 7 days at 4 
°C. 
4.2.9 Functional activity assessment of IFN-PEG20-Fab heterodimers  
Both IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb were then evaluated by in vitro 
assays to determine if there was any retained Fab binding and IFN activity. The 
results were compared against controls, IgG, Fab and PEG20-Fab for anti-rat albumin 
and bevacizumab. As IFN is a pleiotropic protein, both antiviral and antiproliferative 
assays were used to better assess the conjugates retained in vitro activity. SPR was 
used to assess the Fabbeva/Fabalb retained binding kinetics.  
4.2.9.1 Binding properties of IFN-PEG20-Fab heterodimers  
The affinity and avidity of a mAb with its antigen is crucial for biological activity 
(Rudnick and Adams, 2009). Affinity and avidity, although often confused, are 
related to describe the binding properties of mAbs (Rudnick and Adams, 2009). 
Avidity is often referred to as functional affinity and is the accumulated strength of 
multiple affinities from multiple, often cooperative, binding interactions (Rudnick 
and Adams, 2009). Affinity is a thermodynamic term to describe the strength of 
interaction between the single antigen and a single binding region of the mAb 
(Rudnick and Adams, 2009). Affinity is calculated from the formation a complex 
(AB) between interacting proteins, for example mAb (A) and its antigen (B) 
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(Myszka, 1997). However, affinity is often expressed as its reciprocal, which is 
known as the equilibrium dissociation constant (KD=kd/ka). 
 
Figure 4-43. Affinity can be expressed as KD or KA but is often expressed as KD (Myszka, 
1997)  
The binding of IgG is bivalent, whereas the binding of Fab is monovalent. IFN-
PEG-Fab heterodimers were prepared to assess if PEG20 di(bis)sulfone 4 can be used 
to conjugate two therapeutic proteins site-specifically and that the proteins will retain 
their functional activity. The end groups in polymers are thought to be close spatially 
in solution and move more frequently compared to the rest of the polymer structure 
(Shewmake et al., 2008). It has been shown that the conjugates prepared with PEG 
di(bis)sulfone 4 have smaller dynamic volumes than those prepared using PEG bis-
sulfone 1 with the same PEG MW (Khalili et al., 2013). Site-specific conjugation of 
PEG molecules to antibody fragments (Fab) have shown no significant 
conformational changes to the Fabs itself (Lu et al., 2008). To determine if the Fab 
retained activity within the IFN-PEG20-Fab heterodimers, it was necessary to 
determine their binding affinities and compare them to Fab and PEG20-Fab. Surface 
plasmon resonance (SPR) was used for these studies.  
SPR biosensors have become an established method to measure protein-protein 
interactions, such as antibody-antigen interactions in real time, without labelling 
requirements (Markey, 1999; Myszka, 1997). In SPR, one protein or ligand is 
immobilised onto the chip surface (termed ‘ligand’) and monitoring its interaction 
with a second component flowing over the chip in solution (termed ‘analyte’) 
(Myszka, 1997). The SPR instrument measures the change in refractive index of the 
solvent near the surface chip of the immobilised ligand that occurs during complex 
formation and dissociation (Figure 4-44) (Cooper, 2002; Markey, 1999). For the 
binding affinity measurements of the heterodimers and controls, a commercially 
available SPR instrument, BIAcore X100 (Biomolecular Interaction Analysis) was 
used.  
A	+	B 									AB		
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kd	
KA=ka/kd=		[AB]	
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Figure 4-44. Typical SPR biosensor set up (Cooper, 2002) 
The sensor chips used for immobilisation are coated in a gold layer (50 nm 
thick). These provide the conditions for the SPR phenomenon (Figure 4-44) (Cooper, 
2002). Carboxymethylated dextran of varying lengths is covalently attached to the 
gold surface. These chips are called CM chips (e.g. CM3 and CM5). CM3 chips were 
used due to their shorter dextran strands, which reduce surface interactions and 
rebinding effects. To study the binding of bevacizumab conjugates, vascular 
endothelial growth factor (VEGF, ~38 kDa) was immobilised on a CM3 chip. Rat 
albumin (~65 kDa) was immobilised on another CM3 chip to study the Fab anti-rat 
albumin conjugates.  
The binding response is related to mass changes on the chip surface and results 
in changes in the measured intensity of the refractive index. The signal generated is 
given in resonance units (RU), which are approximately proportional to a change in 
mass (few pg per millimetre squared) (Myszka, 1997). The resulting plot is known as 
a sensogram and involves three steps: association, dissociation and regeneration 
(Figure 4-45). The association step is the analyte in running buffer flowing over the 
immobilised ligand. Association relates the analyte binding to the immobilised 
ligand. The dissociation phase occurs when the analyte is replaced by buffer to allow 
the analyte-ligand complex to dissociate. The regeneration step involves flowing a 
buffer solution to remove remaining bound analyte from the immobilised receptor 
without causing any damage to the immobilised ligand. The regeneration step 
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prepares the chip surface for the next kinetic analysis cycle (Figure 4-45) (Cooper, 
2002). 
 
Figure 4-45. Typical sensogram binding curve observed on SPR (Cooper, 2002) 
Since Fabbeva and Fabalb were obtained by proteolytically digesting 
bevacizumab and polyclonal anti-rat albumin IgG, it was necessary to determine the 
binding affinity of these Fabs. It was also necessary to evaluate the corresponding 
PEG-Fab conjugates as controls. These controls were prepared to understand how the 
PEG bis-sulfone 1 affects the binding affinity of the parent Fabs and how this 
compared to the heterodimer binding affinities. Heterodimers, IFN-PEG20-Fabbeva 
and IFN-PEG20-Fabalb were prepared to assess if the PEG20 di(bis)sulfone 4 can be 
used to conjugate two proteins and while retaining their activities. A summary of all 
the constructs that were prepared and tested regarding their binding affinity is seen in 
Table 4–2. 
Table 4–2. Summary table of prepared constructs tested by SPR 
Antibody Fab PEG-Fab Heterodimer 
Bevacizumab Fabbeva PEG20-Fabbeva IFN-PEG20-Fabbeva 
Anti-rat albumin IgG Fabalb PEG20-Fabalb IFN-PEG20-Fabalb 
 
Binding capacity of the chip surface is dependent on the level and activity of 
the immobilised ligand. The SPR response correlates with mass concentration of 
material on the chip surface. This depends on the relative MW of the analyte and 
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ligand, and on the stoichiometry of interaction between analyte and ligand. The 
maximum binding capacity (Rmax) of the sensor surface ligand with analyte in RU 
can be calculated as follows: 
Rmax=MW analyte/ MW ligand × Sm × RL 
Rmax is the maximum capacity of binding analyte, where RL is the actual level 
or amount of ligand on the chip surface; Sm is the binding stoichiometry between 
analyte and ligand. Not all of the immobilised ligand will be available for binding to 
the analyte, as some of the ligand may be damaged during immobilisation and 
regeneration, thus the theoretical Rmax is often higher than the experimental Rmax. The 
Rmax of immobilised ligand is optimally between 50 to 150 RU for conducting kinetic 
studies. The use of a low ligand density will help to minimise mass transfer and 
rebinding limitations.  
Three steps are performed to immobilise a ligand on a CM3 chip: 
1. Ligand pre-concentration  
2. Immobilisation step 
3. Regeneration step. 
 
Pre-concentration assay 
Electrostatic attraction provides an efficient means for associating positively charged 
ligands onto the negatively charged carboxymethylated dextran on the sensor 
surface. To do this, the pH of the ligand solution should between pH 3.5 and the 
isoelectric point of the ligand, so that the sensor surface and the ligand carry opposite 
charges. The pI of rat albumin is 5.7 (Sigma product information). Human VEGF165 
has a pI value of 8.6. Many proteins have a tendency to aggregate or denature at low 
pH, so it is necessary to determine an optimum pH, which is a compromise between 
efficient pre-concentration and not denaturing/precipitating the ligand. To determine 
the optimum pH for interactions between the ligand and the sensor chip, a pH 
scouting experiment was performed for rat albumin with sodium acetate at pH 
4,4.5,5, 5.5 (§ 2.2.11.11).  
Interestingly, at pH 5.5 (pink line, Figure 4-46), low association of the rat 
albumin to the sensor chip was observed. However, at pH 5.0 (blue line, Figure 4-46) 
the highest binding of rat albumin to the sensor chip was observed, so this pH was 
used for immobilisation of rat albumin to the CM3 chip. Lower interaction was 
observed at pH 4.0 and 4.5 (green and orange lines respectively, Figure 4-46). Since 
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the response correlated with pH, until pH 5.5, this shows the interactions are driven 
primarily by electrostatic interactions. However at pH 5.5, there is sharp drop in 
associated compared to pH 5.0, this is due to the pH being close the pI of rat albumin 
(pI=5.7). Sodium hydroxide (50 mM) was used to regenerate the CM3 chip for 
immobilisation.  
 
Figure 4-46. pH scouting assay using rat albumin (1 μg/mL) in sodium acetate buffer. It was 
found that 10 mM sodium acetate pH 5.0 was the optimum pH for the immobilisation of rat 
albumin to the CM chips. 
 
Ligand Immobilisation 
Immobilisation of the CM3 chip by amine coupling is conducted in three steps: 
1. Activation: For coupling to take place, the carboxylic acids on the sensor chip 
surface are modified into activated esters using a 1:1 ratio of 1-theyl-3-(3-
dimethylaminopropyl)-carbodiimide (EDC) and N-hydroxysuccinimide (NHS). 
(Figure 4-47). 
2. Coupling: The ligand was injected over the NHS-activated carboxymethyl dextran 
surface. Amines in the ligand undergo reaction to covalently bond to the activated 
carboxylic acids on the dextran matrix (Figure 4-47). The ligand binds in a non-
specific way to the chip surface.  As most proteins contain several amine groups, 
efficient attachment to the sensor surface can be achieved while maintaining ligand-
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binding surfaces that can then be utilised to evaluate the analyte. Amine coupling is 
the most widely used coupling technique; other techniques include thiol and ligand 
coupling.  
3. Deactivation: Since not all the activated dextran carboxylic acids will have 
undergone a reaction with the ligand to be immobilised, a blocking amine solution 
such as ethanolamine is injected to quench remaining active succinimide ester 
moieties. This avoids covalent binding of the analyte to the sensor chip surface.  
 
 
Figure 4-47. Activation by EDC/NHS of carboxymethyl dextran sensor surface and amine-
coupling mechanism (adapted from BIAcore Sensor Surface Handbook).  
 Manual control on the BIAcore was used to immobilise separate CM3 chips 
with both VEGF and rat albumin. The optimum conditions for VEGF immobilisation 
was found to be 0.2 μg/mL in sodium acetate pH 5.5 for 150 sec to immobilise with 
the Rmax of ~100 RU (Figure 4-48). For rat albumin immobilisation, the optimum 
conditions were 0.2 μg/mL in sodium acetate pH 5.5 for 180 sec, to immobilise CM3 
with the Rmax of ~70 RU (Figure 4-49). The theoretical Rmax for VEGF (100 
RU=38,000/50,000 ×1 ×RL) and rat albumin (100 RU=65,000/50,000 ×1 ×RL) were 
76 RU and 130 RU respectively. Prior to achieving the optimum conditions for rat 
albumin immobilisation, different concentrations of rat albumin (0.1 to 1 μg/mL) 
were tried in conjunction with different contact times (120 sec-180 sec), to achieve a 
low RU. A low RU was necessary to avoid bulk transport effects and achieve 
accurate affinity data. 
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Figure 4-48. Manual immobilisation of VEGF (0.2 μg/mL) onto a CM3 chip using amine 
coupling to achieve 110 RU. 
 
Figure 4-49. Manual immobilisation of rat albumin (0.2 μg/mL) onto a CM3 chip using 
amine coupling to achieve 72 RU. 
The VEGF and rat albumin immobilised chips were then used for kinetic 
assays involving the novel heterodimeric constructs.  
50 mM NaOH,  
60 s 
EDC/NHS,  
200 s 
0.2 µg/mL VEGF,  
150 s 
Ethanolamine,  
180 s 
110 RU 
50 mM NaOH,  
60 s 
EDC/NHS,  
200 s 
0.2 µg/mL rat albumin,  
180 s 
Ethanolamine,  
180 s 
72 RU 
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 Regeneration 
Regeneration is the process to remove bound analyte from the immobilised ligand 
while causing minimal change or damage to the immobilised ligand. Regeneration is 
required to prepare the chip for he next analysis. To determine the optimum 
regeneration conditions for rat albumin, scouting experiments were conducted. 
Scouting experiments were performed by repeated cycles of analyte binding and chip 
regeneration and examining the response level after each cycle. Recommended 
regeneration buffers include, sodium hydroxide, sodium chloride, magnesium 
chloride and SDS. The most widely used regeneration solution is 10 mM glycine-
HCl at pH 1.5-3. Regeneration conditions were examined at pH 2.25 and pH 2.75 (§ 
2.2.12).  
It was found that glycine-HCl pH 2.25 was the optimal regeneration condition 
for rat albumin. This was determined, as literature recommends no more than 10% 
increase in baseline after repeated cycles of binding and regeneration. A decrease in 
the baseline can be observed for pH 2.75, showing the removal of rat albumin after 
regeneration. Regeneration using glycine-HCl pH 2.25 showed a steady baseline, 
after 4 binding and regeneration cycles, thus pH 2.25 was used for the regeneration 
of the rat albumin chip after kinetic analysis of the rat albumin derivatives. For 
VEGF immobilisation the optimum regeneration condition was pH 2.0 (Khalili et al., 
2012, 2013). 
 
Figure 4-50. Regeneration optimisation of rat albumin immobilised chip using glycine-HCl 
A) pH 2.25 and B) pH 2.75. Results showed the glycine-HCl pH 2.25 was optimum for 
regeneration of the immobilised rat albumin chip.  
 A control-binding assay was conducted using the VEGF immobilised chip to 
determine whether IFN binds to VEGF. No increase in RU was observed after IFN 
A) B) 
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injection (Figure 4-51), showing IFN does not bind to VEGF, thus binding data 
achieved for IFN-PEG-Fabbeva, is from the Fabbeva binding to VEGF not IFN. 
 
Figure 4-51. Binding assay of His8IFN (green line; 100 μg/mL) and blank (red line; HBS+ 
EP running buffer) using VEGF immobilised CM3 chip. No binding observed for His8IFN to 
VEGF.  
4.2.9.2 Kinetic assay for IgG, Fab and PEG20-Fabs  
As discussed in §1.2.1.1, protein activity is dependent on conjugation chemistry, site 
of conjugation, size of conjugating moiety and the number of conjugating moieties. 
For example, protein activity can be reduced by PEG conjugation near or at the 
receptor-binding site. Fee has shown as five-fold decrease in antibody binding 
affinity by conjugating at cysteine residues compared to non-conjugated antibodies 
(Fee, 2007). This reduction in activity is thought to be due to steric hinderance from 
the conjugated moiety (Luxon et al., 2002b; Subramanian et al., 2007).   
For the kinetic and affinity analysis, different concentrations of IgG, Fab and 
PEG20-Fab were allowed to flow over the chip with the corresponding immobilised 
ligand. For bevacizumab the concentration range was from 0.5 μM to 0.015625 μM 
and for Fabbeva the range was from 1.0 μM to 0.0625 μM (Figure 4-51 A and B). 
While for anti-rat albumin IgG the concentration range used for kinetics analysis was 
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from 0.167 μM to 0.0209 μM and for Fabalb was from 0.5 μM to 0.03125 μM (Figure 
4-52 A and B). PEG20-Fabbeva (range of 0.5 μM to 0.03125 μM, VEGF, 110 RU, 
Figure 4-51 C) and PEG20-Fabalb (0.5 μM to 0.03125 μM, rat albumin, 72 RU, Figure 
4-52 C) were also examined to calculate their kinetic constants. The concentration of 
the bevacizumab derivatives and anti-rat albumin derivatives were calculated from 
Bradford assay and UV (A280 nm) respectively, with respect to protein molecular 
weight. The kinetic fitting curves and residual plots of bevacizumab derivatives and 
anti-rat albumin derivatives were calculated using a 1:1 binding model. The fitting 
parameters were determined to ensure the kinetic rate constants and binding data 
achieved were significant and within the acceptable ranges.  
The residual plots (Figure 4-51 A-C) of the bevacizumab derivatives suggested 
that there was no difference between the experimental curve (coloured curves) and 
the fitted cube (black curve) when applying the 1:1 binding model as it scattered 
around zero. The Chi
2
 values were <1 suggesting a good fit (Table 4–3). The SE 
value of Ka and Kd for bevacizumab, Fabbeva and PEG20-Fabbeva were less than two 
orders of magnitude for the Ka and Kd values (Table 4–3). The experimental Rmax 
achieved for the bevacizumab samples was lower than the immobilisation level for 
VEGF (110 RU) and the theoretical Rmax (76 RU). If a greater experimental Rmax had 
been achieved for the bevacizumab samples, it would suggest that the 1:1 binding 
model was not fitting or that there were impurities within the analyte samples. The tc 
values were greater than 10
9
 indicating that no mass transfer was observed within the 
bevacizumab samples kinetic analysis (Table 4–3). As the kinetic analysis 
parameters (Chi
2
, SE, Rmax and tc) achieved for the bevacizumab samples were 
within the acceptable ranges, therefore the kinetic analysis data achieved could be 
taken as valid (Table 4–3). The kinetic and affinity analysis was conducted twice for 
bevacizumab and three times for Fabbeva and PEG20-Fabbeva, the average Ka, Kd and 
KD achieved can be seen in Table 4–4. 
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Table 4–3. Kinetic constants and parameters of bevacizumab and its derivatives using the 
VEGF immobilised chip (110 RU) 
Sample 
ka 
(×104  
M
-1
 
s
-1
) 
SE (ka) 
kd 
(s
-1
) 
SE (kd) 
KD 
×10
-
9
(M) 
Rmax 
SE 
(Rmax) 
Chi
2
 tc 
Bevacizumab 6.77 2.50×10
2
 
2.25×10
-
4
 
2.40×10
-
6
 
3.40 21.9 0.047 0.569 6.63×10
15
 
Fabbeva 2.81 54 
1.54×10
-
4
 
1.40×10
-
6
 
5.47 23.02 0.024 0.308 2.83×10
14
 
PEG20-
Fabbeva 
2.23 52 
1.73×10
-
4
 
1.70×10
-
6
 
7.78 20.57 0.026 0.5 1.33×10
15
 
 
The kd represents the strength in the interactions between the antibody and 
antigen, where a slower dissociation rate (smaller kd value) results in a stronger 
binding interaction between analyte and ligand. While, a smaller ka value is related to 
a slower association rate, thus there is less binding between analyte and ligand. 
Therefore ka and kd allow a great insight into the behaviour of the antibody fragment 
and how conjugation affects it.  
Fabbeva and PEG20-Fabbeva were observed to have a slower ka compared to 
bevacizumab. This could be due to the monovalent nature of Fabbeva and PEG20-
Fabbeva when compared to bevacizumab. However, Fabbeva and PEG20-Fabbeva both 
displayed faster dissociation rates compared to bevacizumab, 6.23 ×10
-4
 s
-1
 and 6.04 
×10
-4
 s
-1
 respectively. These results show how the PEG20 bis-sulfone 1 conjugation to 
the disulfide interchain did not affect the binding of the Fabbeva to VEGF.  
Table 4–4. Average kinetic constants and parameters of bevacizumab and its derivatives 
using the VEGF immobilised chip (110 RU). 
Sample 
ka 
(×10
4 
M
-1
 s
-1
) 
kd 
(×10
-4
 s
-1
) 
KD 
 (×10
-9
 M) 
n 
Bevacizumab 6.70 ± 0.10 2.24 ± 0.02 3.34 ± 0.08 2 
Fabbeva 2.51± 0.32 1.55 ± 0.10 6.23 ± 0.67 3 
PEG20-Fabbeva 2.38 ± 0.30 1.53 ± 0.20 6.04 ± 1.49 3 
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Figure 4-52. The fitting curve and residual plot applying the 1:1 fitting model of A) 
bevacizumab, B) Fabbeva, C) PEG20-Fabbeva.  
 
A) IgGbeva 
B) Fabbeva 
C) PEG20-Fabbeva 
  
255 
 
Figure 4-53. The fitting curve and residual plot using the 1:1 fitting model of A) anti-rat 
albumin IgG, B) Fabalb and C) PEG20-Fabalb. 
IgGalb 
Fabalb 
PEG20-Fabalb 
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The residual plots (Figure 4-52 A-C) of the anti-rat albumin derivatives 
suggested that there was no difference between the experimental curve (coloured 
curves) and the fitted cube (black curve) when applying a 1:1 binding model as it 
scattered around zero. The Chi
2
 values achieved for anti-rat albumin IgG, Fabalb and 
PEG20-Fabalb were below 1, showing the 1:1 binding model is a good fit to the data 
obtained (Table 4–5). The experimental Rmax achieved for the anti-rat albumin IgG 
samples were lower than the immobilisation level for rat albumin (72 RU) and the 
theoretical Rmax (130 RU), showing that the samples fit to the 1:1 binding model 
(Table 4–5). The tc values were greater than 109 indicating that no mass transfer was 
observed within the anti-rat albumin samples kinetic analysis (Table 4–5). As the 
kinetic analysis parameters (Chi
2
, SE, Rmax and tc) achieved for the anti-rat albumin 
samples were within the acceptable ranges, therefore the kinetic analysis data 
achieved could be taken as valid (Table 4–5). The average kinetic and affinity 
analysis for anti-rat albumin IgG (n=1), Fabalb (n=4) and PEG20-Fabbeva (n=3) can be 
seen in Table 4–6.  
Table 4–5. Kinetic constants and parameters of anti-rat albumin IgG and its derivatives 
using the rat albumin immobilised chip (72 RU). ND=not determine as data lost. 
Sample 
ka 
(×104 
M
-1
 s
-1
) 
SE 
(ka) 
kd 
(s
-1
) 
SE 
(kd 
×10
-6) 
KD  
(M)  
Rmax 
SE 
(Rmax) 
Chi
2
 tc 
anti-rat 
albumin 
IgG 
3.56  ND 4.33×10
-5
 ND 
1.22 
×10
-9
 
2.426 ND 0.029 
1.79 
×10
18
 
Fabalb 3.02  65 2.61×10
-4
 1.00 
8.66 
×10
-9
 
48.8 0.059 0.96 1.50×10
23
 
PEG20-
Fabalb 
1.92 49 2.91×10
-4
 1.30 
15.1 
×10
-8
 
26.9 0.043 0.14 2.16×10
15
 
 
For the polyclonal anti-rat albumin IgG (Table 4–6), a slower association and 
dissociation was observed compared to monoclonal bevacizumab (Table 4–4). The 
association rate for Fabalb was found to be similar to anti-rat albumin IgG, but Fabalb 
was found to have a slower dissociation rate compared to anti-rat albumin (Table 4–
6). This slower dissociation rate for Fabalb was thought to be due to the monovalent 
binding to rat albumin compared to anti-rat albumin IgG. PEG20-Fabalb was found to 
have a much slower association compared to both Fabalb and anti-rat albumin IgG. 
However, PEG20-Fabalb was found to have a slower dissociation rate than anti-rat 
albumin IgG but a comparable dissociation rate than Fabalb (Table 4–6). The 
association rate for PEG20-Fabalb (1.92 ×10
4 
M
-1 
s
-1
) is slower compared to both Fabalb 
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(3.02 ×10
4
 M
-1 
s
-1
) and anti-rat albumin IgG (3.56 ×10
4
 M
-1 
s
-1
, Table 4–6). This 
result implies that the strength of binding to rat albumin was affected by the 
interchain disulfide conjugation. This is quite different to the findings for PEG20-
Fabbeva, where the ka and kd were not changed drastically by disulfide conjugation 
(Table 4–4). This is most likely due to the polyclonal nature of Fabalb, therefore it can 
be determined that the binding affinity has been retained. However, the exact binding 
affinity is difficult to determine due to the polyclonal nature of the antibody, where 
there are many different binding and rebinding effects. With PEG-Fabalb there may 
be effects from PEG shielding, and the lack of bivalency compare to IgG. 
Table 4–6. Average kinetic constants and parameters of anti-rat albumin IgG and its 
derivatives using the rat albumin immobilised chip (72 RU) 
Sample 
ka 
(×10
4 
M
-1
 s
-1
) 
kd 
(×10
-4 
s
-1
) 
KD (M) n 
anti-rat albumin 
IgG 
3.56 4.33 ×10
-5
 1.22 ×10
-9
 1 
Fabalb 3.13 ± 0.13 2.41 ± 0.22 7.72 ± 0.70 ×10
-9
 4 
PEG20-Fabalb 1.66 ± 0.47 3.34 ± 0.56 22.2 ± 1.15 ×10
-8
 3 
 
4.2.9.3 Kinetic and affinity analysis of novel IFN-PEG-Fab heterodimers 
The binding properties for the Fabs in the heterodimers, IFN-PEG20-Fabbeva and IFN-
PEG20-Fabalb were then evaluated by SPR. The concentration ranges tested for IFN-
PEG20-Fabbeva and IFN-PEG20-Fabalb were 1.0 μM to 0.0625 μM and 0.125 μM to 
0.0078125 μM respectively. The residual plots (Figure 4-54) achieved for IFN-
PEG20-Fabbeva and IFN-PEG20-Fabalb suggested that the experimental curves 
(coloured curves) fitted in the 1:1 binding model curves (black curves) well, as the 
residual plots were scattered around zero, except for the highest IFN-PEG20-Fabalb 
concentration tested (Figure 4-54 B). The Chi
2
 value achieved for IFN-PEG20-Fabbeva 
was less than 1 suggesting a good fit to the 1:1 binding model (Table 4–7). However, 
the Chi
2
 value for IFN-PEG20-Fabalb was greater than one, suggesting it does not fit 
the 1:1 binding model well, this is most likely due to the polyclonal nature of Fabalb 
within the heterodimer. Where Fabalb is binding to different epitopes on rat albumin. 
However, the experimental Rmax (43.17 RU, Table 4–7) achieved for IFN-PEG20-
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Fabalb was less than the Rmax achieved, suggesting the IFN-PEG20-Fabalb analysis fits 
with the 1:1 binding model.  
 
Figure 4-54. The fitting curve and residual plot using the 1:1 fitting model of A) IFN-PEG20-
Fabbeva and B) IFN-PEG20-Fabalb.  
The tc values were greater than 10
9
 for both heterodimeric molecules 
indicating that no mass transfer was observed within the samples kinetic analysis 
(Table 4–7). As the kinetic analysis parameters (Chi2, SE, Rmax and tc) achieved for 
IFN-PEG20-Fabbeva were within the acceptable ranges, the kinetic analysis data 
achieved could be taken as valid (Table 4–7). As the SE, Rmax and tc parameters were 
within the acceptable ranges for IFN-PEG20-Fabalb, the data achieved was viewed as 
preliminary. The kinetic and affinity analysis was conducted three times for IFN-
A) IFN-PEG20-Fabbeva 
B) IFN-PEG20-Fabalb 
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PEG20-Fabbeva and two times for IFN-PEG20-Fabalb, the average Ka, Kd and KD 
achieved can be seen in Table 4–7.  
Table 4–7. Kinetic constants and parameters achieved by IFN-PEG20-Fabbeva and IFN-
PEG20-Fabalb. The affinity is achieved by Fabalb and Fabbeva within the heterodimers.  
Sample 
ka 
(M
-1
 
s
-1
) 
SE 
(ka) 
kd 
(s
-1
) 
SE (kd) KD (M) Rmax 
SE 
(Rmax) 
Chi
2
 tc 
IFN-
PEG20-
Fabbeva 
1.05 
×10
4
 
39 
1.55×10
-
4
 
1.90×10
-
6
 
14.7×10
-
8
  
12.01 0.059 0.0835 1.04×10
15
 
IFN-
PEG20-
Fabalb 
1.68× 
10
5
 
4.7× 
10
2
 
2.48×10
-
4
 
1.50×10
-
6
 
1.47 
×10
-8
 
43.17 0.067 1.88 
3.12 
×10
17
 
 
The results show that both IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb retained 
binding to their respective antigens. It was observed that the dissociation rate of IFN-
PEG20-Fabbeva was similar to Fabbeva and PEG20-Fabbeva, suggesting conjugating the 
interchain disulfide of Fabbeva does not change the dissociation rate or binding of 
Fabbeva to VEGF. This is in agreement with the finding by Khalili and co-workers 
(Khalili et al., 2012, 2013). This observation was also found for IFN-PEG20-Fabalb 
where the dissociation rate was similar to Fabalb binding to rat albumin. However, it 
was noted that the dissociation rate for PEG20-Fabalb was not similar to those 
observed for Fabalb and IFN-PEG-Fabalb, suggesting this result needed further 
investigation. This result could be due to the sample purity, as it was difficult to 
prepare PEG20-Fabalb in good purity (§ 4.2.7).  
Nonetheless, the trend observed that conjugation to the interchain disulfide 
does not affect the strength of binding to the antigen (kd) (Khalili et al., 2012; Yang 
et al., 2014). Interestingly, it has also been found that the dissociation rate of Fabbeva 
did not vary with different sizes of PEG bis-sulfone 1 (Khalili et al., 2012). This 
could possibly be due to the site-specific nature of disulfide conjugation meaning the 
PEG molecule is away from the binding region. Further, Fabbeva-PEG-Fabbeva 
constructs were found to have a decreased dissociation rate, showing a tighter 
interaction between antibody and antigen (Khalili et al., 2013). This finding was 
thought to be a reflection of the bivalent nature of the construct and the flexibility of 
the PEG di(bis)sulfone 4 linker allowing for better binding to the antigen, compared 
to bevacizumab IgG. Interestingly, when calculating the retained ka for IFN-PEG20-
Fabbeva and IFN-PEG20-Fabalb in comparison to Fabbeva and Fabalb respectively, both 
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heterodimers retained ~54% association (Table 4–8). While, the dissociation constant 
for IFN-PEG20-Fabbeva (1.79 ± 0.30 ×10
-4
 s
-1
) and IFN-PEG20-Fabalb (2.51 ± 0.04 
×10
-4
 s
-1
) were found to increase slightly compared to Fabbeva and Fabalb (Table 4–8). 
The fast dissociation rates observed for Fab vs. IgG is thought to be due to i) 
monovalent binding of Fab and ii) the mass difference between the two molecules, 
where the Fab can diffuse from the bulk to the sensor surface more quickly than IgG. 
Where IgG is bivalent and allows rebinding to the ligand. Thus, the faster 
dissociation rates observed for the IFN-PEG20-Fab heterodimers are thought to be 
due to the monovalent binding of the Fab to the antigen, but also possibly the 
conjugation to the PEG may aid the diffusion from the bulk to the sensor surface. 
Nonetheless, this data suggests that the novel IFN-PEG20-Fabbeva and IFN-PEG20-
Fabalb heterodimer conjugates have retained their binding affinities to their antigens.  
Table 4–8. Average kinetic constants and parameters achieved for IFN-PEG20-Fabbeva and 
IFN-PEG20-Fabalb and controls (Fab and PEG20-Fab). Association (ka) was found to be 
similar between Fab, PEG-Fab and IFN-PEG-Fab heterodimers suggesting retained 
association. However, dissociation rates were found to be faster, possibly due to the 
monovalent nature of Fabs vs. IgG.  
Sample 
ka 
(M
-1
 s
-1
) 
kd 
(×10
-4
 s
-1
) 
KD (M) 
Fabbeva 2.51± 0.32 ×10
4
 1.55 ± 0.10 6.23 ± 0.67×10
-9
 
PEG20-Fabbeva 2.38 ± 0.30 ×10
4
 1.53 ± 0.20 6.04 ± 1.49×10
-9
 
IFN-PEG20-Fabbeva 1.37 ± 0.50 ×10
4
 (54%) 1.79 ± 0.30  1.36 ± 0.24×10
-8
 
Fabalb 3.13 ± 0.13 ×10
4
 2.41 ± 0.22 7.72 ± 0.70×10
-9
 
PEG20-Fabalb 1.66 ± 0.47 ×10
4
 3.34 ± 0.56 2.22 ± 1.15×10
-8
 
IFN-PEG20-Fabalb 1.68 ×10
5
 (53.7%) 2.51 ± 0.04 1.49 ± 0.03×10
-9
 
 
To assess if the binding affinities of the IFN-PEG20-Fabbeva and IFN-PEG20-
Fabalb conjugates were statistically different from their respective controls, a one-way 
ANOVA was conducted on the KD data achieved for the conjugates. As previously, 
the one-way ANOVA was used in conjunction with a post hoc test, the Tukey’s test. 
The assumptions of the Tukey’s test are that i) the observations being tested are 
independent and ii) there is equal variation across the sets of data (Dytham, 2011).  
It was found that the equilibrium dissociation constant (KD) IFN-PEG20-Fabbeva 
was statistically different from both Fabbeva and PEG20-Fabbeva (Figure 4-55). This 
statistical difference between the heterodimers and controls could be due to the 
addition of the IFN molecule on the PEG20 di(bis)sulfone 4. As, IFN-PEG20-Fabalb 
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was also shown to be statistically different from both Fabalb and PEG20-Fabalb (Figure 
4-56). The KD is calculated as Kd/Ka. Therefore, the KD is statistically different to 
PEG-Fab and IFN-PEG-Fab most likely due to the association rates slowing, 
therefore differing KD are achieved for both Fabalb and Fabbeva conjugates. 
 
Figure 4-55. One-way ANOVA conducted on KD data achieved for bevacizumab samples, 
statistical different samples are marked with red stars (*). IFN-PEG20-Fabbeva is shown to be 
statistically different from Fabbeva and PEG20-Fabbeva. 
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Figure 4-56. One-way ANOVA conducted on KD data achieved for anti-rat albumin 
samples, statistical different samples are marked with red stars (*). IFN-PEG20-Fabalb is 
shown to be statistically different from Fabalb and PEG20-Fabalb. 
4.2.9.4 In vitro cell based evaluation of IFN-PEG20-Fab heterodimers 
To assess the retained biological activity of the interferon component of the IFN-
PEG20-Fabbeva and IFN-PEG20-Fabalb heterodimers, two in vitro assays were used. An 
antiviral and an antiproliferative assay were used. Since cell based assays are 
inherently variable (Meager, 2006) efforts for their optimisation are described in 6.2-
6.3 Appendices I and II. NIBSC IFNα-2a was used as control in these assays. As 
described (§3.3.6.1), NIBSC IFNα-2a allows for uniform reporting of IFN potency in 
universally accepted International Units (IU) (Meager, 2006). Therefore, direct 
bioactivity comparisons can be made between IFN conjugates prepared and tested 
from different laboratories.  
First, IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb were subjected to testing in the 
antiviral assay. The raw data are plotted as shown for both IFN-PEG20-Fabbeva and 
IFN-PEG20-Fabalb (Figure 4-57). The effective dose at 50% (ED50) was calculated 
into specific activity (MIU/mg) using the calculations in 6.1 Appendix I. As 
discussed previously (§3.3.6.1), the accepted range for the experiments conducted 
with NIBSC IFNα-2a was 200-300 MIU/mg allowing for 20% variation or %CV in 
the experiments conducted. 
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Figure 4-57. Representative graph of NIBSC IFN α-2a, IFN-PEG20-Fabbeva and IFN-PEG20-
Fabalb with the ED50 (Kd) for calculating the specific activity (MIU/mg). 
Full sigmoid curves were achieved for NIBSC IFN α-2a and IFN-PEG-Fabbeva, 
however for IFN-PEG20-Fabalb a full sigmoid curve was not achieved. Further, a 10-
fold lower Kd was observed for IFN-PEG20-Fabalb than IFN-PEG-Fabbeva. It was 
thought this stunted curve observed for IFN-PEG20-Fabalb was due to the Fabalb 
binding to albumin within the media composition. The antiviral assay was conducted 
three times for both IFN-PEG20-Fabalb and IFN-PEG-Fabbeva, in all cases the stunted 
curve for IFN-PEG20-Fabalb was observed (Figure 4-57).  
In an attempt to prepare a full curve for IFN-PEG20-Fabalb, different media 
compositions were investigated (DMEM+FCS, DMEM-FCS, DMEM+RPMI, 
RPMI-FCS) to conduct the antiviral assay with which did not contain albumin. As a 
positive control DMEM+FCS was also tested. The antiviral assay was conducted 
using NIBSC IFN α-2a in order to assess how the different media compositions 
affected the antiviral assay results, and if an alternative media composition could be 
used to test the bioactivity of IFN-PEG20-Fabalb.  
As discussed previously, specific activity range for NIBSC IFNα-2a is 254 
MIU/mg. Therefore, the accepted range for the experiments conducted with NIBSC 
IFNα-2a was 200-300 MIU/mg ± 20% CV. Thus, NIBSC IFN α-2a achieves a Kd 
(ED50) between 0.5-1. Using DMEM+FCS, NIBSC IFNα-2a achieved an ED50 of 
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0.53 (Figure 4-58), which is within the expected range. When NIBSC IFNα-2a was 
in the presence of different media compositions, an increase in the Kd was observed. 
The shift observed was from 0.5 (positive control) to ~2.0 (different media 
compositions) (Figure 4-58). The higher Kd’s observed were for all media 
compositions with no FCS, suggesting no media with no FCS would be suitable for 
conducting the antiviral assay to test IFN-PEG20-Fabalb. For assessing the activity of 
IFN-PEG20-Fabalb, possibly different cell lines e.g. 2D9 cells could be investigated or 
the antiviral assay could be optimised with an alternative media e.g. serum free 
media for testing the biological activity of IFN-PEG20-Fabalb (Meager, 2006). 
 
Figure 4-58. Graph and table of NIBSC IFN α-2a antiviral activity in different media types 
(DMEM+FCS, DMEM-FCS, DMEM+RPMI, RPMI-FCS). A shift in Kd for NIBSC IFN α-
2a was observed when conducting the antiviral assay with different media compositions. 
The mean specific activity achieved for the novel IFN-PEG20-Fabbeva was 7.60 
± 2.56 MIU/mg (3.3% retained activity; n=3) (Table 4–9). For His8IFN α-2a, the 
mean specific activity achieved was 231.31 ± 10.95 MIU/mg (n=3) (Table 4–9). The 
mean specific activity achieved for PEG20-IFN was 3.95 ± 1.69 MIU/mg (1.7% 
retained activity, n=3) (Table 4–9). IFN-PEG20-IFN dimer achieved a mean specific 
activity of 2.12 ± 0.64 MIU/mg (0.94% retained activity, n=4) (Table 4–9). Despite 
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having a reduced antiviral activity all of the disulfide conjugates achieved complete 
inhibition of cell death from EMCV infection at saturating doses.  
Table 4–9. Summary of in vitro specific activity values achieved and n numbers for disulfide 
conjugated IFN-PEG20-Fabbeva, IFN-PEG20-IFN conjugates and controls. The IFN-PEG20-
Fabbeva heterodimer has retained the greatest specific activity, followed by disulfide 
conjugated PEG20-IFN, IFN-PEG20-IFN when compared to native His8IFN α-2a.  
Value His8IFN α-2a PEG20-IFN IFN-PEG20-IFN IFN-PEG20-Fabbeva 
Mean specific 
activity 
(MIU/mg) 
231.31 3.95 2.12 7.60 
ST.DEV of 
specific activity 
(MIU/mg) 
10.95 1.69 0.64 2.56 
Retained activity 
(%) 
100 1.7 0.94 3.3 
n number 3 3 4 3 
 
To better compare the specific activity achieved between the novel IFN-PEG20-
Fabbeva heterodimer and controls, the achieved specific activities of all the disulfide 
conjugated IFN species were plotted onto a bar graph (Figure 4-59). It can be seen 
that the order of activity is IFN with 100% retained activity, followed by IFN-PEG20-
Fabbeva (3.3%), PEG20-IFN (1.7%) and IFN-PEG20-IFN (0.94%) (Figure 4-59). 
Interestingly the IFN-PEG20-Fabbeva had greater retained activity than the IFN-
PEG20-IFN homodimer. This could be possibly due to the 1:1 binding required 
between IFN and IFNAR receptor, therefore by conjugating two IFNs together the 
second IFN is unable to bind to its own receptor or both IFNs are trying to bind to 
one receptor and impeding one-another. However, the data shows that the novel IFN-
PEG20-Fabbeva has retained activity. Overall, the IFN disulfide conjugates have 
reduced activity compared to native IFN. It is well documented in literature that 
conjugating proteins to PEG results in a reduction in activity (Grace et al., 2005). 
Analogous to conjugating PEG to a protein, conjugating (or fusing) two 
proteins together will invariably reduce the binding properties, and hence the 
activity, of each protein. For example, the IFN within Albuferon™ (recombinantly 
expressed Albumin-IFN fusion) retained 2% activity (Subramanian et al., 2007). The 
length, flexibility and non-covalent properties of the linker is thought to be an 
important consideration to help ensure the two protein moieties can maintain their 
  
266 
binding characteristics (Arai et al., 2001; Shewmake et al., 2008). It is also reported 
that longer flexible linkers could lead to greater retained binding affinity (Reeves et 
al., 2011; Shewmake et al., 2008). From the results achieved, it is thought that with 
site-specific conjugation and the linker length and the flexibility of the PEG in the 
PEG20 di(bis)sulfone 4, that allowed for retained activity of IFN. 
 
Figure 4-59. Specific activity (MIU/mg) of IFN, PEG20-IFN, IFN-PEG20-IFN, IFN-PEG20-
Fabbeva tested within the antiviral (A549/EMCV) assay. IFN-PEG20-Fabbeva retained activity 
when assayed in the antiviral assay. 
IFN is a pleiotropic protein; therefore to better judge the specific activity of the IFN-
PEG20-Fabbeva heterodimer and controls, the disulfide-conjugates were subjected to 
an in vitro antiproliferative assay. As outlined in §3.3.6.4, Daudi cells were used to 
assess the antiproliferative activity of IFN-PEG20-Fabbeva. The antiproliferative assay 
was optimised as outlined in 6.1 Appendix II, in order to ensure the data achieved 
was accurate and reproducible. As in the antiviral assay, NIBSC IFN α-2a was run on 
every plate as a control.  
 Raw data was plotted as shown for IFN-PEG20-Fabbeva (Figure 4-60 B). The 
effective dose at 50% (ED50) was calculated from the normalised graph (Figure 4-60 
B) into specific activity (MIU/mg) using the calculations in 6.1 Appendix I.  
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Figure 4-60. Representative graphs of A) Transformed plot of IFN-PEG20-Fabbeva, B) normal 
plot of IFN-PEG20-Fabbeva, C) transformed plot of IFN-PEG20-Fabalb and D) normal plot of 
IFN-PEG20-Fabalb achieved within the antiproliferative assay. IFN-PEG20-Fabalb can be seen 
to have achieved a stunted curve compared to IFN-PEG20-Fabbeva, this is thought to be due to 
the Fabalb binding to components within the media and thus not achieving a full sigmoid 
curve. 
 IFN-PEG20-Fabalb can be seen to have achieved a stunted sigmoid curve 
compared to IFN-PEG20-Fabbeva (Figure 4-60), this is thought to be due to the Fabalb 
binding to components within the media and thus not achieving a full sigmoid curve. 
This was also found within the antiviral assay. Therefore, no accurate specific 
activity data could be achieved for IFN-PEG20-Fabalb, however, it can be determined 
that the IFN within the heterodimer has retained some activity being as a small curve 
was achieved. 
The IFN-PEG20-Fabbeva heterodimer achieved a specific activity of 34.72 ± 
6.30 MIU/mg (n=2) and retained 10.5% activity (Table 4–10). The mean specific 
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activity achieved for IFN was 329.36 ± 97.98 MIU/mg (n=5, Table 3–5). The mean 
specific activity of PEG20-IFN was 5.13 ± 1.44 MIU/mg (1.56% retained activity, 
n=4) (Table 4–10). A specific activity of 0.81 ± 0.09 MIU/mg (0.25% retained 
activity, n=3) (Table 4–10) was achieved for IFN-PEG20-IFN. This shows that the 
IFN-PEG20-Fabbeva retained antiproliferative activity. 
Table 4–10. Summary of antiproliferative activity (MIU/mg) achieved for IFN-PEG20-
Fabbeva heterodimer and controls (IFN, PEG20-IFN and (IFN-PEG20-IFN) 
Sample Specific Activity 
(MIU/mg) 
Percentage (%) 
retained activity 
n number 
His8IFN α-2a 329.36 ± 87.98 100 5 
IFN-PEG20-IFN 0.81 ± 0.09 0.25 3 
PEG20-IFN 5.13 ± 1.44 1.56 4 
IFN-PEG20-Fabbeva 34.72 ± 6.30 10.5 2 
 
To better compare the antiproliferative activity of the heterodimer to IFN-
PEG20-IFN and controls, all of the disulfide conjugates were plotted on a bar graph 
(Figure 4-61). It can be seen that the order of highest activity precedes as follows 
IFN (100%), IFN-PEG20-Fabbeva (10.5%), PEG20-IFN (1.56%) and IFN-PEG20-IFN 
(0.25%). Interestingly, IFN-PEG20-Fabbeva has greater activity than PEG20-IFN. The 
greater retained antiproliferative activity of IFN-PEG20-Fabbeva could be due to the 
flexibility of the linker allowing IFN to bind more effectively to the IFNAR and start 
the JAK/STAT pathways resulting in antiproliferative activity (Bekisz et al., 2010). 
Therapeutically, IFN-PEG20-Fabbeva could be used as a treatment for renal cell 
carcinoma, where IFN is currently used as an antiproliferative agent, thus these 
results show that IFN within the IFN-PEG20-Fabbeva conjugate has retained activity.  
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Figure 4-61. Specific activity (MIU/mg) of IFN, PEG20-IFN, IFN-PEG20-IFN, IFN-PEG20-
Fabbeva within the antiproliferative (Daudi cell) assay. IFN-PEG20-Fabbeva retained activity 
when assayed in the antiviral assay. 
 To best determine the activity of the novel IFN-PEG20-Fabbeva in comparison 
to IFN-PEG20-IFN and controls (IFN and PEG20-IFN) both the antiviral and 
antiproliferative data achieved were compared. Conducting both assays to assess the 
activity of IFN biologics is well documented in literature (Chang et al., 2009b; 
Subramanian et al., 2007). The antiviral and antiproliferative results suggest the 
order of activity achieved for the PEG and bevacizumab derived conjugates to be 
IFN, IFN-PEG20-Fabbeva, PEG20-IFN and IFN-PEG20-IFN (Table 4–11). 
Interestingly, the IFN-PEG20-Fabbeva conjugate was found to be more active in both 
the antiviral and antiproliferative assays than the PEG20-IFN conjugate. This is 
possibly due to the linker length and flexibility of the linker, allowing IFN to better 
bind to the IFNAR. As it is well documented in literature that linker length and 
flexibility are important factors in affecting protein activity (Arai et al., 2001; 
Shewmake et al., 2008). Reduced activity of PEG conjugated proteins is well 
reported in literature. The reduction in protein activity is associated with the steric 
hinderance from the PEG. The results obtained suggest that the PEG20 di(bis)sulfone 
4 can be used to efficiently link two proteins together, where the retained activity of 
IFN is greater than that of PEG20-IFN. The greater retained activity observed in both 
the antiviral and antiproliferative assays could possibly be the result of the smaller 
solution structure of the PEG20 di(bis)sulfone 4 compared to PEG20 bis-sulfone 1, 
which has been reported (Khalili et al., 2013).  
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Table 4–11. Summary table of antiviral and antiproliferative specific activity data achieved 
for IFN-PEG20-Fabbeva, IFN-PEG20-IFN and monoPEGylated controls  
Sample Antiviral specific 
activity (MIU/mg) 
Antiproliferative 
specific activity 
(MIU/mg) 
His8IFN α-2a 231.31 ± 10.95 329.36 ± 87.98 
IFN-PEG20-IFN 2.17 ± 0.77 0.81 ± 0.09 
PEG20-IFN 3.95 ± 1.69 5.13 ± 1.44 
IFN-PEG20-Fabbeva 7.60 ± 2.56 34.72 ± 6.30 
4.3 Conclusion 
The aim of this chapter was to investigate the use of PEG20 di(bis)sulfone 4 prepared 
by synthesis route 2 (§3.2.1) to make IFN-PEG20-Fab heterodimers. It was hoped that 
both IFN and Fabalb/Fabbeva would retain functionality once conjugated to PEG20 
di(bis)sulfone 4 and that the final heterodimers would be prepared in good yield and 
purity.  
 The data achieved for this chapter suggests that PEG20 di(bis)sulfone 4 can be 
used successfully as a linker/spacer to prepare heterodimers in good yield. The IFN-
PEG20-Fabalb heterodimer was prepared as a possible treatment for hepatitis C, which 
could possibly ‘piggy’ back on albumin to last longer in circulation than current 
PEGylated treatments. To investigate the IFN-PEG20-Fabalb heterodimer further the 
activity of the IFN-PEG20-Fabalb would need to be determined. Possibly using serum 
free media within cell based assays or using BIAcore where the binding of IFN to 
IFNAR could be quantified without the need for the use of media. As anti-rat 
albumin Fab was used, the PK properties of the IFN-PEG20-Fabalb could be compared 
to PEG20-IFN and IFN-PEG20-Fabbeva in rats to determine if the PK properties of the 
heterodimer are prolonged due to the Fabalb ‘piggy’ backing onto circulating albumin 
or if the half-life is due to the size of the heterodimer.  
 For determining the binding affinity properties, IFN-PEG20-Fabalb was 
compared to PEG20-Fabalb, to understand how the addition of IFN affected the 
binding properties of Fabalb to rat albumin. PEG20-Fabalb was found to be very 
difficult to produce and purify. SE chromatography was used to purify PEG20-Fabalb 
from what was thought to be PEG20-half Fabalb. This could possibly be due to the 
polyclonal nature of the anti-rat albumin Fab. Therefore, if IFN-PEG20-Fabalb was to 
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be further investigated, possibly expressing the anti-rat albumin IgG could be 
investigated as a monoclonal antibody to produce homogenous products.  
 To investigate the IFN-PEG20-Fabbeva heterodimer as a possible treatment for 
RCC, two areas would need to be further investigated, i) a relevant model for RCC, 
ii) PK properties. The relevant model for RCC where the IFN-PEG20-Fabbeva 
heterodimer could be tested next to bevacizumab and IFN given separately. This 
would be interesting to see to determine if: i) the activity of the IFN-PEG20-Fabbeva 
heterodimer is sustained over a longer period than that of bevacizumab, ii) the IFN-
PEG20-Fabbeva heterodimer is a more direct therapy for RCC and if this results in 
reduced cytokine related cytotoxicity. A possible model for determining if IFN-
PEG20-Fabbeva heterodimer can effectively reduce tumours of RCC is using a patient 
derived model, where a piece of tumour from a RCC patient is inserted into 
immunocompetent humanised mice. A study could then be conducted to determine if 
different doses of IFN-PEG20-Fabbeva and controls (IFN + Fabbeva, IFN-PEG20-Fabalb) 
where successful in reducing or eradicating the tumour. Alternatively, a 3D tumour 
model could be used to assess the activity of the IFN-PEG20-Fabbeva conjugate prior 
to in vivo studies and aid the doses used. 3D in vitro models are advantageous as they 
are more realistic as to the cell environment found in the body, compared to 1D in 
vitro cell cultures.  
 To further develop the use of PEG20 di(bis)sulfone 4 to heterodimeric 
molecules, the scalability of the approach would need to be improved. For example if 
Fabs were to be conjugated at one end of the linker, a more scalable approach could 
be to express the Fab’s in mammalian cells (NS0, Sp20, CH0 cells) rather than the 
digestion of whole IgGs, this could afford greater yields.  
 Further, the PEG20 di(bis)sulfone 4 when made using synthesis route 2 
produced higher yields of IFN-PEG-Fab heterodimers. Therefore, if further 
investigations into the reagent purity, purity of the starting materials and synthesis 
route was conducted, possibly the conversions and final yields of homodimers and 
heterodimers could be vastly improved and could produce a scalable approach in 
making multifunctional protein therapeutics. An alternative approach could be to 
develop a heterobifunctional PEG reagent with a one-pot-reaction, whereby one 
linker end could be conjugated to at a higher pH than the other linker end. This 
would remove the need for a 2-step conjugation approach and 2-CIEC steps, making 
multifunctional proteins an easier and scalable approach.  
  
272 
 As discussed previously, the PEG20 di(bis)sulfone 4 is a flexible linker as it 
can be used to react with both polyhistidine tags and disulfide bridges. Therefore, is a 
very flexible approach. An interesting conjugate to make and test the functionality of 
would be a His8IFN-PEG-Fab conjugate. This approach would combine the higher 
activity of His8IFN (IFN conjugated to at the polyhistidine tag) with the conjugation 
of Fab at the disulfide.  
 Additionally, the PEG MW-structure-activity relationship could be further 
investigated. As in chapter 3, different MWs were investigated to determine if the 
PEG MW affected the activity of the IFN-PEG-IFN dimers. It is reported in literature 
that PEG MW does affect the activity of the protein. However, when making the 
IFN-PEG-Fab heterodimers, only a 20 kDa PEG was used to determine if 
multifunctional proteins could be prepared using PEG20 di(bis)sulfone 4. Therefore it 
would be interesting to determine how/if PEG MW affects the functionality of the 
proteins and if this affects the conversion/yields of the multifunctional proteins. For 
example PEG MWs 10 and 20 kDa could be tested and the activity of IFN compared 
to conjugates (PEG-IFN and IFN-PEG-IFN) made in Chapter 3 using disulfide 
conjugation.  
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Table 4–12. Summary of IFN-PEG20-Fab heterodimers prepared using disulfide conjugation and relevant controls. - = not tested, ND=could not be 
determined. 
PEGylated 
conjugate 
Purification 
method 
Yield 
(%) 
Purity (%) 
AV mean 
Specific 
activity 
(MIU/mg) 
Percentage 
retained 
activity (%) 
AP mean 
Specific 
activity 
(MIU/mg) 
Percentage 
retained 
activity (%) 
KD (nm) 
His8IFN α-2a IMAC, AIEC 72 mg 100 231.31+10.95 100 329.36 ± 87.98 100 - 
PEG20-IFN CIEC 29  3.95 ± 1.69 1.7 5.13 ± 1.44 1.56 - 
IFN-PEG20-IFN CIEC, SEC 0.85  2.12 ± 0.64 0.94 0.81 ± 0.09 0.25 - 
Fabbeva Protein A 39 100 - - - - 6.23 ± 0.67 
IFN-PEG20-Fabbeva 2× CIEC 
IFN: 21 
Fabbeva: 12 
89 7.60 ± 2.56 3.3 34.62 ± 6.30 10.5 13.9 ± 0.24 
PEG20-Fabbeva  CIEC  44 83 - - - - 6.04 ± 1.49 
Fabalb Protein A 42  - - - - 7.72 ± 0.70 
IFN-PEG20-Fabalb 2× CIEC 
IFN: 44 
Fabalb: 
20.5 
 ND ND ND ND 
1.49 ± 0.03 
PEG20-Fabalb SEC 28.8  - - - - 22.2 ± 1.15 
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Chapter 5 Summary of results and general conclusion 
5.1 Summary of Results 
The aim of this thesis was to determine if the homobifunctional PEG reagent 4 could 
be used to make therapeutic homodimeric and heterodimeric protein-protein 
conjugates that were based on IFN. First, IFN-PEG-IFN homodimers were prepared 
using two different site-specific conjugation methods (His-tag and disulfide). The 
PEG di(bis)sulfone 4 selectively undergoes bis-alkylation by a sequence of addition-
elimination reactions with either the two free thiols from a reduced disulfide (Figure 
1-13) or two histidine residues (Figure 1-14) within the polyhistidine tag. Site-
specific histidine conjugation takes advantage of the his-tags, which are often used in 
the purification of recombinant proteins, as it can increase expression yields and aid 
refolding (Cong et al., 2012). Disulfide conjugation utilises the interchain disulfide 
bond, without the need for engineering in cysteines (Balan et al., 2007). Often, 
uncoupled cysteines are engineered into proteins for conjugation, however this is 
technically challenging as aggregation and disulfide scrambling often occurs during 
the refolding or purification process (Doherty et al., 2005). Disulfides have been 
conjugated to using maleimide conjugation, however it has been shown that this 
reagent undergoes hydrolysis leading to dePEGylation. Critically, it has been shown 
that maleimide based conjugation undergo exchange reactions to acidic by products 
in vivo (Alley et al., 2008; Shen et al., 2012).  
Preparation of the His8IFN-PEG-His8IFN dimer and the other IFN dimers are 
examples of a recombinant-chemical conjugation approach to the preparation of 
dimeric and multifunctional proteins. IFN α and PEGylated IFN α are clinically used 
to treat Hepatitis B and C (Ahad et al., 2009). The PEG-IFNs that have been 
developed have become first line treatment and the PEGylation approach combines 
the advantages of reduced immunogenicity, increased body resistance time and 
protection from proteolytic digestion (Veronese and Morpurgo, 1999). The hope is 
that a hybrid approach to multifunctional proteins will be able to combine the 
advantages of site-specific conjugation with recombinant protein technology.  
IFN was expressed recombinantly with an 8-polyhistidine tag (§3.2.2), which 
allowed the same molecule to be used throughout this PhD project. Both the 
polyhistidine tag and the natural disulfides could be conjugated site-specifically with 
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the PEG di(bis)sulfone reagent 4. Like any thiol alkylation, the conjugation reaction 
with the protein cysteines is much more favoured than at other sites on the protein, 
including a histidine tag. Thiol conjugation only occurs if the IFN is first partially 
reduced. Without prior reduction, His-tag conjugation results. If the disulfides in IFN 
are first reduced, then conjugation to the cysteine thiols occurs.  Thus, site-specific 
his-tag and disulfide conjugation was conducted on the His8IFN α-2a to create IFN 
homodimers. It was hypothesised that the IFN dimers derived from conjugation at 
the polyhistidine tag would have greater activity than PEG-IFN conjugates, due to i) 
the site-specific nature of conjugation, reducing conjugation near or at the binding 
sites and ii) the greater number of IFNs present within the molecule which are able to 
bind to IFNAR complex. 
Assessment of the activities of the different IFN-PEG-IFN homodimers was 
performed by optimised in vitro antiviral and antiproliferative assays (6.2-
6.3Appendix II and III). Interestingly, it was found that His8IFN-PEG20-His8IFN 
retained 2.95% activity compared to 0.92% activity for IFN-PEG20-IFN (Table 3–7). 
This was thought to be due to the conjugation site. Conjugation to the polyhistidine 
tag is thought to be further away from the binding surfaces of IFN and this provides a 
conjugate with greater activity compared to the conjugation at an IFN disulfide that 
may be nearer to the IFN binding surface. The highest retained activity for IFN has 
been claimed to be at His
34
 (37% bioactivity) and the lowest retained activity was 
found at Lys
164
 (6% bioactivity) at the C-terminus of IFN (Wang et al., 2002). These 
PEG positional isomers were the result of random lysine conjugation preparing PEG-
INTRON
®
, and showed the importance of conjugation away from the binding sites 
of the protein to retain a higher activity. Consequently, conjugation to H
34
 has been 
shown to be unstable where the PEG-H
34
 bond undergoes hydrolysis in aqueous 
solution, resulting in the de-conjugation of the PEG from the protein (Pedder, 2003; 
Wang et al., 2000). This inherent instability of PEG-H
34
 bond contributes to the 
relatively short-half-life of PEG-INTRON
®
 (Pedder, 2003).  
Alterative strategies have been described to prepare protein homodimers. These 
include DNL using an AD-DDD coupling to prepare PEGylated IFN dimers (Chang 
et al., 2009b) and flexible bis-maleimide cross linkers to prepare carbonic anhydrase 
II (Mack et al., 2011). The DNL 20 kDa monoPEGylated IFN-IFN dimer was 
reported to have an antiviral activity of 10 ×10
12
 U/mmol. The activity was reported 
to be 5-fold greater than PEGASYS
®
 (Chang et al., 2009b). The His8IFN-PEG20-
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His8IFN (5.78 ± 1.62 MIU/mg) was found to be 2-fold more potent than PEGASYS
® 
(2.75 ± 0.37 MIU/mg), while IFN-PEG20-IFN (2.12 ± 0.64 MIU/mg) was found to 
have comparable activity to PEGASYS
®
. The DNL approach is a complex method, 
with several disadvantages; i) each protein/PEG molecule must be 
expressed/prepared with either the DDD or AD domain for fusing together to make 
the monoPEGylated dimer, ii) the AD and DDD peptides are ‘locked’ together by the 
cysteine residues forming a disulfide bridge, however during mild redox conditions 
during DNL conjugation some disulfides may reduce causing some proteins to 
aggregate or denature along with the AD and DDD peptides (Rossi et al., 2012). 
Further, in some cases fusion partners may have incompatible manufacturing 
properties, resulting in protein aggregation or misfolding of one of the fusion 
proteins, whilst the other partner maybe unharmed. In principle the recombinant-
chemical approach described in this thesis may be more practical to implement.  
Precursor proteins can be recombinantly prepared using the optimum expression 
system and then dimerised by site-specific conjugation using the PEG di(bis)sulfone 
4.  
It is well documented in literature that increasing PEG size correlates with 
decreasing protein activity. For example, a study found a 12 kDa monoPEGylated 
IFN was found to retain ~25% activity compared to 1.2% retained activity for the 40 
kDa monoPEGylated IFN with the antiviral assay using A549 cells (Grace et al., 
2005). Increasing PEG MW was also found to correlate with decreasing activity for 
the disulfide-conjugated IFN-PEG-IFN homodimers, PEG-IFN and (PEG)2-IFN 
conjugates. Prior to potency testing, all of the disulfide conjugated IFN products 
were subject to anti-IFN Western blot and were found to be pure. The specific 
activity achieved for IFN-PEG10-IFN was 5.99 ± 2.08 MIU/mg, whereas IFN-PEG20-
IFN achieved a specific activity of 2.12 ± 0.64 MIU/mg. Therefore the IFN-PEG10-
IFN dimer was found to retain a 2-fold greater activity compared to corresponding 
IFN-PEG20-IFN  
As discussed, enough of the different IFN-PEG-IFN dimers were prepared to 
characterise them in terms of their purity, identity and biological potency (Chapter 
3). The His8IFN-PEG20-His8IFN dimer was prepared pure but at low yield (1.5%; 
Table 3–7) when compared to PEG20-His8IFN (17.6%) producing using PEG bis-
sulfone 1. Disulfide-bridging conjugation was then examined to determine if IFN-
PEG-IFN homodimers could be more efficiently prepared. It was found that the yield 
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of the IFN-PEG20-IFN (0.85%;Table 3–7) and IFN-PEG10-IFN (1.1%;Table 3–7) 
remained low, suggesting that the conjugation reactivity was not limiting the yield of 
the homodimers. Investigations into the PEG di(bis)sulfone 4 reagent revealed two 
possible factors affecting conversion and yield of the homodimers to be related to 
reagent purity and possible hydrolysis. Synthesis route 2, developed by G.Tekle, was 
used for the preparation of the PEG20 di(bis)sulfone 4 for preparing the IFN-PEG-Fab 
heterodimers. However, for the preparation of multifunctional protein-protein 
conjugates in larger quantities, more work needs to be done to optimise the synthesis 
route, purification and characterisation of PEG di(bis)sulfone 4, to prepare the purest 
reagent to achieve better conversion and yield of protein-protein conjugates.  
IFN-PEG20-Fabbeva (IFN yield=21%; Fabbeva=12%) and IFN-PEG20-Fabalb (IFN 
yield=44%; Fabalb=20.5%) were successfully prepared. Disulfide conjugation was 
used to conjugate both His8IFN and Fabbeva to PEG20 di(bis)sulfone 4. The rationale 
to examine the preparation of IFN-PEG20-Fabbeva was based on the fact that 
bevacizumab plus interferon α is an approved treatment for metastatic renal cell 
carcinoma (RCC) (Rini et al., 2008). IFN-PEG20-Fabalb was prepared as a possible 
longer lasting form of IFN. The PEGylated Fabs, PEG20-Fabbeva and PEG20-Fabalb 
were prepared as controls using PEG20 bis-sulfone 1. PEG20-Fabbeva were prepared 
with a final yield of 44% and were prepared in good purity (83%) (Table 4–12). 
However, it was found that PEG20-Fabalb was difficult to make, as an impurity 
assumed to be heavy or light chain was conjugating to PEG (PEG-heavy chain). The 
PEG-heavy chain was found to have a similar binding affinity to PEG20-Fabalb during 
CIEC, therefore SEC purification was used to purity the PEG20-Fabalb. A final yield 
of 28.8% was achieved of PEG20-Fabalb (Table 4–12). Site-specific disulfide 
conjugation has never been conducted on a polyclonal antibody or antibody fragment 
before. However it was found more difficult to prepare the PEG-Fabalb, where the 
yield was lower than for PEG-Fabbeva, where Fabbeva was prepare from monoclonal 
bevacizumab IgG. 
To determine if IFN, Fabalb and Fabbeva had retained activity within the IFN-
PEG20-Fabalb and IFN-PEG20-Fabbeva heterodimers, in vitro assays were conducted. 
When conducting the antiviral and antiproliferative assays on IFN-PEG20-Fabalb 
conjugate, a 10-fold difference in IFN activity and a stunted sigmoid curve were 
observed. It was thought that Fabalb was binding to components of the media. In spite 
of this complication, it does appear that the IFN component of IFN-PEG20-Fabalb 
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conjugate was active. However, an accurate specific activity for the IFN-PEG20-
Fabalb could not be determined. If the assay was optimised with serum free media, a 
specific activity for the IFN-PEG20-Fabalb might be determined.  
Bioactivity data was determined for IFN-PEG20-Fabbeva, where in the antiviral 
assay a specific activity of 7.60 ± 2.56 MIU/mg, while in the antiproliferative assay a 
specific activity of 34.72 ± 6.30 MIU/mg was achieved (Table 4–12). This shows 
that IFN within the novel IFN-PEG20-Fabbeva heterodimer had also retained its 
activity. Often when producing multifunctional proteins, the activity of the proteins 
is greatly reduced. For example, Albuinterferon, a HSA-IFN α fusion, retained 1% of 
IFN α (Subramanian et al., 2007). Often, reduced activity is due to the steric 
interference of the two proteins, in this case albumin and IFN. It was hoped by using 
the PEG as a spacer to link the two proteins, that both proteins would retain their 
activities. The order of activity determined by the antiviral and antiproliferative 
assays was; IFN (100% retained activity), IFN-PEG20-Fabbeva (3.3% retained 
activity), PEG20-IFN (1.7%) and IFN-PEG20-IFN (10.5% retained activity, Table 4–
12). Surprisingly, the IFN-PEG20-Fabbeva heterodimer was found to have retained 
greater activity than PEG20-IFN. This could possibly be due to the conformation of 
the heterodimer. It would be interesting to prepare an IFN-PEG20-Fabbeva 
heterodimer, where the IFN has been conjugated to the PEG di(bis)sulfone 4 using 
his-tag conjugation.  
It was also necessary to determine if Fabbeva and Fabalb within the IFN-PEG20-
Fabbeva and IFN-PEG20-Fabalb heterodimers had retained binding. SPR was used to 
determine the binding of Fabbeva and Fabalb within the IFN-PEG20-Fabbeva and IFN-
PEG20-Fabalb. It was observed that the association rate of IFN-PEG20-Fabbeva was 
similar to Fabbeva (2.51 ± 0.32 ×10
4
 s
-1
) and PEG20-Fabbeva (2.38 ± 0.30 ×10
4
 s
-1
), 
suggesting conjugation to the interchain disulfide does not impede binding to VEGF. 
A similar association rate of IFN-PEG20-Fabalb to Fabalb (3.13 ± 0.31×10
4
 s
-1
) and 
PEG20-Fabalb (1.66 ± 0.47 ×10
4
 s
-1
) was observed. Interestingly, when calculating the 
retained ka IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb, in comparison to Fabbeva and 
Fabalb respectively, both heterodimers retained ~54% association rates. The slower 
association rates achieved for the conjugated Fabs compared to the unconjugated 
Fabs could be due to steric shielding from the PEG, and the PEG+IFN for the 
heterodimers, explaining the similar retained association rates for the IFN-PEG-Fab 
heterodimers. The slowing of the association rates has also been described, with 
  
279 
varying PEG MW, where it is reported that the slower association rates could also be 
due to the PEGylated molecules blocking the association of other PEGylated 
molecules to bind to the ligands, especially at higher immobilised ligand densities 
(Khalili et al., 2012). 
The dissociation rate gives an indication as to the propensity of an analyte to 
remain bound to the ligand. The dissociation rates of PEG20-Fabbeva and PEG20-Fabalb 
were found to remain similar to that of Fabbeva (1.55 ± 0.10 ×10
-4
 s
-1
) and Fabalb 
(2.41±0.22×10
-4
 s
-1
, Table 4–8) respectively. The dissociation rates for IFN-PEG20-
Fabbeva (1.79 ± 0.30 ×10
-4
 s
-1
) and IFN-PEG20-Fabalb (2.51 ± 0.04 ×10
-4
 s
-1
) were 
found to increase slightly compared to Fabbeva and Fabalb (Table 4–8). The faster 
dissociation rates observed for the heterodimers, could possibly be due to the 
monovalent binding of the Fab to the antigen, but also possibly the conjugation of the 
PEG may aid the diffusion from the bulk to the sensor surface. The dissociation of 
bevacizumab and F(ab’)2-beva were found to be similar, with Fabbeva being quicker at 
dissociation, suggesting monovalent binding is quicker (Khalili et al., 2012). This 
data suggests that the novel IFN-PEG20-Fabbeva and IFN-PEG20-Fabalb heterodimers 
have retained the activity of both the conjugated proteins. These are successful 
examples of how the PEG20 di(bis)sulfone 4 can be used in conjunction with 
disulfide-conjugation to prepare multifunctional proteins. 
5.2 General discussion and conclusions 
To further develop the concept of using PEG di(bis)sulfone 4 to prepare 
multifunctional proteins, it is important to investigate three areas: i) purity/quality of 
the starting reagents, ii) synthesis procedure to prepare PEG di(bis)sulfone 4, iii) 
experimental procedure to prepare multifunctional proteins at larger scale with better 
conversions/yields. The main limitation with using the PEG di(bis)sulfone 4 reagent 
is the scalability of the current experimental approach. When producing the IFN 
dimers, it became apparent that the purity of the PEG di(bis)sulfone 4 affects the 
conversion and final yield of the end multifunctional protein. The purity of the PEG 
di(bis)sulfone 4 was found to be affected by the purity of the starting reagents used to 
prepare the PEG di(bis)sulfone 4 and the synthesis process used to prepare the PEG 
di(bis)sulfone 4. For producing the heterodimers, an alternative synthesis route (2) 
was used to prepare PEG di(bis)sulfone 4. The alternative synthesis route prepared 
higher conversion and yields of dimer compared to synthesis route 1 due to the purer 
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PEG di(bis)sulfone 4. Therefore, to prepare higher yields of multifunctional proteins 
it is important to use the purest starting reagents to prepare the purest 
homobifunctional reagent 4. Further, it is important to optimise the experimental 
process in preparing the multifunctional proteins, as the process must have as few 
steps as possible to minimise loss and to make the process scalable. For example, a 
one step synthesis could be investigated, such as conjugating one protein to one 
linker end at a lower pH, then increasing the pH to activate the other linker end for 
conjugating a second protein. As the main limitation with the current synthesis route 
for producing the IFN-PEG-Fab heterodimers, is that the unconjugated PEG 
di(bis)sulfone 4 reagent must be removed to ensure conjugation is conducted at the 
unconjugated linker end (X-PEG-Fab) to prepare the IFN-PEG-Fab heterodimer.  
 Further, it would be interesting to investigate maing a His8IFN-PEG20-Fab, 
conjugate. The functional activity of the His8IFN-PEG20-Fab would be interesting, as 
in chapter 3 it was found that the His8IFN-PEG20-His8IFN dimer had greater activity 
than IFN-PEG20-IFN. This is thought to be due to the conjugation site. The 
polyhistidine tag is thought to be further away from the protein-binding site than the 
thiols from the disulfides. Therefore it would of interest to investigate if, for 
example, His8IFN-PEG20-Fabbeva has greater activity than IFN-PEG20-Fabbeva. 
 In chapter 3, different PEG MWs were investigated when making the IFN-
PEG-IFN dimers, however this was not investigated when producing the IFN-PEG-
Fab heterodimers. Therefore it would be interesting to investigate the PEG MW-
structure-activity relationship with the heterodimers and if this affects the functional 
activity and conversion of the heterodimers. For example PEG MWs 10 and 20 kDa 
could be tested and the activity of IFN compared to conjugates (PEG-IFN and IFN-
PEG-IFN) made in Chapter 3 using disulfide conjugation.  
 To develop the IFN-PEG10-IFN, IFN-PEG20-Fabbeva and IFN-PEG-Fabalb 
conjugates, PK studies would need to be conducted to prove the conjugates are better 
than current treatments and ultimately have PK properties’ better than current 
treatments. However, to do this the enough of the conjugates would need to be 
produced from one-batch. From the current experimental procedures this may be a 
problem, especially in case of IFN-PEG10-IFN. Therefore, as stated previously, the 
purity of PEG di(bis)sulfone 4 would need to be improved to result in better 
conversions and yields of the conjugates. Further, the experimental procedures to 
make the conjugates would need to be improved for their scalability e.g. in the case 
  
281 
of IFN-PEG10-IFN a SEC purification step would need to be replaced with CIEC for 
increased scalability.  
The main achievements of this thesis, is that the IFN-PEG-IFN and IFN-PEG-
Fab conjugates were prepared utilising two site-specific conjugation approaches and 
that the conjugates made were found to retain activity. The IFN-PEG-IFN conjugates 
were made using both his-tag and disulfide conjugation, where it was found that 
His8IFN-PEG20-His8IFN retained 2.95% activity compared to 0.92% activity for 
IFN-PEG20-IFN. This shows the flexibility of the homobifunctional reagent 4, as two 
conjugation approaches can be used. It would be interesting to investigate the activity 
of His8IFN conjugated to PEG di(bis)sulfone 4 by his-tag conjugation and conjugate 
Fab to the other end by disulfide conjugation to prepare His8IFN-PEG20-Fabbeva, as 
would this conjugate have greater activity than IFN-PEG20-Fabbeva, further this 
demonstrates the possibilities available using the homobifunctional reagent 4. As, the 
homobifunctional reagent utilises his-tags, which are often cleaved off after 
expression, as they often have no use. With the IFN-PEG-Fab heterodimers, it 
showed that PEG di(bis)sulfone 4 is able to conjugate two different proteins, 
allowing both proteins to retain activity, this had not been shown before with both 
antibodies and helical barrel proteins. To conclude, the work described in this thesis 
demonstrates encouraging results regarding utilising PEG di(bis)sulfone 4 to prepare 
protein-protein conjugates. 
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Chapter 6 Appendix 
6.1 Appendix I: Calculations 
Quantification of His8IFN α-2a 
ProtPram software was used to calculate the extinction coefficient for reduced and 
oxidised His8-IFN α-2a, as can be seen below: 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured 
in water. 
 
Ext. coefficient    18700 
Abs 0.1% (=1 g/ l)   0.914, assuming all pairs of Cys residues form 
cystines 
 
 
Ext. coefficient    18450 
Abs 0.1% (=1 g/ l)   0.901, assuming all Cys residues are reduced 
 
Calculating the protein concentration using UV (A=280 nm) 
Beer-Lamberts Law calculation was used to calculate the concentration of the 
protein: 
𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 = 𝑒𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (𝜀)  × 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 
× 𝑙𝑒𝑛𝑔𝑡ℎ 𝑜𝑓 𝑝𝑎𝑡ℎ𝑤𝑎𝑦 
To calculate the estimated protein concentration from UV at absorbance 280 nm, the 
following calculation was used: 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 =
𝑈𝑉 𝑎𝑏𝑠𝑜𝑟𝑏𝑎𝑛𝑐𝑒 𝑣𝑎𝑙𝑢𝑒 (280 𝑛𝑚)
𝑒𝑥𝑡𝑖𝑛𝑐𝑡𝑖𝑜𝑛 𝑐𝑜𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑡 (𝜀) × 𝑙𝑒𝑛𝑔𝑡ℎ
 
 
MicroBCA assay for Protein concentration determination 
To calculate the protein concentration: 
a) The average is calculated from each of the BCA standards and IFN α-2a samples 
b) The average of the MicoBCA standard blank is subtracted from the MicroBCA 
standards and IFN α-2a samples. 
c) The standard deviation is calculated for each MicroBCA standard and IFN α-2a 
sample. 
d) 2
nd
 order linear least squares regression model was used to calculate the protein 
concentration: 
𝑦 = 𝑚2𝑥
2 + 𝑚1𝑋 + 𝑏 
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This model was used as an alternative to 1
st
 order least squares regression (y=mx+b), 
where absorbance vs protein concentration should form a liner curve. This is due to 
the some of the BCA calibration curve points not being within the linear part of the 
curve (200 µg/mL), furthermore some of the points between (20-0 µg/mL) may not 
completely fit within the linear of line of the curve due to pipetting errors etc. Thus 
to compensate the 2
nd
 order linear least squares regression model is used to best fit 
the data of the MicroBCA assay. 
 
Antiviral assay calculations 
To calculate from the sample concentration to the starting concentration of the 
dilution plate the following calculation was used: 
𝑉1 = 𝐶2 × 𝑉2 ÷ 𝐶1  
To calculate from the sample ED50 (pg/ mL) to sample specific activity (IU/ mg), the 
following calculations were used: 
a) 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑜𝑓 𝑁𝐼𝐵𝑆𝐶 𝐼𝐹𝑁 ∝ −2𝑎 =
𝑁𝐼𝐵𝑆𝐶 𝑠𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝐼𝑈/ 𝑚𝐿)
𝑁𝐼𝐵𝑆𝐶 𝐸𝐷50( 𝐼𝑈/ 𝑚𝐿)
 
b) 𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 𝑓𝑜𝑟 𝑠𝑎𝑚𝑝𝑙𝑒 =
𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛( 𝑝𝑔/ 𝑚𝐿)
𝑠𝑎𝑚𝑝𝑙𝑒 𝐸𝐷50(𝑝𝑔/ 𝑚𝐿)
 
c) potency of sample compared to NIBSC =
sample dilution factor (b)
NIBSC dilution factor (a)
 
d) 𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐼𝑈/ 𝑚𝐿) =
𝑠𝑎𝑚𝑝𝑙𝑒 𝑝𝑜𝑡𝑒𝑛𝑐𝑦 (𝑐) × 𝑁𝐼𝐵𝑆𝐶 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (63,000 𝐼𝑈/ 𝑚𝐿) 
e) 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐼𝑈/ 𝜇𝑔) =
(𝑑)𝑠𝑎𝑚𝑝𝑙𝑒 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐼𝑈/ 𝑚𝐿) 
𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑡𝑜𝑐𝑘 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛(𝜇𝑔/ 𝑚𝐿)
 
f) 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐼𝑈/  𝑚𝑔) = 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐼𝑈/
 𝜇𝑔)(𝑒) × 1000 
g) 𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (106 𝐼𝑈/ 𝑚𝑔) =
𝑠𝑎𝑚𝑝𝑙𝑒 𝑠𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝑎𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (𝐼𝑈/ 𝑚𝑔)(𝑓)
106
 
 
  
284 
Table 6–1. Raw antiviral potency data achieved for disulfide PEGylated IFN compounds 
Value 
His8IFN α-
2a 
PEGASYS® PEG5-IFN 
(PEG5)2-
IFN 
PEG10-IFN 
(PEG10)2-
IFN 
IFN-PEG10-
IFN 
PEG20-
IFN 
(PEG20)2-
IFN 
IFN-
PEG20-
IFN 
Specific 
activity (×10
6
 
IU/ mg) 
223.44 
243.82 
226.68 
2.37 
2.46 
2.47 
59.28 
44.5 
0.87 
0.83 
0.82 
3.5 
3.26 
4.06 
6.43 
7.06 
0.1 
0.17 
0.09 
3.74 
6.4 
7.84 
5.23 
4.72 
5.55 
0.52 
0.54 
0.6 
1.96 
3.03 
1.53 
1.94 
Mean 
specific 
activity (×10
6
 
IU/ mg) 
231.31 2.43 51.89 0.84 4.86 0.12 5.99 3.95 0.55 2.12 
ST.DEV of 
specific 
activity (×10
6
 
IU/ mg) 
10.95 0.06 10.45 0.03 1.766 0.04 2.08 1.69 0.04 0.64 
Percentage 
(%) retained 
activity  
100 - 22.4 0.36 2.1 0.05 2.59 1.7 0.24 0.92 
n number 3 3 2 3 5 3 3 5 3 4 
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6.2 Appendix II: Optimisation of the antiproliferative assay for the 
determination of the in vitro activity of IFN α and β 
Interferons α and β have been shown not only to elicit antiviral activity, but also 
antiproliferative effects. The antiproliferative activity of IFNs was first described by 
Paucker in 1962 and colleagues who demonstrated that a 24 h exposure of L-cells to 
either UV-irradiated Newcastle disease virus or to IFN led to a temporary decline in 
cell growth. Interferons exert antiproliferative effects though cell cycle arrest 
particularly of the G0 and G1 phases (Sangfelt et al., 1997; Tiefenbrun et al., 1996). 
A variety of cell types including Daudi, ME15, H9 and U-266 cell lines have shown 
to be sensitive to the antiproliferative activity of IFNs and their conjugates (Borden 
et al., 1982; Foser et al., 2003; Sangfelt et al., 1997). However, human Burkitts 
lymphoma or Daudi cell line, shown in Figure 6-1, is the most widely utilised cell 
lines (Meager et al., 2001) and this is due it being highly sensitive to type I IFNs bit 
insensitive to type II and type III IFNs (Meager et al., 2001). 
 
Figure 6-1. Microscopy images of Daudi cells, A-B) following haematoxylin and eosin 
(H&E) staining and C) growing in RPMI medium. 
 
A B
C
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Growth characteristics of Daudi cells at different cell densities 
Firstly to better understand the growth characteristics of the Daudi cells, a general 
growth curve was undertaken. A growth curve was conducted to determine if the 
Daudi cells were within the exponential phase after 72 h incubation required in the 
antiproliferative assay. The Daudi cell number was counted every 24 h and recorded 
over a five-day period (method 2.2.11.6). The Daudi cell growth curve in Figure 6-2, 
shows the initial lag phase (Figure 6-2, 1) which is the time it takes for the cells to 
recover from subculture and start to spread, which for Daudi cells is ~12 h. The 
Daudi cell number increases exponentially, this is the log phase (Figure 6-2, 2). The 
doubling time of the Daudi cells is ~24 h, thus if the cells were plated at 100,000 
cells/well, the cells would be still be within the log phase of the growth curve after a 
72 h incubation period. Thus, the assay is assessing the inhibition of the Daudi cells 
multiplication by IFN α-2a. The growth curve shows the cell number plateauing 
between days 3 and 4 (Figure 6-2, 3), this is where the culture becomes too confluent 
and the growth rate slows down or stops.  
 
Figure 6-2. General growth curve for Daudi cells (cells/ cm
2
) 
 The antiproliferative assay is built on the understanding that the cell growth 
in inhibited by the presence of IFN, thus it is necessary to determine a cell number, 
which over the incubation period (72 h), is within the exponential growth phase. 
Thus, confirming the inhibition of growth when in the presence of IFN rather than 
the cell death being due to alternative factors. In order to examine the response of the 
different seeding densities to MTT, different cell densities were seeded and the MTT 
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response was measured every day for 4 days in the absence of any IFN, method 
2.2.11.6.  
 
Figure 6-3. Daudi cell density optimisation for the antiproliferative assay 
It can be observed in Figure 6-3 that all the all the cell densities showed an increase 
in cell number. At 200,000 cells/well, a steady growth rate peaked after 2 days and 
plateaued thereafter, which could be the result of exhaustion of media. The lowest 
cell densities tested (12,500 and 25,000 cell/ well) over the 4 days did not increase in 
number sufficiently, thus were unsuitable cell densities. The optimum seeding 
densities were 50,000-100,000 cells/ well due to them showing sufficient growth 
over 4 days as they provide a greater endpoint range to measure.  
 
Optimisation of cell density 
In order to achieve a sufficient decrease in cell viability, different cell 
numbers were tested in order to ensure the assay is assessing the inhibition of Daudi 
cell growth due to the presence of IFN. For this experiment (method 2.2.11.7) the 
Daudi cells were seeded at the densities of 4×10
5
, 2×10
5
, 1×10
5
, 5×10
4
, 2.5×10
4
, 
1.25×10
4
 cells per well of a 96 well U-bottom plate along with 2-fold serial dilutions 
of the standards. For IFN-α, the two different standards used were PEGASYS® and 
NIBSC IFN α-2a. For IFN β, the two standards used were Betaferon® (IFN β-1b) 
and NIBSC IFN-β1b. The plates were incubated for 72 h (3 days) at 37  °C, cell 
viability was assessed by the addition of MTT. Following a 3 h incubation with 
MTT, the media was aspirated and the blue formazan crystals dissolved in sterile 
DMSO by agitation for 30 min. The absorbance at 570 nm was then measured using 
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a plate reader. In all experiments the appropriate controls (media alone and cell 
suspension) were included. 
 
Figure 6-4. Effect of Daudi cell density on the antiproliferative effects of (A) NIBSC IFN α-
2a, (B) PEGASYS
®, (C) NIBSC IFN β-1b, (D) Betaferon®. Optimum seeding density was 
found to be 100,000 cell/ well.  
Figure 6-4 that there is a dose dependent decrease in cell density from the 
dose response curves. At low seeding densities, only a very small change in 
absorbance was seen upon the additions of different concentrations of IFN α and –β. 
Whereas for the highest cell densities, large decreases in absorbance can be seen, this 
is likely a result of increased rate of nutrient depletion and build-up of toxic by-
products caused by the increased amount of cells. It was deduced from this 
experiment that the optimum seeding density was 100,000 cells/well since this gave 
the greatest difference in absorbance from ~1.5 to 0.5 at 570 nm.  
 
Optimisation of sample concentration  
From Figure 6-5 it was observed that optimisation of sample concentration 
was required. Therefore, following method Effect of sample incubation time on cell 
viability Daudi cells were seeded at ~1×10
5
 cells per well, the concentration of IFN-α 
or β was varied. A lower starting concentration of NIBSC IFN-α was used since in 
the previous experiment the curve did not plateau also a higher concentration NIBSC 
IFN-β since the cell viability did not reach the lowest cell viability. The results of 
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this experiment can be seen in Figure 6-5 where it can be observed that the cell 
viability does not decrease below 40%. Therefore, next different incubation times 
(72, 96 and 120 h) were then examined to see if the cell viability would decrease 
below 40%. Intriguingly, a much higher starting concentration of IFN β sample was 
required to prepare the same effects as IFN α suggesting that overall IFN α has 
greater antiproliferative effects than IFN β. 
 
Figure 6-5. Optimisation of the concentration of NIBSC IFNα , PEGASYS®, NIBSC IFN β-
1b and Betaferon
®
 on the proliferation of Daudi cells. 
 
Effect of sample incubation time on cell viability 
To determine if the cell viability would decrease below 40% with the increased 
sample incubation time, the same sample concentrations were used and the plates 
were incubated for (72,96 and 120 h), method 2.2.11.8. As shown in Figure X, longer 
incubation times of 92 or 120 h did result in a reduction of cell viability to about 20% 
at the highest sample concentration. However, these increased incubation times were 
found to have decreased r-squared values. The r-squared value gives an indication of 
how well the line fits the data points on the graph. This variability may be from 
evaporation of media from the edges of the plate, which can be overcome by 
excluding the edges of the plate in future assays. Based on the data achieved, the 
incubation time of 72 h was decided on.  
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Figure 6-6. Effect of sample incubation time on the antiproliferative activity of (A) NIBSC 
IFN α-2a, (B) PEGASYS®, (C) NIBSC IFN β-1b and (D) Betaferon® on the proliferation of 
Daudi cells. The different incubation times were 72 h (blue line), 96 h (green line) and 120 h 
(red line).  
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6.3 Appendix III: Optimisation of the antiviral assay for IFN potency 
testing 
50 % Tissue Culture Infective dose (TCID50) assay for EMCV using A549 cells 
 
Figure 6-7. Results of the MTT assay to keep record of the TCID50 for EMCV virus. Viable 
cells are coloured purple and virus infected cells are where no colour is visible. Columns 1 
and 12 are negative controls. 
To determine the EMCV virus stock strength a TCID50 assay was used (§2.2.10.6). 
The TCID50 can be defined as the dilution of the virus required to prepare a 
pathological change in 50% of the inoculated wells. A549 cells were infected with 
EMCV virus stock diluted to achieve concentrations of 10
-2
 to 10
-9
 and the CPE 
monitored from 72 to 96 h. The plates were harvested with MTT after 120 h, where 
MTT shows the effect of virus the wells are clear while wells containing viable cells 
are shown by a purple colour (Figure 6-7). Using MTT provided an easy, non-
subjective assessment of viable cells rather than visual inspection, which is prone to 
error. To obtain the most accurate TCID50 value, columns 2 to 11 were used for 
EMCV infection for each of the virus dilutions as opposed to using less replicates 
which would increase the variability and reduce the accuracy of the results. The plate 
shows 80% viability (CPE) at concentration of 10
-7
. The TCID50 was calculated 
using Reed and Muench’s mathematical technique, for this assay it was found to be 
1.63 × 10
8
 PFU/mL.  
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